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2Use of the terminal rate constant in the assessment of glomerular 
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ABSTRACT
The central theme of this work is the use of the rate constant of the terminal exponential 
from the clearance of a tracer as a measure of glomerular filtration rate (GFR). This rate 
constant is an estimate of GFR divided by the distribution volume of the tracer and 
hence gives GFR normalised to extra cellular fluid volume (ECV). This may be an ideal 
measure of renal function because it indicates how quickly the kidneys can remove 
substances that are distributed in the ECV.
• Experimental data and modelling were used to derive corrections for the one 
pool assumption to give a better estimate of GFR/ECV from the rate constant 
calculated from blood samples taken at 2, 3 and 4 hours.
• Monte Carlo techniques were used to compare the effect o f experimental errors 
on GFR derived from the rate constant and GFR conventionally derived from the 
rate constant and the intercept.
• Using normal volunteers a comparison was made of the appropriateness in adults 
of normalising GFR to ECV and estimated body surface area and additionally, in 
a small group, other whole body parameters including total body water, lean 
body mass and exchangeable potassium.
• The reproducibility of GFR derived by the two approaches was compared.
• Iohexol was compared with Cr-51 EDTA including an assessment of the 
performance of GFR derived from the rate constant with the different 
experimental errors encountered with iohexol.
• A comparison was made of how GFR derived by the two approaches performed 
in identifying changes in renal function as a result o f changes in drug regime.
• The rate constant can be used as a near real time measure of renal function under 
changing conditions and in an extension of this, a study was performed using the 
rate constant as a measure of dialyser performance.
© Nicholas James Bird 2006
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7Chapter 1: Introduction 
1.1 INTRODUCTION
Measurement o f glomerular filtration rate (GFR) is generally believed to be the best 
overall index of renal function in health and disease (Levey 1990, Aurell 1994, National 
Kidney Foundation 2002). It is defined as the volume of fluid that enters the proximal 
tubules of the kidney by filtration at glomerulus per unit of time. Measuring GFR has 
the advantage that it is a direct measure of renal function and that it is known to be 
reduced prior to the onset of any symptoms of renal failure (Smith 1952). Measurement 
of GFR can be useful in many situations including the following areas:
• Detecting the onset of deterioration in renal function in conditions such as diabetes. 
As in many areas of medicine, early detection can optimise the implementation of 
disease management and treatment, and lead to improved outcome (National Kidney 
Foundation 2002).
• Monitoring the progression of the reduction of function in chronic kidney disease.
• Monitoring kidney function in patients being treated with drugs that are potentially 
nephrotoxic e.g. Cyclosporin, in order to make decisions about continuing, stopping 
or swapping drugs.
• Assessment of different drugs for adverse effects on renal function in research 
populations (Watson et al 2005) or assessing the effectiveness of different treatment 
regimes at slowing the progression of chronic renal disease in research populations.
• Calculation of optimum doses of anti-cancer drugs that are excreted from the body 
by the kidneys on an individual patient basis. These drugs are often very toxic to 
various organs in the body and it is vital to ensure adequate therapeutic benefit while 
limiting the toxic side effects to an acceptable level (Calvert et al 1989).
However, as with any diagnostic test, the usefulness of the measurement of GFR will 
depend on its accuracy, reproducibility and convenience. The challenge is therefore to 
ensure that the measurement of GFR is performed in as accurate and reproducible a 
manner as possible, whilst maintaining practicality and accessibility in a variety of 
clinical and research situations. The overall aim of this work was to look at optimising 
the way the measurement of GFR is performed.
1.2 REVIEW
1.2.1 Renal Physiology
The kidneys have two major functions. One is excreting unwanted end-products of 
metabolism, for example urea. The other is regulating the concentration of most of the 
essential constituents of body fluid, including the total amount of water. Each kidney 
contains about 1.3 million nephrons making between 2 and 3 million nephrons in total. It 
is suggested that under normal conditions only about 10% of nephrons are required, 
indicating a large reserve (Gilbert et al 1992). Each nephron is essentially a long tubule; 
at one end is the glomerulus, which is about 200 pm in diameter, and the other end 
opens into the renal pelvis.
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Fig 1.1: Diagram of a nephron
Fig 1.1 shows a diagram of a single nephron. The blood supply to the nephron is unique 
in that there are two capillary beds in series. An afferent arteriole supplies the capillary 
bed of the glomerulus and then this is connected to the peritubular capillary bed by the 
efferent arteriole.
The Glomerulus
The glomerulus consists of up to 50 parallel capillaries that are inside the bulbous end of 
the tubule called the Bowman’s capsule. The permeability of these capillaries is very 
high, up to 50 times higher than that of a typical capillary in other tissues like skeletal 
muscle. Also the pressure inside the glomerular capillaries is high compared to other 
capillaries. This is because the afferent arterioles that supply this capillary bed tend to 
be short and straight and the resistance of the efferent arterioles into which the 
capillaries drain is high. The high pressure and high permeability both encourage the 
passage of fluid and small solutes out of the plasma in the glomerular capillaries into the 
Bowman’s capsule from where they start to flow down the tubule. This passage of water 
and solutes out of the blood into the renal tubules is the process that is known as 
glomerular filtration. The blood flow to the kidneys is large constituting approximately 
20 % of the total cardiac output while the kidneys only actually make up about 0.5 % of 
the total body mass. An average resting adult may have a total cardiac output o f 6 litres 
per minute giving a total renal blood flow of approximately 1.2 litres/minute. This 
equates to a renal plasma flow of around 600 ml/min. Virtually all the blood flow to the
9kidneys goes to the nephrons and so the total flow of plasma through the glomeruli is 
still about 600 ml/min. Approximately 20% of that will be filtered, yielding the normal 
Glomerular Filtration Rate (GFR) of around 120 ml/min. It should be noted that as the 
average rate o f urine production is only about 1 ml/min, more than 99 % of the fluid that 
is filtered out of the blood in the glomerulus is subsequently reabsorbed into the blood 
further along the tubules of the nephrons.
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Fig 1.2: Effect of electrical charge on fractional permeability measured with dextran molecules of 
different sizes and charge in rats (adapted from Ganong 1983)
The actual permeability of the membrane between the glomerular capillaries and the 
Bowman’s capsule varies for different size molecules and for molecules with different 
charge (Fig 1.2). Neutral molecules with an effective molecular diameter of less than 4 
nm are freely filtered, but those greater than 8 nm are almost completely prevented from 
leaving the capillary. The permeability to negatively charged substance is less than to 
neutral substances of the same size because of negative charges in the membrane. Hence 
hardly any albumin, the smallest of the plasma proteins, is filtered, even though its 
effective diameter is 7 nm, because it carries multiple negative charge. Dextran, which is 
a molecule of very similar size to albumin but with neutral charge is filtered more than 
100 times more freely than albumin. So under normal conditions, almost all plasma 
proteins stay inside the capillaries and are not filtered. However, in certain disease 
states, changes to the membrane can increase the permeability to negatively charged 
molecules and albumin can be found in the urine, this is known as proteinuria. Two of 
the physical parameters that affect the passage of fluid and small solutes into the 
Bowman’s capsule of the tubule (i.e. GFR) are therefore:
® hydrostatic pressure difference between the capillaries and the relative low pressure 
in the tubules 
• permeability of the membrane.
A third factor arises from the fact that the large molecules are prevented from leaving 
the capillaries, thus creating a difference in colloid osmotic or oncotic pressure between
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the two sides of the membrane. This osmotic pressure difference works against the 
hydrostatic pressure difference, opposing the passage of fluid and small solutes out of 
the capillaries. These factors can be expressed in an equation as:
GFR = k.S[(Pcc -  Pt) -  (nGC - nT)]
k = capillary permeability
S = surface area of capillary bed
P gc  = hydrostatic pressure in the glomerular capillaries
P t  = hydrostatic pressure in the tubule
FIg c  = osmotic pressure in the glomerular capillaries
IIt = osmotic pressure in the tubule
P gc  is estimated at 60 mm Hg at the start of the glomerular capillaries and P t  is 
estimated at 18 mm Hg. At the start of the glomerular capillaries n Gc is approximately 
28 mm Hg and Hr is assumed to be negligible. The hydrostatic pressure difference of 42 
mm Hg is opposed by the osmotic pressure difference of 28 mm Hg giving a net 
filtration pressure of 14 mm Hg. As the blood passes along the capillaries and fluid 
leaves, the protein concentration and therefore the colloid osmotic pressure rises. There 
will also be some fall in the hydrostatic pressure along the length of the glomerular 
capillaries. Both these effects reduce the net filtration pressure. There is some debate as 
to whether filtration equilibrium (when the net filtration pressure reaches zero) is 
reached in the human. This has fairly important implications as to whether GFR is flow- 
limited or diffusion-limited and this affects how GFR would be expected to respond to 
changes in flow and pressure.
Tubular function
The fluid filtering into the tubule has a composition similar to plasma but with very little 
protein. As the fluid passes down the tubule the composition changes dramatically as 
some substances and water move out of the tubules and other substances are moved into 
the tubules. Some substances are reabsorbed or secreted by passive diffusion and some 
by active transport mechanisms:
• Sodium (Na+) ions diffuse passively from the lumen of the tubules into the tubular 
epithelial cells down a concentration gradient. They are then actively pumped out of 
these cells into the interstitial space by the Na+/potassium(K+) ATPase pump. From 
the interstitial space the Na+ diffuses into the peritubular capillaries. Under normal 
conditions 99.4 % of the Na+ that is filtered is reabsorbed.
• A similar percentage of filtered chloride ions are also reabsorbed by a mixture of 
mechanisms.
• K+ ions are thought to be completely reabsorbed in the proximal portion of the 
tubule but some are then secreted into the distal portion of the tubule.
• Glucose is actively reabsorbed very efficiently in the proximal portion of the tubule. 
Under normal circumstances the glucose is so effectively reabsorbed that essentially 
none appears in the urine. However, like all active transport processes, there is a 
limit to the rate of reabsorption, so if the plasma concentration rises above a certain 
threshold then some glucose will start to appear in the urine. This occurs at a 
concentration of about 180 mg/dL in healthy individuals.
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• The amount o f water lost in the urine is controlled depending on whether the body 
needs to lose or preserve fluid. The walls of the proximal portion of the tubule are 
very permeable to water and as Na+ and other solutes are removed from the tubule, 
water passively diffuses with them maintaining the isotonic concentration of the 
tubular fluid in this portion of the tubule. The kidney is able to form concentrated 
urine because the loop of Henle forms a counter current mechanism whereby the 
osmolality both inside and outside the tubules rise deep in the medulla of the kidney. 
Vasopressin or anti-diuretic hormone increases the permeability of the collecting 
ducts to water. When vasopressin is present, concentrated urine can be produced. 
When there is a fall in vasopressin and a decrease in permeability o f the collecting 
ducts then less water is reabsorbed and more dilute urine is formed. Receptors that 
detect the osmolality in plasma and also the extracellular fluid volume mediate the 
release of vasopressin from the pituitary
• Urea is reabsorbed only through passive diffusion out o f the tubules, this reabsorbs 
around 53% of filtered urea meaning that 47% of filtered urea appears in the urine.
• Various substances are actively excreted by the tubules, such that their rate of 
appearance in the urine is greater than the rate at which they are filtered in the 
glomerulus. Some are naturally produced by the body including various glucuronides 
and 5-hydroxy-indoleacetic acid (the principal metabolite of serotonin) and others 
are substances that might be introduced into the body including penicillin and 
mercaptoacetytriglycine (MAG3).The extraction fraction of MAG3 is approximately 
50%, Tc-99m labelled MAG3 (Fritzberg et al 1986) is used in dynamic renal 
imaging studies (Britton and Maisey 1998).
• Para-aminohippuric acid PAH is an example of a substance that is particular actively 
excreted by the tubules to the extent that almost all the PAH in plasma flowing into 
the kidneys is removed in a single pass. Radiolabelled PAH has been used to 
measure effective renal plasma flow (Peters and Myers 1998).
1.2.2 Factors affecting glomerular filtration rate (GFR)
• Renal blood flow
The degree to which renal blood flow will affect GFR will depend on whether 
filtration equilibrium is reached or not under normal circumstances. Filtration 
equilibrium is reached if at some point before the end of the glomerular capillaries, 
the movement of fluid and solutes out of the capillary ceases because the net 
filtration pressure falls to zero, mainly because of the rising colloid osmotic pressure 
in the capillaries. If this is the case which seems likely (Ganong 1983) then 
glomerular filtration is said to be ‘flow limited’ and any change in renal blood flow 
will have a marked effect on GFR. If however filtration equilibrium were not 
reached under normal circumstance then glomerular filtration would be said to be 
‘diffusion limited’ and moderate changes in renal blood flow would have minimal 
effect on GFR.
• Vascular changes
Afferent arteriolar constriction tends to decrease the rate o f blood flow and decrease 
the glomerular pressure both of which lead to a decrease in GFR. Efferent arteriole
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constriction tends to increase the glomerular pressure and so can lead to an increase 
in GFR. However, this also decreases the blood flow and particularly in the case of 
severe constriction this can outweigh the effect of the increase in pressure and lead 
to a decrease in GFR.
• Sympathetic stimulation
Sympathetic stimulation leads to preferential constriction o f the afferent arterioles 
and has a strong effect decreasing GFR
c
E
E
LLQ_a:i—o
QC
LL
0 —  RPF
—  GFR
1000 50 150 200 250 300
R enal arterial m ean  p r e ssu r e  (m m  Hg)
Fig 1.3: Example of autoregulation of glomerular filtration rate (GFR) and renal plasma flow
(RPF) in the dog kidney (after Ganong 1983)
® Arterial pressure
Large changes in arterial pressure can have a significant influence on GFR. 
However, the mechanism of autoregulation, which is also present in other organs of 
the body, limits these effects over a moderate range of arterial pressures. In the 
kidneys the mechanism of autoregulation is such that the vascular resistance o f the 
afferent arterioles rises and falls with the arterial pressure. It is thought that this is 
due to an innate property of the smooth muscle in the vessel walls that causes it to 
contract in response to being stretched. The autoregulation keeps the renal blood 
flow fairly constant in the face of changing pressure and also limits the change in 
pressure in the glomerular capillaries. These two elements help maintain single 
nephron GFR at a constant level (see Fig 1.3). This is important because o f a 
delicate balance between filtration and reabsorption. If single nephron GFR rises, 
then the speed at which the fluid flows down the nephron rises and reabsorption can 
be insufficient and excessive amounts o f fluid and solutes can be lost from the body. 
Conversely, if  too little fluid volume is filtered and the flow down the tubules is too 
slow then this can affect the ability of the tubules to excrete and too much fluid can 
be reabsorbed (Gilbert et al 1992).
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• Feedback mechanism mediated by angiotensin 2
There is an important feedback mechanism that involves the kidneys and acts to 
maintain blood pressure, with a secondary effect on GFR. Specialised cells in part 
of the tubule form the macula densa which senses the tubular sodium chloride 
concentration. At reduced sodium chloride levels, the macula densa causes the 
granular cells to secrete renin. The release of renin in turn locally converts 
angiotensin to angiotensin 1. Angiotensin 1 is then almost immediately converted 
into angiotensin 2 by angiotensin converting enzyme (ACE). Angiotensin 2 is a 
powerful vasoconstrictor and this vasoconstriction will tend to increase blood 
pressure and reduce blood flow to many organs. Although renal blood flow will thus 
be reduced due to constriction of the afferent and efferent arterioles the locally 
released angiotensin 2 in the region of the efferent arteriole produces selective 
constriction of this arteriole which increases the glomerular pressure and partially 
protects GFR. Angiotensin 2 also acts on the adrenal cortex to increase aldosterone 
excretion, which increases tubular sodium reabsorbtion.
A disturbance of this feedback mechanism occurs in renal vascular hypertension. 
This occurs when there is renal ischaemia, sometimes due to renal artery stenosis. 
The reduced sodium chloride delivery to the macula densa stimulates the feedback 
mechanism as if there is a fall in blood pressure, therefore leading to an increase in 
blood pressure. In this condition, although the GFR is partially preserved (due to the 
efferent arteriole vasoconstriction) there will tend to be some reduction. If there is 
renal artery stenosis, giving an ACE inhibitor will tend to block the protection of 
GFR by dilating the efferent arteriole. However, as the stenosis is unaffected by the 
ACE inhibitor the blood flow to that kidney is still reduced and GFR can drop 
dramatically. This is the basis of a captopril renogram (Britton and Maisey 1998).
• Time of day
There is a slight reduction in GFR during the hours of sleep (Sirota et al 1950)
• Exercise
There has been shown to be a reduction in GFR in response to exercise (Svarsatd et 
1995, Gleadhill et al 2000)
• Food intake
GFR has been shown to rise following the intake of food and this is believed to be 
mediated by a response to circulating amino acids released in the digestion of 
proteins (Wilkinson et al 1990, De Santo et al 1995)
• Pregnancy
GFR has been shown to rise during pregnancy by as much as 40% (Sims and Krantz 
1958)
1.2.3 Measuring GFR
Glomerular filtration rate has already been defined as the volume of fluid that passes 
from the blood into the renal tubules per unit time. It is possible to measure GFR by 
measuring the disappearance from the body of a substance that is eliminated from the 
body by glomerular filtration. The properties of such a substance must lead to it being 
freely filtered in the glomerulus, i.e. it must be sufficiently small (having an effective
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molecular diameter of less than 4 nm if neutral) and must have minimal binding to 
plasma proteins and minimal entry into blood cells. In addition to this, the substance 
must:
• Not be absorbed or secreted by the tubules
• Not be metabolised by the body
• Not be stored in the kidneys
• Not be toxic
• Have no effect on GFR.
• Preferably be easy to measure in plasma and sometimes urine 
Furthermore if the disappearance of the substance is to be measured by the reduction in 
plasma concentrations alone, without measuring the appearance in the urine, then the 
substance must not be removed from the body by any non renal routes.
One way o f quantifying the disappearance of a substance, that is present in plasma, from 
the body is with the concept of clearance. Clearance is defined as the equivalent volume 
of plasma that is completely cleared of substance in unit time. The classical formula for 
this is UV/PT where U and P are the concentrations of the substance in the urine and 
plasma respectively say in mg/ml and V is the volume of urine produced (in ml) in time 
T (min). So U x V is the amount of substance that has appeared in the urine, dividing by 
P gives the volume of plasma that would have contained that amount and dividing by the 
time T in minutes gives the volume of plasma that would have been cleared each minute. 
The clearance of a substance that satisfies the criteria for being suitable for measuring 
GFR, is equal to GFR. Historically, the method of measuring GFR was based on the 
classic formula for steady-state clearance. With this method a constant infusion of 
marker substance is given to the subject and then there is a period of waiting until the 
plasma concentration has reached equilibrium. Then the assumption is made that the 
plasma concentration of the marker will remain constant over a period of at least an hour 
during which the urine can be collected. Sometimes a urinary catheter is used as it is 
important to start with and finish with an empty bladder so that the urine collection is 
precisely all the urine produced within the timed period. At least one blood sample is 
taken at some point during the urine collection and the mean plasma concentration of the 
marker during the collection period determined. In addition the concentration of the 
marker in the urine is measured and the total urine volume. Then U, V, P and T have all 
been directly measured and it is possible to calculate the clearance of the substance from 
UV/PT and hence the GFR.
In 1935 Shannon and Smith identified inulin as a suitable substance for measuring GFR 
by the classic method. Since then inulin has often been regarded as the gold standard to 
compare other markers against. However the difficult chemical assay of inulin 
concentrations has sometimes been a barrier to its use.
The term renal clearance is used to indicate clearance measured from urine collections 
whereas the term plasma clearance is used to indicate the clearance measured from 
plasma samples alone. Plasma clearance therefore may include removal from the body 
by non-renal routes and so overestimate renal clearance. Nosslin (1965) demonstrated 
that the plasma clearance of a substance can be calculated from the total area under the 
curve of plasma concentration plotted against time after a single injection of the
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substance; this curve is sometimes called the plasma clearance curve. In 1967 Gamett et 
al found the renal clearance of Cr-51 EDTA to be similar to that of inulin in man. 
Chantler et al (1969) in addition to comparing renal clearance of inulin and Cr-51 
EDTA, compared renal clearance of Cr-51 EDTA with plasma clearance of Cr-51 
EDTA using the single injection technique with several samples taken from 2 hours after 
the injection onwards. They proposed a correction factor to multiply the clearance of Cr- 
51 EDTA determined by this single injection technique, to give a GFR equivalent to that 
which would be measured from the renal clearance of inulin. In part this was to correct 
for the fact that the area under a single exponential fit to the plasma clearance curve 
from 2 hours onwards, underestimates the total area the clearance curve. This is because 
the full curve following the injection is the sum of at least two exponentials. The pool in 
which an injected marker mixes is known as the distribution volume. If this distribution 
volume behaves as single compartment or pool, then the plasma clearance curve would 
be a simple single exponential. The plasma clearance curve of Cr-51 EDTA is often 
assumed to be bi-exponential (Chantler et al 1969). This is consistent with its 
distribution volume behaving as two compartments, where there is rapid mixing within 
the compartment into which the marker is injected, but then quite slow mixing between 
this compartment and a second compartment. If the distribution volume in fact behaves 
as more than 2 compartments, then the clearance curve will consist o f more than 2 
exponentials. To get an accurate area under the clearance curve it would be necessary to 
take a large number of samples, starting immediately after injection and continuing until 
the curve has essentially become a single exponential and so extrapolating this to infinite 
time will be valid. However, in routine clinical practice it is preferable to be able to 
estimate GFR from a smaller number of samples. A recommended approach (Fleming et 
al 2004) is to take two or three samples between 2 and 4 hours post injection and to fit a 
single exponential to these samples. This gives a slope and intercept from which the area 
under this single exponential can be calculated and from that an estimate of GFR, 
sometimes called the slope intercept GFR. Then a correction is applied to the slope 
intercept GFR to correct for the area under earlier ‘missed’ exponential(s). This type of 
correction is called a correction for the one pool or one compartment assumption. In 
addition to Chantler et al (1969), corrections for the one pool assumption have been 
derived by Brochner-Mortensen (1972), Fleming et al (1991) and Blake et al (1993).
1.2.4 Normalisation of GFR
The magnitude of GFR that a subject requires will depend in some way on their body 
size. Larger subjects needing greater GFR than smaller subjects, one reason being that in 
larger subjects there will be more waste products of metabolism to clear from the body. 
When measuring a subject’s GFR it is often required to ascertain if the level of GFR 
measured is normal for that particular subject, this will depend on the subject’s size and 
may also depend on their age and sex. The measured GFR is often corrected for the size 
of the subject so that it can be compared to a normal value for a standard size subject; 
this is referred to as normalising or indexing the GFR. If it is assumed that normal GFR 
scales linearly with a particular measure of body size, then the normalisation is achieved 
by dividing by the measure of body size and then multiplying by the measure of body 
size for a standard subject. Currently the most common measure of body size to use for 
normalisation is surface area (Fleming et al 2004, Blaufoux et al 1996). The surface area
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is estimated from the height and weight of the subject using either the DuBois formula 
(Du Bois and Du Bois 1916) or the Haycock formula (Haycock et al 1978). The surface 
area of a standard adult subject is assumed to be 1.73 m2 and GFR normalised to body 
surface area is expressed in units of ml/min/1.73 m2.
Surface area was originally considered a suitable parameter to use for normalising renal 
function because studies had shown that kidney weight and basal metabolic rate were 
proportional to surface area for all persons young and old, large and small (Holten 
1931). Other whole body parameters have been suggested as being more appropriate for 
normalising GFR including extracellular fluid volume (Brochner-Mortensen 1980,
White and Strydom 1991, Peters 1992, Gunasekera 1996). The argument for using 
extracellular fluid volume (ECV) is that function of the kidneys is to regulate the 
composition of the extracellular fluid including removing unwanted substances. GFR 
normalised to ECV varies with the proportion of the ECV that is filtered by kidneys in 
unit time and therefore reflects the effectiveness with which the kidneys can regulate its 
composition and the rate that substances can be removed from the ECV. The rate 
constant of the terminal exponential, as estimated by the slope o f the single exponential 
fitted to samples taken between 2 and 4 hours, is an estimate of GFR divided by the 
distribution volume of the marker. The distribution volume of markers such as Cr-51 
EDTA are assumed to represent ECV. Therefore the rate constant leads to a measure of 
GFR which is already normalised to ECV. So one advantage of using the rate constant 
of the terminal exponential in the assessment of GFR is the fact that it is already 
normalised to what may well be the most appropriate measure of body size. A second 
advantage of using the rate constant of the terminal exponential, compared to using 
slope intercept GFR, is that the intercept is not required which means that absolute 
scaling o f the sample concentrations is not required. Therefore GFR can be estimated 
without knowing the exact quantity of marker injected and without the need for making 
volumetrically diluted standards of the injection solution to assay along with the 
samples. It also can be an applicable means of estimating GFR when using an external 
probe to monitor the clearance curve obviating the need to take a sample (Watson 2000). 
A further challenge in terms of normalising GFR is deciding whether a particular 
method is appropriate for all ages of subject including children. McCance and 
Widdowson (1952) suggested that it was because GFR was indexed to surface area that 
low values of normal GFR were reported for children under 1 year. They demonstrated 
that if instead, GFR was normalised to an estimate of total body water, then the 
normalised GFR of these young children was not lower than that of adults, contradicting 
the theory that the kidney was not fully mature at this age. It is also known that GFR 
deteriorates throughout adult life (Grewal and Blake 2005 and Bird et al 2004).
1.2.5 Single sample techniques
In an attempt to further simplify routine clinical measurements of GFR, various methods 
have been derived to estimate GFR from a single plasma sample taken after a single 
injection of marker (Constable et al 1979, Tauxe 1986, Christensen and Groth 1986). 
The basis of these methods is that an estimate of the distribution volume of the tracer is 
made for the subject from their height and weight. The theoretical ‘initial’ concentration 
of tracer is then calculated that would arise if the whole of the known injected quantity 
were evenly distributed in this estimated volume. The lower the measured concentration
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in the single plasma sample compared to this theoretical ‘initial’ concentration, the 
higher the GFR. The different methods use different mathematical formulae to calculate 
an estimate of GFR from the concentration of the single sample; the formulae being 
derived from experimental data where multiple samples were taken. The Christensen 
and Groth (1986) method in particular, was found to give results that were in reasonable 
agreement with multi-sample methods when GFR was greater than 30 ml/min (Picciotto 
et al 1986). This method has gained some acceptance, being recommended by the 
radionuclides in nephrourology committee on renal clearance in 1996 (Blaufox et al 
1996). However, all the single sample methods perform poorly when GFR is low 
(Picciotto et al 1986). They are also less robust than methods involving more samples 
because an erroneous sample concentration as a result o f any kind of mistake is 
undetectable.
1.2.6 Non radioactive tracer studies
Although historically GFR was measured using non radioactive tracers like inulin, it is 
the use of radioactive tracers in particular Cr-51 EDTA and Tc-99m DTPA (Blaufox et 
al 1996, Fleming et al 2004) that has become firmly established. However a non 
radioactive tracer that was safe, relatively simple to assay and gave reliable and accurate 
results would have some advantages over the radioactive tracers. Radiographic contrast 
agents are predominantly eliminated from the body by glomerular filtration. Maher and 
Tauxe (1969) first suggested using contrast agents labelled with radioisotopes for 
measuring GFR. Since iohexol was introduced as a new non-ionic water soluble contrast 
agent in the early 1980s, there has been considerable interest in its suitability as a tracer 
for measuring GFR. Methods have been established for measuring the plasma 
concentration of non radiolabelled iohexol using either x-ray fluorescence of the iodine 
content (O’Reilly et al 1986) or high performance liquid chromatography (HPLC) 
(Krutzen et al 1984).
1.2.7 Creatinine
Use of administered creatinine as a tracer for measuring GFR was first described by 
Rehberg in 1926. Within 10 years biochemical assays were developed that could 
accurately measure the concentration of endogenous creatinine in plasma and urine. 
Creatinine clearance could then be estimated without administering creatinine by 
knowing the plasma concentration during a timed urine collection in which the amount 
excreted is measured. However Shannon (1935) demonstrated that creatinine is far from 
ideal as a marker for measuring GFR as there is significant tubular secretion and that 
creatinine clearance therefore overestimates GFR. Also, there are problems with getting 
accurate urine collections in routine clinical studies. However, it is possible to make an 
assessment of renal function just from the serum creatinine concentration. This is in fact 
the most widely used method of assessing renal function (Levey 1990).
Creatinine is mainly derived from the metabolism of creatine in muscle, its generation 
being proportional to muscle mass. Plasma creatinine level will be at an equilibrium that 
will depend on its rate of generation and its rate of clearance from the body. Plasma 
creatinine level gives an indication of renal function that to some extent is already 
normalised for body size. However, there is significant variability in subjects’ muscle 
mass in proportion to their body size, partially dependent on their age, sex and race. To
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attempt to account for this, formulae have been derived to estimate GFR from plasma 
creatinine taking into account some of these factors (Cockcroft and Gault 1976, Levey et 
al 1999, Levey et al 2000). However, there are significant assumptions in these 
formulae. For example, in Levey et al 2000 the estimated GFR for women is multiplied 
by 0.743 as a general correction for lower muscle mass compared to men. Variability in 
muscle mass, which is not corrected for by the formulae, leads to inaccuracies in the 
estimation of GFR. Another important example of this is the different degree of muscle 
wasting in the elderly. Additional factors can also contribute to inaccuracies when using 
plasma creatinine to estimate GFR:
• Ingestion of cooked meat affects plasma creatinine
• In chronic kidney disease the tubular secretion of creatinine can be increased
• Also in chronic kidney disease the extra renal clearance of creatinine can be 
markedly increased
• Certain drugs, in particular cimetidine, inhibit the tubular secretion of creatinine 
In National Kidney Foundation (2002) the performance of the different formulae are 
compared on the basis of studies reporting the percentage of estimations of GFR that are 
within 30 % of GFR derived from tracer clearance. The best performing formulae was 
Levey et al (2000) with between 84 and 91 % being within 30 %.
1.2.8 Chronic Kidney Disease
Chronic kidney disease is a worldwide public health problem. In the United 
States, there is a rising incidence and prevalence of kidney failure, with poor 
outcomes and high cost. There is an even higher prevalence of earlier stages of 
chronic kidney disease. Increasing evidence, accrued in the past decades, 
indicates that the adverse outcomes of chronic kidney disease, such as kidney 
failure, cardiovascular disease, and premature death, can be prevented or 
delayed. Earlier stages of kidney disease can be detected through laboratory 
testing. Treatment of earlier stages of chronic kidney disease is effective in 
slowing the progression towards kidney failure....Unfortunately, chronic kidney 
disease is “under-diagnosed” and “under-treated” in the United States, resulting 
in lost opportunities for prevention.
National Kidney Foundation 2002. 
Clearly measurement of GFR is vitally important for the early diagnosis and monitoring 
of chronic kidney disease. Additionally, measurement o f GFR is needed in research to 
further understand this prevalent problem, including identifying risk factors and 
assessing the effectiveness of new treatments (Niculescu-Duvaz et al 2006, Schwartz et 
al 2006).
1.2.9 Dosing Chemotherapy
One important use of measurement of GFR is in calculating chemotherapy doses in 
particular for carboplatin. Carboplatin was introduced as an analogue of Cisplatin that 
had reduced unwanted toxic effects, including reduced nephrotoxicity. However, it still 
has haematological toxicity and is known to cause thrombocytopenia. In early studies it 
had been noted that the incidence of thrombocytopenia was higher in patients with 
reduced GFR. About 70% of administered carboplatin is excreted in the urine and it is
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assumed that the toxicity and the therapeutic efficacy are dictated by the area under the 
plasma concentration versus time curve. Calvert et al (1989) measured GFR with Cr-51 
EDTA clearance and Carboplatin clearance. They derived a formula to calculate the 
dose of the drug required to give a target area under the carboplatin concentration versus 
time curve from the GFR:
Dose Carboplatin [mg] = target AUC [mg/ml.min] x (GFR [ml/min] + 25)
Therefore the measurement of GFR is being used to accurately calculate the dose of 
carboplatin on an individual patient basis over a wide range of renal functions. Because 
the toxicity and the efficacy are both deemed to be related to the AUC, similar effective 
treatment should be possible in patients with different levels of renal function with 
similar incidence of side effects. The paper recommends target AUC of 5 -  7 mg/ml.min 
for both previously treated and untreated patients. Accurately identifying the appropriate 
dose for individual patients not only reduces adverse effects but increases the efficacy of 
the treatment leading to improved outcomes.
Interestingly a formula developed for calculating doses of carboplatin for use in children 
(Newell et al 1993, Thomas et al 2000), that has gained wide acceptance, uses the 
terminal rate constant from Cr-51 EDTA clearance rather than the GFR. The terminal 
rate constant is combined with an estimated distribution volume from the weight of the 
patient to give an estimate of GFR to feed into a Calvert like formula. The argument put 
forward for using this approach is that in particular patients, the reported GFR was 
unrealistically high and this was deemed to be due to an unrealistically high distribution 
volume from the intercept of the Cr-51 EDTA clearance curve. One possible cause of 
these unrealistic results is inaccuracy in the administered quantity of tracer. It is notable 
that the terminal rate constant is seen as a more reliable measure to use than the reported 
GFR from the slope and intercept, when making vital calculations such as chemotherapy 
doses in children.
1.3 SIGNIFICANCE OF THE PROBLEM BEING CONSIDERED
The overall aim of this thesis is to investigate methods of improving the accuracy, 
precision and usability of measurements of GFR. In addition to improving the way 
current clearance studies are performed, it is hoped that the development of a simple test 
using a non-radioactive tracer will make accurate and precise assessment o f GFR more 
widely available. In particular such a test could circumvent the need for patients to travel 
to specialist centres. Replacing the use of measurements based on plasma creatinine with 
such a test may be beneficial in many situations including:
• Diagnosing and monitoring chronic kidney disease
• Research to improve the understanding of chronic kidney disease
• Allowing more patients to have accurate calculation of chemotherapy doses
• Identifying patients at risk of adverse drug reactions due to undiagnosed 
reduction in renal function, particularly a problem in the elderly (BNF 2006).
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1.4 OUTLINE OF THESIS
The central theme of the thesis is the use of the rate constant of the terminal exponential 
from the clearance of a tracer as a measure of GFR normalised to extracellular fluid 
volume (ECV). However some of the findings relate to other aspects of the measurement 
of GFR or are results from studies utilising the measurement of GFR. Each of chapters 2 
to 8 is considered as a separate study with its own introduction, methods, results and 
discussion.
• In chapter 2, a combination of experimental data (from the studies reported in 
chapter 6 and 7) and modelling was used to investigate corrections for the one 
pool assumption. The aims were to develop an improved correction for deriving 
GFR/ECV from the rate constant, to derive a correction to give an estimate of 
ECV from the reciprocal of the intercept and to make a careful comparison of 
corrections for correcting the slope intercept GFR.
• De Sadeleer et al (2000b) reported that there was increased uncertainty due to 
experimental error when using the rate constant for assessing GFR, compared to 
the slope intercept approach. However there were severe limitations in their 
Monte Carlo analysis. The aim in chapter 3 was to perform a Monte Carlo 
analysis considering all sources of experimental error to confirm which approach 
has the least uncertainty and to identifying ways o f potentially reducing 
uncertainty.
• There is considerable debate about which is the best whole body parameter to use 
for normalising GFR measurements. Chapter 4 is an experimental study on adult 
normal volunteers where a comparison is made of the appropriateness of 
normalising GFR to different whole body parameters including the approach of 
using the rate constant as a measure of GFR normalised to ECV.
• Chapter 5 is an experimental study of reproducibility of GFR. Various 
comparison were made including comparing reproducibility of GFR derived 
from the rate constant and intercept and GFR/ECV derived from the rate constant 
alone. All comparisons were made for both Cr-51 EDTA and iohexol and also 
comparison of reproducibility was made between the two tracers. The effect of 
food intake on GFR is also investigated in this chapter.
• Chapter 6 is an experimental study looking at agreement between GFR measured 
with iohexol and GFR measured with Cr-51 EDTA. The agreements for the 
different methods of calculating GFR were compared. Two different methods of 
measuring plasma iohexol concentration were compared.
• Chapter 7 reports the results of a clinical trial comparing the effect on renal 
function of different immunosuppressive drugs in transplant patients.
Comparison was made of how GFR calculated by the different methods 
performed in identifying changes in renal function as a result of changes in drug 
regime. Some o f the results of the clinical trial have been published (Watson et al 
2005).
• Chapter 8 reports the results of a study using a probe system to measure the rate 
constant of clearance of Tc-99m DTPA in patients undergoing haemodialysis. 
Changes in the rate constant are used to demonstrate changes in clearance during 
a session of dialysis in response to changes in dialysate or blood flow or as a
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result of deterioration in dialyser function. Some results o f this study have been 
published (Bihl et al 2005)
• Chapter 9 is the conclusion chapter and includes a summary of the key findings 
and suggestions for future work.
• Appendix A (Bird et al 2003) and Appendix B (Bird et al 2004) are related 
papers published during the course of the PhD. Both papers use large numbers of 
routine clinical GFR measurements. Bird et al (2003) looks at the challenge of 
normalising GFR measurements in children. Bird et al (2004) examines whether 
the rate constant measured between 2 and 4 hours post injection reflects the true 
terminal rate constant. Discussion of the key findings and how they relate to the 
rest o f the work in this thesis is included in chapter 9.
In this work both the acceptable symbols 1 and L are intentionally used for litres. In particular ml is used 
as an abbreviation for millilitres but L is used for litres to avoid confusion with the number 1.
22
Chapter 2: Corrections for the one pool assumption
2.1 INTRODUCTION
If the plasma concentration o f a filtration marker such as Cr-51 EDTA is plotted 
against time it is seen that this does not follow a single exponential function. It is 
assumed that this is because the volume into which the tracer distributes is divided 
into real or functional compartments. The simplest multi-compartment model would 
have two compartments and this gives a bi-exponential clearance curve. The plasma 
concentration o f Cr-51 EDTA, sampled between 20 minutes and 4 hours, usually 
gives a very good fit to a bi-exponential and so it is assumed that a 2 compartment 
model gives a good representation of what is happening. Sometimes it has been 
assumed that the two compartment model would have plasma as the first 
compartment and the remainder o f the extracellular fluid (EOF) as the second 
(Chantler et al 1969). But it can be shown that a tracer like Cr-51 EDTA very rapidly 
leaves the intravascular space and that to see the contribution o f this mixing to the 
clearance curve there would have to be rapid sampling within the first few minutes 
after injection (Cousins et al 1997). Therefore the bi-exponential appearance of the 
clearance curve between 20 minutes and 4 hours is evidence that the extravascular 
portion o f ECF is somehow divided into 2 compartments. This in addition to plasma, 
therefore gives a minimum of 3 compartments. A common approach to routine GFR 
measurement is to draw plasma samples only from 2 hours post injection onwards. 
The rational for this is that by 2 hours, an equilibrium has been established between 
the compartments, and that clearance will now reasonably fit a single exponential.
The GFR is calculated from the reciprocal of the total area under the clearance curve. 
The GFR calculated from the area under the single exponential curve fitted to the 
samples taken between 2 hours and 4 hours post injection (slope intercept GFR 
(GFRsi)), overestimates true GFR because of not including the extra area under the 
fast exponential. Therefore various corrections have been proposed to apply to GFRSj 
to correct for the ‘missing’ area and give a better estimate of true GFR (Chantler et al 
1969, Brochner-Mortensen 1972, Blake et al 1993, Fleming et al 1991). These 
corrections are termed corrections for the one-pool assumption. These corrections are 
usually derived by taking early and late plasma samples on a series o f subjects and 
calculating a correction to GFRSi, calculated from only the late samples, to give an 
estimate o f the GFR measured using all the blood samples. The corrections have 
various different mathematical forms.
Volume of Distribution
The reciprocal o f the intercept (1/B’) derived from the samples taken between 2 and 
4 hours give an estimate o f the Volume of Distribution o f the tracer which is a useful 
estimate o f extracellular fluid volume (ECV). In routine clinical GFR measurements 
this volume of distribution can also be used as a quality control check as it can be 
compared with the expected ECV for the height and weight o f the patient and a big 
difference could indicate a problem. The problem could be a different to expected 
volume of tracer injected, maybe due to a tissued injection, or just a mistake in the 
calculation. However, it is important to take into account the medical condition of the 
patient, for example, some patients may be expected to have higher than normal extra 
cellular fluid volume because o f fluid collections. The estimation o f volume of 
distribution from 1/B’ is an overestimation, in much the same way as GFRSj is an 
overestimation o f true GFR, because o f not taking the complete multi-exponential 
clearance curve into account. A correction could therefore be derived to correct 1/B’
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to give a better estimate o f volume o f distribution, there is no simple published 
correction for this purpose.
‘Slone Only’ GFR.
The rate constant o f the terminal exponential, as estimated by the slope of the single 
exponential fitted to the samples taken between 2 and 4 hours, 012% is an estimate of 
GFR/ECV, a normalised measure of GFR which is being proposed in this work as a 
alternative to the conventional measures of GFR. Once again this measure needs to 
be corrected for the one pool assumption. There is one published correction for this 
purpose (Peters 1992), the aim is to test this correction and potentially derive 
improved corrections.
Aims
The aims o f this chapter are
• Modelling the full clearance curve of Cr-51 EDTA using a two compartment 
model and comparison of how well different mathematical forms of the one 
pool assumption corrections fit the model.
• Investigation o f the effect o f adding a third compartment for plasma.
•  Testing how well experimental bi-exponential clearance curves, from samples 
between 20 and 240 minutes post injection, fit the model.
• Derive from the experimental data corrections for the one-pool assumption of 
different mathematical forms to correct GFRsj. Test which corrections give 
the best fit to the data.
• Derive corrections for 1/B’ to give a better estimate of total distribution 
volume o f the tracer and for 0.2  to give a better estimate o f GFR/ECV.
• Split the experimental data randomly into 2 sets, derive the corrections from 
one set and test them on the independent set. Then compare performance of 
corrections derived here with previously published corrections
2.2 METHODS
2.2.1 Experimental data
The experimental data used in this chapter is all from 6 sample Cr-51 clearance 
studies with samples taken at approximately 20,40, 60,120,180 and 240 minutes 
after injection. 220 studies are from transplant patients recruited to the randomised 
control study looking at sirolumus compared to calcineurin inhibitors. Detailed 
methods for these studies are in chapter 7. 110 studies are from patients and 
volunteers recruited to the comparison study with iohexol (in the volunteers 
reproducibility and the effect o f food intake were also studied). Detailed methods for 
these studies are in chapters 5 and 6. The curve stripping technique detailed in 
Chapter 5 was used to obtain a bi-exponential fit to all 6 samples. The zero-time 
intercepts of the fast and slow exponentials were denoted A and B, respectively, and 
the corresponding rate constants, ai and 012. The bi-exponential clearance curve is 
consistent with a 2 compartment model and from A, B, ai and ai the volumes o f the 
two compartments (VI and V2) can be calculated along with the inter-compartmental 
rate constant (k), that defines how quickly mixing occurs between the two 
compartments, and GFR according to the following formulae.
GFR = 1 (1) (Nosslin 1965)
A B
—  + —
a x a 2
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Note as sample concentrations are expressed in %/L, A and B have units o f L"1. 
Sample times are expressed in minutes and so ai and 012 have units o f min'1. Using 
the above formula gives GFR in units o f L/min, to get GFR in ml/min it would be 
necessary to multiply by 1000.
F .= — —  (2)1 A + B v ’
V1+V2 =GFR-t (3)
=> V2 =GFR-t - V 1 (4)
A B+
where r  = -  -  - n2-  (5)
+
a x a 2
t  is the quantity sometimes called mean residence time. 
k = {Accx+Ba2)-V?-GFR  (6)
In addition a mono-exponential fit was performed to the final three blood samples. 
The zero-time intercept o f this exponential was denoted B ’ and the rate constant 012’, 
note that the values o f these are slightly different from B and 012. The slope intercept 
GFR (GFRSi) is calculated from B’ and 0.2
GFRSI = (7)
B1
t
Ka 2 )
Surface area (SA) is calculated from the DuBois formula (DuBois and DuBois 1916). 
Parameters normalised to surface area are denoted for example nVl where 
nVl = (1.73/S A). VI
2.2.2 Obtaining parameters to use in the model
In order to construct the model appropriate values for V I, V2 and k were required. It 
was investigated whether it was appropriate to normalise these quantities to surface 
area before taking overall mean values for all the experimental studies. Appropriate 
values for V I, V2 and k would then be calculated when modelling subjects of 
different sizes.
It was also investigated whether there was a significant dependence o f V I, V2 and k 
on renal function. This is important because a significant dependence could indicate 
an underlying physiological dependence of these parameters on renal function which 
would detract from using fixed volumes (for a particular sized patient) in the model. 
Also a significant dependence might indicate a systematic error effect of renal 
function on these parameters derived from the clearance curve. To investigate these 
dependences the parameters are plotted against normalised GFR (nGFR) and a linear 
trendline fitted. Then using the correlation coefficient of the linear trendline (r2) the
n - 2  
1 — r
degrees of freedom to test for significance of the trend (Altman p 294).
quantity r j -    is calculated and compared against the t distribution with n-2
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2.2.3 Differences between groups
It was possible to divide some of the 330 subjects into groups, to investigate whether 
any differences in volumes or k might be expected between the groups. 146 patients 
were definitely on the drug cyclosporin at the time of the GFR measurement, and 
cysclosporin has been suggested to have an effect on permeabilities of membranes 
(Peters et al 1990) and may therefore affect k and the volumes. 36 patients were 
diabetics, which might also affect the distribution o f extracellular fluid in the body 
and 50 measurements were made on normal subjects.
2.2.4 Two compartment model
The two compartment model is shown diagrammatically in Fig 2.1
inject
volume V2
volume Vi
concentration C2(t) , concentration Ci(t)
GFR
Fig 2.1: Diagram of the two compartment model
C, (t + At) = C, (t) + ~ ( C 2 (t) -  C, ( O ) - ^ C ,  (0
c 2 ( f+ AO = C2 (0  - ~  (C, (t) -  C, (0 )
2
The concentration o f the tracer in the two compartments is calculated every short 
time interval At using the two equations above. At is set to 1 second. The model is 
started at time 0 with the tracer all in compartment 1. Values for A, ai, B and a2 are 
obtained from a double exponential fit to the complete simulated plasma curve. GFR 
is calculated from A, ai, B and 012 using the same formula as for the experimental 
data. In addition the concentrations at 120,180 and 240 minutes are taken from the 
complete curve and a single exponential fitted to get values for B’ and o^’. GFRSi is 
calculated from 012’ and B’ using the same formula as for the experimental data.
Initially, the effect on A, B, B’, ai, a2 and 012’ of varying patient size was investigated 
with V I, V2, GFR and k all scaling with surface area.
Then the model was run with a fixed patient size and varying the GFR between 10 
ml/min and 200 ml/min. From the calculated GFR derived from the simulated full 
curve and GFRSi calculated from the simulated concentrations at 120,180 and 240 
minutes, corrections for the one pool assumption o f various forms were calculated. 
The forms investigated were:
• nGFRcorr= a.nGFRSi + b.nGFRSi2 (which is of the same form as the 
Brochner-Mortensen (1972) correction
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• nGFRcorr = a.nGFRSi + b.nGFRSj2 + c
• GFRco^GFRgi. (a + b.a2’ -  c.(a2’)2)
•  GFRcorr=GFRSi/(l+a.a2’) (which is a form suggested by Peters et al 1999)
• GFRcorr = GFRSj/(l+a.GFRSi) (which is a form suggested by Blake et al 1993)
• A complex form derived from corrections to a2’ and B’ to give better 
estimates o f a2 and B and an estimate o f A/ai which varies with a2’
Then from GFR/(V1+V2) derived from the simulated full curve which is assumed to 
represent GFR/ECV and a2’ calculated from the simulated concentrations at the 120, 
180 and 240 minutes, corrections for the one pool assumption o f various forms were 
calculated to give GFR/ECV from a2\  The forms investigated were:
•  GFR/ECVest = a . <x2* + b (a2’)2
• GFR/ECVest = a . a2’ + b (a2’)2 + c
•  GFR/ECVest= a.a2’+b.(l .73/SA)(a2’)2/B’
This form was arrived at by simplifying the following formula
A B 1-----
GFR /(FI + F2) = ~ ~ —
Y  ^ 2
ctTj a 2
It is assumed that A/ai is negligible compared to B/a2 and that A/ai approximates 
to a constant which scales with surface area.
• A complex form derived from corrections to a2’ and B ’ to give better 
estimates o f a2 and B and an estimate o f A/ai which varies with a2’ and an 
estimate o f A/ai which is a constant which scales with surface area.
Then from (V1+V2) derived from the full curve and B’ calculated from the simulated 
concentrations at the 120,180 and 240 minutes, a correction for the one pool 
assumption was calculated to give (V1+V2) i.e. an estimate o f ECV from 1/B\
The model was run with GFR set to 10, 20, 30, 40 .. etc. up to 200 ml/min/1.73m2. 
For each form o f the corrections the residual sum of squares between the corrected 
measure and the ‘true’ measure derived from the simulated full plasma curve was 
calculated and used to assess how well the correction fits the modelled data.
2.2.5 Three compartment model
The two compartment model was extended to attempt to model the effect o f the rapid 
but not instantaneous mixing between the plasma and the first portion o f the 
interstitial fluid. The mixing between these two compartments gives rise to an 
additional exponential term. It should be remembered that in this early portion of 
there can be a significant difference between arterial and venous concentrations and 
that it theoretically is the area under the arterial curve that needs to be estimated. The 
area under this extra fast exponential is an additional ‘missing area’ when only 
sampling from 2 hours post injection onwards. The aim here is therefore to attempt to 
model this early fast exponential and estimate the magnitude o f the error that 
ignoring this would leave. Several assumptions were made when constructing this 
three compartment model. The first being that the parameters estimated from the 
experimental data and fed into the two compartment model were still valid. The 
second being that compartment 1 is simply divided into plasma and an extra vascular 
portion. A suitable plasma volume was estimated from averaging the male and 
female predicted plasma volumes for subjects of surface area 1.73 m2 from Pearson 
et al (1995). These were 2.73 L and 2.41 L so the volume used for compartment 1A 
was 2.57 L/1.73 m2 giving a volume for compartment IB o f 6.97 L/1.73 m2. To
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estimate the rate constant for the mixing between compartment 1A and compartment 
IB, designated Icab the results in Cousins et al 1997 were examined where arterial 
samples were taken at 30 seconds, 1,2, 3 ,4 , 6, 8 ,10 ,15 , 20, 30, 40, 50 and 60 
minutes post injection o f Tc-99m DTP A. From the plotted arterial clearances it was 
estimated that on average the plasma concentration at 2 minutes was 55% of the 
concentration at 30 seconds. kAB in the 3 compartment model was then adjusted to 
give this ratio o f concentrations in compartment 1A between 30 seconds and 2 
minutes, this ratio being fairly constant with changing renal function. The value of 
kAB used was 1.25 ml/min. The equations used to model the movement o f tracers 
between the three compartments are shown below:
cu if+ At)=CIA(t)+ (ClB (0 -  cu (0) -  Cu (0
IA V \ A
C\B{t + At) = CU! (0 + !p. (C2 it) - CIB(t)) -  (CIB (t) -  Cu (0)
IB " IB
C2 (t + A0 = c2 (t) - (c2 (0 -  C,B (0)
2
The same forms o f the corrections for the one pool assumption were derived from the 
three compartment modelled data and the residual sums o f squares compared.
2.2.6 Corrections derived from all the experimental data
Corrections for the one pool assumption of the various forms were derived from the 
330 experimental studies. The variance of the residuals was used as a measure of 
how well the correction fitted the experimental data and F-tests were used to test for 
significant differences in the variances.
2.2.7 Correction derived from subset of 200 experimental studies
The 330 studies were randomised into 2 groups, one group o f 200 and one group o f 
130. Correction o f the various forms were derived from the group o f 200 and tested 
on the independent group of 130. Again the variance o f the residuals was used as a 
measure o f how well the corrections fitted the experimental data and F-tests were 
used to test for significant differences in the variances.
2.2.8 Combining experimental data with modelling
Corrections for the one pool assumption of the various forms were derived from the 
330 experimental studies with the addition o f a modelled extra fast exponential.
Some o f the corrections were also derived from the 200 studies in the second group 
with the addition o f the modelled extra fast exponential for comparisons with the 
previously published corrections.
2.2.9 Previously published corrections
Previously published corrections were applied to the group of 130 studies both with 
and without the modelled extra fast exponential. The bias and the variance o f the 
residuals were calculated. The published corrections used were:
• Chantler et al 1969: nGFRest=0.93 nGFRsj 
Derived comparing slope intercept with Cr-51 EDTA with inulin constant infusion 
and urine collections (n=25). The Chantler correction was derived to correct for 
differences between plasma clearance and renal clearance, venous and arterial 
sampling and EDTA clearance and Inulin clearance.
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• Brochner-Mortensen 1972 : nGFReSt=0.9908*nGFRSi-0.001218*nGFRs2 
Derived using Cr-51 EDTA (n=74) with samples taken at 15, 30, 60, 90, 120,150, 
180, 210, 240, 270 and 300 minutes plus plasma volume simultaneously measured by 
dye dilution to give a point at time 0. The authors fitted 3 or 4 exponentials to the full 
curve and compared with slope intercept GFR from last 2 hours. Originally derived 
using non-surface area normalised GFR.
•  Fleming et al 1991: nGFR€St=1.00394*nGFRSj-0.00153*GFRSj2
Derived using Cr-51 EDTA (n=30) with samples at 2, 5 ,10 ,15 , 30, 45, 60, 90,120, 
180, 240, 300 minutes plus plasma volume simultaneously estimated with 1-125 HSA 
to give point at 0 minutes. Triple exponential was fitted to full curve and compared 
with slope-intercept GFR from 2 to 4 hours.
• Blake et al 1993: nGFRest=nGFRsi/(l+0.00155*nGFRsi)
Derived using Cr-51 EDTA (n=49) with 11 samples from 5 minutes to 7 hours. Bi­
exponential fitted to full curve and compared with slope-intercept GFR from 2 to 7 
hours.
• Fleming et al 2004: nGFReSt=l .0004*nGFRsi-0.00146*nGFRsi2
In the BNMS guidelines published by Fleming et al (2004) a correction was 
proposed using the mean of the coefficients from the original Brochner-Mortensen 
(1972) equation and a subsequent Brochner-Mortensen (1974) equation for children.
• Peters 1992 : GFR/ECV= (1.06.a2,+9.(a2,)2-0.000093)
Derived using Tc-99m DTPA (n=41) with samples taken at 10, 20, 30,120,180 and 
240 mins. Bi-exponential fitted to the full curve and compared with slope-intercept 
GFR from 2 to 4 hours.
2.3 RESULTS
2.3.1 Experimental Cr-51 EDTA Clearances
Taking all 330 Cr-51 EDTA clearances and using the 2 stage iterative curve stripping 
to fit to give for the double exponential fit values for A, oq, B and a2. There were a 
few problems with this.
2.3.2 Deviations from the standard method
1) In 5 out o f the 330 studies any early exponential was o f insufficient magnitude to 
be fitted. In these cases a single exponential fit was performed to all the samples to 
get B and a2 and A was assigned the value 0. Therefore A/ai is zero and V2 is taken 
as zero but in these cases it was not possible to derive a sensible value for k.
2) In 5 out o f the 330 including point 3 (~60 minutes) in the early exponential would 
have given a negative value when curve stripping. In these cases the early 
exponential was confined to points 1 and 2 and point 3 was included in the second 
exponential. Apart from this slight change in method these cases still provided good 
data and gave estimates o f A, ai, B and a2 as usual.
3) In 2 out of the 330, by chance noise in the data made the 6 data points a good fit to 
a single exponential plus a constant. This was particularly evident when an iterative 
fitting technique was used and then a2 tended to zero to give a fit to Ae'al t+B. 
However, this gives an infinite area under the clearance curve and a GFR of 0! The 
curve stripping method is also iterative but is normally restricted to just 2 iterations. 
If further curve stripping iterations are performed on these two cases, the solution 
does not rapidly converge as usual but slowly converges to give a GFR of 0. Because 
o f this it was decided in these 2 cases to only perform a single iteration o f the curve 
stripping rather than 2.
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2.3.3 O btaining param eters to use in the model
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Fig. 2.2(a) shows k plotted against surface area, (b) shows k normalized to (surface area)2/3 
and (c) shows k normalized to surface area (nk) plotted against surface area. All for the 330 
Cr-51 EDTA clearances and show a linear regression line with its correlation coefficient.
Normalisation o f k
k the diffusion constant between compartment 1 and 2 is plotted against surface area
• 9 A3 • •in Fig 2.2(a) and k normalized to (surface area) is plotted against surface area in 
Fig 2.2(b) and k normalized to surface area is plotted against surface area in Fig
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2.2(c). In each case the correlation coefficient R2 is calculated. For the first 2 options 
the correlation is significant P<0.001 and for 3rd option the correlation is not 
significant P>0.05. Therefore the preferred model for k is to scale, with the volumes, 
to surface area and for each subject nk is taken as k.(surface area [m2]/1.73m2). Fig
2.3 show nk plotted against nGFR the correlation coefficient o f the fit (0.0037) 
showing no significant dependence o f nk on renal function P>0.05. M ean nk for the 
325 subjects where it was possible to calculate k was 0.0999 L/min/1.73m2 (standard 
deviation (SD) 0.0365 L/min/1.73m2)
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Fig 2.3 nk plotted against nGFR for the 330 Cr-51 EDTA clearances with a linear regression 
line and its correlation coefficient
Normalisation o f Volumes
nV l (VI.surface area/1.73m ) was not correlated with surface area (P>0.05), 
however nV2 and n(V l+V 2) were positively correlated with surface area (P 0 .0 0 1 )  
with correlation coefficients o f R2=0.056 and R2=0.053 respectively. Plot o f 
n(V l+V 2) versus surface area is shown in figure 2.4. Conversely normalizing the 
volumes to (surface area/ 1.73m2)372 which has the same units as volume, gives a 
significant negative correlation with surface area for VI (PO.OOl) and V1+V2 
(P O .O l) and no significant correlation for V2. The proportion o f V I to total 
distribution volume (V1/(V1+V2)) was significantly dependent on surface area 
(p<0.01) and this is shown in Fig 2.5. So it could be argued that VI scales most
'i/'j
closely with surface area and V2 with (surface area) and V1/(V1+V2) varies with 
size o f patient. However although the correlations are significant, still the R values 
are low, indicating that the proportion o f the variation in say V1/(V1+V2) that can be 
explained by the correlation with surface area is small. Therefore for the model is 
still seems reasonable to take the mean V1/(V1+V2) and assume that both the 
volumes scale with body size in proportion to one another. However an underlying 
dependence o f V1/(V1+V2) on body size would theoretically lead to a slightly 
different correction for the one pool assumption being required for different size 
subjects with the same level on renal function.
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Fig 2.4. Total distribution volume normalized to surface area for all 330 Cr-EDTA clearances, 
plotted against surface area with linear regression line, its equation and correlation 
coefficient
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Fig 2.5 Proportion of compartment 1 to total distribution volume for all 330 Cr-EDTA 
clearances, plotted against surface area with linear regression line, its equation and 
correlation coefficient.
The mean volume o f compartment 1 for the 330 Cr-51 EDTA clearances, normalised 
for surface area, was 9.54 L/1.73m2 (standard deviation (SD) 1.51 L/1.73m2). The 
corresponding mean normalised volume for compartment 2 was 4.14 L/l .73m2 (SD 
1.25 L /l.73m 2). The mean normalised total distribution volume o f Cr-51 EDTA, that 
is an estimate o f extra cellular fluid volume, was 13.68 L /l.73m 2 (SD 1.80).
Plotting n(Vi+V 2) against renal function is shown in Figure 2.6. Using the 
correlation coefficient o f the trendline, r2 = 0.0108 get P>0.05 indicating no 
significant dependence o f n(V l+V 2) on renal function. Plotting V I/(V I+ V 2) against
y = -0.0568x + 0.8069 
R2 = 0.0244
y = 2.0194x + 9.8246  
R2 = 0.0557
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renal function is shown in Figure 2.7. Again the correlation coefficient o f  the 
trendline, r2=0.0050 indicating no significant dependence on V1/(V1+V2) on renal 
function.
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Fig. 2.6: Normalised total distribution volume (n(V1+V2)) plotted against normalised GFR for 
the 330 Cr-51 EDTA clearances, showing a fitted linear regression line with its correlation 
coefficient.
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Fig.2.7: Normalised total distribution volume (n(V1+V2)) plotted against normalised GFR for 
the 330 Cr-51 EDTA clearances, showing a fitted linear regression line with its correlation 
coefficient.
Differences between groups
Table 2.1 shows that one difference there is between the groups is that both the 
cyclosporin takers and the diabetics are on average significantly larger than the 
normals and on average both groups have significantly lower renal function than the
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normals, which may need to be taken into account when interpreting any significant 
differences in the volumes or k.
Surface 
Area m2
nGFR 
ml/m in/1. 
73m2
Cyclosporin
n=146
1.92 (0.23)
**
42 (16)
**
Diabetics
n=36
1.99 (0.20)
**
60 (36)
**
Normals
n=50
1.79 (0.18) 91 (13)
Table 2.1 mean values for surface area and normalised GFR (from Cr-51 EDTA clearance) 
for the 3 groups shown with standard deviation in brackets ** indicates a significant 
difference from the Normals P<0.001
Table 2.2 summarises the differences in normalised volumes and normalised k 
between the groups. O f note is that the patients on cyclosporin showed no significant 
differences from the group of normals, with very similar mean total distribution 
volumes and mean V1/(V1+V2), even though the cyclosporin group had the lowest 
average renal function and were almost as large on average as the diabetics. However 
the group o f diabetics did show some significant differences. All the mean volumes 
were significantly larger and than for the normals, for the same size of patient. The 
mean normalised rate constant was also significantly larger. The proportional 
increase in mean V2 compared to the normals was greater than the increase in mean 
V I, giving a significant difference in the average proportion o f the total distribution 
volume being in V I. Although these differences are significant they are small 
compared to the variation in these values within any one group, as seen from the 
standard deviation values in the table.
n(Vl+V2) 
L/1.73 m2
nVl 
L/1.73 m2
nV2 
L/1.73 m2 V1/(V1+V2)
nk
L/min/1.7
3m2
Cyclosporin
n=146
13.4 (1.8) 9.5 (1.6) 3.9 (1.4) 0.71
(0.08)
0.098
(0.038)
Diabetics
n=36
15.1 (1.7)
**
10.1
(1.5)
*
5.0 (1.0)
**
0.67
(0.06)
*
0.110
(0.033)
*
Normals
n=50
13.6 (1.2) 9.5 (1.1) 4.2 (0.9) 0.70
(0.06)
0.091
(0.037)
Table2.2 Mean values for normalised volumes and normalised k, derived from Cr-51 EDTA 
clearances, for the 3 groups shown with standard deviation in brackets * indicates a 
significant difference from the Normals p<0.05, ** P<0.001.
2.3.4 Two compartment model results
Results from the model with varying patient size and fixed normalised GFR 
Initially the model was run with fixed normalised GFR and varying the patient size 
from a surface area o f 0.13 m2 to a surface area o f 2.93 m2. It was found, as might be 
expected, with scaling the volumes, k and GFR with surface area, that essentially the 
same values for ai, ai and ai are produced at different patient sizes and that A, B 
and B’ scale with 1/surface area. The maximum variation in ai, (X2, d i\  A*SA, 
B*SA, B ’*SA or nGFRSj from their mean values over the range o f surface areas was
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less than 0.02%. This has the distinct advantage that the model can be run at one 
fixed patient size and for most forms o f the corrections, the corrections derived from 
the model at this patient size will fit the model results for all patient sizes.
Results for the two compartment modelling with fixed patient size
‘Brochner-M ortensen’ type correction from the two compartment model
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Fig 2.8 Two compartment model results for EDTA: nGFR plotted against uncorrected nGFRsi 
Points are results from the model, solid black line is polynomial fit to those points shown with 
its equation and correlation coefficient. Dotted line is identity.
Fig 2.8 shows ‘true’ nGFR plotted against normalised ‘slope-intercept’ GFR 
(nGFRsi) which is the GFR that would be derived from a single exponential fit to 
plasma concentrations o f samples taken at 120, 180 and 240 min uncorrected for the 
‘one pool assumption’. This plot shows that the model predicts that nGFRSj 
overestimates nGFR and that the overestimation increases progressively with 
increasing nGFR. A correction for the ‘one pool assumption’ o f the form o f the 
Brochner-Mortensen (1972) correction was derived from the polynomial fit to the 
model results giving:
nGFRc„rT=0.9921.nGFRsi-0.000952.nGFRSj2 (R2=0.999975)
Using this correction to correct nGFRSi from model and comparing nGFRcorr with 
‘true’ nGFR gives a residual sum of squares o f 1.65 (ml/min/1.73m2)2.
If  a constant is allowed in the polynomial fit the correction become: 
nGFRcon=0.9974.nGFRSj-0.000968.nGFRsi2-0.35 (R2=0.999979)
The residual sum o f squares is then 1.38 (ml/min/1.73m ) .
From the correlation coefficients it can be seen that a second order polynomial does 
fit the data very well whether a constant is used or not. So although adding a constant 
does reduce the residual sum o f squares slightly, in practice it seems reasonable to 
use the form o f the correction without the constant
a?’ based corrections from the two compartment model
Fig 2.9 shows the ratio o f GFR/GFRSj plotted against (X2 ’. Visually the polynomial fit 
to the model results looks a good fit except at low GFRs. From the polynomial fit a 
correction for the one pool assumption based on 012’ was derived.
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GFRc0rr=GFRsi. (0.9393 + 6.57 . a2' - 2 0 7 0  (a2’)2)
Using this correction on the model results gives a residual sum o f squares o f 2.38 
(ml/min/1.73 m 2)2.
y = -2070x2 + 6.57x + 0.9393  
R2 = 0.99410.6
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Fig 2.9 Two compartment model results for EDTA: shows GFR/GFRsi plotted against a2’ 
Points are results from the model, solid black line is polynomial fit to those points shown with 
its equation and correlation coefficient
Note that using a correction based on <12 has the advantage that the same correction 
can be used for normalised or absolute GFRs.
A correction based on 012’ o f the form GFRcorr=GFRSj/(l+constant.a2 ’), suggested by 
Peters et al (1999) was then derived.
An iterative technique was used to optimise the constant by minimising the residual 
sum of squares o f  the errors for GFRC0IT derived using the correction. The value for 
the constant found was 26.45 min. However this form o f correction doesn’t appear to 
fit the model very well and gives a residual sum o f squares o f 229.1 
(ml/min/1.73m2)2. The maximum error when using this correction on the model 
results was 8 ml/min/1.73m2 at an nGFR o f 200 ml/min/1.73m2.
‘Blake’ type correction from the 2 compartment model
Using the assumption that the area missing under the fast exponential is constant and 
incorporating the difference between B and B ’ and ai and 012’ to get a correction o f 
the form nGFRcorr= l 000/(1000/nGFRSj+constant) or as Blake et al (1993) expresses 
it nGFRcorr=nGFRSj/(l+(constant).nGFRsi). The ‘constant’ is really then related to the 
term A /ai+B /a2+B ’/a 2 ’ and Fig 2.10 shows this ‘constant’ term, along with A/aj 
plotted against nGFR, showing that the model predicts that the assumption that this 
term is a constant is perhaps reasonable for a range o f renal function but that for low 
nGFRs , < 40 ml/min/1.73m2, this term looks less constant, this is due to the 
contribution o f the difference between B and B ’ and 012’ and 0 2 . However at low 
nGFRs the term B ’/a 2 ’ is large, limiting the magnitude o f the error in corrected GFR 
by assuming the A /ai+B /a2+B’/a 2 ’ term is constant. Optimising the value o f the 
constant by using an iterative technique minimising the sum o f squares o f the error 
on nGFRCorr from the model, gives a value for the constant o f 0.001272 min/L i.e
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GFRcorr = GFRs;/(l+0.001272.GFRsi) the residual sum o f squares was 22.8
9 9(ml/min/1.73 m") . The maximum error when using this correction was 2 
ml/min/ 1.73m" at an nGFR of 200 ml/min/1.73m2.
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Fig 2.10 Two compartment mode! resuits for EDTA: shows A/a-i and (A /a ^  B/a2-B7 a2’) 
plotted against nGFR
Corrections to a?’ and B ’, estimation o f A/cq and complex form o f an estimation for 
nGFR from 0 b ’ and B ’ from the 2 compartment model
Fig 2.11 shows the true cb  derived from the double exponential fit to the whole 
plasma curve plotted against 012’, derived from the single exponential fit to modelled 
plasma concentrations at 120, 180 and 240 minutes. It can be seen that Ob’ always 
slightly overestimates 012. Corrections to <X2 * to give a better estimate o f Ob were 
derived from the linear fits to the results from the model, and were:
0.2 esF0.97818.a2’ R2=0.999975
And if  a constant is allowed
a 2 est=0.98203.a2’-0.0000322 R2=0.999995
The linear fits are a good fit to the model results whether a constant is allowed or not, 
showing that 012’ always overestimates 012 by about 2%.
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Fig. 2.11 Two compartment modei results for EDTA: true a2 plotted against a2’. Points are 
results from the model, solid line is linear fit to those points shown with equation and 
correlation coefficient. Dotted line is line of identity.
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polynomial fit 
y = -160.7x2 - 1,890x + 0.98772 
R2 = 0.99984
linear fit 
y = -3.948x + 0.99250 
R2 = 0.98564
Fig. 2.12 Two compartment model results for EDTA: B/B’ plotted against a2’. Points are 
results from the model, solid red line is polynomial fit to those points shown with equation 
and correlation coefficient. Solid blue line is linear fit to those points shown with equation and 
correlation coefficient
Plotting B /B ’ against Gb’ as shown in figure 2.12 shows how B ’ slightly 
overestimates B and that this overestimation increases with increasing renal function. 
Both a linear and polynomial fit to the relationship o f B /B ’ to aS  were tried giving 
two forms o f correction to B ’ to give a better estimate o f B.
The linear form was:
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Best=B\( 0.99250-3.948. a 2’)
And the polynomial form was:
Best= B \(0 .98772-1.890. a 2’-160.7.( a 2’)2)
The correlation coefficient to the linear fit was R2=0.98564 and to the polynomial fit 
was R2=0.99984. The linear fit was included because it was found when fitting the 
relationship between B/B’ and a2’ to noisy experimental data it was not always 
possible to get a sensible polynomial fit.
Although a 2’ and B ’ both overestimate a2 and B respectively these two effects do not 
cancel each other out when calculating (B 7a2’). It was not possible to produce a 
good correction that corrected a2* and B’ together because it was not possible to get a 
good fit to the relationships (B/a2)/(B7 a2’) against a 2’ or (B/a2) against (B 7 a2’).
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Fig. 2.13 Two compartment model results for EDTA: A/a-i plotted against a2\ Points are 
results from the model, solid line is linear fit to those points shown with equation and 
correlation coefficient
Plotting A/ai against a2’ as shown in fig 2.13 shows that with this 2 compartment 
model A /ai does vary significantly with renal function. There is a reasonably linear 
relationship between A/a\ and a2’ and from a linear fit the model results an estimate 
o f A /ai can be derived as follows.
(A /ai)est = 0.9063 + 47 .45 .a2’
It should be noted that with patients with the same renal function but varying size 
AJa\ would be expected to vary with size as from the model 1/A scales with 
surface area. Therefore the estimate becomes.
(A/aOest = (1.73/SA).(0.9063 + 47.45.a2’) (or n(A /ai)est = 0.9063 + 47.45.a2’} 
Combining the corrections to a 2’ and B’ and the estimate o f n(A /ai) to give a 
complex estimate o f normalised GFR 
nGFR€St=1000/(n(A/ai)est+(SA/1.73).B corr/^ 2 corr)
Using the simpler correction to a2’ and the linear correction to B ’ get a residual sum 
of squares for error in nGFR^t o f 1.66 (ml/min/1.73m2)2.
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Using the simpler correction to 012’ and the polynomial correction to B ’ get a residual 
sum o f squares for error in nGFR^t o f 1.00 (ml/min/1.73m2)2.
Using the correction to 0.2 with a constant and the linear correction to B ’ get a 
residual sum o f squares for error in nGFRest o f 0.44 (ml/min/1.73m2)2.
Using the correction to ai with a constant and the polynomial correction to B ’ 
improves the residual sum o f squares for error in nGFR^t to 0.18 (ml/min/1.73m2)2. 
The equation for this most complex form o f the estimate o f nGFR is
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Fig. 2.14 Two compartment model results for EDTA: GFR/ECV plotted against a2’. Points are 
results from the model, solid line is polynomial fit to those points shown with equation and 
correlation coefficient. Dotted line is identity.
‘Slope only’ corrections from the two compartment model
Fig 2.14 shows GFR/ECV plotted against 012’, demonstrating how 0.2 underestimates 
GFR/ECV except at low nGFRs (< 40 ml/min/1.73 m 2) and how the magnitude o f the 
underestimation increases with increasing renal function. The magnitude o f the 
underestimation is less than the overestimation o f nGFRSj. For example at an nGFR 
of 110 ml/min/1.73m2, 0.2 underestimates GFR/ECV by 9.4% whereas nGFRSj 
overestimates nGFR by 14.4 %. This might be one advantage with the ‘slope only’ 
approach to expressing GFR because if  the magnitude o f  the correction for the one 
pool assumption is smaller then any errors associated with the correction might be 
smaller.
A correction for the one pool assumption to create a better estimate o f GFR/ECV 
from 012’ was obtained from the polynomial fit to the model results as shown in the 
figure.
GFR/ECVeS, = 0.9018 . a2 + 28.4 (a2’)2 (R2 = 0.99979)
Or if  a constant is allowed
GFR/ECVest = 0.8628 . <x2’ + 31.1 (ct2’)2 + 0.000122 (R2 = 0.99985)
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It is proposed is to multiply GFR/ECV by a standard mean ECV for a person with 
surface area o f 1.73 m2 to give an estimated normalised measure o f GFR which can 
be interpreted in the same way as a conventional normalised GFR i.e. around 110 
ml/min/1.73m2 is normal. From the 330 Cr-51 clearances the mean normalised ECV 
was 13680 ml/1.73m2. This form o f the GFR normalised to ECV estimated from the 
rate constant is termed GFR/ECVi ‘slope only’ estimate o f normalised GFR is either 
called 13680.GFR/ECVest or G FR ^. i.e. using the first form o f the correction derived 
above without a constant gives the correction 
GFR/ECVi = 13680.(0.9018 . <x2’ + 28.4 (a2’)2) [m l/min/13.68L]
The residual sum o f squares when comparing this GFR/ECV] with GFR/ECV. 13680 
was 13.67 (ml/min/13.68L)2 and using the correction with the constant was 9.72 
(ml/min/13.68L)2.
New form o f correction to the a?’from the 2 compartment model
The normalised form o f the correction GFR/ECVest= a.a2,+b.(1.73/SA)(a2,)2/B ’ is
termed GFR/ECV2
An iterative technique was used to optimise a and b giving 
GFR/ECV2=13680.(0.9749.a2,+1.009.(1.73/SA)(a2,)2/B,)
The residual sum o f squares when comparing this with GFR/ECV. 13680 is 1.45 
(ml/min/13.68L)2.
Estimate o f  A /a i and complex form for estimation o f  GFR/ECV from the 2 
compartment model
For calculating a complex form o f the estimate o f GFR/ECV based only on B ’ and 
a 2’ it is necessary also to estimate the term A/a 2
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Fig. 2.15 Two compartment model results for EDTA: n(A/a12) plotted against nGFR. Points 
are results from the model.
As with A /ai, A /aj would be expected to vary with surface area and so 
(A /ai2).(surface area/1.73) is denoted n(A /ai2). Fig. 2.15 shows the variation o f
9 • • • • / - * .  9n(A/ai ) with nGFR. The variation is fairly small and A/a\ is always small 
compared with B /a2, so it seems reasonable to use a constant estimate for A / a 2. 
Combining the corrections for B ’ and a2’ and the estimate o f A /ai and then taking a 
constant for A / a 2 and minimising the sum o f squares o f the errors between 
((A/aOest+B’corr/ a 2 ’corr)/(constant+ B ’c0rr/ a2’COrr ). 13680 and GFR/ECV. 13680 by
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varying the constant with an iterative technique gives an optimised constant o f 33.4 
and residual sum o f squares o f 0.80 (ml/min/13.68L)2. Note that most o f this residual 
sum of squares is not as a consequence o f taking a constant term for A /a i2 as if  exact 
terms are taken for all other terms and a constant used for the A /ai2 term then on 
optimisation the residual sum o f squares is 0.06 (ml/min/13.68L) (constant = 33.0). 
The complex form for the estimate for GFR/ECV becomes
1 '73 ^0.9063 + 4 7 . 4 5 . V  ^ 0 -9 8 7 7 2  - 1 . 8 9 « / - 1 6 0 .7 ( g2V )
SA
G F R / - ___
7 ECVest ”
0.98203- a ,  -0 .0000322
1.73 33 /] | £ '(0 .98772-1 .8 9 g 2 -160.7(or2 ) 2) 
SA (0.98203 • a [  -  0.0000322)2
Correction for volume o f distribution from the 2 compartment model 
From the modelling it is possible to derive a correction to 1/B’ to give a better 
estimate o f the total distribution volume o f the tracer based on ok’. Fig. 2.16 shows 
(V l+V 2)/(1/B’) plotted against showing that 1/B’ overestimates total distribution 
volume and that the magnitude o f the overestimations increases with renal function. 
The magnitude o f this overestimation is quite high being 26 % at a nGFR o f 110 
ml/min/1.73 m2. Using the polynomial order 2 fit to the plot gives a correction 
(Vl+V2)est = 1/B’ . (1.0106 -  20.52 . a 2’ -  1304 . (a2’)2) (R2 = 0.99996)
1.2
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y = -1304x2 -2 0 .5 2 x +  1.0106 
R2 = 0.99996
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Fig. 2.16 Two compartment model results for EDTA: (V1+V2)/(1/B’) plotted against a2’. 
Points are results from the model. Solid line is polynomial fit to those points shown with 
equation and correlation coefficient.
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Fig. 2.17 Model Results: The modelled concentrations in the three compartments plotted 
against time up to 160 minutes for a nGFR of 100 ml/min/1.73m2 and a surface area of 
1.73m2
2.3.5 Three Compartment Model
Fig 2.17 shows an example plot o f the concentrations in the three compartments from 
the model for a GFR of 100 ml/min/ 1.73m2.
The plasma concentration curves from the 3 compartment model fit a triple 
exponential. The extra fast exponential is represented by constant C and rate constant 
oifast such that now the concentration in the plasma is fitted to:
Cp (t) = Ce~a/as,t + A e~a■' + Be~ait
From the 3 compartment model results it is found that the area under the extra fast 
exponential, C/dfast was quite constant only varying from 0.407 to 0.417 for a GFR 
varying from 10 to 200 ml/min/1.73m2, graphically represented in fig 2.18. Fig 2.19 
shows the overestimation o f GFR with the slope intercept method from taking the 
plasma concentration at 120, 180 and 240 minutes with the 2 compartment model 
and the 3 compartment model. This plot shows that the 3 compartment model 
predicts a greater overestimation than the 2 compartment model due largely to the 
extra ‘missing’ area under the extra fast exponential.
_ —  com partm ent 2 
—  com partm ent 1b 
com partm ent 1a
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Fig. 2.18 Three compartment model results: n(C/afast) plotted against nGFR. Points are 
results from the model
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Fig. 2.19 Model results: nGFRsi from both the 2 and 3 modelling plotted against plotted 
against nGFR. Line of identity also shown.
Brochner-Mortensen Type correction from 3 compartment model 
Applying a polynomial fit to the relationship between nGFRsj and nGFR from the 3 
compartment model yields the following corrections for the one pool assumption. 
GFRCorr-0.954l.GFRsi-0.0009450.GFRsi*1 which fits the model leaving a residual sum 
of squares o f 8.88 (ml/min/1.73m2)2.
GFRcon-^O.9420.GFRSi-0.0009104.GFRsj2+0.8561 which fits the model leaving a
9  9residual sum o f squares o f 7.11 (ml/min/1.73m“) .
Ob’ based corrections from 3 compartment model
Applying a polynomial fit to the relationship between GFR/GFRSj and 012’ from the 3 
compartment model gives the following correction.
GFRcorT=GFRSi . (0.9312 + 2.38 . a 2’ -  2382 (a2’)2)
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Using this correction on the model results gives a residual sum o f squares o f 4.57 
(ml/min/1.73 m2)2.
Deriving a correction o f the form GFRcorFGFRsj/O+constant.af) as before from the 
3 compartment model results gives the following correction. 
GFRcorr=GFRsi/(l+ 37 .7 .a2’)
Using this correction gives a residual sum of squares o f 267 (ml/min/1.73m2)2.
Blake type correction from 3 compartment model
The ‘missing area’ is now A/a]d<Vafast+(B/a2-B7a2’), but can still be calculated from 
the model as l/nG FR -l/nG FR sj fig 2.20 shows this ‘missing area’ plotted against 
nGFR for both the 2 and 3 compartment models. From this plot it can be seen that as 
stated before overall the magnitude o f the ‘missing area’ was higher with the 3 
compartment model largely due to the contribution o f C/afast. It can also be seen that 
an assumption that this ‘missing area’ is roughly constant holds even better than for 
the 2 compartment model for nGFR greater than 50 m l/m in/1.73m2, once again 
however there is a significant departure from this assumption at lower nGFRs.
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Fig. 2.20 Model results: 1000/nGFR-1000/nGFRsi plotted against nGFR for both the 2 and 3 
compartment modelling. Points are results from the model
The correction o f this form is:
GFRCon- = GFRSi/(l+0.00158.GFRSi) the residual sum of squares was 2.39 
(ml/min/1.73 m2)2.
Slope only correction from 3 compartment model
A correction o f the form GFR/ECV] was again derived from the polynomial fit to the 
relationship between GFR/ECV and a2’ from the 3 compartment model. Giving the 
following correction:
GFR/ECV, = 13680 . (0.8707 a 2’ + 42.87 (a2’)2) R2 = 0.9997
Residual sum o f squares was 21.28 when comparing with GFR/ECV. 136800.
If a constant term is allowed then the residual sum o f squares was 14.41 
(ml/min/13.68L)2.
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New form o f correction to the cb’from the 3 compartment model 
The correction o f the form denoted GFR/ECV2 was 
GFR/ECV2= 13680.(0.9903,a2’+ 1,250.(a2’)2/nB ’)
The residual sum o f squares when comparing this with GFR/ECV. 13680 is 5.77 
(ml/min/13.68L)2.
Relationship between a?’and a? from the 3 compartment modelling
With the 3 compartment modelling the relationship between 012’ and 012 was very
similar to with the 2 compartment modelling, with 012’ always slightly overestimating
012. The linear fit fits the relationship well giving a correction to 012’ to give a better
estimate o f 012 of:
a 2 est=0.97641.a2’ R2=0.999954
Compared with a 2 est=0.97818.a2’ R2=0.999975 from the 2 compartment modelling 
which is only a 0.2% difference in the multiplication constant.
Again allowing a constant gives a slightly better fit. 
a 2 est=0.98216.a2’-0.000045 R2=0.999997
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Fig. 2.21 Model results: B/B’ plotted against a2’ for both the 2 and 3 compartment modelling. 
Points are results from the modei solid lines are polynomial fits to those points shown with 
the equation and correlation coefficient
Relationship between B ’and B from the 3 compartment modelling 
Again the relationship between B ’ and B was very similar with the 3 compartment 
modelling as with the 2 compartment modelling, with B ’ always slightly 
underestimating B..
Fig 2.21 shows B/B’ plotted against o^’ for both the 2 and 3 compartment models 
with an expanded y-axis. The maximum difference between these 2 relationships is < 
0.4%.
Variation in A /a i and A/cq+C/afast with the 3 compartment model 
Fig 2.22 shows the variation in A/ai with Ob’ from both the 2 and 3 compartment 
modelling and the variation in A /ai+C/afast with 012’ from the 3 compartment 
modelling. It can be seen that all three relationships are o f a similar form. The overall
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variations in AJa\ and (A/ai+C/afast) with the 3 compartment model is less than the 
variation in A/cp with the 2 compartment model. However the relationships from the 
3 compartment model are slightly less good fits to a linear relationship, although they 
both look reasonably linear up to a nGFR o f 130 m l/m in/1.73m2. An estimate o f A/ai 
derived from a2’ from the 3 compartment model being 
(A/ai)est= 1-0505 + 24.73.a2 ’
An estimate o f A/ai+C/afast derived from a2’ from the 3 compartment model being 
(A/ai+C/a&sOest = 1.4685 + 23.78.a2’
♦ 3 comp, model A/a1 
2 comp, mode A/a1 
■ 3 comp, model A/a1+C/afast
—  Linear (3 comp, model A/a1)
—  Linear (2 comp, mode A/a1)
—  Linear (3 comp, model A/a1+C/afast)
0.000 0.002 0.004 0.006 
ot2’ min'
0.008 0.010 0.012
Fig. 2.22 Model results: A/c^ plotted against a2’ for both the 2 and 3 compartment modelling 
and (A/ch+C/afest) plotted against a2\  Points are results from the model, solid lines are linear 
fits to those points.
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Fig. 2.23 Model results: A/ch plotted against nGFR’ for both the 2 and 3 compartment 
modelling and A a /+ C /a fast2 plotted nGFR’ for the 3 compartment modelling . Points are 
results from the model.
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Variation in A /ai2 and A/a^+Clo^J  with the 3 compartment model
With the 2 compartment model it was shown that it was a reasonable assumption to
assume that AJa\2 approximates to a constant term. Fig 2.23 shows the variation in
A /a i2 with renal function from the 2 and 3 compartment models and A /a i2+C/afast2
with the 3 compartment. It can seen that with the 3 compartment there is even less 
• • 2 2 2  variation with A /a f  or A /ai +C/afast and therefore it is reasonable to assume that
either term is constant.
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Fig. 2.24 Model results: (V1+V2)/(1/B’) plotted against a2’ for both the 2 and 3 compartment 
modelling. Points are results from the model solid lines are polynomial fits to those points 
with equations and correlation coefficients.
Corrections to 1/B’ from 3 compartment model
With the 3 compartment model the extent to which 1/B’ overestimates the total 
volume o f distribution is even greater than with the 2 compartment model 
Fig 2.24 shows (V l+V 2)/(1/B ’) plotted against 0.2 for the 2 and 3 compartment 
models. The second order polynomial fit gives a very good fit to the 3 compartment 
modelled data giving
(Vl+V2)eSt=(l/B ’).(1.016-36.6.a2’-975.(a 2’)2)
Table 2.3 shows a summary o f some of the results from the modelling. The residual 
sum of squares indicates how well the corrections o f different forms fit the modelled 
data.
2 comp, model 
y = -1304x2 -2 0 .5 2 x +  1.0106 
R2 = 0.999961
3 comp, model 
y = -975x2 - 36.60x + 1.016 
R2 = 0.999999
■ 2 comp, model 
3 comp, model
—  Poly. (3 comp, model)
—  Poly. (2 comp, model)
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Result Form Residual sum o f squares
2 comp, model 3 comp, model
nGFR a.nGFRsi+b.nGFRsf 1.7 8.9
a.nGFRSi+b.nGFRsf+ c 1.4 7.1
nGFRSi. (a+b. a2 +c. (a2’ )2) 2.4 4.6
nGFRSj/(l+a .a2’) 229.2 266.7
nGFRsi/(l+a.nG FR si) 22.8 2.4
GFR/ECV 13680.(a.a2,+b.(a2’)2) 13.7 21.3
13680.(a.a2’+b.(a2’)2+c) 9.7 14.4
13680.(a.a2’+b.(a2,)2/nB ’) 1.5 5.8
Table 2.3 Summary of the residual sum of squares when using the corrections of different 
forms on the model results. Units for nGFR are (ml/min/1.73m )2 and for GFR/ECV are 
(ml/min/13.68L)2
2.3.6 Corrections for one com partm ent assumption from experim ental data
Polynomial type correction
Figure 2.25 shows how the uncorrected GFR derived from the slope and intercept o f 
the late samples (nGFRSi) overestimates GFR increasingly with increasing GFR.
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Fig 2.25 nGFRsi plotted against nGFR derived from the 330 Cr-51 EDTA clearances.
Fig 2.26 is the same data as Fig 2.25 plotted the other way round showing the 
polynomial fit to the data yielding one form o f the correction to give an estimate o f  
true nGFR from nGFRsl.
The polynomial correction with the constant set to zero, i.e. o f the same form as the
Brochner Mortensen (1972) is:
nGFRcorrec,ed= 1.0004.nGFRSi-0.001187.nGFRsi2
With the constant not set to zero the correction becomes:
nGFRC0rTCCKd= l .0166.nGFRsi-0.001277.nGFRsi2-0.6
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The variance o f the residuals between the experimental data and these formulae was 
3.94 (ml/min/1.73m2)2 for the form without a constant and 3.92 (m l/m in/1.73m2)2 for 
the form with the constant.
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Fig 2.26 nGFR plotted against nGFRsi for the 330 Cr-51 EDTA clearances. Solid line is 
polynomial fit shown with equation and correlation coefficient, dotted line is identity.
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Fig 2.27 nGFR plotted against nGFRsi for the 330 Cr-51 EDTA clearances shown with the 
results from the modelling.
Fig 2.27 shows the experimental data along with the fit to the predicted relationship 
between nGFR and nGFRsj from the 2 and 3 compartment models. Although the 3 
compartment model data for nGFR is included in the plot it should be noted that the
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nGFR calculated from the experimental data would not be expected to include the 
contribution o f any extra fast exponential as the first blood sample was taken at 20 
minutes and as such the experimental data would not be expected to fit the 3 
compartment modelling o f nGFR. So, in addition, it was calculated from the 3 
compartment model a prediction o f the nGFR that would be measured from a 
biexponential fit to samples taken from 20 minutes onwards call this nGFRx denoting 
nGFR from the 3 compartment model excluding the extra fast exponential, the 
relationship between this and GFRSj is also plotted. It can be seen that the 
experimentally observed relationship between nGFR and nGFRsj is o f  the same form 
as predicted by the modelling. The variance o f the residuals between the 
experimental data and the modelled relationships were calculated and show that the 
experimental data is a closest fit to the 2 compartment model data (variance = 5.43 
(m l/m in/1.73 m2)2) closely followed by the 3 compartment model data excluding the
9  9fast exponential (variance = 5.68 (ml/min/1.73m ) ).
Correction to GFR^i based on the terminal rate constant Ob’
Deriving a correction based on the estimate o f the terminal rate constant 012’, rather 
than estimated normalised GFR, has the advantage that the same correction can be 
applied to normalised or absolute GFR. To derive this correction, GFR/GFRsj was 
plotted against 0 2 ’ (Fig 2.28) this shows how GFRSi increasingly overestimates GFR 
with increasing 012* and the correction formula is 
nGFRcorr=nGFRsi.(0.95796+2.067.a2’-2308.2.(a2)2’)
When using this correction on the variance o f the residuals was 8.17 
(ml/min/ 1.73 m2)2.
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Fig. 2.28 nGFR/nGFRsj piotted against a2’ for the 330 Cr-51 EDTA clearances. Solid line is 
polynomial fit to the data shown with equation.
y = -2308.2x + 2 .067x + 0 .95796
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Fig 2.29 GFR/GFRsi plotted against a2’ for the 330 Cr-51 EDTA clearances shown with the 
results from the modelling.
Fig 2.29 shows the experimental data along with the modelled expected variation in 
GFR/GFRSj for both the 2 compartment and 3 compartment models and the expected 
variation in GFRx/GFRsi for the 3 compartment model as before. It can be seen that 
the experimental relationship is definitely o f the same form as the modeled. 
Calculating the variance o f the residuals the modeled data and the experimental data 
shows that the experimental data is the best fit to the 3 compartment model excluding 
the fast exponential.
Peters type
To create a correction o f the form nGFRcorr=nGFRsj/(l+constant.a2’) the constant 
was optimised to give the minimum residual sum of squares using the iterative 
technique giving the following correction. 
nGFRCOrr=nGFRsi/( 1 +24.1. a2 ’)
The variance o f the residuals was 7.67 (ml/min/ 1.73m2)2.
Blake type correction
The form o f correction suggested by Blake et al (1993) is: 
nGFRCOrr=nGFRSj/( 1 +constant.nGFRSi)
Using a correction o f this form relies on the assumption that the effect o f the 
‘missing area’ under the early one or two exponentials plus the effect o f the 
difference between B ’ and B and a2’ and a 2 is relatively constant over the whole 
range o f renal functions. As previously shown the constant required for any 
individual subject to give an exact correction is l/nG FR -l/G FR Sj. To see how 
constant this term is l/nGFR6 -  l/nGFRsi is plotted against nGFR6 in figure 2.30. 
Using the iterative technique to optimise the constant by minimising the residual sum 
of squares gives a value for the constant o f 0.00138.
The proposed correction derived from the experimental data is then 
nGFRcorr= nGFRsl/( 1+0.00138.nGFRsi)
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The variance o f the residuals was 4.08 (ml/min/1.73m2)2.
Fig 3.31 also shows the experimental data superimposed on the model results for 
1/nGFR -  l/nG FRsi plotted against nGFR for the 2 and 3 compartment models and 
l/nG FRx -l/nG FR Si plotted against nGFRx for the 3 compartment model. The 
optimum value for the constant predicted by the 2 compartment model was 0.00127 
and 0.00158 for the 3 compartment model. The value that the 3 compartment model 
predicts that would be found when comparing nGFRsj with nGFRx was 0.00117. It 
should be noted that the value o f the constant derived from experimental data is 
likely to be influenced by the proportion o f subjects with low GFRs.
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Fig 2.30 1/nGFR-1/nGFRsi plotted against nGFR for the 330 Cr-51 EDTA clearances shown 
with the results from the modelling.
Relationship between a? and aT from the experimental data 
Plotting a2 against a2’ (Fig 2.31) get the relationship a2 = 0.9723. a2’ (R2=0.996327). 
If  the constant for this linear fit is not set to zero then the relationship would have 
been a2 = 0.9732. a2’-0.000004 with an almost identical R2 o f 0.996328. An estimate 
o f true a2 term derived from a2\  derived from all 300 subjects, is:
(a2)est = 0.9723. <x2’
This relationship is very similar to that predicted from the 2 and 3 compartment 
models.
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Fig 2.31 a2 plotted against a2’ for the 330 Cr-51 EDTA clearances. Solid line is linear fit, 
shown with equation and correlation coefficient. Dotted line is the line of identity.
1.02
0.98
0.96 —
0.94
CD
£
0.92
.y = -631.4718x2 - 0.6701 x + 0.989a 
R2 = 0.1759
0.9
0.86  —
0.84
0.000 0.001 0.002 0.003 0.004 0.005 0.006 0.007 0.008 0.0100.009
a 2’ min'1
Fig 2.32 B/B’ plotted against a2’ for the 330 Cr-51 EDTA clearances. Solid line is polynomial 
fit shown with equation and correlation coefficient.
Relationship between B and B ’ from the experimental data
Fig 2.32 shows B/B’ plotted against ob’showing the same form o f the relationship as 
predicted by the modelling with B ’ overestimating B and the overestimation 
increasing with increasing renal function. The polynomial fit to the data gives a form 
for estimating B from B ’
Bes, = B ’.(0.9890-0.67. a2’-631(a2’)2) R2=0.1759
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Best =  B ’.(0.9991-6.17. a2’)R2=0.1692
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Fig 2.33 nA/cq plotted against a2’ for the 330 Cr-51 EDTA clearances. Solid line is iinear fit 
shown with equation and dotted line is expected from the 2 compartment model.
nA/ai from the experimental data
1/A is expected to scale with surface area and therefore A/ai is expected to be 
dependent on surface area (SA). To remove the dependence on surface area A/ai is 
multiplied by SA/1.73 and this is termed nA /ai. Fig 2.33 shows nA/aj plotted against 
012’ this reveals a similar pattern as predicted by the modelling with nA/ai increasing 
with increasing renal function. A linear fit to the experimental data gives a formula 
for estimating nA/ai from ai of 
(nA/ai)est -  92.80.a2’+0.8329
Complex form for estimating nGFR from experimental data
Combining the estimates o f (X2 , B and nA/ai to get a complex correction for the one 
pool assumption o f the form:
1000
nGFR-  =   TT------------ ^ -i ------n A /  1 | 8/1 ^es.
V / « x ) „  1.73 ( a , \ ,
This is the full equation
1000
U G F R est f  ,  .  , . 2 4
92.8 • a ,  +0.8329 +
B '
SA
0 .9 8 9 0 -0 .6 7 - ^  - 6 3 1 A a.
1.73 0.9723 a 2
Using this correction on the experimental data gives a variance o f  the residuals o f
4.16 (ml/min/1.73m2)2.
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Fig 2.34: GFR/ECV plotted against a2’ for the 330 Cr-51 EDTA clearances. Solid line is 
polynomial fit shown with equation and correlation coefficient. Dotted line is identity.
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Fig 2.35 GFR/ECV plotted against a2' for the 330 Cr-51 EDTA clearances and for the 
modelling.
Slope only corrections from the experimental data
Fig 2.34 shows GFR/ECV plotted against 012’ showing how ot2 ’ underestimates 
GFR/ECV and how this underestimation increases with increasing renal function. 
GFR/ECV1=13680.(0.9462. a 2’+23.11. (a2’)2) [ml/min/13.68 L]
The variance o f the residual was 3.15 (ml/min/13.68 L)
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The slightly different form with a constant was:
G FR/ECV |=13680.(0.9639. a 2’+21.28. (a2’)2-0.000037) [ml/min/13.68 L]
The variance o f the residual was then 3.14 (ml/min/13.68 L) indicating very little 
benefit o f the constant term.
Fig 2.35 shows the experimental data with the results from the modelling 
superimposed. From the 3 compartment modelling (GFR/ECV)X was calculated as 
(A /ai+B /a2)/(A /ai2+B /a22) instead o f (C/afastN V ai+ B /a 2)/(C/afast2+A /ai2+B /a22) to 
reflect the expected relationship between GFR/ECV and a2’ when the extra fast 
exponential will not be included and this is also plotted as ‘3 compartment model 
excluding fast exponential’. The fit to the experimental data and expected 
relationship from the 2 compartment model and the ‘3 compartment model excluding 
the fast exponential’ are all nearly superimposed. From the variance o f the residuals 
the experimental data is a slightly better fit to the ‘3 compartment model excluding 
the fast exponential’.
New form o f correction to the ob’from the experimental data
Two forms o f the new correction were derived one without including the 
normalisation term and one with the normalisation term. The iterative technique was 
used to optimise the values o f the constants. The first form was as follows. 
GFR/ECV2=13680.(0.9774.a2,+0.9427.(a2’)2/B ’) [ml/min/13.68 L]
The variance o f the residuals was 2.30 (ml/min/13.68 L)2 
The second form gave the following correction.
GFR/ECV2=13680.(0.9666.a2’+ l. 155.(1.73/SA).(a2’)2/B ’) [ml/min/13.68 L]
The variance o f the residuals was 1.88 (ml/min/13.68 L)"
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Fig 2.36 nA/a-|2 plotted against a2’ for the 330 Cr-51 EDTA clearances. Solid black line is 
linear fit shown with equation and correlation coefficient. {new_all6data.xls/ch3_37}
Estimation o f n A /a r  and complex form o f estimation o f GFR/ECV
As with A /ai, because 1/A is expected to scale with surface area (SA), A / a 2 is
multiplied by SA/1.73 to remove this dependence giving nA/a\z and this is the term
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that the modelling suggests can be taken as a constant. Fig 2.36 shows nA /ai2 plotted 
against 012’ this clearly shows that in fact there is a large amount o f scatter in this 
term and also the dependence on renal function is significant (R ‘=0.0575, n=325, 
P<0.001). However, as this term is always small compared with B /0C2 , for the 
complex form o f the correction nA /aiz is still taken as a constant. The iterative 
technique optimises the value for this constant as 46 min2/L. The form o f the 
complex correction is:
(GFR! E C V )est =
B.nA/, +
S A \ / a Oes, (a2)t
1.73
SA
nA/
v a
+
B,
M e
The actual correction was:
1.73
SA
■I 92.8• a 2 +0.8329 | +
B ' - \ 0 .991 -6 .17 -# -,
(GFR! E C V )est =
0.9723 •
1.73
SA
-46 + -
B'A  0 .991 -6 .17  •# ,
0.9723 • a ,
The variance o f the residual using this correction was 2.04 (ml/min/13.68 L)"
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Fig 2.37 (1/B’)/(V1+V2) plotted against a2’ for the 330 Cr-51 EDTA clearances and for the 
modelling.
Correction to 1/B’ from experimental data 
Fig 2.37 shows a plot o f (Vl+V2)/(1/B*) against 012’ showing how 1/B’ overestimates 
V1+V2 and how the overestimation increase with increasing renal function. The 2nd 
order polynomial fit to the experimental data gives a correction to 1/B’ to give a 
better estimate o f the total distribution volume V1+V2 of: 
(Vl+V2)es,=(l/B,).(1.0233-27.76.a2’-1055.(a2’)2)
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The plot also shows the modelled relationship for (Vl+V2)/(1/B’) against 012’for the 
2 compartment and 3 compartment models and also from the 3 compartment model 
the expected relationship between (Vl+V2)x/(1/B’). Where (Vl+V2)x is the expected 
distribution volume measure if  samples are taken 20 minutes onwards and a bi­
exponential fit used and so the extra fast exponential is not included. From the 
variance o f the residuals, the experimental data was shown to best fit to this 3 
compartment modelling excluding the fast exponential.
Split Data
The 330 subjects were randomised into 2 groups, the first group o f 200 subjects and 
the second group o f 130 subjects. From the first group corrections for the one pool 
assumption to give nGFR or 13680.GFR/ECV, o f the various forms were derived. As 
expected the corrections had slightly different coefficients than those derived from 
all 330 subjects. The corrections were as follows:
nGFRcorr=0.9998.nGFRSi-0.001153.nGFRSi2
2
csi
nGFRcorr=1.0212.nGFRSj-0.001268.nGFRSj2-0.80
nGFRcorr=nGFRSi(0.9528+5.67. a2’-2713(a2’)2) 
nGFRcorr=nGFRsi/(1+0.00135,nGFRsi) 
nGFRc0rr=nGFRsi/(l+23.7. a2’)
_ 1000nGFResl f  i \
87.0 '(X-i + 0.8344 +
£ '•
SA
0.9837 + 2.19- a 2 -829-1 a ,
1.73 0.9751-<z2
GFR/ECVi=l 3680.(24.18. (a2’) +0.9422.a2’) 
GFR/ECVi=13680.(23.53. (a2’)2+0.9486.a2’-0.000014) 
GFR/ECV2=13680.(0.9805.a2’+0.918.(a2’)2/B’) 
GFR/ECV2=13680.(0.9679.a2’+ l . 155.(1.73/SA).(a2’)2/B’)
• (87.0 ■ a [  +0.8344j  + 
(GFR /  ECV)es, = -----------------------------
S '-I 0.9974 -  5.13 -a2
0.9751 -a2
B'-\ 0 .9974-5 .13 -a ,
1.73 1—  •43 + -
SA ' 0 .9751-a2
These corrections were then tested on the independent second group and the 
variances o f the residuals calculated.
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Result Form o f correction Variance 0 '  residuals
Incestuous
data
n=330
Independent
data
n=130
nGFR a.nGFRsi+b.nGFRSi2 3.94 5.25
a.nGFRSi+b.nGFRs2+c 3.92 5.29
nGFRSi. (a+b .(X2 ’ +c. (012 ’ )2) g 17*** 11.66***
nGFRSi/(l+a.a2’) 7 67*** g 7 7 ***
nGFRsi/(1 +a.nGFRsi) 4.08 5.28
1000/((nA/a1)est+(SA/1.73).(BeSt/(a2)est)) 4.16 5.72
13680*
GFR/ECV
13680.(a.a2’+b.(a2,)z) 3.15* 3.25**
13680.(a.a2,+b.(a2,)2+c) 3.14* 3.24**
13680.(a.a2,+b.(a2,)2/B’) 2 30*** 2 72***
13680.(a.a2,+(1.73/SA).b.(a2,)2/B’) 1.88*** 1 61***
13680.((1.73/SA).(nA/a1)est+Best/(a2)est)/
((1.73/SA).(nA/a12)est+Best/((a2)est)2)
2.04*** 2 72***
Table 2.4 Summary of the variance of the residuals when app ying corrections of the
different forms derived from experimental data to either the same set of experimental data or 
an independent set. Indication of significant difference in variance to that for the first form of 
correction (nGFRcorr=a.nG F R sj+ b .nG F R Sj2) * P<0.05, ** P<0.01, ***P<0.001. Unit for variance 
of the residuals are (ml/min/1.73m2)2 for estimations of nGFR and (ml/min/13.68L)2 for 
estimations of 13680.GFR/ECV.
Table 2.4 summarises the variance of the residuals for the corrections derived here 
and shows some o f the statistical comparisons. It shows that for the one pool 
assumption corrections to derive nGFR that the forms of correction based on 012’ 
perform significantly less well than forms o f correction based on nGFRSi. With the 
polynomial forms adding a constant did not improve the performance. The 
polynomial form without the constant (like Brochner-Mortensen 1972) and the form 
like Blake et al (1993) performed equally well. The very complex form of the 
correction offered no obvious advantage.
All the one pool assumption corrections to derive GFR/ECV fit the experimental data 
significantly better than the corrections to derive nGFR.
Addition statistical comparisons on the different forms o f correction for deriving 
GFR/ECV, not shown in the table, reveal that the forms of the corrections involving 
B’ as well as 0 2 ’ performed significantly better than the forms only involving for 
both the incestuous and independent data (all p<0.01 mostly p<0.001). The 
difference between the (a.a2,+(1.73/SA).b.(a2,)2/B’) form and the (a.a2,+b.(a2,)2/B’) 
forms was statistically significant (p<0.05) for the incestuous data but not for the 
independent data.
2.3.7 Combining experimental data with modelling
The 3 compartment modelling predicts that the contribution o f this third extra-fast 
exponential to the plasma concentration in the first experimental sample at 20 
minutes is less than 0.0005 %. Therefore the experimental data completely misses 
this exponential term and is unaffected by it. However the modelling predicts that the 
area under this exponential term does affect the calculation o f GFR, GFR/ECV and 
ECV particular at higher levels of renal function. It predicts that not taking this fast 
exponential into account when nGFR is 120 ml/min/1.73m2 leads to 5% 
overestimation o f GFR, a 5% underestimation in GFR/ECV and an 11 % 
overestimation in ECV. It is possible that the accuracy of the corrections derived
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from the experimental data could be improved by adding in the modeled contribution 
o f the third exponential. From the modelling nC/afast was almost constant (see fig 
2.18) but varied slightly with renal function and the fit to this gives nC/afast = 0.41 -  
0.95. (X25. Similarly nC/afast2 was 0.62 -  5.94 o^’. The contribution of these were 
added in to the calculations of nGFR, GFR/ECV and ECV from the bi-exponential fit 
to the experimental data and the corrections for the one compartment assumption 
were derived as before.
The Brochner-Mortensen form of the correction from all 330 studies becomes: 
nGFRcorr = 0.9925.nGFRSi -  0.001400.nGFRsi2 
The Blake form of the correction becomes:
nGFRcorr = nGFRsi/(1+0.00178.nGFR)
The two forms o f the correction to the rate constant to give GFR/ECV become: 
GFR/ECVi=13680.(0.9394.a2’+30.78.(a2’)2/B’) 
GFR/ECV2=13680.(0.9680.a2’+1.522.(1.73/SA).(a2’)2/B’)
The correction to 1/B’ to get an estimate of distribution volume or ECV becomes: 
ECVest=(l/B’).(1.0201-37.27.a2’-898.(a2’)2)
2.3.7 Published correction formulae
Experimental
(n=130)
Experimental plus 
modelled third exponential 
(n=130)
Variance of 
residuals 
(ml/min/1.73m2)2
Bias
ml/min/1.73 m2
Variance of 
residuals
(ml/min/1.73m2)2
Bias
ml/min/1.73m2
Chantler et al (1969) 26.83 1.8 ** 48.12 3.4 **
Brochner-Mortensen (1972) 5.31 i p lyi * 6.77 1.0 **
Fleming et al (1991) 8.68 -1.3 ** 4.34 0.3
Blake et al (1993) 5.47 -0.7* 6.57 0.9 **
Fleming et al (2004) 7.69 -1.2 ** 4.48 0.4*
a.nGFRSi+b.nGFRSi 5.25 0.4 4.60 0.3
nGFRsi/(l+a.nGFRSi) 5.28 0.1 4.57 0.2
Table 2.5 Summary of the variance of the residua s and the bias when applying corrections
to the second group of experimental data with and without the modelled third exponential. 
a.nGFRsi+b.nGFRSi and nGFRsi/(1+a.nGFRsi) indicate the corrections derived from the first 
group of 200. Significance of the bias is indicated * P<0.05, ** P<0.001
Table 2.5 summarises the comparisons with the published corrections. The Chantler 
et al (1969) correction clearly gives significantly the poorest fit to the experimental 
data (P 0 .0 0 1 ). For the experimental data as measured there is no significant 
difference between the Brochner-Mortesen (1972), the Blake et al (1993) and the 
corrections of the same forms derived from the independent group o f experimental 
data. The Fleming et al (1991) and the Fleming et al (2004) corrections gave a 
significantly poorer fit to the experimental data, the biases showing that they tended 
to slightly over correct.
When the modelled extra-fast third exponential is added to the experimental data 
then it is the Fleming et al (1991) and Fleming et al (2004) that offer the best fit and 
also a  similar fit to the corrections derived here. In this case the Brochner-Mortesen 
(1972) and the Blake et al (1993) were a significantly poorer fit (P<0.05) with the 
biases showing a tendency to undercorrect. Fig 2.38 graphically shows the magnitude
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of some o f the published equations along with the 2 and 3 compartment modelling 
results.
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Fig 2.38 Magnitude of some of the published corrections to nGFRsi and the results of the 
modelling plotted against nGFRsi
With the Peters (1992) correction to o^’ to give GFR/ECV the variance o f the 
residuals was 5.35 (m l/m in/13.68L)2 when compared with the experimental data 
from the second group o f 130. This was a significantly poorer fit to the data than all 
the corrections to give GFR/ECV derived here (P<0.01). When compared to the 
experimental data with the modelled extra-fast third exponential added, the variance 
o f the residuals was greater, at 7.34 (m l/m in/13.68L)2 and a significantly poorer fit 
than all the corrections derived here (P<0.001).
2.4 DISCUSSION
2.4.1 Experim ental data
In the 5 studies where it was not possible to separate an early exponential, this could 
have been due to a number o f reasons:
® Experimental noise or procedural error obscuring the early exponential
• In particular a partially tissued injection leading to further C r-51 EDTA 
entering the blood stream during the course o f the study, affecting the 
clearance curve.
® A real change in GFR during the course o f the measurements for example 
food intake, exercise or other stress (Wilkinson et al 1990)
• A fundamental property o f those particular subjects causing the different 
pattern o f clearance. For example abnormally rapid mixing between the two 
compartments could cause any early exponential to have largely disappeared 
by 20 minutes.
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2.4.2 O btaining param eters to use in the model
The main purpose o f the modelling in this chapter was to simulate the expected 
pattern o f clearance for subjects o f different sizes and with different levels o f renal 
function, and to use this to predict how well different forms o f correction for the one 
pool assumption are likely to perform. In constructing the model it was necessary to 
make assumptions about how the compartmental volumes and the diffusion constant 
between the compartments are likely to vary with varying patient size. The final 
assumption was that all the volumes and the diffusion constant scale linearly with 
surface area. This was a reasonable assumption because although for example there 
was a significant dependence o f V1/(V1+V2) on surface area, this dependence only 
accounted for 2% o f the variation in V1/(V1+V2). Fig 2.39 illustrates the 
dependence o f total distribution volume on surface area
20
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Fig 2.39: V1+V2 plotted against surface area for the 330 Cr-51 EDTA clearances. Solid line 
is linear fit to the data shown with equation and correlation coefficient.
No significant differences were found for the mean normalised volumes or k between 
normals and patients on cyclosporin. However some significant differences were 
discovered between normals and diabetics, this is discussed further in chapter 6. The 
implication for constructing corrections for the one pool assumption is that there is a 
slight theoretical advantage to using a different corrections for diabetics, however in 
practice this would clearly be impractical. It was concluded however that it would be 
worth ensuring that any correction formula derived from experimental data used a 
reasonable mix o f subjects to ensure that the corrections give the best overall 
accuracy when used on a mix o f subjects.
2.4.3 Com partm ental Modelling and the corrections for the one pool assumption 
to give nG FR
The two compartment model predicts that slope intercept GFR (GFRSj) overestimates 
GFR by 3 ml/min/1.73m2 at 50 ml/min/1.73m2 and 20 ml/min/1.73m2 at 120 
ml/min/ 1.73m2. The modelling also demonstrates that although the difference 
between GFRSi and true GFR is largely due to the ‘missing area’ under the fast 
exponential there is also a contribution due to the fact that the slope and intercept 
measured from the samples at 2, 3 and 4 hours are not the true slope and intercept o f
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the second exponential. The two compartment modelling predicts that o f the different 
‘simple’ forms o f correction for the one pool assumption to estimate nGFR, the 
polynomial based on nGFRSi would give the best fit to the data. Another factor of 
note was that the form nGFRSi/(l+a.(X2’) gives a very poor fit to the modelled data. 
The very complex form of the correction, that involves estimating (X2, B and nA/ai 
separately, did potentially offer the best fit to the modelled data.
The 3 compartment model produces a plasma clearance curve that fits a triple 
exponential. The early fast exponential has a half life o f about 1 minute regardless of 
renal function. This extra fast exponential is predicted to contribute about 9% of the 
tracer concentration in a 5 minute sample, but only 0.3% in a 10 minute sample. 
Therefore, to experimentally measure this extra fast exponential multiple samples 
would have to be taken between 0 and 5 minutes. Ideally these samples would be 
arterial because o f the difference between arterial and venous concentrations in the 
first minutes following tracer injection. One implication is that if  the third 
compartment does exist then any multi-sample plasma clearance that doesn’t include 
multiple samples before 5 minutes is likely to underestimate true GFR by around 2 % 
at a nGFR of 50 ml/min/1.73m2 and 5% at a nGFR of 120 ml/min/1.73m2. Therefore 
any correction for the one pool assumption derived from experimental data that 
doesn’t include multiple samples before 5 minutes would also lead to a similar 
underestimate o f nGFR when used on late samples.
It is worth considering the philosophical point as to how important it is in routine 
clinical practice, to produce an absolute measure o f GFR. If normal ranges were 
established with and all experience was with a technique for measuring GFR that 
underestimated GFR by 5% then there may be an argument for carrying on using a 
technique that underestimates GFR by 5%. Interestingly Irwin et al (2005) recently 
highlighted a problem o f switching corrections. They suggest that as the Calvert 
Formula (Calvert at al 1989) was originally calculated to optimise carboplatin doses 
to GFRs corrected with the Chantler correction, that applying the Calvert formula 
using GFRs corrected with the Brochner-Mortensen correction could lead to 
underdosing o f carboplatin by up to 14%.
The 3 compartment modelling predicts that a different form of correction for the one 
pool assumption to estimate nGFR is likely to give the best fit to the data, than that 
predicted by the 2 compartment modelling. The simple Blake et al (1993) form of 
correction (nGFRCOrr=nGFRSi/(l+a.nGFRSi)) being the best fit to the modelled data. 
The form nGFRSi/(l+a.(X2’) again gives a very poor fit to the modelled data.
2.4.2 Compartmental modelling and the corrections for the one pool assumption 
to give GFR/ECV
The correction to &2 needed to give an estimate o f GFR/ECV was predicted by the 
modelling to be smaller than the correction needed to nGFRSi to give nGFR. For an 
nGFR of 110 ml/min/1.73m2, the two compartment model predicts that nGFRSi 
overestimates nGFR by 14 % whereas ai underestimates GFR/ECV by 9 %. The 
three compartment modelling predicts that nGFRSj overestimates nGFR by 20 % and 
that (X2’ underestimates GFR/ECV by 14 %.
Of the ‘simple’ corrections for the one pool assumption to give GFR/ECV both the 
two and three compartment modelling predict that the correction o f the form 
GFR/ECV2-13680.(a.a2’+b.(a2’)2/nB’) would give the closest fit to the data.
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However, the correction of the form GFR/ECVi=13680.(a.a2’+b.(a2’)2) does also fit 
the modelled data reasonably well and does have the advantage that it gives an 
estimate o f GFR/ECV that is truly ‘slope only’ not requiring calculating B \  Again 
the very complex form of the correction did potentially offer the best fit to the 
modelled data.
2.4.3 Compartmental Modelling and the corrections for the one pool assumption 
to give distribution volume
The modelling shows that it should be possible to use 1/B’ to estimate the total 
distribution volume of the tracer which in turn is an estimate of ECV. This is often 
used as a quality assurance check when performing routine clinical GFR 
measurements using multiple samples taken from 2 hours onwards (Fleming et al 
2004). The distribution volume indicated by 1/B’ is compared against an expected 
ECV for that height and weight of patient; if  there is a big discrepancy then an 
assessment needs to be made as to whether there is a technical problem with the 
study. The modelling shows that 1/B’ always overestimates the total distribution 
volume and that the extent o f the overestimation increases quite dramatically with 
increasing renal function see table 2.6. The extent and variation of this 
overestimation makes it sensible to perform some kind o f correction for the one pool 
assumption to 1/B’ even if  only using the measure o f total distribution volume for 
quality assurance. Clearly if  there is interest in the distribution volume in its own 
right then performing a good correction for the one pool assumption will be even 
more crucial. The form of correction that fits the modelled data well is 
(Vl+V2)Kt = (l/B’).(a+b.a2’+c.(a2’)2)
nGFR ml/min/1.73m2 30 110 160 200
Predicted overestimation of 
(V1+V2) by 1/B’ with 2 
compartment model
4% 26% 47% 70%
Predicted overestimation of 
(V1+V2) by 1/B’ with 3 
compartment model
7% 40% 69% 98%
Table 2.6. Magnitude to which 1/B’ overestimates V1+V2 at differen 
2 and 3 compartment model.
nGFRs predicted by the
2.4.4 Does the experimental data fit the modelling?
In general the relationships found between measures derived from just the late 
samples and measures derived from the full curve, eg. between nGFR and nGFRSj, 
from the experimental data were extremely similar to those predicted by the 
modelling. Although the compartmental volumes and intercompartmental diffusion 
constant used in the modelling were derived from the same experimental data, this 
still indicates that the models are likely to be a good representation o f the body’s 
handling o f the tracers.
2.4.5 Experimental data and the corrections for the one pool assumption
The conclusions from the comparisons of the different forms of the corrections for 
the one pool assumption to give nGFR from nGFRSi using the experimental data are: 
• Adding a constant to the correction of the form a.nGFRSi+b.nGFRSj2 offers no 
advantage
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• The best fit to the experimental data was with the corrections o f the forms 
a.nGFRSi+b.nGFRSi2 and nGFRSi/(l+a.nGFRSi)
• The corrections based on o^’; (nGFRsi^a+b.o^’+ c . ^ ’)2) and nGFRSj/(l+a.a2’) 
gave significantly poorer fits to the experimental data (P<0.001)
• The very complex form o f the correction offers no obvious advantage
Respective conclusions for corrections to give GFR/ECV from the rate constant are:
• Adding a constant to the correction of the form a.a2’+b.(a2’)2 offers no 
advantage
• The best fit to the experimental data was with the correction o f the form 
a.a2,+(1.73/SA).b.(a2,)2/B’ being significantly better than the correction o f the 
form a.a2’+b.(a2’)2
•  However, the correction of the form a.o^’+ b . ^ ’)2 will be useful in applications 
where only the rate constant is measured.
• The very complex form of the correction offers no obvious advantage
2.4.6 Comparison with previously published corrections
The Chantler et al (1969) correction gave a very poor fit to the experimental data.
The Brochner-Mortensen (1972) and Blake et al (1993) gave the best fit to the 
experimental data and there was no significant difference between these and the 
corrections o f the same forms derived here. However when the modelled third 
exponential was added to the data the magnitude o f the correction needed becomes 
greater. Fleming et al (1991) is the most likely o f the published corrections to 
correctly take into account the third exponential and indeed it was the best fit to this 
combined experimental and modelled data. The corrections derived here from this 
combined experimental and modelled data gave very similar results to Fleming et al 
(1991). The correction in the British Nuclear Medicine Society guidelines (Fleming 
et al 2004) also gave very similar results. Although the similarity is coincidental it 
reassuringly supports adopting the nationally recommended correction. It should be 
noted that the magnitude of the correction that Brochner-Mortensen et al (1974) 
derived for children was slighter greater than all the corrections for adults. So 
theoretically the best correction for adults may not be the best correction for children.
The only previously published correction to give GFR/ECV from the rate constant 
(Peters 1992) gave a significantly poorer fit to the data than all the corrections 
derived here both with and without the addition o f the modelled third exponential. 
Therefore the proposal is that when a correction for one pool assumption is needed to 
estimate GFR/ECV from the terminal rate to use one of the corrections derived here. 
When an estimate o f the intercept (B’) is available the correction o f the form 
GFR/ECV2 = 13680.(a.a2’+(1.73/SA).b.(a2’)2/B’) should be used.
If only the rate constant is known, for example from probe data, the correction o f the 
form GFR/ECVi = 13680.(a.a2,+b.(a2’)2) should be used.
Whether it is justifiable to use the corrections derived here using the combination of 
the experimental data and the modelled third exponential is debatable. In the rest of 
this work it is these two corrections derived purely from the experimental data that 
are employed in various situations. However because of the type o f comparisons that 
are made, it would not have affected any of the conclusions if  the corrections derived 
with the modelled third compartment were used.
Overall the correction for the one pool assumption for GFR/ECV is smaller than the 
correction for nGFR and the errors on fitting the experimental data to the correction
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are significantly smaller. This could be seen as one advantage of the approach of 
using the rate constant only.
There is no previously published simple correction to give a good estimate of ECV 
from the reciprocal o f the intercept. The magnitude o f the correction required is 
large. Therefore it is proposed to use the correction derived here, again either with or 
without the modelled third compartment. In routine assessment o f GFR, this estimate 
of ECV can be compared against ECV predicted from surface area or weight as a 
quality control check. This quality control check is equally applicable whether 
expressing GFR normalised to surface area or ECV.
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Chapter 3: Monte Carlo Analysis of Uncertainty due to Experimental Errors
3.1 INTRODUCTION
There are very few published papers on assessment of the errors affecting the 
uncertainty in measures o f GFR. Russell (1993) used Monte Carlo simulation to look 
at the particular question o f optimum sampling regimes for multi-sample clearance 
studies fitted to a bi-exponential used to estimate GFR. He used a standard deviation 
of 0.5 minutes for the sample times. For sample concentrations he made the 
assumption that counting statistics did not dominate and applied a standard deviation 
of 3 % for all sample concentrations, as he was simulating clearance of Tc-99m 
agents (and 1-131 orthoiodohippurate) this may be reasonable. Interestingly he 
determines this value o f 3 % from 100 plasma samples that were pipetted and 
counted in duplicate, which does take into account some o f the sources of error but 
not others, including errors that affect the making o f the standard. His conclusion 
was, that o f the regimes that he studied for Tc-99m DTP A, a good regime was 6 
samples from 10 to 240 minutes post injection, logarithmically distributed, i.e. 
intervals between samples getting greater towards the end of the study.
De Sadeleer et al (2000a) used Monte Carlo simulation to look at GFR estimated 
from a single exponential fit to Cr-51 EDTA clearances derived from blood samples 
taken from 2 hours post injection onwards. The particular questions they looked at 
were A) the interval between two blood samples and B) the number o f blood samples. 
They used 8 levels of renal function and the only errors they simulated were those in 
sample time (using a standard deviation o f 1 or 2 minutes) and sample concentration 
(using a standard deviation o f 1,2 or 5 %). They found that the overall uncertainty in 
the clearance expressed as a percentage caused by these errors was greatest at low 
GFRs, but was higher at normal levels o f renal function than for GFRs o f around 50 
to 60 ml/min/1.73m2. They conclude that taking two blood samples at 2 and 3 hours 
gave a significantly higher uncertainty in GFR compared to two samples at 2 and 4 
hours particularly, at low and high GFR. Also that going to two samples at 2 and 5 
hours, only led to a small further decrease in uncertainty except at very low GFR. 
Their results show that increasing the number of blood samples taken (always 
between 2 and 4 hours) steadily decreases the uncertainty in the estimation o f GFR 
for all levels o f GFR, they looked at 2, 3, 5,13 and 25 samples. However they 
conclude that the reduction in uncertainty going from 2 to 5 samples was ‘minimal’ 
and an ‘important’ reduction was only achieved by going to 13 samples.
De Sadeleer et al (2000b) published another paper using the same methods where 
they did try to compare the uncertainty in slope alone with that in the slope intercept. 
However they only simulated errors in the sample times and sample concentrations, 
they did not take into account errors in the injected volume, errors in the making of 
the standard and errors in height and weight, all o f which lead to errors in the ‘slope- 
intercept’ estimation but not in the ‘slope only’ estimation. So rather unsurprisingly 
for most levels o f renal function, they found the uncertainty in the ‘slope only’ 
greater than the uncertainty in the ‘slope-intercept’, due to the compensating effect 
the error in the intercept has on the error in the slope. But, interestingly for terminal 
rate constants greater than 0.009 min'1, corresponding to nGFR greater than about 
104 ml/min, they show the uncertainty in the ‘slope only’ as less than that in the 
‘slope-intercept’. They conclude that this is because the effect from the error in the 
intercept is greatly over compensating causing a larger error in the opposite direction 
than the error in the slope. Watson (2000) published a letter pointing out some o f the 
limitations in the De Sadeleer et al (2000b) paper.
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In this chapter the aim is to look at as many sources o f error that affect estimations of 
GFR as possible, and where possible to use realistic estimates o f those errors. To 
investigate the effect o f the errors on ‘slope only’ and ‘slope-intercept’ estimates of 
GFR and also in a single sample GFR technique and in the estimation o f Distribution 
Volume (DV).
In addition the aims are:
• To identify which sources o f error are most crucial in the different methods
• To assess which of the methods gives the lowest uncertainty
• Identify best ways to try to reduce the uncertainty
• Investigate the effect o f such reductions
3.2 METHODS
3.2.1 Uncertainties in the input parameters
For each of the parameters that feed into the calculations of the measures o f GFR and 
Distribution Volume (DV) a standard deviation was chosen to represent the 
uncertainty o f that parameter.
Weight
The uncertainty in weight will depend on the accuracy, repeatability and precision of 
the scales used and on the variability in the weight o f clothing etc. worn by the 
patient at the time o f weighing. Note the clothes worn, excluding coats, usually 
weigh somewhere between 1 and 2 kg. Pocket contents, watches and jewellery can 
weigh a further 0.5 kg. Shoes can weigh up to a 1 kg, if  patients are always weighed 
with their shoes off this should not be an issue. To reflect the sources o f uncertainty 
the standard deviation in weight was chosen as 0.5 kg.
Height
The uncertainty in height will be dependent on the accuracy and repeatability to 
which a patients height can be measured and the precision with which this height is 
recorded. Note the effect of precision is that if  there are no other sources o f error 
recording a continuous variable, like height, to the nearest whole number, in this case 
centimetre, leads to a variability with a standard deviation of approximately 0.3 cm. 
This variability caused by the precision is not normally distributed, but the 
assumption is that when this combined with other sources o f error the resulting 
variability still approximates to being normally distributed. The standard deviation of 
the uncertainty in height was chosen as 1 cm.
Injection Volume
The uncertainty in the injection volume will depend on the variability in the amount 
drawn up into the injection syringe and on any variation in the proportion off this 
amount that is successfully administered into the lumen o f a vein. The second of 
these sources o f uncertainty will be mainly due to the effectiveness of the flushing 
technique used, but also if  any tracer is extravasated then that could be interpreted as 
an error in the administered volume. However, the effect would be more complicated 
if  the extravasated tracer gradual diffuses into the blood stream. Initially the standard 
deviation was chosen as 0.05 ml for the 2 ml injection. This reflects the current local 
practice which is to only use apparent volume in the 2 ml syringe to assess the 
injected volume.
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This is a source of error that could be improved on, if  weighing of syringes is used 
and very careful flushing used. Therefore it was investigated what the effect of 
reducing this error from 0.05 ml to 0.01 ml.
To standard volume
This is the volume o f the injection solution that is pipetted into a volumetric flask for 
dilution to make a standard. Locally this is always 0.1 ml pipetted with a fixed 0.1 ml 
pipette and the standard deviation to use was calculated from measured variability in 
the pipettes used. This variability was derived from the results o f 32 sets of quality 
control checks on these pipettes, performed over a 2 year period. The pipette checks 
consist o f 5 or 10 weighed pipettings o f water using a precision balance with a 
precision o f 0.0001 g. Reported for each pipette check, was the coefficient of 
variation, which gives a measure of the variability o f the 5 or 10 pipetting and the 
absolute error, which is the difference between the mean weight pipetted and 0.1 g. 
The mean coefficient o f variation was calculated to give an idea o f the average 
variability o f the pipettes at any one moment and this was combined with the 
standard deviation o f the absolute errors to give a measure of the overall error 
between any one pipetting and 0.1 ml.
The mean coefficient o f variation was 1.34 % and the standard deviation o f the 
absolute errors was 1.30 % giving an overall uncertainty o f 1.86% or 0.0019 ml. 
Standard Volume
This is the volume in which the standard is diluted, in a volumetric flask. The 100 ml 
flasks used state +/- 0.1 ml at 20°C, in addition there is variability caused by 
temperature variations and variability caused by the operators ability to fill to exactly 
the marked line. The standard deviation was chosen as 0.2 ml.
Counting statistics
Samples, standards and backgrounds are counted for 1500 seconds and for each 
sample and the background and standard the standard deviation was taken as the 
square root o f the counts as predicted by poisson statistics. There could be additional 
sources o f error from for example the repositioning o f the samples within the counter, 
but it was assumed that these were negligible. Also investigated was the effect of 
simulating increasing the counting time thus reducing the counting statistics.
Times
As previously if  times are recorded to the nearest minute this will lead to a variability 
with a standard deviation of around 0.3 minutes. Combined to this are additional 
sources o f error. One is due to the fact that the injection and the blood sampling can 
take a finite length o f time, particular when taking the sample is difficult. Another 
source o f error could be how accurately an analogue clock can be read. Another 
source of error which could potentially be large is the difference in time between 
different clocks or watches if  the same time piece is not used for recording all the 
times. A further source o f is in the operator recoding the time, for example in 
practice it is difficult to look at the clock while actually taking a blood sample and it 
then easy to forget to look at the clock while completing the procedure i.e. flushing 
the line with saline and transferring the sample from the syringe to sample tube. And 
then when it comes to writing the time on a recording sheet to estimate the number of 
minutes that have passed. Also times can be recorded in error. Overall the standard 
deviation o f the injection and sample times was taken as 1 min.
Sample and standard volumes
The samples and the standard are pipetted into counting tubes. The volume pipetted 
is 3 ml using a variable pipette (0.5 -  5 ml). As in the case o f the 0.1 ml pipette the 
variability in these volumes was calculated from 30 actual quality control checks
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performed on these pipettes over a 2 year period. In this case though as multiple 
samples are pipetted with the same pipette on the same occasion, the error fed into 
the Monte Carlo simulation is in two parts. The first being the offset which would be 
how far from 3 ml the mean volume pipetted by that pipette would be on that 
occasion, for each run o f the simulation this part o f the error is the same for the 3 
samples and 1 standard. The second is the variability about that offset which in each 
run has a different value for each sample and the standard. The offset was taken from 
the standard deviation of the absolute errors found at the checks, which was 1.03 % 
or 0.0309 ml and the variability was taken from the mean coefficient of variation 
from the checks which was 0.57 % or 0.0171 ml.
3.2.2 Dataset Groups
Group A
Real patient data was used to feed in to the Monte Carlo model. The first sets of 
simulations were performed on Group A, 6 patient studies who had Cr-51 EDTA 
GFR studies that were chosen to give a spread of renal function, having GFRs of 19, 
41, 53, 72,102 and 129 ml/min/1.73m2 respectively. In this group as well as looking 
at the overall uncertainty with all the sources of uncertainty applied, each of the 
sources o f uncertainty were applied one at a time to assess the contribution of each to 
the overall uncertainty.
Group B
Group B was a random group o f 20 consecutive patients having Cr-51 EDTA GFR 
studies.
3.2.3 Manipulations in the uncertainties in the input parameters
Reducing uncertainty in the injected volume
With both groups o f data the effect of reducing the uncertainty in injected volumes 
from 0.05 ml (2.5%) to 0.01 ml (0.5%) was investigated.
Reducing the uncertainty due to counting statistics
With group A the effect o f simulating increasing the counting time from 1500 to 
15,000 seconds was investigated. With group B the effect o f simulating increasing 
the counting time from 1500 to 10,000 seconds was investigated.
3.2.4 Measures
nGFRRM
This is the ‘slope-intercept’ measure o f GFR normalised to surface area and 
corrected for the one pool assumption using the Brochner-Mortensen (1972) 
correction. 
nGFRss
This is the Chistensen and Groth (1986) single sample technique which was 
proposed as the suggested technique for use in adults expected to have GFRs > 30  
ml/min/1.73m2 by international radionuclides in nephrourolgy committee (Blaufox et 
al 1996).
GFR/ECVi
This is a measure o f GFR normalised to ECV that is entirely based on the terminal 
rate constant but corrected for the one pool assumption using the correction derived 
in chapter 2.
GFR/ECVi =  13680.(0.9462.a2’+23.11 .(012’)2) [ml/min/13.68 L]
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Note this is an estimate o f GFR divided by the distribution volume o f Cr-51 EDTA 
multiplied by the average normalised distribution volume of Cr-51 EDTA of 13680 
ml/1.73m2. Therefore GFR/ECVi is an estimate o f 13680.GFR/ECV not GFR/ECV. 
GFR/ECV?
This a measure o f GFR normalised to ECV that is based on the terminal rate but the 
correction for the one pool assumption contains terms in the intercept and surface 
area (SA) and therefore height and weight. This correction was also derived in 
chapter 2.
GFR/ECV2 = 13680.(0.9666.<x2’+ l. 155.(1.73/SA).(a2’)2/B’) [ml/min/13.68 L]
Once again this is really an estimate of 13680.GFR/ECV.
Distribution Volume
The measure o f the distribution volume (DV) is derived from the intercept o f the 
mono-exponential fit to the plasma concentrations corrected for the one pool 
assumption using a correction derived in chapter 2.
DV =(1/B’)*(1.0233-27.76*a2’-1055*(a2’)2 ) [L]
3.2.5 Monte Carlo simulations
The simulation program was designed so that errors in individual parameters could 
be turned on or off. For each example set of input parameters and each combination 
of errors applied, 10,000 simulations were run. For each o f the simulations 
randomised normalised errors were applied to the chosen parameters and all the 
measures o f GFR and DV were calculated. After the run o f 10,000 simulations the 
mean and standard deviation o f each o f the measures was reported.
3.3 RESULTS
3.3.1 Group A
Initial results from Group A, the 6 subjects chosen with a range o f renal function, are 
summarised in Table 3.1 
Height and Weight
There was no significant difference between the uncertainty caused by weight in 
nGFRsM and nGFRss. Also there was no significant difference between the 
uncertainty caused by height in nGFRBM and nGFRss. Both height and weight led to 
only a small uncertainty in GFR/ECV2 which was significantly less than that in 
nGFRBM and nGFRss- The uncertainty in the estimates o f GFR caused by an 
uncertainty in height o f 1 cm was for all measures significantly greater than that 
caused by an uncertainty in weight of 0.5 kg (PO.01).
‘Injection volume’, ‘volume to standard’ and ‘Standard volume’
The ‘Injection volume’, ‘volume to standard’ and ‘Standard volume’ all contribute to 
relating the concentrations measured in the samples to the amount o f tracer injected. 
Therefore the uncertainties in these measures contribute to the uncertainty in this 
relationship. There was no significant difference between the uncertainty caused by 
these measures in nGFRBM and nGFRss. These measures only led to small 
uncertainties in GFR/ECV2. Of these measures, uncertainty in injection volume of 
0.05 ml led to the greatest uncertainties in the final estimates of GFR and DV, being 
significantly greater than the uncertainties caused by an uncertainty in the volume to 
standard o f 0.0019 ml (p<0.01). The uncertainties caused by the uncertainty in the
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standard volume of 0.2 ml were small and contributed very little to the uncertainty of 
these three measures combined.
Counting Statistics
The uncertainty caused by counting statistics was significantly greater for 
GFR/ECVi and GFR/ECV2 than for nGFRBM and nGFRss (P<0.001). Although the 
uncertainty caused by counting statistics in GFR/ECVi and GFR/ECV2 were similar, 
the uncertainty in GFR/ECV2 was significantly lower (P<0.05).
Times
The uncertainty caused by the uncertainty in sample times of 1 min was significantly 
greater for GFR/ECVi and GFR/ECV2 than for nGFRBM and nGFRss (PO.Ol). 
Although the uncertainty caused by the uncertainty in times on GFR/ECVi and 
GFR/ECV2 were similar, the uncertainty in GFR/ECV2 was again significantly lower 
(P<0.05).
Sample Volumes
The uncertainty caused by the modelled uncertainty in sample volumes was 
significantly greater for GFR/ECV1 and GFR/ECV2 than for nGFRBM and nGFRss 
(PO.Ol). Although the uncertainty caused by the uncertainty in sample volumes on 
GFR/ECV1 and GFR/ECV2 were similar, the uncertainty in GFR/ECV2 was once 
again significantly lower (PO.Ol).
nGFRBM nGFRss GFR/ECVi GFR/ECV2 DVest
Weight 0.22 % 0.24 % - 0.02 %
Height 0.37 % 0.40 % - 0.03 %
Injection
volume
2.24 % 2.62 % - 0.21 % 2.50%
Volume to 
standard
1.66% 2.05 % - 0.15% 1.86%
Standard
volume
0.18% 0.21 % - 0.02 % 0.20 %
Counting
statistics
2.29 % 1.37% 4.65 % 4.38 % 3.07 %
Times 0.67 % 0.53 % 1.27% 1.18% 1.20%
Sample
volumes
1.79% 1.37% 2.43 % 2.29 % 1.88%
Overall 4.37 % 3.89 % 5.46 % 5.27 % 4.96 %
Table 3.1 Results from Group A (n=6) showing the effect on uncertainty from each source of 
uncertainty applied individually and the overall uncertainty with all the sources of uncertainty 
applied.
All uncertainties applied
The overall uncertainty when all the uncertainties are applied was significantly 
greater for GFR/ECVi and GFR/ECV2 than for nGFRBM and nGFRss (PO.05).
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There was no significant difference between nGFRBM and nGFRss- The overall 
uncertainties for GFR/ECVi and GFR/ECV2 are not very different in magnitude 
however the difference is significant.
3.3.2 M easures (Group A)
nGFRRM and nGFRss
The largest contributors to the overall uncertainty in nGFRBM and nGFRss were the 
injection volume, counting statistics, the volume to standard and the sample volumes.
GFR/ECV, and GFR/ECV?
The overall uncertainty in GFR/ECV 1 was dominated by the uncertainty caused by 
counting statistics which was significantly greater than the uncertainty caused by the 
sample times and the sample volumes (p<0.05). Although there are more small 
contributions to the uncertainty in GFR/ECV2 this is still dominated by the 
uncertainty caused by counting statistics.
3.3.3 Dependence of the magnitude of uncertainty on renal function
Figs 3.1 shows that the magnitude o f uncertainty for nGFRss with height and weight 
decreases with increasing renal function, whereas for GFR/ECV2 the uncertainty is 
much smaller but increases with renal function. The magnitude o f uncertainty for 
nGFRBM with Height and Weight decreases with increasing renal function but with 
much less variation than for nGFRss-
1.9 %
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Fig 3.1 Plot of the uncertainties caused by the uncertainty in height and weight combined 
plotted against nGFRBM for nGFRBM, nGFRss and GFR/ECV2 for Group A.
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Fig 3.2 Plot of the uncertainties caused by the uncertainties in ‘Injection volume’, ‘volume to 
standard’ and ‘Standard volume’ combined plotted against nGFRBM for nGFRBM, nGFRSs, 
GFR/ECV2 and DV for Group A
Fig 3.2 shows the magnitude o f uncertainty in the measures o f GFR and DV arising 
from the combination o f the uncertainties in ‘Injection volum e’, ‘volume to standard’ 
and ‘Standard volum e’ plotted against renal function. Again the uncertainty in 
nGFRss seems to decrease markedly with increasing renal function, the uncertainty 
in nGFRBM decreases only slightly with increasing renal function. The uncertainty in 
GFR/ECV2 again is small and increases with increasing renal function. The 
uncertainty in DVest seems remarkably constant with changing renal function. The 
variation in uncertainty with renal function follows a less clear cut pattern with the 
other sources o f uncertainty. Also there is on obvious pattern to how the overall 
uncertainty (with all the uncertainties applied) varies with renal function.
3.3.4 M anipulations in the uncertainties in the input param eters (G roup A)
nGFRBM nGFRss GFR/ECV, GFR/ECV2 DVest
Overall 4.37 % 3.89 % 5.46 %* 5.27 %* 4.96 %
-Inj vol 0.01 ml 
(change)
3.67 % 
(-0.69 %)
2.94 % 
(-0.96 %)
5.46 %* 
No change
5.27 %* 
No change
4.32 % 
(-0.64 %)
-Count 15000s 
(change)
3.62 % 
(-0.74 %)
3.62 % 
(-0.27 %)
3 .18%  
(-2.28 %)*
3.03 %* 
(-2.14% )*
3.99 % 
(-0.98 %)
-Both
(change)
2.86 % 
(-1.51 %)
2.61 % 
(-1.28% )
3 .20%  
(-2.26 %)*
3.03 % 
(-2.14% )*
3 . 17%
(-1.79% )
Table 3.2 Results from group A (n=6) showing the overall uncertainty before and after 
changes to two of the sources of uncertainty. The magnitude of the change in uncertainty is 
shown in brackets and * indicates a significant difference in uncertainty or change to those 
for nGFRBM (P<0.05)
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Decreasing the uncertainty in injected volume
Decreasing the uncertainty in injected volume from 0.05 ml to 0.01 ml makes the 
average overall uncertainty in nGFRBM decrease from 4.37 % to 3.67 %, there is a 
slightly greater, but not significantly different, decrease in the average overall 
uncertainty in nGFRss from 3.89 % to 2.94 %. The average overall uncertainty in 
DVest decreased from 4.96 % to 4.32 %. After this reduction there is still no 
significant difference in the overall uncertainty in nGFRBM and nGFRss and clearly 
there is still a significantly greater uncertainty in GFR/ECVi and GFR/ECV2 than 
nGFRBM as the uncertainties in GFR/ECVi and GFR/ECV2 are unaffected by the 
reduction. The results are summarised in table 3.2.
Increasing the counting time to 15.000 s per sample
Decreasing the uncertainty caused by counting statistics by simulating increasing the 
counting time per sample from 1500 sec to 15000 sec. Overall uncertainty in 
nGFRBM decreased from 4.37 % to 3.62 %. There was a smaller, but not significantly 
different, decrease in overall uncertainty in nGFRss from 3.89 % to 3.62 %.The 
decrease in overall uncertainty for GFR/ECVj and GFR/ECV2 was significantly 
greater than the decrease in overall uncertainty for nGFRBM, for GFR/ECVj it 
decreased from 5.46 % to 3.18 % and for GFR/ECV2 it decreased from 5.17 % to
3.03 %. After this reduction there is still no significant difference in the overall 
uncertainty in nGFRBM and nGFRss, the overall uncertainty in GFR/ECVi is now 
less than that for nGFRBM but not significantly different, the overall uncertainty in 
GFR/ECV2 is significantly less than that for nGFRBM (p<0.05). Also the overall 
uncertainty in GFR/ECV2 is still significantly less than that for GFR/ECVi.
Both decreasing the uncertainty in injection volume and increasing the counting time 
With both the decrease in injected volume uncertainty and the increase in sample 
counting time applied together, there was a significantly greater reduction in overall 
uncertainty for GFR/ECVi and GFR/ECV2 than nGFRBM (PO.01). Resulting in 
there being no significant difference between the overall uncertainty in any o f the 
measures o f GFR or DV (P>0.05).
3.3.5 Group B
Results from group B, the 20 sequential patients hopefully giving a representative 
mix of clinical patients are summarised in Table 3.3.
nGFRBM nGFRss GFR/ECVi GFR/ECV2 DVest
Overall (SD ) 3.36 (0.53) 
%
2.99 (1.19)
%*
3.50 (1.04)
%
3.17(1.13)
%
4.91 (0.53)
%*
Overall
Inj vol 0.01 ml
2.58 % 
{-0.79 %}
2.28 %* 
{-0.71 %}
3.50 %* 
no change
3.17%* 
no change
4.24 %* 
{-0.67%}*
Overall 
Count 10000s
3.19%
{-0.17%}
2.81 %* 
{-0.18%}
2.29 %* 
{-1.21 %}*
2.08 %* 
{-1.08%}*
4.17% * 
{-0.73 %}*
Both 2.36 % 
{-1.00%}
2.05 %* 
{-0.94 %}
2.29 % 
{-1.21 %}*
2.06 %* 
{-1.10%}
3.36 %* 
{-1.55%}*
Table 3.3 Results from group B (n=20) showing the mean overall uncertainty (with standard 
deviation in brackets). Also shown are the mean overall uncertainties after changes to two of 
the sources of uncertainty {The magnitude of the change in uncertainty is shown in curly 
brackets}. * indicates a significant difference in uncertainty or change to those for nGFRBM 
(P<0.05)
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In general the average overall uncertainties with the larger group o f patients were 
lower than those found with group A. Examining the results for group A in detail 
show that this is at least partly due to the one patient in this group, with the lowest 
renal function in whom is low . This leads to large uncertainties in the measures o f 
GFR (but not DV) which affect the mean uncertainties for the group.
Fig 3.3 shows the dependence o f the overall uncertainty on renal function for 
nGFRBM and nGFRss- From the correlation coefficients it is calculated that the 
dependence for both is significant (PO.OOl). However it can be seen that the 
variation with renal function is greater for the single sample technique -  w ith the 
uncertainty for this technique greater than nGFRBM at low GFRs but less at higher 
GFRs.
W ith group B the overall uncertainties for the GFR/ECV techniques are closer to that 
for nGFRBM than with group A. In fact the overall uncertainty for GFR/ECV 2 is 
slightly less than that for nGFRBM- However, there is for this group no significant 
difference between the overall uncertainty for GFR/ECVi and nGFRBM or 
GFR/ECV 2 and nGFRBM- The uncertainty for nGFRss is once again significantly 
lower than that for nGFRBM (P<0.05) and the uncertainty for GFR/ECV2 is 
significantly lower then that for GFR/ECVi (PO.OOl).
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Fig 3.3 The overall uncertainties in nGFRBM and nGFRss plotted against renal function along 
with linear fits to the data shown with equations and correlation coefficients (Group B)
It is possible to express the uncertainty in the measures o f GFR in absolute units 
rather than as percentages. When expressed in this way the dependence on renal 
function will appear different, this dependence is shown in fig 3.4. The average 
uncertainty (and standard deviation) for nGFRBM is 2.55 (0.62) ml/min/ 1.73m2, for 
nGFRss it is 2.23 (0.29) ml/min/1.73m2, for GFR7ECVi it is 2.81 (0.81)
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ml/min/13.68L and for GFR/ECV 2 it is 2.45 (0.59) ml/min/13.68L. Expressed in this 
way there is still a significant difference between nGFRss and nGFRBM (P O .O l) and 
between GFR/ECV 2 and GFR/ECVi (PO.OOl). Expressed in this absolute way the 
uncertainty for GFR/ECV 1 is now significantly greater than that for nGFRBM 
(P O .O l), however the uncertainty for GFR/ECV2 remains slightly less than that for 
nGFRBM but the difference is still not significant.
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Fig 3.4. The absolute overall uncertainties in the measures of GFR plotted against nGFRBM 
(GroupB)
3.3.6 M anipulations in the uncertainties in the input param eters (G roup B)
Decreasing the uncertainty in injected volume
Decreasing the uncertainty in injected volume from 0.05 ml to 0.01 ml leads to the 
average uncertainty in nGFRBM decreasing from 3.36 % to 2.58 %, there is a similar 
decrease in the average uncertainty in nGFRss from 2.99 % to 2.28 %. The average 
uncertainty in DVest decreased from 4.91 % to 4.24 %. After this change the overall 
uncertainty in nGFRss is still significantly less then that for nGFRBM (P O .O l). There 
is still a significantly greater uncertainty in GFR/ECV] and GFR/ECV2 than nG FRBM 
as expected because the uncertainties in GFR/ECV] and GFR/ECV2 are unaffected 
by the change.
Increasing the counting time to 10.000 s per sample
The uncertainty caused by counting statistics was decreased by simulating increasing 
the counting time per sample from 1500 sec to 10000 sec. With this change, the 
uncertainty in nGFRBM only decreased from 3.36 % to 3.19 % there was a similar 
small decrease in the uncertainty in nGFRss from 2.99 % to 2.81 %. The decrease in 
overall uncertainty for GFR/ECV] and GFR/ECV2 was much greater and 
significantly different compared to the decrease in overall uncertainty for nG FRBM; 
for GFR/ECVj it decreased from 3.50 % to 2.29 % and for GFR/ECV 2 it decreased 
from 3.17 % to 2.08 %. After this reduction the overall uncertainty in nGFRss is still
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significantly less than that for nGFRBM (P<0.05). The overall uncertainties in 
GFR/ECV i and GFR/ECV2 are now significantly less than that for nGFRBM 
(p<0.001). Also the overall uncertainty in GFR/ECV2 is still significantly less than 
that for GFR/ECV 1 (PO.OOl).
Both decreasing the uncertainty in injected volume and increasing the counting time 
With both the decrease in injected volume uncertainty and the increase in sample 
counting time applied together, there was a significantly greater reduction in overall 
uncertainty for GFR/ECVi and DV than nGFRBM (PO.Ol). After the change the 
overall uncertainty in nGFRss is still significantly less than that for nGFRBM (PO.O l) 
and the overall uncertainty in GFR/ECV2 is still significantly less than that for 
GFR/ECVi (PO.OOl). Also after the change the overall uncertainty in GFR/ECV2 
was now significantly less than that for nGFRBM (PO .O l) but there was no 
significant difference in the overall uncertainty for GFR/ECVi and nGFRBM (P>0.05).
3.3.7 ‘Blake’ correction
Using the original estimates of uncertainties in the input parameters the average 
overall uncertainty in normalised GFR calculated with the Blake et al (1993) 
correction for the one pool assumption was 3.37 % with a standard deviation o f 0.49 
%. This is almost identical to that for the normalised GFR calculated with the 
Brochner-Mortensen (1972) correction and so there is no difference between the 
uncertainty in the normalised GFR calculated with these two correction formulae.
3.4 DISCUSSION
One useful thing to come from the results o f Group A is to look at, for each measure 
o f GFR, which parameters contribute the most to the uncertainty. The first thing that 
is clear is that with the initial estimates of the uncertainties used here, the 
uncertainties in the measures of GFR/ECV are dominated by the uncertainty from the 
counting statistics. If  the simplified assumption is made that the different sources of 
uncertainty combine in quadrature, then for both GFR/ECVi and GFR/ECV2, 
counting statistics contribute about 75% of the overall squared uncertainty. It 
therefore follows that anything that could be done to improve the counting statistics 
would be expected to greatly improve the overall uncertainty for the measures of 
GFR/ECV. If  it were possible to reduce the uncertainty due to the counting statistics 
by a half, then the error due to sample volumes would then be equally as important as 
the counting statistics. The contribution of the uncertainty in times, with a standard 
deviation o f 1 min, is less important.
For the corrected normalised GFR measured from the slope and intercept (nGFRBM) 
and the normalised single sample method (nGFRss) there seem to be four key 
parameters contributing to the uncertainty; injection volume; the volume to standard; 
counting statistics and the sample volumes. A reduction in the uncertainty o f any o f 
these parameters could be expected to lead to a small reduction in the overall 
uncertainty. Once again the uncertainty in times when assumed to have a standard 
deviation o f 1 minute seems to only make a relatively small contribution to the 
overall uncertainty. The uncertainty in making the standard up to 100 ml would 
appear to be so small as to make no real contribution to the overall uncertainty. The 
contribution to the overall uncertainty from the uncertainties in height and weight are
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also very small. It is worth remembering that the overall uncertainties estimated by 
the methods in this chapter really only reflect the amount o f variability found if  the 
same test was repeated twice on the same patient. They therefore do not reflect the 
uncertainty in predicting the true measure. For example assuming that for the 
purpose o f normalisation we are trying to predict the true surface area of the patient. 
The combination of the uncertainties in height and weight only show how variable 
this prediction would be, and not the presumably much larger uncertainty in the 
prediction o f the true value of surface area.
It was also investigated whether the form of the correction for the one pool 
assumption for slope intercept G F R  affected the uncertainty. In particular comparing 
the Blake (1993) correction which has the form nGFRcorr= n G F R Si / ( l +0.0025.n G F R Si) 
with the Brochner Mortensen (1972) correction and no difference was found.
One criticism of using the terminal rate constant to give a normalised measure of 
GFR is that there may be more variability in the result than with the more 
conventional slope intercept approach (Piepz & Ham 1997, De Sadeleer et al 2000b). 
It is argued that this is because with the slope intercept approach, errors in the slope 
are at least sometimes partially compensated for by the resulting error in the intercept. 
From the results for group A it can be seen that the uncertainties in counting statistics, 
times and sample volumes do have a significantly greater effect on GFR/ECV i and 
GFR/ECV2 than on nGFRsM- With Group A the 6 datasets chosen to give a even 
spread o f renal function and the initial estimates of the uncertainties in the 
parameters it would appear that the overall uncertainties in GFR/ECV 1 and 
GFR/ECV2 were significantly greater than for nGFRBM- However with the larger 
Group B o f 20 hopefully representative datasets there was no significant difference 
between the overall uncertainty in nGFRBM and that for GFR/ECV 1 or GFR/ECV2. 
The reason for this discrepancy between Group A and Group B can probably be 
explained at least in part by looking at the dependence o f the overall uncertainties on 
renal function for example represented in fig 3.5. From this figure it can be seen that 
at low renal function the tendency is for the uncertainty in GFR/ECV2 to be higher 
than that for nGFRBM whereas at higher renal function the tendency is for the 
situation to be reversed. Therefore the mix of patients in the data sample will affect 
comparisons between the two methods. Group B is intended to be representative of 
the clinical workload in the local department, in which the proportion of patients 
with low GFRs is fairly small, partly due to the high proportion of studies performed 
on oncology patients for pre or post chemotherapy assessment of renal function. 
Therefore the conclusion from Group B that there is no significant difference 
between the uncertainty in nGFRBM and GFR/ECV 1 or GFR/ECV2 is probably valid 
for the clinical mix o f patients in the local department with the current protocol.
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A surprising finding is that with Group B there was significantly less uncertainty 
with the single sample method (nGFRss) than in the slope intercept method (nGFRBM) 
although the actual difference is small 2.99 % for nGFRss compared with 3.36 % for 
nGFRBM. De Sadeleer’s (2000a) data had shown that, when using a slope-intercept 
method, increasing the number o f samples reduces the uncertainty. However, the 
finding here is that a technique that only relies on the concentration o f one sample 
can have a lower uncertainty than a technique that uses that concentration o f 3 
samples. It should be pointed out here that the amount o f uncertainty in a measure is 
only one o f the issues when comparing methods. nGFRBM could, and probably is, a 
closer representation o f the true GFR o f the patient than nGFRss even though 
nGFRss has less uncertainty. A fundamental part o f the Christensen and Groth (1986) 
single sample technique is the assumption that the distribution volume o f the tracer 
can be estimated reasonably accurately from the height and weight o f the patient. If 
for a particular patient the true distribution volume o f the tracer is very different to 
this estimate, then the GFR calculated by the single sample technique will be 
significantly different to the true GFR.
From the results from Group B the overall uncertainty in the distribution volume is 
significantly greater than that for any o f the measures o f GFR. It is interesting that 
that the uncertainty in the distribution volume that is based on the intercept is 
significantly greater than the uncertainty in the measures o f GFR/ECV which are 
based on the slope. This is probably because an error in the slope can be amplified 
when extrapolating back to get the intercept.
With a change in experimental technique it should be possible to reduce the 
uncertainty in injection volume. Using weighing o f the injection syringes should
♦ nGFRbm  
G FR/ECV2
 ♦ ±_
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achieve a significant reduction. There are two methods of doing this, one is to weigh 
the syringes empty and again after drawing up the tracer and then to ensure that all 
the contents o f the syringe are injected. This is best achieved by using a three-way 
tap and flushing the injection syringe out with saline at least twice. The second 
method is to weigh the syringe full, then when injecting just depress the plunger once, 
then disconnect the injection syringe and replace it with the saline syringe and flush 
through the same port and line thoroughly. Then weigh the injection syringe with any 
residual remaining. There may be advantages with first method, as with the second 
method there must be a chance of losing a drop of tracer when swapping the syringes. 
Simulating decreasing the uncertainty in the injection volume from 0.05 ml to 0.01 
ml showed roughly a 2 0  % reduction in the overall uncertainty for nGFRBM and a 
25% reduction for nGFRss and a 13 % reduction for DV. After this reduction the 
overall uncertainty in nGFRBM is now significantly less than that for GFR/ECVi or 
GFR/ECV2. Therefore the results here are consistent with ‘slope intercept’ technique 
being superior to the ‘slope only’ technique with respect to uncertainty, as long as a 
good method is used to assess the injected volume.
One might hope though that it would be possible to improve the counting statistics 
because theoretically o f course this can be achieved simply by counting each sample 
for longer. If one could count for four times as long then the uncertainty due to 
counting statistics might be expected to roughly half. Although in practice increasing 
the counting time may be problematic. For example the local department does an 
average o f about 6  GFRs per day counting 3 samples, a background and a standard 
for each o f these, for 1500s which amounts to a total o f 12.5 hours o f counting.
When combined with counting done for other less frequently performed in vitro tests, 
the counting takes roughly the whole of the time between 4 pm and 8 am the next 
morning, which in practice works well but leaves little scope for increasing the 
counting time. It has been argued (Fleming et al 2004) that the best use o f the 
counting time would be to try and count all samples to the same count rather than a 
fixed time with 10,000 as a suggested count. With this approach there is scope, 
within the overall time constraints, to significantly improve the counting statistics for 
samples with the least counts. However, the samples with the least counts are the 
later samples in adult patients with good renal function whereas in fact it is patients 
with poor renal function that have the greatest uncertainty in say GFR/ECV2 at least 
when expressed as a percentage. If it is not possible to simply increase the counting 
time per sample there are other potential scenarios in which the counting statistics 
could be significantly better.
•  One is that it is possible to purchase gamma counters with multiple detectors 
that can count for example 10 samples simultaneously. Therefore it would be 
possible to increase the counting time by ten times within the same overall 
time.
•  It would be possible to use slightly larger plasma samples but it is unlikely 
that this would be significantly helpful.
• It is theoretically possible to increase the activity used. For Cr-51 EDTA the 
effective dose to the patient is very low 0.004 mSv from 2 MBq (ARSAC 
2006). Therefore if the activity were increased 10 fold to 20 MBq then the 
effective dose would still only be 0.04 mSv which is still low. For 
comparison the effective dose received from a cardiac blood pool assessment 
of left ventricular ejection fraction is 6  mSv (from 800 MBq Tc-99m labelled 
erythrocytes) and this is a test which is sometimes used in similar 
circumstances i.e. the assessment o f cardiac function before or after treatment
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with potentially cardiotoxic chemotherapy. However the ARSAC 
(Administration o f Radioactive Substances Advisory Committee) guidelines 
state a diagnostic reference level of 3 MBq for Cr-51 EDTA for assessment 
o f GFR. This does mean that within the ARSAC limit it is possible to 
increase the activity used locally if only by 50%, however the down side of 
this is that this would mean a 50% increase in cost and has been resisted!
• If  Tc-99m DTPA was used instead o f Cr-51 EDTA then the number o f counts 
could be considerably higher. Because only 10% of Cr-51 decays leads to the 
production o f the 320 keV gamma rays, counting the same activity o f Tc-99m 
can give almost 10 times as many counts. The difference is even greater 
because the detector in the counter is more efficient for detecting 140 keV 
gamma rays than 320 keV gamma rays. Also when using Tc-99m DTPA it is 
possible to use greater activity, the ARSAC diagnostic reference level for 
assessing GFR is 10 MBq and cost is not normally an issue. However, decay 
obviously is an issue. But if  10 MBq of Tc-99m DTPA were used instead o f 2 
MBq o f Cr-51 EDTA then if  the counting for the same time per sample were 
performed within 16 hours of administration then there would still be 10  
times as many counts. When using Tc-99m one o f the problems to overcome 
is that if  there is any delay in counting, say due to the counter failing while 
counting on a Friday night, it is possible to completely fail to get a result. 
Another disadvantage of using 10 MBq Tc-99m instead o f say 3 MBq Cr-51 
EDTA is that the effective dose to the patient is 0.06 mSv instead of 0.006 
mSv i.e more than 10 times the dose. So on dose grounds it would be 
preferable to persuade ARSAC to allow use o f 20 or 30 MBq of Cr-51 EDTA 
instead, unfortunately however the cost implication of doing this would be 
considerable.
•  When using other non-radioactive tracers for measuring GFR, for example 
Iohexol, it is possible that the assay for measuring the plasma concentration 
o f that tracer would have less uncertainty than that caused by the counting 
statistics for Cr-51 EDTA. Although clearly it is also possible that the assay 
for measuring the plasma concentration o f such a tracer could give a greater 
uncertainty.
The results here show that if  it were possible to considerably improve counting 
statistics, then the ‘slope only’ measures o f GFR could have a significantly smaller 
uncertainty than a ‘slope intercept’ measure. One conclusion of this is that increased 
uncertainty could not universally applied as an argument against ‘slope only’ GFR.
Another way in which the results of this chapter could be used would be to use the 
uncertainty estimated here to put an uncertainty on a routine clinical report. The 
simplest assumption would be to assume a fixed percentage uncertainty regardless o f 
renal function, i.e . for nGFRsM from the best estimate of the current sources of 
uncertainty create a 95 % confidence interval of 1.96 * 3.36 % = 6 .6 %. So for 
example 90 ml/min/1.73m2 would be reported as 90 (+/- 6 ) ml/min/1.73m2 and 30 
ml/min/1.73m2 would be 30 (+/- 2) ml/min/1.73m2. A slightly more complex 
approach would be to use a linear fit to the variation in absolute uncertainty with 
renal function as shown in fig 3.6
For nGFRsM then the 95% confidence interval will be 0.048 * nGFReM + 1.24, so 90 
ml/min/1.73m2 would be reported as 90 (+/- 6 ) ml/min/1.73m2 and 30 ml/min/1.73m2 
would be 30 (+/- 3) ml/min/1.73m2.
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Fig 3.6 The absolute uncertainty in nGFRBM and GFR/ECV2 plotted against nGFRBM for 
Group B shown with a linear fits with equations
It would also be possible to incorporate the Monte-Carlo code into the calculation o f 
routine GFRs and then run the simulation for each individual and use the uncertainty 
obtained to create a 95 % confidence.
One thing to consider with all these approaches is that the uncertainty reported does 
not depend on the goodness o f fit to the mono exponential. An alternative approach 
with three samples would be to include this, such that if  the fit is poor the 95 % 
confidence interval is greater.
Summary
• With the current local procedures there is no significant difference in 
uncertainty between GFR/ECV derived from the rate constant and nGFR 
derived from the rate constant and intercept
• However when using a recommended (Fleming et al 2004) improved method 
o f assessing the injected quantity o f tracer, then there is a significant greater 
uncertainty in GFR/ECV derived from the rate constant. This is for the 
particular case o f using 2 MBq o f C r-51 EDTA. This finding agrees with the 
findings o f De Sadeleer et al (2000b).
• The uncertainty in GFR/ECV derived from the rate constant is dominated by 
the uncertainty due to counting statistics. In applications where the error due 
to counting statistics may be substantially reduced, the uncertainty in 
GFR/ECV derived from the rate constant may well be significantly less than 
that for nGFR derived from the rate constant and the intercept.
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Chapter 4: Normalisation of Measurements of Glomerular Filtration Rate
4.1 INTRODUCTION
One of the main functions o f the kidneys is to clear the body o f the waste end 
products o f metabolism. The magnitude of GFR that a subject requires will depend in 
some way on their body size, with a larger subject needing a greater GFR than a 
smaller subject on the assumption that there is greater metabolism. The magnitude of 
GFR required may also depend on the amount and type of food and drink that a 
subject tends to eat and the amount o f exercise that they take, but these are harder to 
quantify. Having measured an estimate of a subject’s GFR, it must be established if 
this lies within the normal range. This question can be answered by comparing their 
GFR with normal for that size of subject.
One approach is, having chosen an appropriate measure o f body size for example 
weight, to generate either a look up table of normal values for subjects o f different 
weights or a formula that converts the subject’s weight into an .expected GFR. The 
formula method has the advantage that it is fairly easy to incorporate other factors 
such as age and maybe sex. The other approach is to make the assumption that 
normal GFR varies as a simple linear function o f the chosen body size measure, and 
express the measured GFR for example in ml/min/kg. This has the advantage that 
this ‘normalised’ GFR is compared against a normal range that is then independent 
of body size and can possibly be remembered. However if  it is decided that the 
normal GFR varies with other factors such as age and sex then a single normal range 
cannot be used and this approach loses some of this advantage. An advantage though 
is that threshold values can be set at different levels o f renal function. For example, it 
could be advised not to give a particular drug to a patient if  their GFR is less than 1 
ml/min/kg. In veterinary medicine this method o f expressing GFR is used as it can be 
applied to animals of different sizes, breeds and species (Gleadhill et al 2000). A 
slight modification o f this approach, often used in humans, is instead o f expressing 
the GFR as ml/min/kg, for the example o f weight, to use ml/min/75 kg, if  75 kg is 
the average adult weight in the population used to generate the normal range. This 
means that for a patient o f close to average weight their normalised GFR will be of a 
similar magnitude to their non-normalised GFR. However, having non-normalised 
and normalised GFR of similar magnitude can sometimes lead to confusion. The 
most commonly accepted practice is to normalise GFR to the subject’s surface area 
(Fleming et al 2004, Blaufoux et al 1996) and to express GFR in ml/min/1.73 m2 
where 1.73 m2 is supposedly an average adult surface area. Although o f course it is 
not possible to measure the surface area easily and really what is used for 
normalisation is an estimate of surface area that is a mathematical function o f the 
subject’s height and weight. Surface area was considered a suitable parameter to 
normalise renal function to because studies had shown that kidney weight and basal 
metabolic rate were proportional to surface area for all persons young and old, large 
and small (McCance and Widdowson 1952). If surface area is a better parameter to 
normalise GFR to than weight, it is likely that one o f the reasons is that children who 
have a higher surface area to weight ratio than adults need a GFR that is more in 
proportion to their surface area than their weight. It could also be that in adults if  one 
considers two subjects o f the same weight, one a very tall normal build patient and 
the other short and fat, that the tall subject needs a greater GFR and they will have 
the greater surface area.
Other whole body parameters have been investigated or suggested as being more 
appropriate for normalising GFR: Weight (Peters et al 1994, Gleadhill et al 2000),
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lean body mass (Boer 1984), total body water (McCance and Widdowson 1952) and 
particularly extracellular fluid volume (Brochner-Mortensen 1980, White and 
Strydom 1991, Peters 1992, Gunasekera 1996). The following quote from Friis- 
Hansen 1961 gives a good summary o f the issues:
“Several bodily functions such as kidney function and basal metabolism, have 
often been expressed as a function of body surface area, and a fairly good 
basis for comparison has been found. But when one looks upon this figure 
one wonders if  such a relationship is not just coincidence. If, for instance, 
kidney function is a function o f the extracellular fluid volume, then the 
relationship between kidney function and surface area is only secondary. At 
least one should not look upon surface area as an important functional entity 
o f the body and one should be careful not to draw any far reaching 
conclusions.”
McCance and Widdowson (1952) investigated the fact that very young healthy 
infants have sometimes been shown to have reduced renal function when compared 
to adults, when the GFR is normalised to surface area. They discuss whether this is 
because their kidneys are underdeveloped for their size or whether in fact they have 
good renal function, but there is a breakdown in the use o f surface area as the 
normalisation parameter. This is why they suggest total body water as an alterative, 
showing that using this as a normalisation parameter gives normal renal function in 
these very young infants.
The focus o f this work is investigating the use o f the terminal rate constant o f the 
clearance o f a GFR tracer as a measure o f GFR already normalised to extracellular 
fluid volume. Therefore it would be interesting to be able to investigate how using 
extracellular fluid as a normalisation parameter compares with using surface area or 
other whole body parameters. Use of extracellular fluid volume does have the 
physiological basis that it is the concentrations o f substances within this volume that 
the kidneys are regulating or clearing and there is considerable support for this 
approach (Brochner-Mortensen 1980, White and Strydom 1991, Peters 1992, 
Gunasekera 1996).
If one measured GFR in a series of subjects assumed to have normal renal function 
and then normalised the GFR to a number o f alternative parameters, one could make 
the assumption that the best parameter to use for normalising GFR would produce 
the tightest range o f normalised GFRs, and use this as way to critically assess 
different methods o f normalisation. An ideal method o f normalisation would also 
cope with situations such as fluid imbalance i.e. a patient with fluid collections but 
normal filtration function should have a normal normalised GFR.
The first part o f the work presented in this chapter is a pilot study designed to 
establish the feasibility o f measuring GFR in normal volunteers simultaneously with 
measuring a number o f whole body parameters, with the eventual aim to statistically 
assess which o f these parameters is most suitable for normalising GFR. One 
limitation o f the study is that there may be significant differences in the measurement 
errors for the different parameters. The tightness o f the normal ranges will be 
dependent on measurement error as well as the inherent suitability of the parameter.
A further limitation is that it is subjects o f extreme dimensions, for example severely 
obese, that are the biggest challenge to a normalisation parameter and such subjects 
are not represented here. And also because this study is limited to looking at adult
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volunteers and it is not able to answer the important question o f which method of 
normalisation is likely to be best when comparing children with adult normal ranges.
The whole body parameters chosen for the pilot study were:
• Weight
•  ‘Surface Area’ estimated from the height and weight o f the subject using 
either the DuBois formula (Du Bois and Du Bois 1916) or the Haycock 
formula (Haycock et al 1978). Blake and Grewal (2005) have recently 
compared these two formula and were unable to show that one was 
preferable. They do highlight that the difference between using the two 
formula is small for most o f the population but at the extremes o f patient 
sizes can reach 10  %.
•  Distribution volume o f the tracer used for measuring GFR (Tc-99m DTPA or 
Cr-51 EDTA) which is an estimate o f extra cellular fluid volume.
• Distribution volume of Bromide using Br-77 bromide this is also an estimate 
o f extra cellular fluid volume but measured independently o f the GFR tracer.
•  Exchangeable potassium measured with K-43 potassium chloride. 
Exchangeable potassium measured at 24 hours is slightly less than total body 
potassium because equilibrium with potassium in red cells and maybe the 
brain is not fully reached at this point (Veall and Vetter 1958, Peters and 
Myers 1998).
• Total body water measured from the distribution volume o f tritiated water.
• Fat Free Mass measured with Dual Energy X-ray Absorptiometry (DXA)
The inclusion o f the distribution volume of Br-77 bromide was to assess how this 
independent assessment o f extracellular fluid volume performs because the 
distribution volume o f the GFR tracer is clearly not independent o f the measurement 
o f GFR. Total body water is considered a candidate for normalisation of GFR 
because for substances that are distributed in the body both extracellularly and 
intracellularly, for example urea, it could be argued that the kidneys are regulating 
the concentration o f such substances within this volume or clearing this volume of 
the substances (McCance and Widdowson 1952). Interestingly total body water and 
fat free mass would be expected to perform very similarly because in many body 
composition studies an assumption is made that the hydration o f the fat free mass is 
constant (at 73%). Exchangeable potassium is included because it is a parameter that 
should reflect cell mass or intracellular fluid volume and as such an interesting 
addition to looking at parameters that reflect extracellular fluid volume and total 
fluid volume. Exchangeable potassium should be an index o f the cell mass or 
intracellular fluid volume because almost all potassium in the body is intracellular 
and the concentration is closely maintained (Peters and Myers 1998). Skrabal et al 
(1970,1972 and 1973) had previously used some o f the isotopes used in here 
simultaneously namely Br-77, K-43 and tritium but not Tc-99m.
4.2 METHODS
Local ethics and ARSAC approval was obtained. Two groups of normal volunteers 
were studied. Group A having all the whole body parameters measured with multiple 
isotopes in conjunction with a multi-sample GFR with Tc-99m DTPA. Tc-99m 
DTPA was chosen as the tracer for measuring GFR because the long half life and
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higher energy of Cr-51 make Cr-51 EDTA unsuitable for use with the combination 
o f other isotopes. Group B just had a multi-sample GFR with Cr-51 EDTA.
4.2.1 Administered activities and dosimetry for Group A
The plan for Group A was to administer four different radioisotopes. As samples 
would have to be counted with several radioisotopes present, the ratio o f activities 
used would be important. It was also important, particularly as the subjects were 
normal volunteers, to keep the radiation dose as low as reasonably practical and in 
this case the aim was also to keep the total dose below 1 mSv, to be in the category 
of minor risk as defined by ICRP 62. The blood samples to be analysed for Tc-99m 
would also contain H-3 and Br-77. The H-3, being a very soft beta emitter shouldn’t 
affect the gamma counting. However from the Br-77 there is significant downscatter 
into the Tc-99m window and therefore it would be preferable to have more activity 
o f Tc-99m than Br-77. Also because of the relatively short half life o f Tc-99m 
compared to Br-77 the longer the wait before counting the samples the lower the 
ratio o f Tc-99m to Br-77. The samples counted for K-43 will also contain all the 
other isotopes, the main problem is separating the multiple peaks o f K-43 from those 
of the Br-77. Also the Br-77 has a longer half life than the K-43 57 hours compared 
with 22.3 hours, and as the samples to be analysed for K-43 are taken 24 hours after 
administration more than one half life o f K-43 would have elapsed before counting 
can commence. These factors favour administering significantly more K-43 than Br- 
77. From previous work performed with Br-77 bromide (Cousins et al 2002) it was 
concluded that 1 MBq of Br-77 would be a suitable minimum activity to use. 
However as K-43 gives the highest radiation dose to the patient it was decided that 
the maximum activity o f K-43 that could be used was 3 MBq. The samples to be 
counted for H-3 would also contain Tc-99m and Br-77, the Br-77 has significant P' 
and p+ emissions and would be expected to cause significant interference to the 
tritium counting. However it is possible to keep the samples for tritium counting 
many weeks until the Br-77 has decayed sufficiently to no longer be a problem.
The final activities chosen and the effective dose they deliver were:
• Tc-99m DTPA 15 MBq 0.1 mSv
• Br-77 Bromide 1 MBq 0.08 mSv
• K-43 3 MBq 0.54 mSv
• H-3 4 MBq 0.06 mSv
So the total effective dose from the radioisotopes was 0.78 mSv and the effective 
dose from the DXA was 0.001 mSv not adding significantly to this total.
4.2.2 Subject protocol for Group A
Six volunteers subjects were recruited with no history o f renal disease. There were 3 
males and 3 females and the age range was 27-56 (median 43). Subjects were asked 
to avoid high potassium foods for 4 hours prior to the start o f the study. The Br-77 
sodium bromide solution was produced by the Hammersmith Cyclotron Unit and was 
suitable for intravenous administration, this and the Tc-99m DTPA (Amersham) 
were to be administered intravenously. The K-43 potassium chloride solution was 
also produced by the Hammersmith Cyclotron Unit but however was not cleared for 
intravenous administration, Veall and Vetter (1958) suggest that it is possible to 
measure exchangeable potassium with either intravenous or orally administered 
potassium and so the K-43 was to be given orally. Because tritiated water is highly 
diffusible within the body it is also possible to measure total body water with either 
intravenously or orally administered labelled water. As the same stock solution o f 
tritiated water (Amersham Life Sciences) was to be used for all the volunteers it also
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decided it was preferable to administer the tritium orally as well. The Tc-99m DTPA 
(Amersham Health) solution was diluted with sterile normal saline to approximately
7.5 MBq/ml and 2 ml was drawn up into a pre-weighed syringe which was then 
reweighed, the activity was also assayed in a dose calibrator. The Br-77 sodium 
bromide solution was delivered in a concentration of between 0.44 and 0.80 MBq/ml. 
The calculated volume required to give an activity of 1 MBq was drawn up into 
another pre-weighed syringe which was then reweighed and the activity was assayed 
in a dose calibrator. The tritiated water stock solution was diluted to 4 Mq/ml and 1 
ml was pipetted into a pre-weighed universal pot which was then reweighed. The 
potassium-43 potassium chloride was delivered in a concentration between 0.48 and 
2.67 MBq/ml and the volume required to give 3 MBq was calculated and drawn up 
into a pre-weighed syringe which was then reweighed. The activity was also assayed 
in a dose calibrator. In the first two subjects there was less than 3 MBq supplied and 
these were given 1.5 and 2.5 MBq. At the beginning o f the study, a line was inserted 
into a vein in one arm for blood sampling, a second line was inserted into the 
opposite arm for administering the bromide and DTPA. The DTPA was administered 
and flushed in with saline using a three way tap to thoroughly flush out the injection 
syringe and the time noted. Immediately after the Bromide was administered and 
flushed in with saline in the same way and then the line used for these 
administrations was removed. Then the trititiated water was administered orally and 
the container rinsed with water that was also drunk by the subject to ensure all the 
weighed amount was given and the time was noted. The syringes used for 
administering the Tc-99m DTPA and the Br-77 bromide were assayed in the dose 
calibrator to assess any residual activity remaining which was corrected for. The line 
used for these two administrations was also assayed in the dose calibrator, on both 
Tc-99m and Br-77 settings, to check that no significant activity remained. 10 ml 
blood samples were taken from the remaining line at approximately 20, 30, 40, 60, 
120,180 and 240 minutes after the initial administrations. Before each blood sample 
was taken, 3 ml o f blood was removed from the line and discarded to ensure that the 
samples were representative o f circulating blood at the sample time. After taking 
each sample the line was flushed with normal saline. At the 2 and 3 hour time points 
extra samples were taken for beta counting o f the tritium, to facilitate the 
measurement o f total body water water with the tritium subjects were asked not to 
drink till after the 3 hour sample. After the 240 minute sample the remaining line was 
removed and the K-43 was administered orally in the same way as the tritium and the 
time noted. The empty container was assayed in the dose calibrator to assess any 
residual activity. The subjects were then asked to collect all their urine for the next 
24 hours and on return at approximately 28 hours after the initial administrations (but 
24 hours after the K-43 administration) a further blood sample was taken for gamma 
counting and a sample to be sent for cold potassium concentration measurement and 
a spot urine was taken and a sample from that sent for cold potassium concentration 
measurement.
4.2.3 DTPA and Brom ide analysis in the early blood samples
The 20 to 240 minute blood samples were spun down and 3 ml o f the plasma 
pipetted into counting tubes. Standards were prepared for both the DTPA and the 
bromide by pipetting 0.1  ml o f the solutions administered to the subjects into 
volumetric flasks and making up the volumes. In the case o f DTPA a 250 ml flask 
was used and in the case o f the bromide a 100 ml flask was used. 3 mis o f these 
diluted standards were pipetted into counting tubes as was 3 ml o f water for a
background. The 3 ml plasma samples, standards and background were then counted 
for 1000s in the W allac W izard (Turku -  Finland) automatic gamma counter using a 
dual window where the windows had been chosen to limit crosstalk.
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Fig 4.1 : Example spectra from a Tc-99m and a Br-77 standard showing chosen energy 
windows. Energy scale is approximately 1 keV per channel.
Fig 4.1 shows example spectra from pure Tc-99m and Br-77 standards and the 
windows used which were 117 -  159 keV for Tc-99m and 190 — 620 keV for Br-77. 
Counts were first corrected for the deadtime o f the counter. The counts in each 
window were then corrected for background by subtracting the counts obtained in 
that window with the water background. Then the cross talk correction was 
performed.
Details o f the cross talk correction:
CB is the deadtime and background corrected counts in the Br-77 window 
C T is the deadtime and background corrected counts in the Tc-99m window 
The cross talk factor from Br-77 into the Tc-99m window is calculated from the 
counts in the two windows when measuring the pure Br-77 standard.
X bt -  CT / Cb from the pure Br-77 standard.
There is some cross talk from the Tc-99m window into the Br-77 that is dependent 
on the Tc-99m count rate (see results). Therefore this crosstalk factor X Tb was 
calculated for each individual sample from the Tc-99m count rate. This cross talk 
factor is small but because the magnitude o f the Tc-99m counts is significantly 
greater than the Br-77 counts it can still make a significant difference and is worth 
applying.
The corrected ‘true’ counts are then 
T r — ( C j  — X b t-C b ) /(1 -X b t-X tb )
T b -  (C b  -  X b t .C t) / ( 1 - X Bt-X tb )
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Then the cross talk corrected counts are corrected for decay during the counting.
Then the counts in the plasma samples are expressed as the proportion of the 
appropriate standard counts. The concentration in the standards is calculated from the 
known administered weight, corrected for any residual activity remaining in the 
syringe, and the volumetric dilution factor assuming that the density o f the 
administered solution was 1 g/ml and expressed as the percentage o f the injected 
activity per litre, e.g. if  2.02 g of Tc-99m DTPA was administered to the subject, 
then the concentration o f the standard is 0.1/2.02/250x1000 = 19.8 %/L. Finally the 
concentrations in the plasma samples are expressed as percentages o f the injected 
activity per litre by multiplying by the calculated concentration o f the standard.
4.2.4 Subject protocol for Group B
Group B consists of the 20 normal volunteers recruited to the study involving 
administration o f Iohexol and Cr-51 EDTA in fasting and non-fasting conditions.
The full protocol is in chapter 5. For each volunteer the data looked at here was the 
Cr-51 ETDA clearance data from their first fasting study.
4.2.5 Calculation of measures of GFR and ECV from the DTPA or EDTA 
clearance data.
GFRrm
Using only the plasma concentration o f DTPA or EDTA in the samples from 120 
minutes onwards a single exponential fit to the plot o f concentration against time was 
performed. The GFR is then calculated from the slope (<12 [min'1]) and intercept (B5 
[%/L]) of the fitted single exponential with GFRsi = 1 0 0 0 [ml/L].a2,/B ’ [ml/min]. 
This slope intercept GFR is then corrected for the one pool assumption using the 
Brochner-Mortensen (1972) correction. Because the Brochner-Mortensen correction 
needs to be applied to a surface area corrected GFR the correction becomes 
GFRbm = (SA/1.73) * (0.9908 * (1.73/SA)*GFRs r 0.001218*((1.73/SA)*GFRs,)2) 
[ml/min]
GFR/ECVi and GFR/ECV?
Again using only the late samples, the slope of the single exponential fit, 012’, is an 
estimate o f GFR normalised to the ECV estimated from the distribution volume of 
DTPA. To (*2’ a correction for the one pool assumption is applied, two forms of this 
are used one based solely on 012’ itself and one based also on the intercept B ’ and the 
surface area (SA). These corrections were derived in chapter 3 for EDTA but are 
used here for DTPA and EDTA.
GFR/ECV, = 13680 * (0.9462 * a2’ +23.11 * (a2’)2) [ml/min/13.68 L]
GFR/ECV2 = 13680 * (0.9666 * a2’ + 1.155 * (1.73/SA) * (a2’)2/B’) [ml/min/13.68 
L]
D V te
Again using only the late samples, 1/B’ is an estimate of the distribution volume of 
DTPA which in turn is an estimate of ECV. To 1/B’a correction for the one pool 
assumption is applied this also was derived in chapter 3 for EDTA 
DVia,e = ( l/B ’).(1.0233-27.76.a2’-1055.(a2’)2) [L]
GFR
A double exponential was fitted to the complete plasma clearance curve o f DTPA or 
EDTA using a curve striping technique, detailed in chapter 5, to give A.e'al + B.e'”2,
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A and B have units o f %/L and a\ and a2 units o f m in '1. GFR was calculated from the
double exponential fit as
GFR = 1000 [ml/L]/(A/a 1+B /a2) [ml/min]
DVdtpa
The distribution volume o f Tc-99m DTPA was also calculated from the double 
exponential fit being
D V d tp a  =  (A/ai2+B/a22)/(A/a,+B/a2)2 [L]
GFR/ECVnTPA
Using the complete plasma clearance curve o f DTPA GFR normalised to ECV 
estimated from the distribution volume o f DTPA is therefore 
GFR/ECVDtpa = (A /al+B/a2)/(A /ai2+B/a22) [ml/min/ml]
Then using a value o f 13.68 L as an average normal adult ECV the results is 
expressed
G F R /E C V Dtpa = 13680.(A/ai+B/a2)/(A /a,2+B/a22) [ml/min/13.68L]
4.2.6 Estimate of ECV from the Br-77 brom ide data
A biexponential fit was performed to the plot o f Br-77 bromide concentration from 
20 to 240 minutes after administration to give A .e'al + B.e"a2. Then 
DVBr = (A/a 12+B /a22)/(A/ai +B/a2)2 [L]
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Fig 4.2 : Exampie spectra from a Br-77 and a K-43/K-42 standard showing chosen energy 
windows. Energy scale is approximately 2 keV per channel.
4.2.7 Counting of urine and plasma samples containing Tc-99m, Br-77, H-3 and 
K-43/K-42
The containers used to collect the 24 hour urine collection and the spot urine 
collection were weighed prior to being given to the volunteers. After the urine 
collection these were reweighed to determine the total mass o f urine. Then 20 ml
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aliquots were pipetted into pre-weighed glass counting vials which were then 
reweighed to determine the mass o f urine being counting. These masses were then 
used to assess the total quantity o f the tracers Br-77 and K-43 in the urine 
collections. 3 ml o f plasma from the 28 hour blood sample was pipetted into a plastic 
counting vial in the same way as for the early blood samples. 20 ml o f the previously 
made Br-77 standard was pipetted into a glass counting vial. A K-43 standard was 
prepared by pipetting 0.1 ml o f the administered solution into a 100 ml volumetric 
flask and making up the volume. 3 ml and 20 ml standards for the K-43 were then 
pipetted into the appropriate counting containers. The plasma and urine samples were 
then counted along with 3 ml and 20 ml backgrounds and the 3 ml and 20 ml Br-77 
and K-43 standards for 1000 seconds in the same automatic gamma counter as used 
for the early samples. For each container counted, the spectra was saved and 
exported so that multiple windows could be applied and optimised later. Fig 4.2 
shows example spectra from a 20 ml Br-77 standard and a 20 ml K-43 standard 
which as will be discussed also contains a small proportion o f K-42. Two windows 
were chosen for Br-77 and three windows for K-43 and these are shown in the figure. 
As previously mentioned the H-3 being a very soft beta does not interfere with the 
gamma counting. There are counts in the samples from Tc-99m DTPA and figure 4.3 
shows an example spectra from a spot urine sample in which the largest peak is from 
Tc-99m. However as all the windows for Br-77 and K-43 are well above the Tc-99m 
energy there is no downscatter and the count rate from the Tc-99m is much lower 
than with the counting o f the early blood samples, the maximum being 13,000 cpm, 
so the count rate dependent upwards crosstalk is not significant and so there is no 
need to correct for crosstalk from the Tc-99m. The crosstalk corrections obviously 
need to be applied between the multiple interlaced windows for Br-77 and K-43.
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Fig 4.3 : Example spectra from a spot urine sample showing peaks for Tc-99m, Br-77 and K- 
43 the Br-77 and K-43 energy windows are also shown. Energy scale is approximately 2 keV 
per channel.
Ck = Cki + Ck2 + Ck3 are the deadtime and background corrected counts in the three 
potassium windows from a sample
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Cb = Cbi + Cb2 are the deadtime and background corrected counts in the two 
bromium windows from a sample
Tk = Tki + Tk2 + Tk3 are the ‘true’ counts in the three potassium windows from 
potassium
Tb = Tbi + Tb2 are the ‘true’ counts in the two bromium windows from bromium
Xbki, Xbk2 and Xbk3 are the cross talk factors from bromium into the three 
potassium windows.
Xkbi and Xkb2 are the cross talk factors from potassium into the two bromium 
windows.
The crosstalk factors are calculated from measuring pure standards o f Br-77 or K-43. 
For example:
Xkbi = Cbi / (Cki + Ck2 + C o) from a pure sample K-43
It is required to take the counts in the various windows and derive a estimate o f the 
true counts from the two radionuclides.
Cbi = Tbi + Xkbi-Tk (1)
C b2 =  T b2 +  X kb2-Tk (2 )
Cki = Tki + Xbki-Tb (3)
Ck2 = Tk2 + Xbk2-Tb (4)
C o  ~ Tk3 + Xbk3-Tb (5)
(1) + (2)
Cb -  Tbi + Tb2 + (Xkbi + Xkb2)-Tk = Tb + (Xkbi + Xkb2)-Tk (6)
(3) + (4) + (5)
Ck = Tk + (Xbki + Xbk2 + Xbo )*Tb (7)
(6) -  (Xkbi + Xkb2)-(7)
Cb -  (Xkbi + Xkb2).Ck -  Tb - (Xkbi + Xkb2)-(Xbki + Xbk2 + Xbk3)-Tb (8)
=> Tb = (Cb -  (Xkbi + Xkb2)-Ck)/(1 - (Xkbi + Xkb2)-(Xbki + Xbk2 + Xb o )) (9)
This is the same equation as when there is only one window per isotope so let:
Xkb = Xkbi + Xkb2 (10)
Xbk = Xbki + Xbk2 + Xbk3 (11)
These can be measured directly from pure standards 
Xkb = (Cbi + Cb2) / (Cki + Ck2 + C o) from a pure sample K-43
Xbk = (Cki + C o  + C o) / (Cbi + Cb2) from a pure sample o f Br-77
And then the crosstalk equations can be written as:
Tb = (CB -  Xkb.Ck)/(1 - Xkb.XBk)
Tk = (CK -  XBk.Cb)/(1 - XKb.Xbk)
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K-42 K-43 Br-77
313 keV (0.34 %) 221 keV (4.8 %) 8 8  keV (1.4 %)
1525 keV (18 %)* 373 keV (87 %)* 162 keV (1.1 %)
397 keV (12 %) 200 keV (1.2 %)
593 keV (11 %) 239 keV (23 %)*
617 keV (79 %)* 250 keV (3.0 %)
1022 keV (2.0 %) 282 keV (2.3 %)
304 keV (1.2 %)
439 keV (1.6 %)
485 keV (1.0 %)
521 keV (22 %)*
578 keV (3.0 %)
585 keV (1.6 %)
755 keV (1.7 %)
818 keV (2.0 %)
Others < 0.06 % Others < 0.4 % Others < 1 .0 %
Table 4.1: Principal gamma emissions for K-42, K-43 and Br-77 with abundances shown in 
brackets from Table of Isotopes website
The situation is made more complicated by the fact that there is a proportion o f K-42 
in the K-43. K-42 has a half life o f 12.4 hours and K-43 has a half life o f 22.3 hours 
and therefore the proportion of K-42 to K-43 changes with time. Table 4.1 shows 
that the highest abundance gamma emission for K-42 is at 1525 keV. This is evident 
in the spectra from a K-43/K-42 standard shown in fig 4.4 as the small peak between 
channel 700 and 800. It can be seen that the size o f this peak in proportion to the 
other peaks changes in the 24 hours between the acquisition o f the two spectra 
because the K-42 is decaying faster. This change in proportion o f K-42 to K-43 will 
have a small effect on the crosstalk factors as evident by the two spectra in not 
exactly overlying each other between the photopeaks at lower energies. Also as a 
small proportion o f the counts recorded in the K-43 windows will come from the K- 
42 then decay correcting with the half life for K-43 will not be quite correct. To 
minimise the effects o f changes in crosstalk and decay the samples were always 
measured closely in time to the K-43/K-42 standards used for calculating the 
crosstalk factors and calculating the concentration o f the sample in proportion to the 
administered activity. Note that the three main peaks seen in the potassium spectra 
are the K-43 373keV peak the K-43 617 keV peak and a sum peak from these two 
emission that are in cascade in the decay scheme, at 980 keV.
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Fig 4.4: Spectra from a K-43/K-42 standard at two time points after administration 
normalised to the same maximum count. Energy scale is approximately 2 keV per channel
Below is a summary o f the procedure for calculating the sample concentrations:
• The counts in each o f two Br-77 and three K-43 windows for each sample, 
standard or background were calculated by summing the counts in the 
appropriate channels in the saved spectra.
• A deadtime correction was then applied by multiplying each window count 
by the deadtime factor reported by the counter for that sample, standard or 
background
• A background correction was then applied using the background o f the 
appropriate volume.
• The counts in the two Br-77 windows and the three K-43 windows were 
summed.
• Then the crosstalk corrections were applied as described above.
• Then the counts for Br-77 and K-43 were decay corrected.
• Then the counts for each sample were expressed as a percentage o f  the 
counts in the appropriate standard
• The concentration o f the standards were expressed in percent o f the 
administered activity per litre (%/L) from the known weight o f the Br-77 
bromide and K-43 KC1 administered to the subjects and the known 
volumetric dilution factor, assuming the density o f the tracers to be 1 g/ml.
• Then the concentrations for each sample were converted into %/L by 
multiplying by the concentration o f the appropriate standard in %/L
4.2.8 Calculation of bromide and potassium loss over 24 hours
The total volume in each bottle for each o f the collections was calculated by 
multiplying the ratio o f the total weight o f the urine to the weight o f the 20 ml aliquot 
by 20 ml. The percentage o f the administered activity in each bottle for each 
collection was then calculated by multiplying the concentration by the volume. The
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total bromide loss in the urine over the 24 hours was then calculated by adding the 
percentage in the one or two bottles for the 24 hour collection and the spot collection 
together. The total potassium loss was calculated in the same way.
4.2.9 Calculation of exchangeable potassium from the spot urine sample and the 
late blood sample.
The method o f measuring exchangeable potassium with isotope dilution was first 
described by Corsa et al (1950) using K-42 and by Zollinger et al (1970) using K-43. 
The biochemistry laboratory report the cold potassium in the plasma from the blood 
sample and the urine sample in mmol. The total activity o f K-43 in the body at the 
time o f the 24 hour sample is corrected for the loss in the urine during the 24 hour 
period the loss in the faeces is in healthy subjects much smaller and is expected to be 
less than 0.5 % of the administered activity (Surveyor and Hughes 1967) and this is 
ignored. From the ratio o f the absolute concentration o f potassium in the urine or 
plasma sample to the concentration o f K-43 in the sample relating expressed in terms 
of the total remaining in the body it then possible to ascertain the total amount of 
potassium the radioactive potassium has mixed with i.e. the exchangeable potassium 
(Ke).
Ke [mmol] = (1 -  fraction lost).(sample K [mmol/L])/(sample K-43 [%/L])
4.2.10 Measurement of total body water.
All the beta counting was performed in a Wallac 1400 Automatic Beta counter 
(Turku, Finland) using glass scintillation vials filled with 10 ml Hi-Safe 2 scintillant, 
counting for 1 0 0 0  seconds with a 60 second external standard count. 1 ml of distilled 
water was added to one vial and this is the first vial to be counted in each batch. The 
counter then subtracts the background spectra from subsequent vials in the batch 
before any further analysis is performed. A standard solution was prepared by 
pipetting 0 .1  ml o f the solution administered to the subjects into a 1 0 0  ml volumetric 
flask and making up the volume. 0 .1  ml o f this standard solution was pipetted into 
scinitillation vials and then 0.9 ml of distilled water was added such that the volume 
of aqueous liquid added to the scintillant in each vial to be counted was 1 ml. For 
each subject the percentage o f the administered dose in the counted H-3 standards 
was calculated from the dilution and the known administered weight o f the tritiated 
water stock solution. In addition to these tritium standards, 1ml of the prepared Br-77 
and Tc-99m standards from the last subject were counted to investigate any 
interference in the beta counting from these other isotopes.
Two different quench corrections were tried. The first was the factory defined 
quench correction for H-3 also which incorporates a colour correction. The second 
was using a quench curve derived from quenching with plasma (see below)
Plasma Quench correction
A solution containing 1 MBq / ml tritiated water was prepared and then 4 pL was 
added to each of 10 vials containing 10 ml of scintillant. The vials were then counted 
twice. Then to seven of the vials 0.05, 0.1, 0.2, 0.4, 0.6, 0.8 and 1.0 ml of plasma 
were added and to one further vial 1ml o f distilled was added. The quenched vials 
were then counted and the counting repeated 1, 2, 3 and 13 days later. The relative 
efficiencies o f counting the quenched samples were calculated by comparing the 
quenched and unquenched raw counts for the same vial. These were converted into 
absolute efficiencies by assuming that the counter’s own calculation o f efficiency
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was correct for the unquenched counting. Note that with all the counting performed 
in this study the counts in samples are compared with those from standards.
Therefore the absolute efficiency is not crucial to the measurements. W ith the plasm a 
samples the amount o f actual quenching appeared to decrease with time and so for a 
individual sample the efficiency rose with time this was accompanied by a rise in the 
external standard index SQPE. Fig 4.5 shows a plot o f the efficiencies against SQPE 
for all the countings on the different days including the pink points for 1 ml water. 
This data appears essentially linear and so a linear fit was performed to all the points 
from the countings on different days and the formula (efficiency [%] = 0.2495 x 
SQPE -158.05) used to perform this quench correction.
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Fig 4.5. Quench correction ‘curve’ derived from quenching with different volumes of plasma. 
The pink points represent quenching with 1 ml of distilled water. The far right points 
represent the vials with no plasma added.
Plasma crunching
Because o f the problems o f getting an accurate quench correction for counting 
tritium in plasma, an alternative technique was tried. This involved deproteinising the 
plasma or ‘crunching’ which dramatically reduces it’s quenching effect, so that it 
appears similar to that o f water or the standards. 3 ml o f each plasma sample was 
pipetted into a glass sample tube and then 2 ml o f Tri-chloro Acetic acid (TCA) was 
pipetted into the tube and the tube agitated. This causes all the plasma proteins to 
amalgamate, then the tube is centrifuged for 10 minutes at 1000 G and 1 ml o f the 
clear supernatant was pipetted into the scintillation vial containing scinitillant and 
counted alongside the other plasma samples. The concentration in the crunched 
samples is corrected for the dilution with TCA, one disadvantage o f this approach is 
that any errors in this dilution feed in to the final result.
Standard doping
A further alternative method was also used to get round the quench problems. For 
this method the samples were first counted as normal and then they were weighed
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and 0.1 ml o f diluted standard solution was pipetted into each sample vial. The vials 
were then reweighed to accurately determine the amount o f standard added. Then the 
quenching effect o f each sample is accounted for by referencing the counts to the 
increase in counts when the known quantity o f standard is added.
For all the methods o f beta counting the total body water was estimated both from 
the samples taken at around 1 2 0  minutes and 180 minutes after the administration of 
the tritiated water, mixing should be complete well within 2 hours (Prentice et al 
1952). Because the subjects were not allowed any fluid intake between the 
administration and the taking of these samples it is assumed that the tritium has 
mixed completely with all the water in the body at the time o f administration. 
Therefore no correction is made for loss o f tritium through urine production or 
sweating with the assumption made that for any water that is lost the correction 
proportion o f tritium is lost as well (Veall and Vetter 1958). This is a reasonable 
assumption because the tritium does largely mix with the total body water quite 
rapidly and the amount o f water lost over the 3 hours will be small proportion o f the 
total which is o f the order o f 40 litres. The total body water is calculated simply by 
taking the reciprocal o f the concentration in the plasma sample expressed in percent 
o f the administration per litre which is the volume in which the tracer has been 
diluted.
4.2.11 Dual Energy x-ray absorptiometry (DXA) body composition studies
Dual Energy x-ray absorptiometry (DXA) is accepted as standard method for 
measuring lean body mass in body composition studies (Engelen et al 1998, Van 
Loan 1998, Formica CA 1999). DXA uses two different energies o f x-ray and 
measures the total attenuation through the body at each pixel with the two energies. It 
then uses assumed mass attenuation coefficients for soft tissue and bone and uses 
simultaneous equations to solve for the mass o f soft tissue and bone under each pixel. 
For pixels that it decides have essentially no bone content, from a ratio o f the high 
and low energy attenuation it tries to derive a percentage fat content. This is 
calibrated from a phantom with varying fat content. For pixels that do contain bone 
the percentage fat in the soft tissue is assumed from the nearest surrounding pixels 
that don’t contain bone. In this way the body is divided into 3 compartments by 
mass, bone, lean soft tissue and fat. The term lean body mass can either include the 
bone mass or not but the term fat free mass (FFM) is unambiguous referring to the 
total body mass minus the fat mass. The DXA assessment o f fat free mass was made 
on a Hologic QDR-4500A.
4.3 RESULTS
4.3.1 Residual activities after administration
The mean residual activity in the Tc-99m DTPA syringe after administration was 
0.04 MBq constituting 0.3 % o f the administered activity. In the Br-77 syringe the 
mean residual was 0.002 MBq constituting 0.2 % of the administered activity. After 
the administration o f the Tc-99m DTPA and Br-77 bromide the lines used for the 
administration were assayed for residual activity, however it was not determined how 
much of this small residual was Tc-99m and how much was Br-77 and so no attempt 
was made to correct for this residual. The maximum residual activity measured in the 
line on the Tc-99m setting was 0.010 MBq and if  all this activity was Tc-99m DTPA
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this would constitute an error in the administered quantity used for the calculations o f 
less than 0.1 %. Using the Br-77 setting the maximum residual activity in the line 
was 0.010 MBq and if  all the activity was Br-77 then this would constitute a 
maximum error in the administered quantity used for the calculations o f 1 %.
Because the activity o f  Tc-99m administered was 15 times greater than that o f Br-77 
it is more likely that the majority o f any residual in the line is Tc-99m, unless there 
was a reason to believe that the Br-77 bromide was more likely to get stuck in the 
line than the Tc-99m, as the residuals in the syringes were similar proportions for 
both radiopharmaceuticals then this seems unlikely.
After the oral administration o f the K-43 KC1 there was no measurable residual 
activity in the universal container used for the administration.
4.3.2 Crosstalk between Tc-99m and Br-77 in the pre K-43 administration blood 
samples
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Fig 4.6 : Plot of upwards crosstalk into the Br-77 window as a percentage of the count in the 
Tc-99m window for pure Tc-99m standards of different activities at the time of counting.
The average downscatter into the Tc-99m window from the Br-77 measured with the 
pure Br-77 standards was 7.0% (SD 0.2 %), the factor used for corrections was that 
measured with Br-77 standard counted in the same batch as the samples. The 
maximum magnitude o f the downscatter correction was 5% o f the counts in the Tc- 
99m window. The upwards crosstalk from Tc-99m into the Br-77 window was found 
to be dependent on the count rate. Fig 4.6 shows a plot o f the upwards crosstalk 
against Tc-99m count rate for pure Tc-99m standards o f different activities, the 
equation derived from the linear fit o f the points on this plot was used to estimate the 
upwards crosstalk from the count rate in the Tc-99m window for each individual 
sample. The maximum magnitude o f the upwards crosstalk correction was 5% o f the 
counts in the Br-77 window.
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4.3.3 DTPA results
With the first four volunteers it was found that there was a problem with DTPA 
clearance curves that were not fitting well to bi-exponentials and were giving values 
for GFR that were lower than expected. It was discovered that the DTPA kits had 
been made up with high activities of Tc-99m for other clinical studies and then a 
large dilution made to get Tc-99m DTPA of a concentration o f about 7.5 MBq per ml 
for this study. Because o f this the dilution it is believed that the stability o f the 
radiopharmaceutical was compromised and particularly if  there was a delay between 
the dilution and administration then significant free pertechnetate may be present, 
this effect has been demonstrated by Sampson and Keegan (1985). A radiochemical 
purity analysis o f a DTPA kit made up and diluted as in the first o f these studies did 
reveal a significant proportion of free pertechnetate. This free pertechnetate apart 
from accumulating in the thyroid and other organs also binds to plasma proteins and 
invalidates the measurement of GFR. Because o f this it was necessary to repeat the 
DTPA clearances for the first four volunteers with the same protocol as regards 
DTPA but without the administration o f the other isotopes, the results o f these repeat 
clearances are those used in the further analysis. For the repeats and all subsequent 
studies a separate DTPA kit was used for this study made up with much less activity 
so less dilution was necessary.
The GFR measured from all the samples was in the range 85 -  115 ml/min.
The mean distribution volume measured from all the samples was 14.7 L (SD 2.4) 
when normalised to Du Bois surface area the mean distribution volume was 13.5 
L/l .73m (SD 1.6 ) which is close to the value of mean normalised distribution 
volume for EDTA o f 13.7 L/l.73m 2 obtained in Chapter 2.
4.3.4 Bromide results
The concentration of Br-77 plotted against time for the 6  Group A subjects is shown 
in Fig 4.7. It can be seen that in 5 out of 6  subjects the concentration fitted a bi­
exponential with a small fast component with a mean half life o f 14 (SD 6 ) minutes 
and a larger slow component with a mean half life o f 1790 (SD 580) minutes about 
30 hours. In one subject, N3, the fast component was not distinguishable and a single 
exponential fit to the whole data was used. The calculated distribution volume of 
bromide was always greater than that of DTPA being on average 20 % greater, 
results are shown in Table 4.2. This difference is consistent with that previously 
found (Cousins et al 2002) and is due in part to bromide overestimating extracellular 
fluid volume, because bromide enters erythrocytes and possibly other cells. A 
correction could be applied to the distribution volume o f bromide to make it a more 
representative estimate o f extracellular fluid volume for example Veall and Vetter 
(1958 p206) suggest multiplying by 0.9, however such a correction would not affect 
how good DVsr is a parameter for normalising GFR.
101
tim e  m ins
tim e  m ins
♦ N5 data 
—  fit 
bi-fit
100 150 200
tim e m ins
1%
0 50 100 150 300200 250
Fig 4.7 plots of plasma Br-77 Bromide concentration against time for all 6 volunteers from 
Group A. The yellow lines shoe the bi-exponential fits used and the pink lines show a linear 
fit to all samples.
N1 N2 N3 N4 N5 N6
DVBr (L) 17.2 15.5 13.7 21.9 21.4 16.3
D V dtpa (L ) 14.4 13.0 12.6 18.2 17.0 13.1
D iff % 20.0% 18.6% 9.3% 20.2% 26.0% 24.2%
Table 4.2: The total distribution volume for bromide and DTPA for Group A and the 
difference is percentage by which DVBr is greater than DVdtpa
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Fig 4.8: Plot of distribution volume of Br-77 bromide plotted against distribution volume of Tc- 
99m DTPA from the 6 subjects in group A. Equation of the linear fit to the data points is 
included along with the correlation coefficient.
An alternative method o f estimating the distribution volume o f bromide is to take the 
concentration in the plasma at 28 hours, correct for the loss in the urine as measured 
in the urine collections and to calculate the distribution volume from that sample. It 
is not possible to do this completely accurately because any urine passed between 0 
and 4 hours was not collected and some Br-77 bromide would have been lost in this 
period. However the bromide in the 4 to 28 urine collection (including the spot urine 
at 28 hours) was relatively small mean 4.1 %, range 3.1 % - 5.5 %. Bromide 
distribution volume estimated in this way was well correlated with the bromide 
distribution volume estimated from the bi-exponential fit to the early samples, RT = 
0.96 but was on average 18 % higher. The results from using this alternative measure 
o f bromide distribution volume for normalising GFR were essentially identical to 
those for the first method and so were not considered separately.
4.3.5 Potassium Results
The 24 hour K-43 loss was similar to the bromide loss being on average 4.5 %, range
3.3 -  5.6 %. As expected the concentration o f cold potassium and o f  K-43 was much 
greater in the 24 hour spot urine samples than in the 24 hour plasma samples. Plasma 
cold potassium concentration were in the range 3.4 mmol/L to 4.3 mmol/L and in 
urine 19.3 mmol/L to 77.2 mmol/L and the plasma K-43 concentration were in the 
range 0.11 %/L to 0.20 %/L and the urine concentrations 0.63 % to 4.56 %. Table 4.3 
shows the measured values for exchangeable potassium derived from the plasm a and 
urine samples. These agree reasonably well but the Ke derived from the urine 
samples is likely to be more reliable because the concentrations being measured for 
both cold potassium and K-43 are higher. Also because in a blood sample it is 
possible that before the measurement o f cold potassium is made by the biochemistry 
laboratory that some potassium leaks out from the high concentration in the red cells
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and increases the apparent plasma concentration and this would tend to make the Ke 
from the blood sample an overestimate and this would be consistent with the results 
here. Therefore only the exchangeable potassium derived from the 24 hour spot 
urine sample was considered in the further analysis.
N1 N2 N3 N4 N5 N 6
Ke urine mmol 2630 2550 1600 2910 2860 2910
Ke plasma mmol 2560 2690 1610 3150 3500 3220
Diff -3% 6 % 1% 8 % 2 2 % 1 1 %
Table 4.3: Exchangeable potassium determined from the 24 hour plasma and 24 spot urine 
samples for each of the 6 subjects and the difference shown as a percentage that the 
plasma result is greater than the urine result
4.3.6 T ritium  Results
Effect o f Tc-99m and Br-77 on the H-3 measurements
Time after study
‘tritium’ DPM
8  days 14 days 21  days
Tc-99m standard 1 .6 1 2 .6 0.4
Br-77 standard 6467 1167 145
Example sample 8509 8121 8042
Table 4.4: Disintegrations per minute (DPM) recorded when counting in the beta counter with 
the H-3 protocol for a Tc-99m and a Br-77 standard and an example sample containing 
some residual Br-77 at 3 different time intervals after the study was performed.
By 8 days Tc-99m has decayed by a factor of 4 x 109 so even the full administered 
activity o f 15 MBq would be expected to be less than 0.01 Bq. However it may be 
necessary to consider the possibility of longer lived contaminants in the Tc-99m and 
also the Tc-99 which is a beta emitter. The Tc-99 is probably not a problem because 
with the ratio o f half lives even 1 GBq of Tc-99m would be expected to decay to 
only 3 Bq o f Tc-99. To consider whether longer lived contaminants are likely to be a 
problem it is useful to consider the initial absolute activity of Tc-99m that would be 
expected to be in the samples counted in the beta counter for H-3. The maximum Tc- 
99m concentration in these samples was 4% of the administered dose per litre which 
means decay corrected to the time of injection the maximum activity o f Tc-99m in 
thel ml o f plasma used for the beta counting would be 0.6 kBq. So the activity o f a 
0.1 % long lived contaminant say Mo-99 would be expected to only be 0.6 Bq. This 
may appear to be small, but with 4 MBq of H-3 diluted in a total body water volume 
of 40 L, the activity o f H-3 in the samples would be expected to only be around 100 
Bq. To be sure that long lived contaminants in the Tc-99m were not a problem a Tc- 
99m standard was counted along with the samples for tritium analysis at different 
intervals after the last study as shown in table 4.4. The maximum DPM recorded was 
12.6 and as the maximum concentration of Tc-99m was 20 % o f the standard 
concentration this would imply a maximum DPM in the samples due to Tc-99m of
2.5 which is less than 0.05 % of the tritium counts.
A Br-77 standard was also counted with the samples on the different occasions. At 8 
days the 1 ml o f this standard would contain around 74 Bq o f Br-77 which would be 
expected to give a significant count in the beta counter and the actual counts are 
shown in table 4.4. The counts from the Br-77 standard at 14 and 21 days are within 
4 % of those predicted from Br-77 decay o f the counts recorded on day 8 . On day 8 
from the known Br-77 concentration in the plasma samples the Br-77 would be 
expected to account for up to a 5% increase in the counts recorded for H-3. On day
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14 this would be expected to have fallen to less than 1 % and on day 21 to less 0.12 
%. The DPM recorded for H-3 in the samples decreased between day 8 and day 14 
and day 14 and day 21 as expected from the decreasing contribution o f Br-77. The 
counting used for calculation o f the total body water was all preformed at least 21 
days after the studies were performed and therefore any error caused by the effect o f 
Br-77 should be less than 0.12 %.
It was found that when counting the crunched plasma samples there was significant 
chemiluminescence that lasted for around 60 hours. This is demonstrated in Fig 4.9 
which shows the results o f repeatedly counting two example crunched plasm a sample 
for nearly 140 hours. The chemiluminescence is still seen when counting crunched 
plasma samples that do not contain any radioactivity. It was found that the TCA 
alone mixed with the scinitillant did produce a small amount o f chemiluminiscence 
but that the effect was much greater when the TCA is mixed with plasma before 
being added to the scinitillant as with the crunched samples. In order to avoid the 
need for the counter to attempt to correct for this chemiluminesence it was important 
to make sure that scintillation vials for counting the crunched plasma samples were 
left for at least 3 days after being prepared before counting.
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Fig 4.9: The cpm plotted against time for two example tubes containing crunched plasma 
samples and tritium activity counted repeatedly over a period of more than 130 hours.
The SQPE for all the standards was around 804 and for the plasma samples ranged 
from 775 to 792 but for the crunched plasma samples ranged from 800 to 803.
There was a significant difference between the total body water results from the beta 
counting quench corrected with the counters factory defined quench correction and 
all the other methods. For example the results with the factory quench were on 
average 22 % lower (SD 2%) than those from the standard doping method (P<0.001). 
It appeared that the factory quench correction was overdoing the correction. This was 
confirmed when generating the quench correction with plasma. It also found that the 
extent to which the factory quench correction overestimated the activity in the 
samples increased the longer the samples had been kept and this appeared to be a
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problem with the colour correction. So the factory quench correction was not used 
for the results.
Plasma crunching 
method ( 1)
Plasma derived 
quench correction 
method (2 )
Standard doping 
method (3)
N1 120 min 45.3 L 43.1 L 41.5 L
N1 180 min 45.4 L 42.0 L 41.8 L
N2 120 min 34.4 L 38.4 L 37.5 L
N2 180 min 34.9 L 38.6 L 37.5 L
N3 120 min 31.4 L 32.3 L 31.1 L
N3 180 min 32.6 L 32.6 L 32.6 L
N4 120 min 47.5 L 67.7 L 65.7 L
N4 180 min 50.8 L 55.7 L 55.8 L
N5 120 min 46.6 L 49.8 L 49.2 L
N5 180 min 45.2 L 48.6 L 50.5 L
N 6  120 min 40.2 L 44.4 L 43.2 L
N 6  180 min 41.2 L 44.5 L 45.3 L
Table 4.5 : Total body water derived from the plasma samples taken al around 120  and
around 180 minutes using the three different methods of ‘correcting’ for the quenching of the 
plasma.
O f the three remaining methods there was best agreement between the plasma 
derived quench correction method and standard doping method the mean magnitude 
o f the difference was 2.2 % and the maximum difference was 3.8 %. It was therefore 
decided to use in further analysis the average o f results derived from these two 
methods. There was reasonable agreement between the total body water derived from 
the 1 2 0  minute sample and that derived from the 180 minute sample except in one 
subject. In this subject the total body water derived from the 120 minute sample was 
higher than the lean body mass derived by DXA where as it is expected that the 
hydration o f the fat free mass will be about 80 % (Wang et al 1999) and there it 
seemed reasonable to take the result for the 180 minute sample, in fact it was decided 
to take the result from the 180 minute sample for all the subjects, if  there was any 
delay in the mixing o f the tritium within the total body water then the later sample 
might be expected to give the better result.
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Mean o f plasma derived 
quench correction and 
standard doping methods
Difference between 
120 min and 180 
min result
N1 120 min 42.6 L
N 1 180 min 42.2 L -0.9%
N2 120 min 38.6 L
N2 180 min 38.7 L 0.3%
N3 120 min 31.9 L
N3 180 min 32.8 L 2 .8%
N4 120 min 67.1 L
N4 180 min 56.1 L -17.9%
N5 120 min 49.5 L
N5 180 min 49.6 L 0 .1%
N6 120 min 43.2 L
N6 180 min 44.3 L 2.5%
Table 4.6: The final values of total body water used. These are the average of the values 
derived from the plasma derived quench correction and the standard doping method. The 
values derived at around 120 and around 180 minutes are shown and the difference 
between them (expressed a percentage of the mean of the two)
4.3.7 DXA results
The body composition results determined by DXA are shown in Table 4.7
N1 N2 N3 N4 N5 N6
Lean soft tissue mass kg 46.00 40.90 35.23 59.06 56.41 51.74
Fat Mass kg 14.58 17.37 21.62 28.27 9.90 9.76
Total Bone Mass kg 2.47 2.48 2.14 2.75 3.80 3.11
Fat Free Mass kg 48.47 43.37 37.38 61.81 60.21 54.85
Table 4.7: Body composition results determined by DXA for each of the 6 subjects in Group 
A.
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Fig 4.10: Total body water measured with tritiated water plotted against fat free mass 
measured with DXA for the 6 subjects in group A. Also shown is the linear fit to data points 
with the correlation coefficient and pink line shows the expected relationship if the hydration 
of the fat free mass is 73.2%.
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Fig 4.10 shows the relationship between the estimate o f total body water from the 
tritiated water and the fat free mass from DXA. It can be seen that the two 
measurements are reasonably correlated but that the relationship gives a hydration of 
the fat free mass o f 8 6  % instead o f 73 % so it is possible that there is a bias in one of 
the estimates.
4.3.8 Normalisation results for Group A
Full curve GFR normalised to: Coefficient o f Variation o f normalised 
normal GFR values
Weight 12.7 %
Surface Area (Du Bois) 1 0 .8 %
Surface Area (Haycock) 1 0 .2  %
D V d tp a  (GFR/ECV) 1 2 .2  %
DVsr (full curve) 16.3 %
Exchangeable Potassium (urine) 28.9 % *
Total Body Water (180 min sample) 18.2%
Fat Free Mass 19.4%
Table 4.8: Coefficient of variation (SD/mean [%]) of the GFR, derived from the bi-exponential 
fit to all the samples, normalised to the different measured wholebody parameters. * 
indicates a significant difference to the Surface Area (Du Bois) value (P<0.05).
For each o f the 6  subjects in Group A the GFR, derived from the bi-exponential fit to 
the full Tc-99m DTPA clearance curve, was normalised to the various whole body 
parameters; weight, DuBois surface area, Haycock surface area, D V d tp a , DVsr, 
exchangeable potassium, total body water and fat free mass. Then for each whole 
body parameter the mean and standard deviation (SD) o f the normalised GFR values 
was calculated. Then the coefficient of variation was calculated as SD/mean 
expressed as a percentage. To be in keeping with the way GFR is usually normalised 
to surface area the normalisation would involve dividing the GFR by the whole body 
parameter measured for that subject and then multiplying by a mean normal value for 
that whole body parameter, akin to the 1.73 m2 for surface area. However with the 
variability expressed as the coefficient o f variation the results are not dependent on 
the mean normal value chosen for the whole body parameters. An F-Test was used to 
determine if  any the differences in coefficient of variations were statistically 
significant. The variability in GFR normalised to the measured exchangeable 
potassium was statistically greater than that for GFR normalised to surface area 
(either DuBois or Haycock) (P<0.05). But the differences between variability in GFR 
normalised to the other measures the GFR normalised to surface area were not 
statistically significant (P>0.05). Table 4.8 shows the results.
For each o f the 6  subjects in Group A the GFR, derived from the single exponential 
fit to the data from the plasma samples taken 1 2 0  minutes onwards and corrected for 
the one pool assumption with the Brochner-Mortensen correction, were also 
normalised to the various whole body parameters. For D V d tp a  the normalised GFRs 
were in fact derived from the terminal rate constant, 012’, corrected for the one pool 
assumption with the two alternative corrections derived in chapter 2 to give GFR 
normalise to the distribution volume of DTPA. Then the coefficients o f variation 
were calculated as before. An F-Test was used to determine if  any the differences in 
coefficients o f variation were statistically significant. The variability in GFRbm
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normalised to the measured exchangeable potassium was again statistically greater 
than that for GFR normalised to surface area (either DuBois or Haycock) (P<0.05). 
But the differences between variability in GFR normalised to the other measures the 
GFR normalised to surface area were again not statistically significant (P>0.05). 
Table 4.9 shows the results.
Late sample GFRBm normalised to: Coefficient o f Variation o f normalised 
normal GFR values
Weight 1 0 .2  %
Surface Area (Du Bois) 7.9 %
Surface Area (Haycock) 6.9 %
D V dtpa  (slope only GFR/ECV 1) 14.0 %
D V dtpa  (slope only GFR/ECV2) 13.3 %
DVBr (full curve) 15.3 %
Exchangeable Potassium (urine) 27.5 % *
Total Body Water (180 min sample) 16.8 %
Fat Free Mass 18.5%
Table 4.9: Coefficient of variation (SD/mean [%]) of the GFR, derived from the single 
exponential fit to the samples after 120 minutes, normalised to the different measured 
wholebody parameters. * indicates a significant difference to the Surface Area (Du Bois) 
value (P<0.05).
4.3.9 EDTA results and normalisation for Group B
For the 20 normal volunteers from group B studied under fasting conditions the GFR 
measured from the bi-exponential fit to full Cr-51 EDTA clearance curve was in the 
range 7 0 -1 2 6  ml/min. The mean distribution volume o f EDTA normalised to Du 
Bois surface area was 13.6 L/l .73m2 (SD 1.0) which is very close to the value 
measured for the six DTPA studies from Group A o f 13.5 L/l .73m2. Table 4.10 
shows the variability in the various measures o f GFR and DV normalised to weight, 
surface area or D V edta  expressed as the coefficient o f variation. Note GFR, 
GFR/ECV and D V edta  are derived from the bi-exponential fit to the full clearance 
curve and GFRBm, GFR/ECVi, GFR/ECV2 and D V iate are derived from the single 
exponential fit to the samples taken from 120 minutes onwards. None of the 
differences in variability between the ways o f expressing GFR were found to be 
statistically significant using an F-test (P>0.05). The normalised distribution volume 
did appear to be less variable then the normalised measures o f GFR. For example the 
CV for n D V BDTA being significantly different to that for nGFRBM (P<0.01). The 
results are shown in Table 4.10
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Mean CV
GFR/weight 97 ml/min/70 kg 19.3 %
nGFRsM (GFRbm/SA DuBois) 89 ml/min/1.73m2 13.9%
nGFRBM (GFRbm/SA Haycock) 8 8  ml/min/1.73m2 14.4 %
nGFR (GFR/SA DuBois) 90 ml/min/1.73m2 14.9 %
nGFR (GFR/SA Haycock) 90 ml/min/1.73m2 15.5 %
GFR/ECV 91 ml/min/13.68 L 13.2 %
GFR/ECVi 91 ml/min/13.68 L 13.3 %
g f r / e c v 2 91 ml/min/13.68 L 13.3 %
hD V edta  ( D V edta/  SA DuBois) 13.6 L/l .73m2 7.3 %
nDViate (DViate/ SA DuBois) 14.3 L/l.73m 2 9.2 %
Table 4.10: Mean normalised measures of GFR and DV and the variability in these 
expressed as a coefficient of variation (CV) for the 20 normal subjects in group B.
When looking at a population with range o f ages, it would be expected that the 
variability in normal normalised GFR measurements would be reduced if  the fact 
that GFR is expected to reduce with age is taken into account. A pattern for the 
reduction in expected GFR is derived by Granerus and Aurell (1981). For ages 20 to 
50 they quote:
mean expected GFR [ml/min/1.73m2] = 1 1 6 -  0.35 * age[years]
For ages 50 to 75 they quote:
mean expected GFR [ml/min/1.73m2] =140 -  age [years].
Therefore to correct measured GFRs for the normal subjects for the expected loss 
after the age o f 20, for subjects between 20 and 50:
Age corrected GFR = GFR * 109/(116 -  0.35 * age)
For subjects older then 50:
Age corrected GFR = GFR * 109/(148 -  age)
The results for the age corrected normalised GFRs are shown in Table 4.11. There is 
a slight reduction in the CV for all the measures when the age correction is applied. 
None o f the differences in variability between the ways o f expressing the age 
corrected GFR were found to be statistically significant using an F-test (P>0.05). 
Another study o f normal GFR against age was published by Grewal and Blake 
(2005) and their model is that GFR remains fairly constant, with a mean normal 
value o f 103.4 ml/min/1.73m2 up to the age o f 40 and then declines at a rate of 9.1 
ml/min/1.73m2 per decade.
Mean CV
GFR/weight 105 ml/min/70 kg 17.7%
nGFRBM (GFRbm/SA DuBois) 96 ml/min/1.73m2 12.4 %
nGFRBM (GFRbm/SA Haycock) 96 ml/min/1.73m2 1 2 .8  %
nGFR (GFR/SA DuBois) 98 ml/min/1.73m2 13.5 %
nGFR (GFR/SA Haycock) 96 ml/min/1.73m2 14.1 %
GFR/ECV 99 ml/min/13.68 L 12 .1  %
GFR/ECVi 99 ml/min/13.68 L 12.5 %
g f r / e c v 2 99 ml/min/13.68 L 12.4 %
Table 4.11: Mean normalised measures of GFR after a correction for age and the variability 
in these expressed as a coefficient of variation (CV) for the 20 normal subjects in group B.
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4.4 DISCUSSION 
4.4.1 Upwards crosstalk
One interesting issue to come out of the technical aspects of the studies was the 
discovery of the count rate dependent upwards crosstalk when performing dual 
isotopes studies with Tc-99m and Br-77. This ‘upwards crosstalk’ is not a scattering 
phenomenon but is likely to be due to pulse pile up. This pulse pile up has a 
significant effect on the measurements even when the overall deadtime o f the system 
is reported as less than 1%. The effect on the measurements is reasonably large 
because o f the usual practice o f using many times more activity o f the lower energy 
isotope compared to the higher energy isotope to minimise the magnitude o f the 
downscatter correction and so reduce the uncertainty in the measurements caused by 
the downscatter correction. One potential pitfall would be to allow for upwards 
crosstalk when performing similar dual isotope studies but to measure the magnitude 
o f the upwards crosstalk with for example a pure Tc-99m standard. This would be 
quite likely to overestimate the magnitude o f the upwards crosstalk because the Tc- 
99m standard would usually be o f greater activity than the samples and this could 
produce significant errors in such measurements.
4.4.2 Free Pertechnetate problems
These measurements highlighted the need to be mindful o f radiochemical purity 
when making dilutions from kits made up at higher specific concentrations than 
required. This effect is most likely to be caused by reducing the concentration of the 
reducing agent in the radiopharmaceutical preparation, in this case stannous chloride. 
But it is interesting that the effect seen here must be label that has been attached to 
the DTPA coming off before the DTPA is administered and shows that this particular 
labelling process must be at least partially reversible.
4.4.3 Dual isotope counting with Br-77 and K-43
It is believed that it has been demonstrated that it was possible to accurately 
determine the concentrations o f Br-77 and K-43 in samples containing the two 
isotopes that have complex overlapping spectra as seen in Figs 4.2 and 4.3. This was 
tested by recounting the samples after a period of time when the ratios o f the two 
isotopes has significantly changed and then comparing the final results obtained from 
the two countings. Any problems with the crosstalk correction would be likely to 
cause a difference between the two.
4.4.4 Tritium counting in plasma
It was found that the degree o f quenching observed when measuring tritium in 
plasma makes accurate measurement particularly challenging. A plasma quenched 
sample can have an efficiency that is 40% lower than an unquenched sample (Fig 
4.5). This means that any uncertainty in the quench correction can cause large 
uncertainties in the final result. O f the different techniques tried to resolve this 
problem, the technique referred to as ‘standard doping’ should be accurate and is 
relatively simple to perform. In this technique samples are counted once and then a 
small accurately determined quantity o f the standard is added to each sample and 
then the samples counted again. When employing this technique it is important for 
the two sets o f countings to be performed close together in time because the 
quenching properties of the plasma samples appears to change with time.
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4.4.5 Assessment of whole body parameters for normalising GFR
The main purpose o f the studies performed on Group A, where multiple whole body 
parameters were measured in conjunction with GFR, was a pilot study to look at the 
feasibility of performing these measurements on a larger group o f normal subjects, 
with no expectation that the results would be statistically significant. However the 
results show that when normalising GFR to any o f the independently measured 
whole body parameters that the spread o f the normal values was greater than when 
normalising to surface area or ECV estimated from the distribution volume o f the 
GFR tracer. The spread was so great with exchangeable potassium that the 
differences in the variance compared with the surface area normalised measures was 
significant even though the numbers were so small. It was therefore concluded that a 
study on a larger number o f normal volunteers would be highly unlikely to reveal a 
better whole body parameter to normalise GFR to than surface area or the 
distribution volume o f the GFR tracer. It should be remembered that there are two 
reasons why a particular whole body parameter might be likely to give a greater 
spread o f normal normalised GFRs than another. One is because it is indeed a less 
suitable parameter to index GFR to, but the other could be because the measurement 
error is greater. Because as stated is was concluded that a larger study would be 
highly unlikely to reveal a better whole body parameter and because o f the complex 
nature o f the multiple isotope study and the difficulties o f performing studies on 
large groups o f normal volunteers, it was decided not to proceed to a similar study on 
a larger number o f normal volunteers.
However returning to the pilot study on Group A, within the limitations o f the study 
and although most of the differences do not reach the level o f significance, the order 
o f the magnitude of the coefficients o f variation is certainly consistent with 
extracellular fluid volume being the most appropriate fluid compartment for 
normalising GFR.
With the larger Group B, where only the GFR tracer was administered differences in 
variability between GFR indexed to surface area and the measures o f GFR indexed to 
the distribution of the GFR tracer were investigated. Because in this case, the aim 
was to identify which would be the most appropriate method to use for indexing 
GFR in routine clinical practice, any differences in measurement error between the 
methods would be relevant to this question.
Again although none o f the differences in the variability o f the normal values reach 
significance with the results from Group B it may be possible to draw some cautious 
conclusions
• There is no evidence that GFR derived from the full curve is likely to give a 
tighter normal range than that derived from the single exponential fit to the 
later points, as might be expected if  the full curve method was giving a more 
accurate estimate o f GFR.
• There is no evidence that one of the Haycock or Du Bois surface area is likely 
to prove superior for normalising GFR.
• There is no evidence with the full curve method that normalising GFR to 
surface area is likely to give a tighter normal range than normalising GFR to 
the distribution volume of EDTA.
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• There is no evidence with the usual clinical method o f taking samples from 
120 minutes onwards that normalising the Brochner-Mortensen corrected 
slope-intercept GFR to surface area is likely to give a tighter normal range 
than using slope only to derive a GFR already normalised to the distribution 
volume o f EDTA.
An important issue in terms o f normalisation is whether the current practice of 
normalising GFR to surface area (derived from either the DuBois or Haycock 
formulas) is appropriate for all ages. It might have been possible to show some 
definite advantage o f surface area or extracellular fluid volume if  it had been possible 
to do a similar study including children in the population studied.
In Bird et al (2003), the full text o f which is included in Appendix B, the author and 
co-workers have studied a large series o f clinically referred GFRs in children and 
adults. Here we have shown that in children GFR normalised to surface area is lower 
than GFR normalised to extra cellular fluid volume (ECV) derived from the slope of 
the terminal exponential (Appendix B. Fig 5). And although this was not a normal 
population, from the general spread o f results it was concluded that normal expected 
GFR/ECV is likely to be highest in young children and steadily declines with age. 
Whereas normal expected GFR/BSA would appear to rise during childhood and 
before starting to decline during adulthood (Appendix B. Fig 6 ). It should be noted 
that there were no children under 12  months old and so it was not possible to draw 
any conclusions about changes in normal GFR/ECV in the first year o f life. In the 
paper making the assumption that for a true reflection o f renal function GFR is better 
normalised to ECV than surface area, we concluded that normal renal function is 
likely to follow the pattern o f being maximal at least by the age o f 1 and then 
declines throughout life. And that normalising renal function to surface area is likely 
to lead to an underestimate of true renal function when comparing with normal 
ranges in young children.
The overall conclusion o f this chapter is that the measure o f GFR normalised to ECV 
derived from the rate constant of the terminal exponential is for adults at least as 
good a measure of normalised GFR as GFR normalised to surface area or any of the 
other whole body parameters studied.
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CHAPTER 5: Reproducibility and the Effect of Food Intake
5.1 INTRODUCTION
It is important to assess the reproducibility of any quantitative diagnostic test in order to 
define its clinical value and to specify its limitations. Variation on repetition arises from 
a combination of physiological variation and measurement error. For glomerular 
filtration rate (GFR), there is an underlying diurnal variation (Sirota et al 1950, Wesson 
and Lauler 1961) as well as changes in response to external stimuli, for example exercise 
(Svarstad et al 2002) and food intake (Wilkinson et al 1990, De Santo et al 1995). The 
diurnal rhythm in GFR is thought to reflect changes in circulating atrial naturetic peptide 
rather than arterial pressure (Voogel et al 2001). In many clinical situations GFR is 
measured on repeat occasions to investigate a possible deterioration in renal function 
either due to nephrotoxic drugs or when monitoring the slow progression of chronic 
renal failure (CRF). The significance of any observed change is vitally important. 
Wilkinson et al 1990 found a coefficient of variation of duplicate measurements of GFR 
measured with Tc-99m DTPA of 8 % under ideal conditions. This means that for a 
change to be statistically significant with 95% confidence it has to be more than V2 
x 1.96 x 8 % i.e. more than 22%. Measures to ensure optimum precision (reproducibility) 
will be central to achieving maximum clinical value and any improvement in precision 
could well bring an important increase in clinical value.
In this study the reproducibilities o f GFR measurements based on the plasma clearances 
of chromium-51-etheylenediamine tetraacetic acid (51Cr-EDTA) and iohexol were both 
investigated. Iohexol has been used for measurement of GFR by some centres (Nilsson- 
Ehle 2001, Frenby et al 1995). There are advantages to using a non-radioactive method 
for measuring GFR. In the clinical setting, patients may be able to have the test more 
locally, with samples then being sent to a central laboratory rather than the patient 
having to travel to a specialist centre where radionuclide studies can be carried out. This 
could be an advantage for the individual but could also increase the use of the GFR test. 
Also in the research setting both the absence of a radiation dose and reducing the need to 
for research subjects to travel could make it more feasible to do long-term studies of 
progression of CRF and the efficacy of new therapies.
The principal aims addressed in this chapter are:
• To determine the reproducibility of GFR measured with Cr-51 EDTA and 
Iohexol and to compare the two. This comparison will be dependent on the 
particular experimental procedures used.
• To compare the reproducibility of measures of GFR derived from just the late 
samples (2, 3 and 4 hours) with those derived from the 6  samples that attempt to 
measure the bi-exponential clearance
• To compare the reproducibility GFR normalised to ECV derived principally 
from the slope of the clearance curve from the late samples with the conventional 
GFR derived from the slope and the intercept of the late samples.
• By performing the reproducibility experiments on volunteers using two tracers 
simultaneously that should give independent measures of GFR it will be seen 
whether it is possible to estimate the extent to which the variation in repeat
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measurements of GFR is the result of real variation in the GFR and the extent 
due to experimental error.
• To compare fasting and non-fasting measures of GFR. This will be partly to 
assess the importance of controlling the food intake prior to the GFR test to 
ensure maximum precision. But also to aid in assessing tracers and methods of 
calculating GFR as methods with greater precision should be better at 
demonstrating the expected real change in GFR.
• To assess whether measuring plasma iohexol concentrations with high 
performance liquid chromatography (HPLC) is superior to X-ray fluorescence. 
HPLC was only implemented part way through the study and so only samples 
from some of the subjects were analysed with this method
5.2 METHODS
5.2.1 Subjects
Twenty healthy volunteers (7 male, 13 female, age range 30-59 [median 45], body mass 
index 18-34 [22] kg/m2 and body surface area 1.48-2.09 [1.77] m2), with no history of 
allergy to iodine-containing contrast agents were recruited. They were all studied twice, 
once in the morning after an overnight fast and once in the morning after breakfast. Ten 
were studied on a third occasion in the morning after an overnight fast. For each subject, 
the 2 or 3 studies were completed within six weeks. On each occasion plasma creatinine 
was measured from a blood sample taken at the beginning of the study just prior to the 
administration of the tracers.
Volunteers were instructed to fast from midnight before the study until after the study 
was completed. Water and one cup of tea or coffee were permitted on the morning of 
and prior to the start o f the study. For the non-fasting study, volunteers were asked to 
follow their usual overnight and breakfast routines. Subject height and weight were 
measured at the time of the first study only, except in one volunteer, an amateur boxer 
who was training for a contest, in whom it was measured on all 3 occasions.
All volunteers gave informed consent and the study was approved by the local research 
ethics committee and Administration of Radioactive Substances Advisory Committee of 
the United Kingdom.
5.2.2 Tracers
51Cr-EDTA (Amersham Health, Bucks, UK) was diluted with benzyl alcohol containing 
sodium chloride solution (1% by volume benzyl alcohol, 0.75% by weight NaCl) to 
make a stock solution with a concentration o f 1 MBq/ml. Iohexol (Omnipaque 300; 
Amersham Health, Bucks, UK) was delivered in 20 ml vials containing 300 mg 
iodine/ml. Syringes were weighed before and after drawing up the markers. Two ml of 
the 51Cr-EDTA stock with an activity of approximately 2 MBq and 19 ml iohexol 
containing 5.7 g iodine were injected.
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5.2.3 Administration of tracers
Intravenous lines were inserted into each ante-cubital fossa. The markers were injected 
on separate sides and then each assayed in the samples drawn contralaterally to the side 
injected. The markers were injected in close sequence, the time half way through 
injection being noted as the time of injection. The 51Cr-EDTA usually took less than 5 
sec to administer but the larger volume of viscous iohexol took up to 30 sec to inject. 
Immediately after administration of the bulk of the marker, the syringe was flushed 
several times with normal saline to ensure complete administration of the weighed 
amount, this procedure adding less than 2 0  seconds.
5.2.4 Blood sampling
A baseline blood sample was taken prior to the administration of the tracers as was the 
blood sample assayed for plasma creatinine. 10 ml blood samples were taken from both 
lines nominally at 20,40, 60, 120, 180 and 240 min after marker administration. 
Approximately 3 ml of liquid was withdrawn from the line and discarded prior to the 
collection o f each blood sample, to ensure that samples are representative of circulating 
blood and are not diluted by the liquid contained in the line prior to the sample being 
taken. The mid-time point time of sampling was taken as the sampling time. Line 
patency was maintained with heparin-saline. The samples were transferred from the 
syringe into heparinised glass tubes, centrifuged at 800-1000 G for 15 min and plasma 
separated.
5.2.5 Cr-51 EDTA sample analysis
For each stock solution of 51Cr-EDTA, two volumetrically diluted 1:1000 standards 
were prepared. 3 ml aliquots of plasma, standards and water (as a blank) were counted 
in an automatic gamma counter (Wallac 1480 Wizard 3”, Turku, Finland) which is a 
well counter with a 3” sodium iodide scintillation detector. Each sample was counted for 
1000 sec with an energy window of 250 to 380 keV for the 320 keV gamma emission of 
Cr-51. Appropriate corrections were made for counter dead-time, background and 
radionuclide physical decay during counting. If the corrected counts in the two standards 
differed by more than 2% then an additional standard was prepared and the two closest 
standards used (if they differed by less than 2%). The volume of Cr-51 EDTA 
administered was determined from the total weight drawn up into the syringe assuming 
no post-injection residue and assuming a density of the Cr-51 EDTA solution of 1 g/ml. 
The concentrations of the standard and subsequently the plasma samples were expressed 
as percent of the injected dose per litre (%/L).
5.2.6 Iohexol sample analysis by X-ray fluorescence
It has previously been demonstrated that it is possible to measure the concentration of 
iodine containing radiographic contrast agents using X-ray fluorescence (XRF) (Brown 
and O’Reilly 1991, Frenby et al 1995). These groups used a purpose built XRF analyser 
that used two 11 GBq americium-241 sources for the irradiation and measured the K- 
line characteristic X-rays from iodine at around 30 keV with a sodium iodide 
scintillation detector. With this technique scattered primary photons that enter the 
detector have energies around 54 keV. One problem with this method is that with the 
sodium iodide detector there is an iodine escape peak from the detection of these 
scattered primary photons close in energy, and usually much larger than, the peak due to
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the iodine characteristic X-rays which makes accurate determination o f the iodine 
concentration difficult. Gronberg et 1983 demonstrate using a solid state germanium 
detector which doesn’t suffer from the iodine escape peak problem. In this study the use 
of a commercially available XRF analyser (Lab X 3500, Oxford Instruments) was 
investigated. This uses an X-ray generator for the irradiation and a gas filled (argon) 
proportional counter for the detector. This equipment was leased for the duration o f this 
project. For each subject iohexol concentration in the plasma samples was assayed by X- 
ray fluorescence (XRF) o f the iodine content. For each sample, a disposable holder is 
assembled in which the sample is separated from the irradiation beam and the detector 
by a taut piece o f 6 pm  thick film (Fig 5.1)
sample
film
DetectorX-ray source
Fig 5.1: Diagram of the X-ray fluorescence analyser and photograph of the sample holders.
Before commencing the study measurements were made to demonstrate that the 
determination of iodine concentration is not dependent on the volume o f sample above a 
volume o f 1.5 ml which is required to evenly cover the film. The parameters o f the 
analyser were optimised for measuring the L characteristic X-rays from iodine at ~ 4-5 
keV. The X-ray target was palladium, the voltage 9 kV and the tube current 100 pA. The 
detector was filled with argon. Once the sample was inside the analyser, air was 
displaced from the measuring chamber by helium gas to prevent emission of 
characteristic X-rays from argon in the air or absorption of the characteristic X-rays 
from the iodine by argon. The energy window of the detector was set to include all the L 
characteristic X-rays from iodine but to minimise the background by examining the 
spectrum from normal plasma and plasma containing iohexol. The analyser was 
calibrated by preparing plasma standards with accurately known concentrations o f the 
iohexol from the same production batch administered to the subjects. The standards were 
prepared so that each had 0.1 ml of added solution to 3.8 ml of plasma to ensure a 
consistent background signal. The concentrations were 0, 0.34, 0.69, 1.03, 1.36, 1.72 and 
3.39 g/L chosen to cover the whole range of concentrations likely to be measured in 
samples. The standards were counted several times and the mean counts per second 
(cps) for each standard was plotted against iohexol concentration and a calibration factor 
was derived from the linear fit (Fig 5.2). This calibration was repeated several times 
during the two and a half years of using the system, and the gradient was consistent to 
within +/- 2%. Each sample to be analysed was irradiated for 300 seconds and this was 
repeated three times. The average cps from the baseline plasma sample for that subject 
was subtracted from the average cps for the other samples. The cps was then converted 
into an absolute concentration of iohexol in g/L. This was then expressed as a
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concentration in %/L o f the injected dose, using the measured weight o f the 
administered iohexol. It was discovered that if samples were left in the sample holders 
prior to being analysed then some evaporation o f liquid can take place and so each 
sample was only transferred to a sample holder immediately prior to analysis.
500 4   ---------------------------- — i ----------------------------------------------------------------------------------- ------------------- --------------------------------------
0 0.5 1 1.5 2 2.5 3 3.5
concentration of Iohexol g/L
Fig 5.2: Calibration plot of cps from the X-ray fluorescence analyser against known iohexol 
concentration.
5.2.7 Iohexol sample analysis by High Performance Liquid Chromatography
It has previously been demonstrated that it is possible to measure the concentration of 
Iohexol with High Performance Liquid Chromatography (HPLC) (Krutzen et al 1984, 
Nilsson-Ehle 2001). For this study an HPLC system was purchased and an iohexol assay 
established. This was used for the last subjects to be studied in parallel with XRF 
analysis.
Preparation o f solvents.
A citric acid / citrate buffer solution was prepared. The quantities o f citric acid and 
sodium citrate were calculated to give a target molarity o f 20 mM and a target pH o f 4.5. 
2.91 g HPLC grade sodium citrate (tri-unsaturated salt) and 2.14 g HPLC grade citric 
acid (both Fisher Scientific, UK) were dissolved in 1000 ml HPLC grade water using a 
magnetic stirrer. The pH o f the buffer was tested with a pH meter which was calibrated 
before each use with standard pH 7.01 and pH 4.01 solutions. The pH o f the buffer was 
adjusted to 4.5 (+/-0.05) if necessary with sodium hydroxide or more citric acid. The 
buffer solution was stirred for 30 minutes to reduce the dissolved gas. The buffer was 
then filtered through a 0.45 pm filter (Millipore Corporation, MA, USA) using a suction 
system. HPLC grade acetonitrile (Fisher Scientific) was then added to give 5% by 
volume i.e. 54 ml to 1000 ml buffer and the mixture mixed well. This acetonitrile / 
buffer solution was solvent A. Solvent B was 100% HPLC grade methanol (Fluka, 
Germany). A 0.33 M solution of HPLC grade perchloric acid (Fisher Scientific) was also 
prepared for deproteinising the plasma.
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Preparation of samples
0.8 ml of each plasma sample was pipetted into a pre-weighed plastic sample tube which 
was then re-weighed to determine the mass of plasma. The volume o f plasma in each 
tube was calculated from the density of plasma for that subject assuming the average 
volume pipetted for the 7 samples was 0.8 ml. Then 3.2 ml of the 0.33 M perchloric acid 
solution was pipetted into the sample tube and the tube re-weighed to determine the 
mass of acid added. The volume of acid was determined from the density o f the acid 
assuming the average volume pipetted was 3.2 ml. Hence the dilution factor for each 
sample was determined as accurately as possible. The sample tube was then centrifuged 
at 1000G for 15 minutes to precipitate the aggregated proteins to the bottom of the tubes.
0.5 ml o f the clear protein free diluted plasma was drawn up into a 2 ml luer lock 
syringe. 0.1-0.2 ml was then filtered through a 0.2 pm hydrophylic filter (Milex-LG, 
Millipore Corporation) into a 1.5 ml glass sample vial designed for use in the HPLC 
auto-sampler.
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Fig 5.3: Diagram of solvent gradient in the HPLC protocol 
HPLC System and protocol
The HPLC system was from Agilent Technologies and a G1379A Online degasser, a 
G1312A Binary Pump, a G1313A automatic injector and a G1314A UV detector. The 
column used was a C l8 25cm x 4.6mm, 5 pm (Discovery, Supelco, PA, US). Samples 
were analysed with the pump running at 0.9 ml/min. The column is equilibrated running 
100% solvent A. A gradient was set up so that for 10 minutes after sample injection 
100% solvent A is run and then between 10 and 11 minutes there is a gradient linearly 
increasing the proportion of methanol (solvent B) up to 100%, then 100% methanol is 
run for 2 minutes, then between 13 and 14 minutes there is a gradient decreasing the 
proportion of methanol down to 0%. Then from 14 to 30 minutes the system is run with
—  - solvent A 
 solvent B
T
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100% solvent A to re-equilibrate the column prior to injection of another sample at 30 
minutes. This is graphically illustrated in Fig 5.3.
The peaks for iohexol appear before 10 minutes, the purpose of the methanol gradient is 
to flush the column of constituents of plasma with longer retention times. The volume of 
sample injected was set to 20 pm  and each sample was analysed twice immediately in 
sequence. The UV detector was set for a wavelength of 254 nm. Iohexol exists in two 
isomeric forms which appear as two separate peaks. The maximum of the first peak 
(peak 1) appears between 6.5 and 6.8 minutes and the maximum of the second peak 
(peak 2) between 7.2 and 7.5 minutes in HPLC traces. The peaks were easily identified 
in all samples analysed. The areas under the peaks were determined after subtracting the 
trace baseline fixed to standard time points. The area of Peak 1 was determined from 
integrating between the time o f the minimum of a repeatedly identified trough before the 
peak and the minimum of the trough between peak 1 and peak 2. After peak 2 the trace 
reliably returned to its baseline and so the area o f peak 2 was taken from integrating 
between the end of peak 1 and a fixed time point on the baseline after the peak see Fig 
5.4. As expected no iohexol peaks were identified in the baseline plasma samples, 
therefore the ‘areas under the peaks’ were determined by integrating between the time 
points determined for peaks in the samples analysed immediately prior to and 
immediately after these baseline samples.
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Fig 5.4: Example HPLC trace from the lowest concentration plasma sample from a subject.
The HPLC was calibrated using the same plasma standards as used to calibrate the XRF 
system. These were prepared for the HPLC system in the same way as subject samples
i.e. deproteinisation with perchloric acid etc. The area under peak 2 and peak 1 plus peak
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2 was plotted against the concentration of iohexol and calibration factors derived from 
the linear fits (Fig 5.5). Each sample was analysed twice, all the samples being analysed 
once in order starting with the lowest concentration sample and then once starting with 
the highest concentration. The areas from the baseline sample were subtracted and the 
sample areas converted into absolute concentrations of iohexol using the calibration 
factors. Both the area under peak 2 and the sum of peakl plus peak 2 were considered. 
The concentrations were then expressed in %/L of the injected dose, using the measured 
weight o f iohexol administered.
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Fig 5.5: Calibration plots of area under peak 2 and peak 1 and 2 combined from HPLC against 
known iohexol concentration.
5.2.8 Data analysis
The plasma time-concentration curves for both markers usually appeared bi-exponential 
between 20 to 240 min, consistent with a 2-compartment model o f distribution. The 
zero-time intercepts of the fast and slow exponentials were denoted A and B, 
respectively, and the corresponding rate constants, oq and a 2 . Two methods o f fitting the 
bi-exponential were used, a curve stripping technique and an iterative technique.
Curve stripping
The curve stripping technique essentially has two iterations.
© A single exponential fit is performed to the concentrations o f the last three blood 
samples giving a first estimate o f B and ci2 for the slow exponential.
• The contribution of this first estimate of the slow exponential is subtracted from 
the measured concentrations of the early three blood samples. Then a single 
exponential fit is performed to the resultant values for these three samples, giving 
a first estimate of A and ai for the fast exponential.
• The contribution of this first estimate of the fast exponential is then subtracted 
from the measured concentrations for the last three blood samples. Then a single
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exponential fit is performed to the resultant values for these three samples, giving 
a second/final estimate of the slow exponential.
• The contribution of this second estimate of the slow exponential is subtracted 
from the measured concentrations of the early three blood samples. Then a single 
exponential fit is performed to the resultant values for these three samples, giving 
a second/final estimate of the fast exponential.
Iterative fitting
The iterative technique gives a general bi-exponential fit that will usually give a closer 
fit to the measured data than the curve stripping technique. The basics of how the 
iterative fitting program works (Fylstra et al 1998) are as follows
• An initial estimate of the variables, in this case A, a i, B and 012, is made. Here the 
solution from the curve stripping technique was used.
• The weighted sum of squares o f the errors is calculated -  denote E
7 = 1
where tj, y* are the points to be fitted a;, is chosen to
be Vyi which represents the error due to counting statistics.
• Each variable is considered in turn -  denote the current variable V
• An appropriate small increment to that variable is chosen, AV
• The sum of squares of the errors is recalculated with the current variable set to 
V+AV and then V-AV and the other variables unchanged - denote E v+av and Ey.Av*
• An estimate of the first partial derivative of the error function with respect to V 
(dE/dV) can be made for V+i4AV and V-'AAV. (Ev+av-E)/A V  and (E -E v-av)/A V
• If the second partial derivative of E with respect to V ( ((E v+av-E )/A V  - (E-Ey. 
av)/A V )/A V  ) is positive then it is possible to predict the existence of a minimum in 
the error function with respect to V (see Fig 5.6)
• An adjustment to the estimate of the current variable towards the predicted minima is 
made
• Then the second variable is considered
• All the variables are considered many times in an iterative fashion
• The solution converges if with further iterations there is no further reduction in the 
error
Predicted s '
position of
minimum in s '
error function
V -’/ jAV V+/4AV V-AV V  V+AV
Fig 5.6. Diagramtic representation of Error function with varying one variable (V)
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The implementation o f this iterative technique used was from the ‘Solver’ (Lasdon and 
Warren, Frontline Systems, NV) provided with Excel (Microsoft corporation).
nGFRctrip and nGFR,>
GFR was derived from the bi-exponential fit to the clearance curve from all 6  samples 
from the following formula:
GFR= 1000 [ml/L]/(A/ai+B/a2) [ml/min] (Nosslin 1965)
These GFRs were then normalised to the estimate of the surface area o f the patient 
derived from the DuBois formula (DuBois and DuBois 1916). The surface area 
normalised GFR derived from the curve stripping technique was termed nGFRstriP and 
that derived from the iterative fit was termed nGFRjt
GFR/ECVctrip and GFR/ECV,>
GFR divided by the distribution volume (DV) of the tracer is derived from the bi­
exponential fit to the clearance curve from all 6  samples from the following formula: 
GFR/DV = (A/ar+B/a2)/(A/ai2+B/a22) [m in1]
DV is an estimate of ECV and in order to get a measure of normalized GFR of similar 
magnitude to nGFR the term ‘GFR/ECV’ is used to mean GFR/ECV multiplied by an 
average adult ECV of 13680 ml. This comes from Chapter 2 where the average surface 
area normalised distribution volume of Cr-51 EDTA was found to be 13.68 L/l.73m2 
this value was used for iohexol as well as Cr-51 EDTA. Hence:
GFR/ECV = 13680.(A/ai+B/a2)/(A/a,2+B/a22) [ml/min/13.68L]
Again this was calculated from the curve stripping fit and the iterative fit and termed 
GFR/ECVstrip and GFR/ECVit.
ECV
The measure ECV was the estimate of ECV derived from the distribution volume of the 
tracer derived curve stripping fit to the bi-exponential clearance curve.
ECV = (A/ai2+B/a22)/(A/ai+B/a2) 2 [L] (Nosslin 1965)
nGFRnM
A single exponential with intercept B’ and rate constant (12 (to distinguish them from B 
and <X2, the corresponding variables obtained from the 6 -point curve) was fitted to the 
last 3 sample points, nominally at 2,3 and 4 hours. The GFR is then calculated from the 
slope (a2’ [min'1]) and intercept (B’ [%/L]) of the fitted single exponential with GFRsi = 
1 0 0 0 [ml/L].a2’/B’ [ml/min]. This slope intercept GFR is then normalised to surface area 
nGFRsi = (1.73/suface area [m2]).GFRSi [ml/min/1.73m2]
The normalised slope-intercept GFR is then corrected for the one pool assumption using 
the Brochner-Mortensen (1984) correction and termed nGFRBM- 
nGFRBM = 0.9908 * nGFRSi-0.001218 * nGFRs 2 [ml/min/1,73m2]
GFR/ECVi and GFR/ECV?
Again using only the late samples c^’is an estimate of GFR/ECV. To 012’ a correction for 
the one pool assumption is applied, two forms of this are used one based solely on 012’ 
itself and one based also on the intercept B’ and the surface area (SA). These corrections 
were derived in chapter 2 and again are multiplied by an average adult ECV of 13.68 L.
123
GFR/ECV, = 13680 * (0.9462 * a2’ + 23.11 * (a2’)2) [ml/min/13.68 L]
GFR/ECV2 = 13680 * (0.9666 * a2’ + 1.155 * (1.73/SA) * (a2’)2/B’) [ml/min/13.68 L]
5.2.9 Estimated GFR (eGFR) from plasma creatinine
The plasma creatinine concentrations were converted into estimated GFRs using a 
formula from Levey et al (2000).
eGFR = 186x creatinine[fjmol / L]
88.4
black) ml/min/1.73m2
x age[years] 0 203 x (0.742 if female)x(1.21 if
5.2.10 Statistics
Reproducibility
Estimates of repeatability were made from the within subject standard deviation for the 
volunteers who had repeat fasting measurements. This comes from the one-way analysis 
of variance (Bland 2000):
iv(xi -x2 y
Within subject standard deviation = J -
2 n
where xi and X2 refer to first and second measurements and n is number of paired 
measurements.
The within-subject coefficient of variance (CV) was calculated from within subject 
standard deviation and the overall mean.
X, -x-
Comparison of reproducibility between different methods and markers was made from 
the F-test on the ratio of within subject variances.
The standard deviation of the differences between repeat measures of GFR is a 
combination of the real changes in GFR and error in the two measurements and 
approximates to ([standard deviation of the real differences]2 + 2  x [measurement 
error]2)05.
Effect of food intake
The difference between fasting and non-fasting GFR was evaluated for all measures of 
GFR using the paired Student t-test. For volunteers with 2 fasting measurements, the 
difference was based on the first of the 2  and then again on the average of the 2 .
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5.3 RESULTS
5.3.1 Reproducibility
One subject (an amateur boxer training for a contest) studied 3 times displayed a weight 
change of 7.5% between his 2nd (non-fasting) and 3rd (fasting) studies. Otherwise normal 
volunteer weight was assumed to remain unchanged.
Comparing iterative fitting with curve stripping
Mean Mean
difference
between
replicates
SD of 
differences
Within
subject
standard
deviation
C V
nGFRstrip 
(ml/min/1.73m2)
89.9 -2.4 1 0 .6 7.3 8.1 %
nG FRit 
(ml/min/1.73m2)
89.2 -2.5 11 .2 7.7 8 .6  %
GFR/ECVstrip  
(ml/min/13.6 8L)
91.0 -5.3 8 .8 7.0 7.7 %
G F R /E C V it 
(ml/min/13.6 8L)
8 8 .8 -6 .2 12.3 9.4 10.5%
Table 5.1: Reproducibility of fasting GFR measures from complete plasma clearance curve with 
Cr-51 EDTA (n=10) comparing iterative fitting and curve stripping methods.
For Cr-51 EDTA the iterative fitting technique always produced a tighter fit to the six 
points compared to the curve stripping technique, reducing the sum of squares of the 
errors by between 4 % and 91 % (mean 43 %). For iohexol the iterative fitting also 
always reduced the sum of squares of the errors (range 2 % - 87 %, mean 43 %). 
However, in 4 out of 50 iohexol clearances the iterative technique converged to a 
solution with a2 = 0, i.e. the best fit was a single exponential plus a constant. This gives 
an infinite area under the clearance curve and hence a GFR of 0. In two further iohexol 
clearances the iterative technique converged to a solution with a very fast first 
exponential with a very high magnitude. This gave spurious GFR results of 2.5 and 0.5 
ml/min compared to 111 and 118 ml/min with the curve stripping technique. Therefore 
iterative fitting was deemed to have failed in 6/50 iohexol clearances so it was 
abandoned with respect to iohexol studies. Table 5.1 shows GFR reproducibility under 
fasting conditions for Cr-51 EDTA based on all 6  plasma samples. From F-testing, there 
were no significant differences between any of the methods with respect to within- 
subject variances. However, the variability of the results was greater with iterative fitting 
compared to curve stripping, rather than the other way round.
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Comparison of measures of GFR
Mean Mean
difference
between
replicates
SD of 
differences
Within
subject
standard
deviation
CV
nGFRBM 
(ml/min/l ,73m2)
8 8 .2 -0.4 9.7 6.5 7.4 %
nGFRstrip
(ml/min/l ,73m2)
89.9 -2.4 1 0 .6 7.3 8.1  %
GFR/ECVslnp 
(ml/min/l 3.6 8 L)
91.0 -5.3 8 .8 7.0 7.7 %
GFR/ECVi 
(ml/min/l 3.6 8 L)
91.3 -5.8 10.3 8 .0 8 .8  %
g f r / e c f v 2
(ml/min/l 3.6 8 L)
91.0 -5.2 9.8 7.6 8.3 %
ECV (L) 13.8 +0.51 1.33 0.96 7.0 %
1/B’ (L) 17.0 + 0.9 2.3 1.7 9.9 %
Table 5.2: Reproducibility of fasting GFR measures with Cr-51 EDTA (n=10)
Mean Mean
difference
between
replicates
SD of 
differences
Within
subject
standard
deviation
C V
nGFRsM 
(ml/min/l .73m2)
83.8 + 0 .6 9.5 6.4 7.6 %
n G F R strip 
(ml/min/l.73m2)
84.4 + 1.9 12.9 8.7 10.4 %
GFR/ECVstrip  
(ml/min/l 3.6 8 L)
89.7 + 5.3 16.7 11 .8 13.2 %
G F R /E C V i 
(ml/min/l 3.6 8 L)
90.1 + 5.8 20.3 14.6 16.2%
G F R /E C F V 2 
(ml/min/l 3.68L)
89.3 + 5.2 19.2 13.4 15.0%
E C V  (L) 13.4 -0.45 1.14 0.83 6 .2  %
1/B’ (L) 16.4
0001 2 .1 1.5 9.4 %
Table 5.3: Reproducibility of fasting GFR measures with lohexol measured with XRF (n=10)
Table 5.2 shows a summary of the reproducibility under fasting conditions o f measures 
of G F R  from all 6  samples and just the final 3 for Cr-51 E D T A , along with 1/B’ and 
E C V . From F-testing, there were no significant differences between any of the measures 
of G F R  with respect to within-subject variances. Table 5.3 shows the corresponding data 
for iohexol for which F-testing shows G F R /E C V strip, G F R /E C V j and G F R /E C V 2 had 
significant greater within-subject variances compared to GFRBm (p < 0.05).
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With iohexol the mean weighted residual error when fitting the single exponential to the 
final 3 samples was significantly greater than with Cr-51 EDTA (8 x l0 '5 c.f. 2 x l0 '5, 
PO.OOl). This was also true for the residual error when fitting the bi-exponential to all 6 
samples (2 lxlO '5 c.f. 6x1 O'5, PO.OOl) Comparing the tracers GFR/ECVi and 
GFR/ECV2 had significantly higher within-subject variances with iohexol than with Cr- 
51 EDTA (PO .05). In contrast the within subject standard deviation for nGFRBM was 
almost identical between Cr-51 EDTA and iohexol.
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Fig 5.7: Relation between fractional changes in nGFRstrip, based respectively on Cr-51 EDTA 
and iohexol, between the first and second fasting measurements.
The changes between the two separate and independent measurements o f fasting nGFR 
based respectively on 51Cr-EDTA and iohexol correlated with each other (R=0.89, n=10, 
P<0.001) (Fig 5.7) indicating that the variation between the two measures reflects, at 
least partly, real changes in GFR. This correlation was also significant for GFR/ECV 
whether the subject with a weight change was excluded or not (R=0.69, n=9, P<0.05 and 
R=0.64, n=10, PO .05). This is in contrast to fasting 1/B’ and ECV (Fig 5.8), both of 
which showed no significant correlations between corresponding changes (P>0.05).
Plasma creatinine in the fasted subjects ranged from 48 to 138 pmol/L (mean 78 
pmol/L). The coefficient o f variation in the replicates was 15.5 %. When the plasma 
creatinine was converted into the estimated GFR (eGFR) the coefficient o f variation was 
essentially the same (15.3 %). There was a significant correlation between the change in 
eGFR between the two fasted measures and the change in nGFRstrip measured with Cr- 
51 EDTA (R=0.73, P<0.05). There was one subject, again the amateur boxer, who had a 
big difference between the two fasted measures o f GFR, nGFRstrjP with C r-51 EDTA 
was 83 and 101 ml/min/l.73m2 respectively whose corresponding plasma creatinines
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were 138 pmol/L (which is abnormal) and 93 pmol/L respectively giving eGFR values 
of 56 and 88 ml/min/l .73m". This difference between the renal function on the two 
occasions could have been a result of his training. If this subject is excluded then the 
correlation between change eGFR and nGFRstrip with Cr-51 EDTA becomes much 
weaker and not significant (R=0.29).
.10
o
X©£o 1
>oHi
0.90
x
0.13
CM
§* 0.80
03*4-
I.70
.60
0.70 0.900.80 1.00 1.10 1.20 1.30
fa stin g 2 /fa stin g 1  ECV Cr-51 EDTA
Fig 5.8: Relation between fractional changes in ECV, based respectively on Cr-51 EDTA and 
iohexol, between the first and second fasting measurements. The subject in whom there was a 
7.5 % weight change is indicated in pink.
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Fig 5.9: Relation between fractional changes in a2’ and 1/B’ between the first and second fasting 
measurements for Cr-51 EDTA.
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Fig 5.10: Relation between fractional changes in a2’ and 1/B’ between the first and second 
fasting measurements for iohexol.
The fractional changes in 1/B’ correlated with the corresponding fractional changes in 
012’ between the two fasting measurements for both MCr-EDTA (Fig 5.9) and iohexol 
(Fig 5.10), suggesting that the change in 1/B’ resulted from errors in fitting 012’. In 
contrast, there were no significant correlations when fractional changes in 1/B’ or ECV 
based on one marker were compared with fractional changes in 0 ,2 ’ based on the other. 
The patient with the 7.5 % weight gain was excluded from these comparisons as a real 
change in ECV and hence 1/B’ would be expected.
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5.3.2 Effect of food intake
Measure Mean fasted Mean difference 
with food intake
P value 
* P<0.05 
** P<0.01
nGFRsM 
(ml/min/l.73m2)
87.9 + 4.9 0.0045 **
nGFRstrip
(ml/min/l.73m2)
89.3 + 4.6 0.0067 **
GFR/ECVstrip
(ml/min/13.68L)
90.8 + 3.1 0.052
GFR/ECVi 
(ml/min/l 3.6 8 L)
91.0 + 2.9 0.086
g f r / e c f v 2
(ml/min/l 3.6 8 L)
90.7 + 3.1 0.046 *
ECV (L) 14.0 + 0.30 0.17
1/B’ (L) 17.2 + 0.85 0.077
Table 5.4: Effect of fooc 
10 subjects in whom it \
intake on GFR based on Cr-51-EDTA (n=20). The fasting value in the 
vas measured twice was the first
Measure Mean fasted Mean difference 
with food intake
P value 
* P<0.05 
** PO.01
nGFRBM 
(ml/min/l .73m2)
87.8 + 5.0 0.0015 **
nGFRstrip 
(ml/min/l.73m2)
88.7 + 5.2 0.0013 **
GFR/ECVstrip
(ml/min/13.68L)
89.4 + 4.5 0 .0 2 2  *
GFR/ECVi 
(ml/min/l 3.6 8 L)
89.5 + 4.3 0.035 *
g f r / e c f v 2
(ml/min/l 3.6 8 L)
89.4 + 4.4 0.018*
ECV (L) 14.1 + 0.17 0.29
1/B’ (L) 17.5 + 0.62 0.15
Table 5.5: Effect of food intake on GFR based on Cr-51-EDTA (n=20). fhe fasting value in the
10 subjects in whom it was measured twice was the average o f the two
The mean non fasting GFR was greater than the mean fasted GFR for all the measures 
with both tracers. This was also true whether only the first fasted study was considered 
or both fasting studies were considered for the 50% of subjects who had two fasting 
studies. Table 5.4 summarises the results for Cr-51 EDTA when only the first fasting 
study is considered. The increases as a result o f food intake were significant for
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iiGFRbm, nGFRstrip (P<0.01) and GFR/ECV2 (P<0.05) but although quantitatively 
similar were not significant for G F R /E C V strip and G F R /E C V i. On average there was an 
increase in ECV and 1/B’ but this was not significant. Table 5.5 summarises the results 
when both fasting studies were considered when available. The results are similar but in 
this case the increases in GFR/ECVstriP and GFR/ECVi are significant (P<0.05). In 
contrast the small increases in ECV and 1/B’ are reduced and are not approaching 
significance. The magnitude of the increase in GFR as a result of food intake for Cr-51 
EDTA would appear to be 4-5 ml/min/l.73m2.
Table 5.6 summarises the results for iohexol when only the first fasting study is 
considered. The increases as a result of food intake were significant for nGFRBM and 
nGFRstrip (P<0.05) but the increases in the other measures were not significant. Table 5.7 
summarises the results when both fasting studies were considered when available. There 
was essentially no difference compared with the results based on only the first fasting 
study was considered with no obvious reduction in variability.
Measure Mean fasted Mean difference 
with food intake
P value 
* P<0.05 
** P<0.01
nGFRBM  
(ml/min/l.73m2)
85.1 + 3.8 0.023 *
nGFRstrip 
(ml/min/l.73m2)
83.8 + 5.7 0 .0 1 1  *
G F R /E C V strip 
(ml/min/l 3.6 8 L)
86.4 + 4.9 0.092
G F R /E C V i  
(ml/min/l 3.6 8 L)
85.9 + 5.5 0 .1 0
G F R /E C F V 2
(ml/min/13.68L)
85.7 + 5.3 0.083
E C V  (L ) 14.0 + 0 .1 0 0.41
1/B’ (L) 17.2 + 0.09 0.45
Table 5.6: Effect of food intake on GFR based on Iohexol (n=20). The fasting value in the 10 
subjects in whom it was measured twice was the first
The changes in GFR induced by food intake based respectively on Cr-51 EDTA and 
iohexol correlated with each other (R=0.48, n=20, P<0.05 Fig 5.11). The two markers 
also correlated significantly (p < 0.05) with each with respect to changes in ECV 
following food intake (R=0.47, n=20, P<0.05 Fig 5.12), indicating that whilst food 
intake had no consistent effect on ECV, changes were nevertheless at least partly 
physiological and not entirely due to experimental error.
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Measure Mean fasted Mean difference 
with food intake
P value 
* P<0.05 
**P<0.01
nGFRBM 
(ml/min/l.73m2)
85.3 + 3.6 0 .0 2 0  *
nGFRstrip 
(ml/min/l.73m2)
84.3 + 5.3 0.015 *
G F R /E C V strip 
(ml/min/l 3 .6  8L)
87.7 + 3.6 0.18
G F R /E C V i  
(ml/min/l 3.6 8 L)
87.3 + 4.1 0.18
g f r / e c f v 2
(ml/min/l 3.6 8 L)
87.0 + 4.0 0.15
E C V  (L ) 13.9 + 0 .2 2 0.32
1/B’ (L) 17.6 + 0.29 0.35
Table 5.7: Effect of food intake on GFR based on Iohexol (n=20). The fasting value in the 10 
subjects in whom it was measured twice was the average o f the two
The change in eGFR derived from the plasma creatinine following food intake was more 
often a decrease rather than the expected increase. The mean change when comparing 
with the first fasted study was -2.7 ml/min/l.73m2 and when comparing with the average 
of the two fasting studies when available the mean difference was -2.1 ml/min/l.73m2 
these were not significant. However the change in eGFR did correlate positively with the 
change in nG FRstrip measured with Cr-51 EDTA (R=0.52, n=19, P<0.05) (Fig 5.13). If 
for the subject with the abnormally low renal function on the first fasting measurement 
the second fasting measurement is used the correlation actually improves slightly to 
R=0.53.
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Fig 5.11: Relation between fractional changes in nGFRstrip, based respectively on Cr-51 EDTA 
and iohexol, between the non-fasting and the first fasting measurements.
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Fig 5.12: Relation between fractional changes in ECV, based respectively on Cr-51 EDTA and 
iohexol, between the non-fasting and the first fasting measurements
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n o n -fa stin g /fa stin g  nGFRstrip Cr-51 EDTA
Fig 5.13: Relation between fractional changes in eGFR from creatinine and the change in 
nGFRstrip based on Cr-51 EDTA, between the non-fasting and the first fasting measurements. 
Subject with low renal function in first fasting measurement shown in pink.
For Cr-51 EDTA, there was a significant inverse correlation between the change in 1/B’ 
induced by food intake and the corresponding change in a2’(R=0.67, n=20, P<0.01 Fig 
5.14A), suggesting again that the change in 1/B’ was caused by errors in the fitting o f (X2 
and implying that the change in o^’ is partly the result of fitting errors. This indicates 
that GFR based on the slope and intercept, such as nGFRBM, would be partially 
‘protected’ from errors in fitting o f the second exponential and therefore would tend to 
be more robust than measures based on the slope alone (e.g. GFR/ECVi). The 
corresponding relation for iohexol is shown in Fig 5.14B and shows an even stronger 
correlation (R=0.81, n=20, P<0.001). As for changes between the 2 fasting 
measurements, no significant correlations were observed when changes in 1/B’ or ECV 
based on one marker were compared with corresponding changes CL2 based on the other
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Fig 5.14 Relation between the fractional changes in 1/B’ and a2’ between the non-fasting and 
first fasting measurements for Cr-51 EDTA on the left and iohexol on the right.
5.3.3 HPLC results
The last three volunteers to be studied had their plasma iohexol concentrations assayed 
by HPLC in addition to XRF. All three had two repeat fasting studies performed, it was 
therefore possible to make some assessment of the reproducibility o f GFR measured 
with iohexol assayed by HPLC. The results using just the area under peak 2 and the area 
under peak 1 and peak 2 from the HPLC traces were essentially identical and so only the 
results using the area under both peaks is presented here. The results are summarised 
with Table 5.8.
Iohexol HPLC 
Within subject 
standard 
deviation (n=3)
Iohexol
HPLC
CV
(n=3)
Iohexol
XRF
CV
(n=10)
Cr-51
ETDA
CV
n=10
nGFRBM 
(ml/min/l.73m2)
1.2 1.4% 7.6 % * 7.4 % *
nGFRstrip 
(ml/min/l.73m2)
1.3 1.6% 10.4% * 8.1 % *
GFR/ECVstnp 
(ml/min/l 3.68L)
2.5 3.0 % 13.2% * 7.7 %
GFR/EC V i 
(ml/min/l 3.68L)
2.9 3.4 % 16.2% * 8.8 %
g f r /e c f v 2
(ml/min/l 3.68L)
2.6 3.1 % 15.0% * 8.3 %
ECV (L) 0.41 2.7 % 6.2 % 7.0 %
1/B’ (L) 0.45 2.4 % 9.4 % 9.9 %
Table 5.8: Reproducibility of fasting GFR measures with Iohexol measured with HPLC (n=3) and 
comparison with all results for Iohexol measured with XRF and all results for Cr-51 EDTA. * 
indicates the within subject standard variance significantly higher than that for HPLC (P<0.05).
Although the number was very small the reproducibility of all the measures o f GFR 
appeared very good. In fact the reproducibility when using HPLC to assay iohexol was 
significantly better when compared with the reproducibility using XRF in all 10 subjects
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for all the measures of GFR (P<0.05) using an F-test. The reproducibility when using 
HPLC to assay iohexol was also significantly better when compared with the 
reproducibility with Cr-51 EDTA in all 10 subjects for nGFRBM and nGFRstrip (P<0.05).
5.4 DISCUSSION
5.4.1 Comparison of iterative curve fitting with curve stripping
The iterative curve fitting led to spurious results in 6  out of 50 iohexol clearances with 
nGFRit being zero or less than 3 ml/min/l.73m2 in these normal volunteers. This 
demonstrates a danger with using the iterative technique particularly with noisy data. 
With the Cr-51 EDTA clearances, where the data would seem to be less noisy, there 
were no implausible results with the iterative fitting. However, even though the fits to 
the data were closer than with the curve stripping technique, this didn’t offer any 
obvious benefit with the reproducibilities being slightly worse than with the curve 
stripping. The curve stripping technique less prone to give erroneous results, presumably 
because of its inherent assumptions about the relative sizes of the two rate constants.
5.4.2 Reproducibility
The reproducibility for nGFRBM measured with Cr-51 EDTA was very similar to that 
reported by Wilkinson et al (1990) for Tc-99m DTPA the coefficient of variation being
7.4 % compared with 8 %. The reproducibility for nGFRBM measured with iohexol was 
also very similar, the coefficient of variation being 7.6 %. This is despite there being 
significantly more noise in the individual plasma samples with iohexol assayed with 
XRF. The reproducibility for nGFRstrip was slightly poorer with iohexol than Cr-51 
EDTA. But there was a much bigger difference between the two tracers in terms of 
reproducibility for the measures of GFR/ECV the difference being significant for 
GFR/ECVi and GFR/ECV2. For both tracers, nGFRBM gave the lowest within-subject 
standard deviation. In contrast GFR/ECVj and GFR/ECV2 gave the highest, the 
difference compared to nGFRsM reaching significance with iohexol. These results are 
consistent with these measures derived principally from the rate constant of the terminal 
exponential (‘slope only’ measures) being more susceptible to experimental error than 
nGFRBM which is derived from the slope and the intercept. This is because a measure of 
GFR based on the slope and intercept, such as nGFRBM, is partially ‘protected’ from 
errors in fitting of the second exponential because errors in the slope can be partially 
cancelled out by the resulting error in the intercept.
This is further supported by the strong correlations between the fractional changes in 
1/B’ and 0 ,2’ for both markers, indicating that a considerable proportion of the variation 
in (X2’ between the repeat measures was associated with an opposing change in 1/B’.
Because nGFRBM gave the lowest within-subject standard deviation, the 3 early blood 
samples offered no obvious reproducibility advantage. So although not necessarily more 
accurate than 6 -sample measures, nGFRBM provided good precision.
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Because of separate administration and separate blood sampling, the corresponding 
measurements o f GFR with the two markers were completely independent so the 
significant correlations between the changes in GFR between the repeat fasting studies 
indicates that a considerable proportion of the within-subject variability was the result of 
real changes in GFR. The absence of correlation for the corresponding relations based 
on 1/B’or ECV indicates that there was no real change in distribution volumes between 
the two fasting measurements.
5.4.3 Effect of food intake
A significant increase in GFR following moderate food intake compared to fasting, was 
demonstrated, in line with previous observations (Wilkinson et al 1990, De Santo et al 
2002). The average magnitude of the change was 4-5 ml/min/l.73m2, (Wilkinson et al 
1990 reported an average of 3 ml/min), however it is likely that the real underlying 
change in GFR varied from subject to subject as the food intake will have been variable. 
It has been suggested that this increase is the result of an increase in circulating amino 
acids (De Santo et al 2002) and so the size of the response is likely to be governed by the 
amount of protein eaten. Therefore if for routine GFR tests there is no control of food 
intake there is considerable potential for increased variability in measurement of GFR. 
Hence when GFR is measured repeatedly in the search for longitudinal changes, the 
within-subject reproducibility, and hence the ability to detect real changes in renal 
function, would be improved if the protein intake prior to the measurement was similar 
on each occasion. This could be achieved by instructing patients to fast, to avoid high 
protein foods or by giving a standardised meal prior to measurement.
The effect of food was most clearly demonstrated with Cr-51 EDTA but a significant 
effect was also demonstrated with iohexol with some of the measures of GFR. eGFR 
derived from the plasma creatinine entirely failed to demonstrate a significant rise in 
response to food. The average change in fact being a decrease which was not significant. 
This would indicate that plasma creatinine is not sensitive enough to detect changes in 
normal renal function of the kind of magnitude as that produced by food intake.
However there was a significant correlation between change in eGFR and change in 
GFR measured with Cr-51 EDTA indicating that at least some of the change in eGFR 
must be due to the real change in renal function.
The effect of food intake enabled comparison of the various methods of calculating GFR 
because if a particular method has a large measurement error, it would be more difficult 
for it to detect a change. Accordingly, some of the methods demonstrated the effect of 
food intake more convincingly than others. nGFRBM and nGFRstrip appeared best able to 
demonstrate the change with either tracer. Of the other measures GFR/ECV2 was better 
than the others being able to demonstrate a significant change with Cr-51 EDTA when 
only the first fasting study was considered whereas the change in GFR/ECVstriP and 
GFR/ECVi did not reach significance. As there seemed to be very little difference in the 
ability of GFRbm and GFRstriP to demonstrate the effect this is further evidence that there 
is little or no advantage of having the extra data from the early blood samples in terms of 
reproducibility. Using only the first fasting study, it was also not possible to demonstrate 
a significant increase in response to food for 6 -sample GFR/ECVstriP measures with 
either iohexol or 51Cr-EDTA. This implies that derivation of GFR/ECVstrip from the 6 - 
sample curve is sensitive to experimental error.
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Comparing fasting and non-fasting conditions, the fractional change in 1/B’ was again 
significantly inversely related to the fractional change in CC2’ for both markers. This 
shows that much of the change in 012’ between the two measures is associated with an 
opposing change in 1/B’. Therefore it is likely that a significant portion of the change in 
d 2 is due to errors in fitting the single exponential, again leading to greater 
experimental error in GFR/ECVi or GFR/ECV2 than in GFRbm-
There was not only a significant correlation between the change in GFR (in particular 
nGFRstrip) with food intake between Cr-51 EDTA and iohexol but there was also 
significant correlation in the change in ECV. This implies that some of the difference 
between ECV measured on the two occasions is due to a real change in ECV. ECV is 
not a fixed quantity and in particular may vary with hydration. Therefore a real change 
in ECV between any repeat measure is expected especially if the hydration status of the 
patients is not controlled. In this particular comparison, some of the subjects may have 
been more likely to be slightly dehydrated in the fasting studies. It may be that the real 
changes in ECV are a contributing factor to measures of GFR/ECV being less sensitive 
for detecting changes in GFR than measures of GFR. Therefore if using measures of 
GFR/ECV to look for changes in renal function it may be particularly important to 
minimise any changes in ECV due to hydration. This may be achieved by instructing 
patients to ensure that they are adequately hydrated prior to each test.
5.4.4 HPLC
The fact that the iohexol sample data is noisier than the Cr-51 EDTA data would appear 
to be due to the particular assaying technique with XRF. Although only three 
reproducibility studies were performed with assaying the iohexol with HPLC this 
showed considerable promise. The reproducibility of these three studies with HPLC was 
excellent and despite the small number was significantly better than that measured with 
XRF. Even more interesting is the possibility that GFR measured with iohexol assayed 
with HPLC could be more reproducible GFR measured with Cr-51 EDTA. This could 
well be the case because the reproducibility between repeated assays o f the same sample 
with HPLC was much better than can be expected with counting statistics when 
measuring Cr-51 EDTA (see results in chapter 6 ).
5.4.5 Conclusion
• Measures of GFR/ECV seem more susceptible to noise in the data than measures 
of GFR potentially making them less reproducible. This is particularly true for 
measures based on the slope of the terminal exponential from late samples but 
also appears to be true for GFR/ECV derived from the bi-exponential clearance 
curve. It should be appreciated, however, that this study was performed under 
rigorous research conditions. In a setting where there may be less accurate 
control over the amount of tracer administered and the making of standards the 
balance between the reproducibility of ‘slope only’ measure and ‘slope intercept’ 
measures may be different.
• True variation in ECV may also contribute to making measures of GFR/ECV 
less reproducible.
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• Taking early samples offered no advantage in terms of reproducibility.
• There is a clear increase in GFR of around 5ml/min/1.73 m in response to food.
• To maximise the precision of the GFR test patient preparation should include 
trying to standardise protein intake and ensuring adequate hydration. There may 
also be an advantage in performing the test at a standardised time of day due the 
diurnal variation.
• The iohexol data measured with XRF was noisier than the Cr-51 EDTA data. 
However in particular nGFRBM was as reproducible with iohexol as Cr-51 
EDTA.
• HPLC may offer considerable advantage in terms of reproducibility for 
measuring iohexol concentrations.
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Chapter 6: Comparison between iohexol, Cr-51 EDTA and plasma 
creatinine for estimating glomerular filtration rate
6.1 INTRODUCTION
In 1935 Shannon and Smith identified inulin as a suitable substance for measuring 
glomerular filtration rate (GFR) and since then inulin has often been regarded as the 
gold standard. However the difficult chemical assay of inulin concentrations was a 
barrier to routine use. Around the same time as Cr-51 EDTA was suggested as a simpler 
alternative to inulin (Chantler et al 1969), radiographic contrast agents labelled with 
radioisotopes were also suggested (Maher and Tauxe 1969). Contrast agents were found 
to be predominantly eliminated from the body by glomerular filtration however different 
contrast agents varied in their suitability due to different levels of binding to plasma 
proteins. Guesry et al 1975 first suggested using a non-radioactive contrast agent and 
measuring the concentration in plasma samples by x-ray fluorescence (XRF) of the 
iodine content of the contrast agent. Iohexol was introduced as a new non-ionic water 
soluble contrast agent in the early 1980s with reduced toxicity. Olsson et al 1983 first 
described measuring the clearance of iohexol as part of the phase I safety and tolerance 
study and reported that 1 0 0  % of injected iohexol is recovered unmetabolised in the 
urine over 24 hours. They also concurrently measured Cr-51 EDTA clearance in 10 
subjects and concluded from comparing the clearances that iohexol is mainly excreted 
by glomerular filtration.
Interest in using iohexol for estimating GFR was clearly rapid in onset both as an 
adjunct to radiographic procedures where iohexol is administered and as an alternative 
to the by now well established standard approach of using radiolabelled chelating agents 
(EDTA or DTP A). At least in Sweden iohexol has been used for routine clinical GFR 
assessment (Nilsson-Ehle 2001), but use in the UK has been limited. There have been 
other studies comparing GFR determined from clearance of Cr-51 EDTA and iohexol 
(Krutzen et al 1984, O’Reilly et al 1986, Effersoe et al 1990, Brandstrom et al 1998, 
Pucci et al 2001) and Tc-99m DTP A and iohexol (Stake et al 1990). However no studies 
have used independent administration and sampling methods for the two tracers and so 
some experimental errors will affect the measurements with both tracers, which may 
affect agreement between the tracers. Assay of iohexol concentration in plasma was 
achieved in these comparison studies using either high performance liquid 
chromatography (HPLC) or XRF using a purpose built commercially made instrument 
called the Renalyzer (PRX 90, Provalid, Sweden) which is no longer available. The 
Renalyzer uses high activity (11 GBq) Am-241 sources for excitation and a sodium 
iodide detector to measure K-line characteristic X-rays.
One purpose o f the present study was to assess the accuracy of GFR determined by 
iohexol against the gold standard of Cr-51 EDTA clearance using completely 
independent administration and sampling methods and using a very different instrument 
for XRF analysis. Later in the study it was also decided to compare the suitability of the 
XRF method against HPLC. An important further aim was to use the degree of 
agreement between the two independent tracers to compare the different measures of 
GFR in particular comparing, slope only against slope intercept measures. Measures 
demonstrating better agreement between the tracers are likely to be more precise. One
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motivation for investigating the use of iohexol was to look at the feasibility of 
developing a ‘postal service’ for measuring GFR. The idea being a service that avoids 
the need for the patient to journey to a specialist unit. Instead, administration of the 
tracer and blood sampling could be performed locally and the samples posted to a 
central laboratory for analysis. Such an approach would not be appropriate for 
radioactive tracers but could be well suited to iohexol.
A remote postal service would be simplified if knowledge of the exact amount of marker 
administered was not critical to the measurement of GFR. Therefore use of the slope 
only approach could be a considerable advantage in this setting.
There would be little point in developing a postal service GFR based on iohexol if it 
offered no clear advantage over the widespread approach of estimating GFR from 
plasma creatinine. Therefore GFR from iohexol clearance was compared against GFR 
estimated from plasma creatinine using the method described by Levey et al (1999).
A separate aspect o f this study was to compare the distribution volumes measured for 
Cr-51 EDTA and iohexol and the divisions of the distribution volumes into two 
functional compartments. This was partly to assess whether correction for the one pool 
assumption derived from Cr-51 EDTA were likely to be applicable to iohexol. But also 
there was academic interest in whether it is possible to demonstrate differences between 
the tracers as a result of their different sizes. Iohexol has a molecular weight of about 
900 Da, only about 2.5 times that of Cr-51-EDTA. A dependence of ECV on size has 
been shown previously in studies that have compared markers of more widely differing 
molecular size (Tc-99m-DTPA [500 Da], inulin [6  kDa] and [Br-77]bromide (Cousins 
et al 1997 and Cousins et al 2002).
6.2 METHODS
6.2.1 Subjects
This chapter considers data from the 50 studies performed on the twenty healthy 
volunteers also used in the chapter 5. In addition sixty patients (40 male, 20 female, age 
range 28-79 [median 56], body mass index 20-41 [28] kg/m2), with no history o f allergy 
to iodine-containing contrast agents, who were referred for clinically-indicated 
measurement of GFR, were recruited. Thirty six were diabetics, 10 had cancer, 9 had 
skin disease and were receiving or being considered for cyclosporine treatment and one 
was referred from the nephrology service. Diabetics being treated with metformin were 
excluded from the study because of a potential adverse interaction between metformin 
and iohexol. The routine clinical GFR protocol consisted of administration of Cr-51 
EDTA and taking of three blood samples between 2 and 4 hours after injection. The 
patients were asked to consent to additional blood samples and administration of 
iohexol. Unlike the volunteers the patients were only studied once, they were given no 
specific instructions regarding food intake prior to the start of the study. Patient height 
and weight were measured on the day of the study. Plasma creatinine was measured 
from a blood sample taken immediately prior to the administration of the tracers.
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6.2.2 Study Protocol
The protocol for the patient and volunteer studies was the same and is described in detail 
in chapter 5. This involves independent administrations of iohexol and Cr-51 EDTA into 
different arms separated by a few minutes and independent blood samples for analysis of 
Cr-51 EDTA and iohexol taken from different lines. In this way as far as possible 
measures of GFR derived from Cr-51 EDTA and iohexol should be subject to entirely 
different experimental errors.
6.2.3 Sample analysis
Sample analysis was the same as described in detail in chapter 5. Samples from all the 
studies were assayed for iohexol using the X-ray Fluorescence (XRF) technique. In 15 
studies (5 patient and 10 volunteer studies on 4 volunteers) plasma from samples was 
also assayed for iohexol using the high performance liquid chromatography technique 
(HPLC).
6.2.4 Data analysis
Measures derived from all six samples
Only the two iteration curve fitting method was used for fitting a bi-exponential 
(A.e~a, t + B.e~ai t ) to the plasma clearance curves from all 6  samples.
Then GFR normalised to body surface area from all 6  samples is: 
nGFR = (1,73/SA). 1000 /(A/a,+B/a2) [ml/min/l .73m2]
Where SA is the body surface area in m calculated by the DuBois and DuBois (1916) 
formula.
Normalised distribution volume is:
n(Vl+V2) = (1.73/SA) (A/a,2+B/a22)/(A/al+B/a2)2 [L/1.73m2]
If the distribution volumes of Cr-51 EDTA and iohexol are different then GFR/(V1+V2) 
will be inherently different for the two tracers. However this inherent difference is 
corrected for if GFR/(V1+V2) is multiplied by the mean distribution volume of the 
appropriate tracer, therfore:
GFR/ECV=x.l000.(A/al+B/a2)/(A/a12+B/a22) [ml/minlx L]
Where x is the average n(Vl+V2) for the tracer, here jc is derived from the current data. 
The volumes of the two functional compartments of the distribution volume were also 
calculated:
V1=1/(A+B) [L]
V2= (Vi+V2) - V l  [L]
And the intercompartmental rate constant:
k = (A.a,+B.a2).Vi2 -  GFR/1000 [L/min]
These three quantities were normalised to body surface area to get nVi, nV2 and nk.
Measures derived from late samples
A single exponential with intercept B’ and rate constant a2’ was fitted to the last 3 
sample points, nominally at 2, 3 and 4 hours.
The normalised slope-intercept GFR is then:
nGFRsi = ( 1.73/SA). 10 0 0 /(B’/a2’) [ml/min/l .73m2]
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nGFRsi was corrected for the one pool assumption using the Brochner-Mortensen (1984) 
correction for both isotopes and termed nGFRBM.
nGFRBM = 0.9908 * nGFRsr0.001218 * nGFRsi2 [ml/min/l.73m2] 
a2’ was also corrected for the one pool assumption to give estimates of GFR/ECV using 
the corrections derived in chapter 2 .
GFR/ECV, =*.1000.(0.9462 * a2’ + 23.11 * (a2’)2) [ml/min/xL]
GFR/ECV2 = *.1000.(0.9666 * a2’ + 1.155 * (1.73/SA) * (a2’)2/B’) [ml/min/*L] 
Again where x is the average n(Vl+V2) for the appropriate tracer.
In addition corrections for the one pool assumption of the same form as nGFRBM, 
GFR/ECVi and GFR/ECV2 specifically for iohexol were derived from the current data. 
For consistency corrections for Cr-51 EDTA were also derived from the current data. 
nGFRsi corrected with the appropriate derived correction was termed nGFRcon- and the 
measures of GFR/ECV derived with appropriate derived corrections were termed 
GFR/ECVti and GFR/ECVt2.
6.2.5 Estimated GFR (eGFR) from plasma creatinine
The plasma creatinine concentrations were converted into estimated GFRs using a 
formula from Levey et al (2000).
eGFR = 186x creatinine[jumol / L]
\ 88.4
x age[years\ 0203 x (0.742 if female)x(1.21 if
black) ml/min/l.73m
6.2.6 Statistics
Comparison of measures e.g. volumes was made with paired student T-tests. Pearson’s 
regression analysis was used to examine correlation between measures of GFR. Bias was 
assessed by calculating the mean difference and testing whether this was significantly 
different to zero. Agreement between measures was quantified from the bias and the 
standard deviation of the differences. Also calculated was the standard deviation of the 
percentage differences, which is a more suitable quantity if the differences get larger as 
the measure gets larger. Comparisons on agreement between measures was made with a 
paired student T-test on the squared differences. Limits of agreement are calculated at 
the 95% level.
6.3 RESULTS
Two of the Cr-51 EDTA clearance curves from all 6  plasma samples were too close to a 
single exponential to be separated into a bi-exponential. This was also true for five 
iohexol clearances. In these studies nGFR was calculated from a single exponential fit to 
all six points, V2 is assumed to be zero and an inter-compartmental rate constant can not 
be calculated. In ten of the iohexol clearances iterative fitting, as discussed in chapter 5, 
would have given erroneous results. In these studies if the curve stripping technique is 
iterated many times then there is also a divergence from a sensible result. Because of 
this in these studies only one iteration of the curve stripping technique was performed 
rather than two.
143
6.3.1 Renal Function
The range of nGFR values (based on the 6  sample Cr-51 EDTA clearances) in all the 
studies performed on the normal volunteers was 65 -  124 (median 90) ml/min/l.73m2.
In all the studies performed on patients it was 16 -  146 (median 75) ml/min/l.73m2. 
Dividing the patients into groups: the range of nGFR values for the thirty six diabetic 
patients was 16 -1 3 3  (median 53) ml/min/l .73m2, for the ten cancer patients was 59 -  
130 (median 100) ml/min/l.73m2 and for the thirteen dermatology patients was 53 -  146 
(median 95) ml/min/l .73m2. Based on all 110 studies nGFR measured with Cr-51 
EDTA was 3 ml/min/l.73m2 higher than that measured with iohexol (P<0.01).
6.3.2 Compartmental volumes and inter-compartmental rate constant
The results for the mean normalised compartmental volumes and inter-compartmental 
rate constant derived from the bi-exponential clearance curves are shown in Table 6.1. 
The volume of distribution (n(Vl+V2)) for iohexol was significantly lower than that for 
Cr-51 EDTA (P<0.01). This would appear to be due to a difference in the volume of 
compartment 1, with nVl being significantly lower for iohexol than Cr-51 EDTA 
(PO.Ol). In contrast nV2 was slightly higher for iohexol than Cr-51 EDTA although 
this difference was not significant (P>0.05). The difference in the total distribution 
volume is also apparent in the data from late samples with 1/B’ being significantly 
greater for Cr-51 EDTA than iohexol (P<0.05).
Cr-51 EDTA iohexol
n(Vl+V2) L/1.73m^ 14.21 (1.65) 13.70(1.94)**
nVi L/1.73mz 9.78 (1.43) 9.16(2.03)**
nV2 L/1.73mz 4.43 (1.17) 4.53 (1.83)
nk L/min/1.73m2 0.098 (0.035) 0.105 (0.059)
Table 6.1: Compartmental volumes and the inter-compartmental rate constant for all 110 studies 
mean (standard deviation). ** indicates a significant difference between iohexol and Cr-51 EDTA 
(P<0.01).
Non-fasting normals (n=20) Diabetic (n=36)
Cr-51 EDTA
n(Vl+V2) L/1.73m2 13.7 (1.5) 15.1 (1.7) **
nV, L/1.73nr 9.4 (1.4) 10.1 (1.5)
nV2 L/1.73m2 4.3 (1.0) 5.0 (1.0)*
nk L/min/1.73m2 0.099 (0.048) 0.110(0.033)
iohexol
n(Vl+V2) L/1.73m2 13.6(1.6) 14.2 (2.0)
nV, L/1.73m" 9.2 (2.0) 9.2 (2.3)
nV2 L/1.73m" 4.4 (1.7) 5.0 (1.8)
nkL/min/ 1.73m2 0.097 (0.042) 0.117(0.062)
Table 6.2: Compartmental volumes and the inter-compartmental rate constant for the non-fasting 
normals and the diabetic patients mean (standard deviation). * indicates a significant difference 
between diabetics and normals (P<0.05) ** P<0.01.
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The results for the mean normalised compartmental volumes and inter-compartmental 
rate constant derived for two specific groups: the diabetics and the non-fasting normal 
studies are shown in Table 6.2. The diabetic patients had a significantly higher 
distribution volume of Cr-51 EDTA compared with the non-fasting normals (P<0.01). 
The volume of compartment 2, nV2 , for Cr-51 EDTA was also significantly larger in the 
diabetic patients (P<0.05). This indicates that the diabetic patients may have expanded 
extra cellular fluid volume compared to normals. The differences did not reach 
significance when measured with iohexol. However, if  the volumes for the diabetics are 
compared against all 50 repeat fasting and non-fasting studies in the 20 normal 
volunteers then the difference in n(Vl+V2) and nV2 reaches significance.
6.3.3 Corrections for the one pool assumption
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Figure 6.1: Modelled plasma clearance curves for a subject with a nGFR of 80 ml/min/1,73m2 for 
Cr-51 EDTA and iohexol.
Because the sizes of the two functional compartments o f the extracellular fluid volume 
are different between Cr-51 EDTA and iohexol the shape of the plasma clearance curve 
would be expected to be slightly different. This was illustrated by modelling the plasma 
clearance using the mean parameters for the two tracers, the modelled clearance curves 
for a nGFR of 80 ml/min/l. 73m2 are shown in Fig 6.1. Because o f the different shape o f 
the clearance curve ideally corrections for the one pool assumption would be slightly 
different between the two tracers. There are no published corrections specific for 
iohexol. Corrections for the one pool assumption for iohexol were derived from the 
current iohexol data (Fig 6.2). For consistency corrections for Cr-51 EDTA were also 
derived from the current data. Table 6.3 shows the derived corrections o f the form of 
Brochner-Mortensen (1972).
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nGFRCorr = a x nGF -^si b x nGFRsi2
A b
Brochner-Mortensen 0.9908 -0.001218
From current iohexol data 1.0065 -0.001324
From current Cr-51 EDTA data 0.9943 -0.001143
Table 6.3: Corrections for the one pool assumption of the form of Brochner-Mortensen (1972)
The correction derived to correct a2’ to GFR normalised to ECV o f the two types were: 
GFR/ECVti = 13700x(1.130.a2’ -  0.000236) iohexol
GFR/ECVt2 = 13700x(0.9294.a2’ + 1.507x(1.73/SA) x (a2 ’)2/B ’) iohexol
GFR/ECVt, = 14210x(0.9650.a2’ + 20.37x(a2’)2) Cr-51 EDTA
GFR/ECVt2 = 14210x(0.9575.a2’ + 1.225x(1.73/SA) x (a2 ’)2/B ’) Cr-51 EDTA
The corrections o f these two forms derived in chapter 2 from 330 Cr-51 EDTA 
clearances were also used for both tracers. Table 6.4 shows from using the modelling 
results for three example levels o f renal function a comparison o f using the tracer 
specific versions of the corrections for the one pool assumption and corrections ignoring 
the difference between the tracers. One o f the important points to note is that for the 
same renal function the modelling predicts that there is a bigger difference between a2’ 
for the two tracers than nGFRsi. The fact that there is only a small difference between 
the nGFRsi predicted for the two tracers means that it is unlikely there will be much 
advantage o f using a tracer specific correction for correcting nGFRsi. This is bourn out 
by the differences between the corrected nGFRBM and nGFRCOrr for Cr-51 EDTA and 
iohexol in the table. The other important point to note is that with the correction to a2’ to 
give a GFR normalised to extracellular fluid volume that it appears to be less important 
whether a tracer specific equation to derive GFR/ECV is used than multiplying the 
GFR/ECV by an appropriate mean distribution volume for that tracer. Therefore in the 
further results both the tracer specific forms o f the corrections (GFR/ECVt 1 and 
GFR/ECVt2 above) and the corrections taken from chapter 2 (termed GFR/ECVi and 
GFR/ECV2) are multiplied by 13700 ml for iohexol and 14210 ml for Cr-51 EDTA to 
give the final normalised measure.
0.012 -i
y = 1 .13 0 x -  0 .000236  
R2 = 0 .965 y = -0 .001324x2 + 1.0064x 
R2 = 0.957
sub jec ts  
Line of Identity 
fitted line
su b jec ts  
line of identity 
fitted line
100
nG FRS| m l/m in/1,73m '
Fig 6.2: The plots of the experimental data for iohexol used to derive the tracer specific 
corrections for nGFRCOrr and GFR/ECVf
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nGFR 
ml/min/l.73m2 Diff 012’
Diff 
GFR/ECVi (a)
Diff 
GFR/ECVi (b)
Diff 
GFR/ECVti (c)
30 -2.5 % -2 .6  % 1.1 % -0 .2  %
80 -2 .6  % -2.9 % 0 .8  % -0 .2  %
120 -2.5 % -2 .8  % 0 .8  % 2.9 %
Diff nGFRsi Diff nGFRBM Diff nGFRcorr
30 0.5 % 0.5 % -0 .2  %
80 -0.4 % -0.4 % 0.1  %
120 -0.9 % -0.7 % 0.9 %
Table 6.4: Results of modelling with dilFferences between corrected modelled Cr-51 EDTA and
iohexol measures. GFR/ECV! (a) is 13680.(0.9462.a2,+23.11.a2’2) for both tracers (b) is 
14210.(0.9462.02+23.11.a2’2) for Cr-51 EDTA and 13700.(0.9462.a2+23.11.a2’2) for iohexol and 
(c) is 14210.(0.9650.a2,+20.37.a2’2) for Cr-51 EDTA and 13700.(1.130.o2’-0.000234) for iohexol. 
nGFRBM is 0.9908.nGFRSr0.001218.nGFRSi2 for both tracers and nGFRCi3rr is 0.9943.nGFRSr 
0.001143.nGFRSi2 for Cr-51 EDTA and 1.0064.nGFRSi-0.001324.nGFRSi for iohexol.
6.3.4 Relation between Cr-51 EDTA and iohexol
The correlation between iohexol and Cr-51 EDTA for the various measures of GFR are 
summarised in Table 6.5 and the agreement between the two is summarised in Table 6 .6 . 
The best agreement between the two tracers was achieved with the GFR measures 
derived from the slope and intercept from the last 3 plasma samples, the agreement for 
nGFRsM and nGFRc0rr being significantly better than that for any of the other measures 
(P<0.05). The agreement between the tracers using the standard Brochner-Mortensen 
correction for the one pool assumption was in fact slightly better than when using the 
different corrections for each tracer derived from the current data. For the two measures 
derived from the full bi-exponential clearance curve, there was significantly better 
agreement between the tracers for nGFR than GFR/ECV (P<0.001). The agreement for 
GFR/ECV was significantly better than the agreement for GFR/ECVi, but not 
significantly different to that for GFR/ECV2, GFR/ECVti and GFR/ECVt2. The 
agreement for GFR/ECV2 was significantly better than for GFR/ECVj. Bland Altman 
plots for some of the measures are shown in Fig 6.3.
intercept slope R2
nGFR 9.4 ml/min/l.73m2f 0.85J 0.885
nGFRcorr 8 .6  ml/min/l.73m2f 0.861 0.943
nGFRsM 7.4 ml/min/l.73m2f 0 .8 8  J 0.942
GFR/ECV 5.1 ml/min/l 3.7L 0.91 0.798
GFR/ECVi 6.1 ml/min/l 3.7L 0.91 0.714
GFR/ECV2 6.1 ml/min/l 3.7L 0.90J 0.758
GFR/ECVti 8.3 ml/min/13.7L o .m 0.743
GFR/ECVt2 4.8 ml/min/l3.7L 0.91 0.760
Table 6.5 Correlation between measures of GFR derived from Cr-51 EDTA and iohexol. t  
indicates an intercept significantly different to 0 (P<0.05). $ indicates a slope significantly 
different to 1 (P<0.05).
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Mean difference 
(iohexol-Cr-51 
EDTA)
Standard deviation of 
differences
Standard deviation 
of % differences
nGFR -2.9 ml/min/l.73m2f 9.9 ml/min/l.73m2 12.1  %
nGFRcorr -2.8 ml/min/l.73m2f 7.3 ml/min/l.73m2 * 10.1  % *
nGFRBM -2 .2  ml/min/l.73m2| 7.0 ml/min/l.73m2 * 9.7 % **
GFR/ECV -2.0 ml/min/l 3.7L 13.9 ml/min/l3.7L ** 17.3 % **
GFR/ECVi -1.8 ml/min/l 3.7L 17.1 ml/min/l3.7L ** 18.9% **
g f r / e c v 2 -2.4 ml/min/l 3.7L 15.3 ml/min/l3.7L ** 17.5 % **
GFR/ECVti -2.0 ml/min/13.7L 15.6 ml/min/l3.7L ** 17.8 % **
GFR/ECVt2 -2.4 ml/min/13.7L 15.4 ml/min/l3.7L ** 17.3 % **
Table 6.6 Comparison of agreement between measures of GFR derived from Cr-51 EDTA and 
iohexol * = significantly different agreement between Cr-51 EDTA and iohexol compared with 
nGFR (P<0.05) ** (P<0.001). t  indicates mean difference significantly different to 0 (P<0.01).
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Fig 6.3: Bland-Altman plots showing agreement between measures of GFR based on Cr-51 
EDTA and iohexol.
As shown on the Bland-Altman plots the difference nGFRBM (iohexol) -  nGFRBM (Cr- 
51 EDTA) decreased significantly with increasing renal function. This was also the case
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for nGFR but not for any of the measures of GFR/ECV. This significant decrease 
indicates that at low levels of renal function that GFR based on iohexol tends to slightly 
exceed that based on Cr-51 EDTA and at high levels of renal function it is the other way 
round. On average all the measures of GFR were lower for iohexol than Cr-51 EDTA 
and this constituted a significant bias for nGFR, nGFRc0rr and nGFRBM. The pattern of 
the relationship between the measure of GFR with iohexol and Cr-51 EDTA is 
confirmed by the intercept of the regression line for nGFR, nGFRBM and nGFRCOrr being 
significantly different to 0  and the slope of the regression line being significantly 
different to 1. The slope of the regression line was also significantly different to 1 for 
some of the measures of GFR/ECV.
6.3.5 Relation between nGFR and GFR/ECV
Fig 6.4 shows for Cr-51 EDTA GFR/ECV plotted against nGFR. These two measures 
are different because one is normalised to surface area and one is normalised to ECV 
estimated from the distribution volume of Cr-51 EDTA. The extent to which they differ 
will depend on the extent to which the normalised distribution volume for that subject 
differs from the average normalised distribution volume. The difference could therefore 
be because the subject truly has an ECV different to the average for a subject with that 
particular surface area or could be because of experimental error. If it is that a subject 
has an ECV significantly different to average then this should be reflected when 
measured with iohexol. Therefore the extent to which the differences between 
GFR/ECV and nGFRBM reflect this real magnitude of ECV can be investigated by 
plotting nGFRBM/(GFR/ECV) for one tracer against the other. This is equivalent to 
plotting n(Vl+V2)/mean(n(Vl+V2)) for one tracer against the other this shown in Fig 
6.5. The correlation is highly significant and R = 0.62 indicating that a reasonable 
proportion of the difference between nGFR and GFR/ECV is due to a real difference in 
these quantities and not experimental error. The equivalent relation for the measures of 
GFR derived from the late samples was investigated by plotting nGFRBM/(GFR/ECV2) 
for iohexol against nGFRBM/(GFR/ECV2) for Cr-51 EDTA (Fig 6 .6 ). The correlation is 
again highly significant and R=0.59 indicating that a reasonable proportion of the 
difference between nGFRBM and GFR/ECV2 is likely to be due to a real difference in 
these to quantities and not experimental error.
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6.3.6 Comparison of iohexoi clearance with plasma creatinine for the estimation of 
GFR
eGFR derived from the plasma creatinine was compared with measures o f GFR derived 
from iohexoi clearance. Either nGFR or nGFRBM derived from Cr-51 EDTA was taken 
as the gold standard with similar results (see Table 6.7). GFR derived from plasma 
clearance o f iohexoi and in particular that derived from the late samples had 
significantly better agreement with the gold standard than eGFR.
GOLD STANDARD 
nGFR Cr-51 EDTA
GOLD STANDARD 
nGFRBM Cr-51 EDTA
nGFR Cr-51 EDTA (3.8 % ***)
nGFRBM Cr-51 EDTA (3.8 % ***)
nGFR iohexoi 11.5% *** 10.9% ***
nGFRBM iohexoi 10.4 % *** 9.2 % ***
eGFR 19.2% 18.6%
Table 6.7: Comparing agreement with the standard deviation of the percentage differences 
between measures of GFR derived from iohexoi clearance and plasma creatinine and the gold 
standard, *** indicates a significantly better agreement than eGFR (P<0.001)
Because it is recognised that normalising GFR to body surface area may not be ideal and 
that there might be real advantages in normalising to estimates of ECV, measures of 
GFR/ECV based on Cr-51 EDTA were taken as the gold standard. In this case it was not 
possible to demonstrate a significant advantage over plasma creatinine.
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GOLD STANDARD 
GFR/ECV Cr-51 EDTA
GOLD STANDARD 
GFR/ECV2 Cr-51 EDTA
GFR/ECV Cr-51 EDTA (2 .8  % ***)
GFR/ECV1 Cr-51 EDTA (3.4%***) ( 1 .6 %***)
GFR/ECV2 Cr-51 EDTA (2 .8  % ***)
GFR/ECV iohexoi 16.6 % * 16.1 % *
GFR/ECVj iohexoi 18.7% 18.0%
GFR/ECV2 iohexoi 17.4 % 16.7%
eGFR 20.7 % 20.5 %
Table 6.8: Comparing agreement with the standard deviation oft he percentage differences
between measures of GFR/ECV derived from iohexoi clearance and plasma creatinine and the 
gold standard, * indicates a significantly better agreement than eGFR (P<0.05), *** P<0.001.
6.3.7 HPLC
70 plasma samples were assayed twice for iohexoi the root mean square (r.m.s.) 
difference between the replicate assays was 0.13% the maximum difference was 1.42 %. 
All the plasma samples assayed for iohexoi were assayed three times by X-ray 
fluorescence (XRF). The r.m.s difference between replicates for XRF with baseline 
subtracted was 7.95 %, with a maximum difference of 30.9 %.
The baseline signal with HPLC was very small such that the average signal to noise ratio 
(s.n.r.) for HPLC was 463 ranging from 83 -  1050. In contrast the baseline signal with 
XRF was very large such that the average s.n.r. for XRF was only 0.15 ranging from 
0.02-0 .35.
In 15 studies samples were assayed for iohexoi with both XRF and HPLC. For these 15 
studies, using Cr-51 EDTA as the gold standard, HPLC gave better agreement with gold 
standard than XRF for all measures (see table 6.9). The improvement with HPLC 
compared to XRF was significant for nGFRBM and the measures o f GFR/ECV but not 
for nGFR. For the HPLC data the agreement with gold standard for nGFRBM was 
significantly better than that for nGFR, GFR/ECVi and GFR/ECV2 (P<0.05).
For all the measures GFR with HPLC there was still a significant bias with GFR 
measured with iohexoi underestimating GFR measured with Cr-51 EDTA (P<0.05). For 
nGFRBM the bias was -2.5 ml/min/1.73m2.
XRF HPLC
nGFR 9.0 % 4.8 %
nGFRBM 7.8 % 2 .6  % **
GFR/ECV 16.4% 8 .6  % **
GFR/ECVi 15.9% 7.1 % **
GFR/ECV2 14.9 % 6.3 % **
Table 6.9: Comparing agreement with the standard deviation oft he percentage differences
between measures of GFR derived from iohexoi clearance measured with either XRF or HPLC 
and the same measures derived from Cr-51 EDTA, ** indicates a significantly better agreement 
for HPLC compared to XRF (P<0.01). Data is for the 15 studies where samples were assayed 
for iohexoi with both XRF and HPLC.
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6.4 DISCUSSION
6.4.1 Volumes
Anatomically not only is there a clear distinction between intracellular and extracellular 
fluid spaces but also the extracellular fluid space is clearly divided into plasma (~ 3L) 
and the interstitial fluid ( -1 1L). The plasma clearance of tracers confined to the 
extracellular fluid space e.g. Cr-51 EDTA have a clear bi-exponential appearance when 
sampled between 20 and 240 minutes. This is interpreted as the extracellular fluid space 
acting as two separate compartments with mixing between the compartments being 
relatively slow compared to mixing within each compartment. However, closer analysis 
of the curves reveals that the volume of the ‘first’ compartment into which the tracer is 
introduced and from which the tracer is cleared is much greater than plasma being 
around 9L. Early sampling over the first few minutes following injection shows there is 
a third exponential component that results from the reasonably rapid mixing between the 
plasma and the first portion of the interstitial space (Cousins et al 1997). The interstitial 
fluid is acting as two compartments and it has been suggested by Cousins et al (1997 and 
2 0 0 2 ) that this is in fact the division between a fluid and a gel phase o f the interstitial 
space and that functionally the division varies with the molecular size of the tracer. They 
were able to show that the volume of the first compartment for inulin (6  kDa) was much 
smaller than that of the smaller molecule Tc-99m DTP A (-500 Da). In this study it has 
been possible to demonstrate a significant difference in the volume of the first 
compartment for two molecules much closer in size Cr-51 EDTA (-400 Da) and iohexoi 
(-900 Da). This is consistent with the fluid / gel phase model. Also the total distribution 
of the two molecules was found to be significantly different when estimated from the 
clearance curves. This is also consistent with smaller molecules penetrating further into 
the gel phase and highlights the fact that estimation of extracellular fluid volume will be 
dependent on the tracer used. This is further complicated by the fact that different 
molecules used for estimating ECV may vary in the extent to which they are truly 
excluded from cells, for example bromide entering red cells (Veal and Vetter 1958 and 
chapter 4).
In this study a significantly expanded extracellular fluid volume compared to normals 
was demonstrated in diabetics; this has previously been reported by Brochner-Mortensen 
and Ditzel (1982). They interestingly show that this expanded extracellular fluid volume 
only partially explains the abnormally high values of GFR found in patients with early 
stages of diabetes and that there is some underlying hyperflltration which they 
demonstrate by using a measure of GFR/ECV as a true reflection of renal function.
6.4.2 Correction for the one pool assumption for iohexoi
Most routine clinical evaluations of GFR are performed with two or more samples taken 
from two hours after injection onwards (Fleming et al 2004) and any routine 
implementation using iohexoi would be likely to follow this methodology. When taking 
only late samples a correction needs to be made for the one pool assumption. Because it 
has been shown here that the functional compartments of the ECV that shape the 
clearance curve are different for iohexoi compared to Cr-51 EDTA, then any correction 
for the one pool assumption would be ideally be slightly different for iohexoi than those 
that have been previously derived from Cr-51 EDTA data. However it has been
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demonstrated by use of modelling that the difference for corrections of the form of 
Brochner-Mortensen (1984) would be very small and that it is probably acceptable to 
use for example the Brochner-Mortensen correction for either tracer. This was supported 
by the fact that there was slightly better agreement between the tracers when correcting 
the late sample data for both with the Brochner-Mortensen correction than when using 
slightly different corrections for each tracer derived from the current data. The 
modelling showed that there would be a bigger difference in corrections to derive an 
estimate of GFR normalised to ECV from o^’ (the rate constant o f the terminal 
exponential). However, the discrepancy that would be caused by using a correction that 
was ideal for Cr-51 EDTA on iohexoi data would in most cases be less than 3%. It has 
been shown that this discrepancy can be reduced if the same correction to 0.2 is used to 
get GFR divided by the distribution volume, but then in the case of iohexoi this is 
multiplied by the mean normalised distribution volume for iohexoi.
It should also be noted that any single sample correction derived with one tracer (e.g. 
Christensen and Groth (1986) derived with Tc-99m DTP A) would be likely to give a 
systematic error when applied to another tracer like iohexoi.
6.4.3 Comparison of GFR from iohexoi against Cr-51 EDTA
Comparing nGFRBM for iohexoi measured with XRF and Cr-51 EDTA there was a bias 
of -2.2 ml/min/1.73m2 and the standard deviation of differences (SDD) of 7.0 
ml/min/1.73m2, for nGFR the bias was -2.9 ml/min/1.73m2 and the SDD 9.9 
ml/min/1.73m2. The biases are with iohexoi underestimating GFR compared to Cr-51 
EDTA.
Quantitative agreement between iohexoi and Cr-51 EDTA for all 110 studies using XRF 
expressed as limits of agreement was -16 to +11 ml/min/ 1.73m2 for nGFRBM and -2 2  
to +16 ml/min/1.73m2 for nGFR. The pattern of differences observed with the Bland- 
Altman plots indicates that it might be preferable for the comparison to consider the 
percentage differences rather than the absolute differences and then the limits of 
agreement were -20 to +18% for nGFRBM and -25 to +22% for nGFR. However in 
practice which is considered makes very little difference to the statistical analysis and 
the conclusions. This level of agreement is of a similar magnitude but slightly higher 
than that found with repeat studies on the same subject in chapter 5. The within subject 
standard deviation includes some real variation in GFR between the two occasions of 
measurement and ideally good agreement between the tracers would have been 
demonstrated with better agreement than with repeat studies on the same subject. It is 
therefore debatable whether this is an acceptable level of agreement and whether 
iohexoi, with the particular method of XRF analysis, could be used as a replacement for 
Cr-51 EDTA. With the 15 studies performed with HPLC the agreement was 
considerably better, for nGFRBM the limits o f agreement were -8  to +3 ml/min/ 1.73m2 
(or -  8% to +2 %) and for nGFR they were -11 to +5 ml/min/1.73m2 (or -  13% to + 6  
%). Although the numbers were small, HPLC does appear to be a significantly better 
method for assaying the iohexoi and using this method iohexoi could be used in place of 
Cr-51 EDTA. Particularly as it is probable that the measurement error for GFR derived 
from iohexoi measured with HPLC is less than that for Cr-51 EDTA. For HPLC the 
r.m.s. difference between replicate measurements on the same sample was only 0.14 %. 
For Cr-51 EDTA for an average count of 10,000 the r.m.s. difference between replicates
154
due to counting statistics alone would be 1.4 % and for the later samples where the count 
can be as low as 3000 the r.m.s. difference between replicates would be 2.6 %.
Comparison with previously published results
Levels of agreement between the two tracers both with XRF and HPLC were compared 
against previously published results. Some papers only quote correlation coefficients to 
demonstrate agreement which is not adequate (Bland 2000). However, using XRF 
O’Reilly et al (1986) quote an R of 0.90 and 0.85 for two different doses of iohexoi 
which are a bit low but the others quote 0.95, 0.97 and 0.97 (Effersoe et al 1990, 
Brandstrom et al 1998 and Stake et al 1990) which are very comparable with the 0.97 for 
nGFRBM and 0.94 for nGFR found here. Using HPLC the quoted values were 0.98, 0.96 
and 0.99 (Kurtzen et al 1984, Brandstrom et al 1998 and Pucci et al 2001). For the 15 
studies performed here with HPLC the correlation coefficient was 0.99 for the nGFRsM 
and 0.98 for nGFR. From the studies that do give quantitative information on the 
agreement Effersoe et al (1990) using XRF have a standard deviation of differences 
(SDD) of 7.9 ml/min/1.73m2 but with a bias of 10.8 ml/min with iohexoi overestimating 
GFR compared to Cr-51 EDTA and Brandstrom et al (1988) using XRF had a SDD of
5.0 ml/min. Therefore the SDDs found here of 7.0 ml/min/1.73m2 for nGFRBM and 9.9 
ml/min/1.73m for nGFR are not too different but probably not the best that can be 
achieved with XRF. Using HPLC Brandstrom et al (1988) had an SDD of 6.2 ml/min 
and Pucci et al (2001) had the best agreement with a SDD of 3.7 ml/min/1.73m2 
demonstrating that the SDDs found here for HPLC of 2.5 ml/min/1.73m2 for nGFRBM 
and 4.1 ml/min/1.73m2 for nGFR are realistically achievable.
Bias
Effersoe et al (1990) conclude that their large bias with GFR from iohexoi 
overestimating GFR from Cr-51 EDTA is likely to be due to calibration problems with 
the XRF equipment. It is possible that calibration problems are responsible for the 
smaller bias found here. Indeed the fact that the bias was smaller and not significant with 
the measures of GFR/ECV would be in keeping with this fact as measures derived from 
the ‘slope only’ are not dependent on the accuracy of the absolute calibration of the 
assay. However with the limited HPLC data the bias was significant for all the measures 
of GFR and GFR/ECV. Other causes of a bias could be different levels of tubular 
secretion of the two tracers or different levels of extrarenal clearance or different protein 
binding. Brochner-Mortensen and Rodbro (1976) reported that the extrarenal clearance 
of Cr-51 EDTA was on average 3.7 ml/min which might explain the bias found here if 
there was essentially no extrarenal clearance of iohexoi. However because the bias was 
greater for higher levels of renal function it may be more likely that it was caused by 
some calibration problem,
6.4.4 Comparison of measures of GFR
The best agreement between the tracers was found with nGFRBM this even being 
significantly better than the agreement found with nGFR derived from all six samples. 
This is consistent with nGFRBM being the most reproducible measure of GFR as 
discovered in chapter 5. The average difference between the tracers with the measures 
of GFR/ECV derived from the late samples was twice as great as that for nGFRBM- 
Cleary nGFRBM derived from the slope and intercept is a more precise measure than the
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measures of GFR/ECV derived from the slope only and this is attributable to it’s 
robustness to experimental errors. When using HPLC which reduces the experimental 
error for iohexoi it still seems likely that nGFRBM offers superior precision. The 
robustness of nGFRBM to experimental errors has to be seen as an advantage even when 
all is done to keep experimental errors to a minimum. Therefore it is concluded that 
when considering setting up a postal service for measurement of GFR that it is not 
possible to ignore the quantity of tracer injected and only derive GFR/ECV from the 
terminal rate constant. To do so would be likely to compromise the sensitivity of the test 
for monitoring changes in GFR with time.
However it should be remembered that GFR normalised to surface area is fundamentally 
a different quantity to GFR normalised to ECV. This was neatly demonstrated here 
using the data from the independent tracers. For example if GFR normalised to surface 
area was greater than GFR normalised to ECV it was shown that this was likely to be 
due to the subject truly having a greater ECV than average for a subject with the same 
surface area. The GFR normalised to ECV could well be a better assessment of true 
renal function (Brochner-Mortesen 1980, Peters 1992). Therefore it is suggested that 
when measuring GFR to consider both GFR normalised to ECV as well as surface area.
6.4.5 Comparison of GFR estimated from plasma creatinine with GFR from 
iohexoi
Use of plasma creatinine to assess renal function is widespread. Creatinine is mainly 
derived from the metabolism of creatine in muscle, its generation being proportional to 
muscle mass. Plasma creatinine level will be at an equilibrium that will depend on its 
rate of generation and its rate of clearance from the body. The assumption is then that 
plasma creatinine can be related to GFR that is already normalised for body size because 
a larger person will have a larger muscle mass and require a larger GFR. However, to 
relate this estimate of GFR to GFR normalised to surface area, it is necessary to take into 
account the fact that different subjects with the same surface area have differing muscle 
mass depending on a number of factors including sex, age and race. To account for this, 
formulae have been derived to estimate GFR from plasma creatinine taking into account 
some o f these factors (Cockcroft and Gault 1976, Levey et al 2000). From inspecting the 
formula used here (Levey et al 2000), it can be expected that the estimate o f GFR will be 
fairly crude. In particular, gender differences are generalised with a multiplication factor 
of 0.743 for women on the basis of different body composition to men. There are other 
inherent inaccuracies with using plasma creatinine for estimating GFR. One is that 
creatinine is secreted by the proximal tubules as well as being filtered in the glomerulus. 
This is compounded by the fact that as renal disease progresses the degree of tubular 
secretion sometimes increases which can lead to an overestimate of GFR when derived 
from plasma creatinine. Another factor is although extra-renal creatinine excretion is 
minimal in people with normal kidney function, it can be markedly increased in patients 
with chronic kidney disease. The situation is further complicated when considering GFR 
estimated from plasma creatinine using one of the formulae because of the effect of the 
spectrum of diseases in the populations used to derive the formula. A further concern is 
that muscle wasting in disease will affect plasma creatinine and also that formula like 
the one used here inadequately correct for reduced muscle mass in patients beyond the 
age range of patients used to generate the formula.
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Taking nGFRBM derived from Cr-51 EDTA as the gold standard, the errors with eGFR 
from plasma creatinine were significantly worse and approximately twice as large as 
those from nGFRBM from iohexoi using XRF. The limits of agreement for eGFR and 
nGFRBM were -33% to +39%. If GFR/ECV derived from Cr-51 EDTA is taken as the 
gold standard the difference between the measures of GFR/ECV derived from iohexoi 
and eGFR were less clear cut. This is because the experimental errors in the iohexoi 
concentrations measured with XRF make the agreement between measures o f GFR/ECV 
from iohexoi and Cr-51 EDTA fairly poor. However the error with eGFR was still worse 
if only statistically so compared with GFR/ECV not GFR/ECVi or GFR/ECV2. In 
conclusion taking Cr-51 EDTA clearance as the gold standard GFR derived from 
iohexoi clearance was more accurate than eGFR from plasma creatinine.
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Chapter 7: Comparison of Sirolimus and Calcineurin Inhibitors for 
Immunosuppression following Transplantation
7.1 INTRODUCTION
One of the key uses of measurement of GFR clinically is monitoring renal function for 
patients on potentially nephrotoxic drug regimes. It is also used in the research context 
of identifying whether one drug regime is superior to another in terms of reduced 
nephrotoxicity. The aim of the work in this chapter is to compare the use GFR/ECV with 
GFR in the context of statistically identifying the difference between drug regimes in a 
randomized control trial.
Following receiving transplanted organs, patients receive long term immunosuppressive 
drugs to reduce the incidence of rejection. The immunosuppressive drugs that have been 
used are often calcineurin inhibitors, principally cyclosporin and tacrolimus. However a 
major problem is that these drugs are known to be nephrotoxic. Some of the effects these 
drugs have on renal function are short term and have reported to be reversible (Watson 
et al 2005). But long tern exposure to the drugs have also been shown to produce chronic 
non-reversible interstitial fibrosis and vascular changes, one of the main consequences 
of which is reduction in renal function (Woolfson and Neild 1997). Despite these 
problems calcineurin inhibitors are thought to be essential to limit early transplant organ 
rejection. However to limit the incidence of chronic renal problems there is interest in, at 
some point after transplantation, switching patients from calcineurin inhibitors to some 
alternative immunosuppressive drug (Watson et al 2005). Some studies have reported 
that switching to the ftmgal derived antibiotic sirolimus gave some improvement in renal 
dysfunction (Dominguez et al 2000).
This study involved both renal and liver transplant patients who were taking cyclosporin 
or tacrolimus and had evidence of reduced renal function. The patients were randomized 
as to whether they switched to the drug sirolimus or not. It was investigated if switching 
to sirolimus gave a benefit in terms of renal function measured
7.2 METHODS
7.2.1 Patients
Ethics and ARSAC approval was obtained for the study. Adult patients were recruited 
who had received kidney or liver transplants between 6  months and 8 years previously 
and who were taking cyclosporin or tacrolimus. Patients were only recruited to the study 
if they had evidence of reduced renal function defined by a serum creatinine between 
120 and 400 pmol/L. If on inclusion into the study the baseline GFR measurement was 
greater than 70 ml/min/1.73m2 then patients were subsequently excluded. Thirty nine 
renal transplant patients and thirty liver transplant patients were initially recruited. On 
recruitment, patients were randomized as to whether they would switch to sirolimus or 
remain on their calcineurin inhibitors. The study was designed so that in both the renal 
and liver transplant patient groups there should be equal numbers of switching and non­
switching patients. In this study the switch in drugs was abrupt with the relevant patients 
receiving their last dose o f cyclosporin or tacrolimus on the evening following 
randomisation and the following day receiving 8 mg of sirolimus. The dose was then
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reduced to 4 mg/day and was then adjusted following measurements of the concentration 
of sirolimus circulating in the blood to achieve a target concentration of between 5 and 
15 ng/ml. Baseline GFR measurements were performed on the day of randomization. 
GFR measurements were then repeated 3 months and 1 year later. In the case of the 
renal transplant patients there was a further measurement of GFR at 2 years. Patients’ 
height and weight were measured at the time of each GFR measurement.
7.2.2 GFR protocol
Administration
Chromium-51 etheylenediamine tetraacetic acid (Cr-51 EDTA) (Amersham Health) was 
prepared in a stock solution with an initial concentration of nominally 1 MBq/ml. 3 ml 
of this stock solution was drawn up into a pre-weighed 5 ml syringe which was then 
reweighed to ascertain the weight of the solution to be administered to the patient. The 
activity given to the patient was between 2.5 and 3 MBq. A line was inserted into one 
arm of the patient for the collection of samples, usually into the antecubital fossa. The 
administration of the Cr-51 EDTA was made into the contralateral arm either using a 
butterfly or a line that was removed after the administration. The time halfway through 
administration was recorded. The administration was made using a 3-way tap and the 
syringe that had contained the Cr-51 EDTA was flushed through twice with saline to 
ensure that essentially all of the weighed amount was administered.
Blood sampling
Blood samples were taken nominally at 20,40, 60, 120,180 and 240 minutes after 
administration of the tracers. At each time, 3 ml of blood was withdrawn from the line 
and discarded and then a 10 ml sample was taken. The time midway through the 
administration and midway through the taking of each sample were recorded. The 
samples were centrifuged at ~ 800-1000 G for 15 minutes and 3 ml of plasma pipetted 
into counting tubes for gamma counting.
Standard preparation and gamma counting
Two independent standards were prepared by pipetting 0.1 ml of the Cr-51 EDTA 
solution administered to the patient into a 10 0  ml volumetric flask and making up the 
volume. 3 ml of the each standard was pipetted into counting tubes and counted along 
with the plasma samples as a counting tube containing 3 ml of water as a background. 
The samples, standards and background were counted in an automatic gamma counter 
(Wallac 1480 Wizard 3”, Turku, Finland) for 1000 seconds each, with an energy 
window of 250-380 KeV. The deadtime corrected counts per minute (CPM) from the 
samples and standards were corrected for background subtracting the CPM from the 
background tube. The CPM were corrected for the decay of Chromium-51 during the 
counting session using the half life of 27.7 days.
If the corrected CPM for two standards differed by more than 2 % a third standard was 
usually prepared in order to try and identify which standard was in error otherwise the 
mean of the two standards was used. The concentration of the standard was expressed in 
the percentage o f the administered dose per litre (%/L) using the weight of the Cr-51 
EDTA solution given to the patient and assuming a density of 1 g/ml. The concentration 
in each of the samples was then be expressed as percentage of the administered dose per
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litre (%/L) from the ratio o f the final corrected sample CPM to the final corrected 
standard CPM multiplied by the standard concentration in %/L. The plasma clearance 
curve is the concentration of the samples plotted against time since administration in 
minutes.
7.2.3 Calculation of measures of GFR and ECV from the Cr-51 EDTA clearance 
data.
nGFR
A double exponential was fitted to the complete Cr-51 EDTA plasma clearance curve 
using a two iteration curve striping technique, detailed in chapter 5. The fitted curve has 
the formula A.e'aI + B.e’a2 and GFR was calculated from 
GFR= 1000 [ml/L]/(A/ai +B/012) [ml/min] (Nosslin 1965)
This GFR was then normalised to the estimate o f the surface area of the patient derived 
from the DuBois formula (DuBois and DuBois 1916). The surface area normalised GFR 
derived from the complete plasma clearance curve was termed nGFR 
nGFR = (1.73/suface area [m2]).GFR [ml/min/1.73m2]
DV
The distribution volume of Cr-51 EDTA calculated from the double exponential fit to 
the complete plasma clearance curve was termed DV and calculated from 
DV = (A /ar+B/a22)/(A/ai+B/a2) 2 [L] (Nosslin 1965)
GFR/ECV
The distribution volume of Cr-51 EDTA is an estimate o f the extracellular fluid volume 
(ECV) and therefore GFR divided by DV is an estimate of GFR/ECV derived from the 
complete plasma clearance curve. To get a measure of normalized GFR of similar 
magnitude to nGFR the term ‘GFR/ECV’ is used to mean GFR/ECV multiplied by an 
average adult ECV of 13.68 L. This comes from Chapter 2 where the average surface 
area normalised distribution volume of EDTA was found to be 13.68 L/1.73m2. 
GFR/ECV is calculated from:
GFR/ECV = 13680.(A/ai+B/a2)/(A/ai2+B/a22) [ml/min/13.68L] 
nGFRBM
Using only the plasma concentration Cr-51 EDTA in the samples from 120 minutes 
onwards a single exponential fit to the plot of concentration against time was performed. 
The GFR is then calculated from the slope (012’ [min'1]) and intercept (B’ [%/L]) of the 
fitted single exponential with GFRsi = 1 0 0 0 [ml/L].a2’/B’ [ml/min]. This slope intercept 
GFR is then normalised to surface area 
nGFRsi = (1 .73/suface area [m2]).GFRsi [ml/min/ 1.73m2]
The normalised slope-intercept GFR is then corrected for the one pool assumption using 
the Brochner-Mortensen (1984) correction and termed nGFRBM- 
nGFRBM = 0.9908 * nGFRsi-0.001218 * nGFRsi2 [ml/min/1.73m2]
GFR/ECV, and GFR/ECV,
Again using only the late samples, the slope of the single exponential fit 1x2’(this is the 
rate constant of the terminal exponential) is an estimate of GFR normalised to the ECV
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estimated from the distribution volume of Cr-51 EDTA. To c^’ a correction for the one 
pool assumption is applied, two forms of this are used one based solely on ai itself and 
one based also on the intercept B’ and the surface area (SA). These corrections were 
derived in chapter 2 and again are multiplied by an average adult ECV of 13.68 L. 
GFR/ECVi = 13680 * (0.9462 * a2’ + 23.11 * (a2’)2) [ml/min/13.68 L]
GFR/ECV2 = 13680 * (0.9666 * a2’ + 1.155 * (1.73/SA) * (a2’)2/B’) [ml/min/13.68 L]
7.2.4 Statistics
Significance o f changes and differences between groups were assessed with 2-sided t- 
tests. P values less than 0.05 were treated as significant and P values less than 0.01 were 
treated as highly significant
7.3 RESULTS
7.3.1. Changes in GFR for all patients
Some patients were lost from the study at different points due to a variety of reasons.
One patient’s baseline GFR was too high, two patients who switched to sirolimus 
switched back before their 3 months GFR due to acneform rashes and two patients 
refused their 3 month GFR, so of the 69 patients recruited, data from 64 patients 
contributed to the analysis. Two further patients who switched to sirolimus switched 
back after the 3 months GFR and one renal transplant patient switched back after the 1 
year GFR. One renal transplant patient who was randomized to remaining on calcineurin 
inhibitors was switched to sirolimus after 1 year for clinical reasons. The 64 patients that 
contributed to the analysis on initial assessment had normalized GFR (nGFR) in the 
range 13-68 with a mean of 42 (SD 12) ml/min/1.73m2. The 32 patients randomized to 
switching medication had normalized nGFR in the range 13-67 with a mean of 44 
ml/min/1.73m2 and the 32 non switchers had normalized nGFR in the range 16-68 with 
a mean of 40 ml/min/1.73m2. The two groups appeared well matched. Fig 7.1 shows the 
spread of baseline nGFR in the two groups.
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Fig 7.1: Baseline nGFR for al 64 patients analysed
All:
Changes at 
3 months
nGFR
m l/m in/1.73m 2
GFR/ECV
ml/min/13.68 L
nGFRsM
m l/m in/1.73m 2
GFR/ECVi 
m l/m in/13.68 L
g f r / e c v 2
m l/m in/13.68 L
sw
itc
he
rs
n=
31
mean + y g *** + 7 0  *** + 7 6  *** + 0  9  *** + 6  9 ***
SD 4.7 6 . 8 4.4 6.5 6 . 2
95%
Cl 6 .0 -9 .5 4.5 - 9.5 6.0 - 9.2 4 .5 -9 .3 4.7 - 9.2
range 0.5 - 22.4 -6.0 - 26.7 0.4-20 .1 -6 . 6  - 24.5 -6.2 - 23.3
no
n-
Sw
itc
he
rs
 
n=
32
mean -0 . 6 +0.4 -0 . 6 0 . 0 +0 . 1
SD 6.5 6 . 1 6 . 1 5.8 5.7
95%
Cl -2 .9 - 1.7 - 1 .8 -2 . 6 -2 .8 - 1.5 -2 . 1  - 2 . 2 -2 .0 - 2 . 1
range -25 .7-10 .8 -12 .2-9 .5 -24.3 - 9.9 -12 .2 -9 .0 -12 .0 -8 .7
Difference 
in means
+8.4 +6 . 6 +8.3 +6.9 +6.9
P=0.0000002 P=0.00015 P=0.00000006 P=0.000044 P=0.000022
Table 7.1: Details of the changes in the measures of GFR at 3 months for all the patients. 
Showing mean, standard deviation (SD), 95% confidence interval (Cl) and total range. ***
indicates a significant change (P<0.001). Also shown is the difference in mean change between 
the group of switchers and the group of non-switchers and the P value associated with that 
difference.
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All:
Changes at 
12  months
nGFR 
ml/min/1.73m2
GFR/ECV 
ml/min/13.68 L
nGFRBM
ml/min/1.73m2
GFR/ECV! 
ml/min/13.68 L
GFR/ECV2
ml/min/13.68 L
Sw
itc
he
rs
n=
28
mean + 8.5 *** -j- 7 1  *** + 8.1  *** -f 7  2  *** _j_y ^ ***
SD 7.1 8.4 6.5 8 .2 8.1
95%
Cl 5.7-11.2 3.8 -10.3 5.6 -10.6 4.0 -10.3 4.1 -1 0 .4
range -3.0-21.1 -8.4 - 25.4 -2.5 -19.0 -8.0 - 23.7 -7 .6-23 .2
no
n-
sw
itc
he
rs
n=
28
mean -1.9 -0.9 - 1.8 -0.9 -1.0
sd 9.7 9.2 9.2 9.1 9.1
95%
Cl -5.7-1 .9 -4.5 - 2.6 -5.3-1.8 -4.5 - 2.6 -4.5 - 2.5
range -30.9 - 15.6 -25.9 - 14.2 -30.1 - 14.5 -24.6 -14.2 -24.9 -14.2
Difference 
in means
+10.4 +8 .0 +9.8 +8.1 +8.3
P=0.00003 P=0.0013 P=0.00002 P=0.00099 P=0.00069
Table 7.2: Details of the changes in the measures of GFR at 12 months for all the patients. 
Showing mean, standard deviation (SD), 95% confidence interval (Cl) and total range. ***
indicates a significant change (P<0.001). Also shown is the difference in mean change between 
the group of switchers and the group of non-switchers and the P value associated with that 
difference.
Tables 7.1 and 7.2 show the results for the changes in GFR, for the renal and liver 
transplant patients combined, at 3 and 12 months respectively. There was an increase in 
GFR at 3 months in the patients switching to sirolimus which was shown to be highly 
significant (P<0.001) by all the measures of GFR. The magnitude of this increase was 8 
ml/min/1.73m2 for nGFR and nGFRsM and 7 ml/min/13.68L for the measures of GFR 
normalised to ECV. The patients remaining on their calcineurin inhibitors on average 
showed little change in GFR in the 3 months. All the measures of GFR showed a highly 
significant difference between the groups (P<0.001) indicating a significant benefit in 
terms of renal function when switching to sirolimus. At 12 months the increase from 
baseline GFR is still evident in the patients on sirolimus and is still highly significant 
with all measures of GFR (P<0.001). The average magnitude of the increase was very 
similar to at 3 months but there is greater variability. On average there was a small 
decrease in GFR at 12 months from baseline in the patients remaining on their 
calcineurin inhibitors but this was not significant (P>0.05). The changes in GFR are 
illustrated graphically in Fig 7.2 and 7.3 for nGFRBM and GFR/ECV2 respectively. The 
difference between the between the two groups remained highly significant, P<0.001 for 
all measures o f GFR except GFR/ECV where P=0.0013. This indicates the significant 
benefit of switching to sirolimus remained at 12  months.
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Fig 7.2 Mean (+/- 95% Confidence interval) change in nGFRBM from baseline at 3 and 12 months 
for all patients.
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Fig 7.3 Mean (+/- 95% Confidence interval) change in GFR/ECV2 from baseline at 3 and 12 
months for all patients.
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7.3.2. Changes in GFR for the renal transplant patients
If just the renal transplant patients are considered, the mean baseline nGFR was 38 
ml/min/1.73m2 in the patients who were to switch to sirolimus and 37 in the patients 
who were to remain on their calcineurin inhibitors. Tables 7.3, 7.4 and 7.5 show the 
results for the changes in GFR at 3, 12 and 24 months respectively for the renal 
transplant patients. Again, the patients switching to sirolimus showed a highly 
significant rise in GFR at 3 and 12 months (PO.OOl for all measures of GFR). The 
mean rise in GFR was greater at 12 months than at 3 months. By 12 months the patients 
remaining on calcineurin inhibitors had a mean fall in nGFR and nGFRBM of 3 
ml/min/1.73m2 and in the measures of GFR/ECV of 2 ml/min/13.68L although this was 
not significant (P>0.05). At 3 months the difference in change in GFR between the 
groups was highly significant (PO.OOl for nGFR, nGFRBM and GFR/ECV2, PO.Ol for 
GFR/ECV and GFR/ECVi). At 12 months the difference in change in GFR between the 
groups was highly significant (PO.OOl for nGFR and nGFRBM, PO.Ol for GFR/ECV, 
GFR/ECVi and GFR/ECV2). At 24 months the patients on sirolimus still showed a rise 
in GFR compared to baseline, this was highly significant with nGFRBM (PO.OOl), 
nGFR (PO.Ol), GFR/ECV1 (PO.Ol) and GFR/ECV2 (PO.Ol) and significant with 
GFR/ECV (PO.05). The difference between the change in GFR at 24 months for the 
two groups was highly significant with nGFR and nGFRBM (PO.Ol) an significant with 
GFR/ECV, GFR/ECVi and GFR/ECV2. Therefore for renal transplant patients there was 
still a clear benefit in switching to sirolimus in terms of renal function at 2  years after the 
switch.
Renal: 
Changes at 
3 months
nGFR 
ml/min/1.73m2
GFR/ECV 
ml/min/13.68 L
nGFRBM 
ml/min/1.73m2
GFR/ECVi 
ml/min/13.68 L
GFR/ECV2
ml/min/13.68 L
Sw
itc
he
rs
n=
17
mean +7.0 *** +6.5 *** _lj-j j *** +6 .2  *** +6 .2  ***
sd 3.9 6 .0 3.8 5.8 5.6
95%
Cl 5.0-9.0 3 .4 -9 .6 5 .1 -9 .0 3 .2 -9 .2 3 .4 -9 .1
no
n-
sw
itc
he
rs
n=
20
mean -1.3 +0.1 -1.4 -0.1 -0.1
sd 7.2 5.8 6.7 5.3 5.2
95%
Cl
1 l to 0 -2 .6 -2 .9 -4 .5 -1 .7 -2 .6 -2 .4 -2 .6 -2 .3
Difference 
in means
+8.3 +6.4 +8.5 +6.3 +6.4
P=0.00013 P=0.0023 P=0.000051 P=0.0015 P=0.00096
Table 7.3: Details of the changes in the measures of GFR at 3 months for the renal transplant 
patients. Showing mean, standard deviation (SD) and 95% confidence interval (Cl). *** indicates 
a significant change (P<0.001). Also shown is the difference in mean change between the group 
of switchers and the group of non-switchers and the P value associated with that difference.
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Renal: 
Changes at 
12  months
nGFR 
ml/min/1.73m2
GFR/ECV 
ml/min/13.68 L
nGFReM
ml/min/1.73m2
GFR/ECVi 
ml/min/13.68 L
g f r / e c v 2
ml/min/13.68 L
sw
itc
he
rs
n=
15
mean + 1 0 .2  *** +8.5 *** + 9  7  *** +8.4 *** +8 .6  ***
sd 7.0 7.8 6.1 7.7 7.5
95%
Cl 6.3 -1 4 .0 4 .2 -12 .8 6.3-13 .1 4.2 -1 2 .7 4 .4 -1 2 .7
no
n-
sw
itc
he
rs
n=
17
mean -3.3 -2.3 -3.3 -2.3 -2.4
sd 11.3 9.7 10 .8 9.4 9.5
95%
Cl -9 .5 -2 .5 -7 .3 -2 .7 -8 .8  - 2 .2 -7 .1 -2 .6 -7 .2 -2 .5
Difference 
in means
+13.5 + 10.8 +13.0 +10.7 +10.9
P=0.00040 P=0.0017 P=0.00027 P=0.0015 P=0.0012
Table 7.4: Details of the changes in the measures of GFR at 12 months for the renal transplant 
patients. Showing mean, standard deviation (SD) and 95% confidence interval (Cl). *** indicates 
a significant change (P<0.001). Also shown is the difference in mean change between the group 
of switchers and the group of non-switchers and the P value associated with that difference.
Renal: 
Changes at 
24 months
nGFR 
ml/min/1.73m2
GFR/ECV 
ml/min/13.68 L
nGFReM
ml/min/1.73m2
GFR/ECVi 
ml/min/13.68 L
g f r / e c v 2
ml/min/13.68 L
Sw
itc
he
rs
n=
14
mean +9.0 ** +7.4* + 9  2 *** + 7 4  ** +7.5 **
sd 8 .0 9.4 8 .0 8.9 8.9
95%
Cl 4.4-13 .6 2 .0  - 12.8 4.6-13.8 2.2 - 12.5 2.4 -12.7
range -5.0-20.7 -7.8 - 20.2 -5.5-21.3 -7.9-21.0 -7.9-21.1
no
n-
sw
itc
he
rs
n=
13
mean -2.7 -2 .0 -2.5 -2 .1 -2.1
sd 11 .8 9.6 1 1 .0 9.1 9.1
95%
Cl -9 .8 -4 .4 -7.8 - 3.7 -9.2-4.1 -7.6 - 3.4 -7 .6 -3 .4
range -33.0 -15.4 -16.0-15.1 -31.0-14.3 -15.4-15.0 -15.5 -14.9
Difference 
in means
+ 11 .6 +9.4 +11.7 +9.5 +9.6
P=0.0057 P=0.016 P=0.0038 P=0.012 P=0.010
Table 7.5: Details of the changes in the measures of GFR at 24 months for the renal transplant 
patients. Showing mean, standard deviation (SD), 95% confidence interval (Cl) and total range. 
Significance of changes indicated *** (P<0.001), ** (P<0.01), * (P<0.05). Also shown is the
difference in mean change between the group of switchers and the group of non-switchers and 
the P value associated with that difference.
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7.3.3. Changes in GFR for the liver transplant patients
If just the liver transplant patients are considered the mean baseline nGFR was 50 
ml/min/1.73m2 in the patients who were to switch to sirolimus and 46 in the patients 
who were to remain on their calcineurin inhibitors. Tables 7.6 and 7.7 show the results 
for the changes in GFR at 3 and 12 months respectively. The patients switching to 
sirolimus showed a highly significant rise in GFR at 3 months (P<0.001 nGFR and 
nGFRBM and P<0.01 GFR/ECV, GFR/ECVi and GFR/ECV2). The patients remaining on 
calcineurin inhibitors on average showed a very small rise in GFR at 3 or 12 months 
which was not significant. At 3 months the difference in change in GFR between the 
groups was highly significant for nGFR and nGFRBM (P<0.001) and significant for 
GFR/ECV, GFR/ECVi and GFR/ECV2 (P<0.05). At 12 months for the patients 
switching to sirolimus nGFR and nGFRBM still demonstrated a highly significant rise 
from baseline (p<0.01), GFR/ECVi and GFR/ECV2 showed a significant rise from 
baseline (p<0.05) but GFR/ECV just failed to show a significance to the rise. The 
difference in change in GFR between the groups was significant with nGFR and 
nGFRBM (P<0.05) but not significant with GFR/ECV, GFR/ECVi and GFR/ECV2 
(P<0.05). Therefore for liver transplant patients there appeared to be a clear benefit, in 
terms of renal function, in switching to sirolimus which remained at 1 year after 
switching. However at one year this was harder to demonstrate significantly with the 
number of patients studied (13 switchers and 11 non-switchers).
Liver: 
Changes at 
3 months
nGFR 
ml/min/1.73m2
GFR/ECV 
ml/min/13.68 L
nGFRBM
ml/min/1.73m2
GFR/ECVi 
ml/min/13.68 L
GFR/ECV2
ml/min/13.68 L
sw
itc
he
rs
n=
14
mean _f.g 7  *** +7.5 ** +8.3 *** +7.8 ** +7.8 **
sd 5.6 7.9 5.0 7.4 7.0
95%
Cl 5 .0 -1 2 .0 3 .0-12.1 5 .4 -1 2 .2 3 .5-12 .1 3 .7 -1 1 .9
no
n-
sw
itc
he
rs
n=
12
mean +0.7 +0 .8 +0 .6 +0.3 +0.4
sd 5.2 6 .8 5.0 6.9 6 .6
95%
Cl -2 .6 -4 .0 -3 .6-5 .1 -2 .6 -3 .7 -4 .1 -4 .7 -3 .8 -4 .6
Difference 
in means
+8 .0 +6 .8 +7.7 +7.5 +7.4
P=0.00094 P=0.029 P=0.00061 P=0.012 P=0.011
Table 7.6: Details of the changes in the measures of GFR at 3 months for the liver transplant 
patients. Showing mean, standard deviation (SD), 95% confidence interval (Cl). Significance of 
changes indicated *** (P<0.001), ** (P<0.01). Also shown is the difference in mean change 
between the group of switchers and the group of non-switchers and the P value associated with 
that difference.
167
Liver: 
Changes at 
12 months
nGFR 
ml/min/1.73m2
GFR/ECV 
ml/min/13.68 L
nGFReM
ml/min/1.73m2
GFR/ECVi 
ml/min/13.68 L
g f r / e c v 2
ml/min/13.68 L
Sw
itc
he
rs
n=
13
mean +6.5 ** +5.4 +6 .2  ** +5.7* +5.8*
sd 6.9 9.1 6.5 8.9 8.7
95%
Cl 2 .3 -1 0 .6 -0.1 -1 0 .9 2 .2 -10.1 0.3-11 .1 0 .5 -11 .0
no
n-
sw
itc
he
rs
n=
ll
mean +0.3 + 1.2 +0 .6 + 1.1 + 1.1
sd 6 .2 8.3 5.6 8.7 8.4
95%
Cl -3 .9 -4 .5 -4 .4 -6 .9 -3 .1 -4 .3 -4 .7 -7 .0 - 4 .5 - 6 .8
Difference 
in means
+6 .2 +4.2 +5.5 +4.5 +4.6
P=0.032 P=0.26 P=0.037 P=0.22 P=0.20
Table 7.7: Details of the changes in the measures of GFR at 12 months for the liver transplant 
patients. Showing mean, standard deviation (SD), 95% confidence interval (Cl). Significance of 
changes indicated ** (P<0.01), * (P<0.05). Also shown is the difference in mean change
between the group of switchers and the group of non-switchers and the P value associated with 
that difference.
7.3.4. Changes in distribution volume of Cr-51 EDTA (DV)
Changes in distribution volume as calculated from the full plasma clearance curve are 
shown in Table 7.8. None of these changes in distribution volume reached significance, 
the closest was the increase in DV at 24 months (mean 0.85 L) where the P value was 
0.06. However, there is on average an increase in distribution volume that accompanies 
the increase in GFR on switching from calcineurin inhibitors to sirolimus. This increase 
in DV is probably a real increase in ECV. The increase in DV would explain why on the 
magnitudes of the average increases in the measures of GFR/ECV are slightly smaller 
then the magnitudes of the increases in the measures of GFR.
Change in DV L
3 months 12 months 24 months
Renal Switchers 0.33 (1.55) 0.72(1.55) 0.85 (1.55)Non-Switchers -0.63 (2.60) 0.23 (3.63) -0.03 (2.50)
Liver Switchers 0.42 (1.47) 0.21 (1.52)Non-Switchers -0.15(1.01) -0.18(0.81)
Table 7.8: Changes in distribution volume of Cr-51 EDTA calculated from the complete plasma 
clearance curve (DV)
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7.4 DISCUSSION
This randomized control study has shown that for renal and liver transplant patients with 
sub-optimal renal function receiving calcineurin inhibitors, that a switch to sirolimus 
within 8 years of transplantation, results in a significant improvement in renal function 
compared to the controls. The improvement in renal function is evident at 3 months after 
switching to sirolimus and is maintained at 12 months. In the case of renal transplant 
patients, the improvement is still maintained at 24 months.
Switching to sirolimus was in some cases associated with side effects, particularly skin 
rash and mouth ulcers. In most case this was successfully managed with reducing the 
dose of sirolimus while keeping the circulating sirolimus concentration within the target 
dose range.
It is possible that there is a physiological mechanism whereby calcineurin inhibitors 
decrease extracellular fluid volume in a reversible way that is related to their 
vasoconstrictive effect on renal arteries (Shihab 1996). Therefore switching to sirolimus 
could give a real increase in extracellular fluid volume.
Assuming that the improvement in renal function is real, it is possible to make some 
cautious observations about the different measures of GFR.
When the renal and liver transplant patients are pooled together as one group, all the 
measures of GFR considered were able to demonstrate the rise in GFR in the patients 
switching to sirolimus at both 3 and 12 months as highly significant with P values of less 
than 0.001 in all cases. In a randomized control study the requirement is to demonstrate 
the statistical benefit by comparing with the controls. In this study, even though the 
mean change in GFR for the controls might be a small fall in GFR it is more difficult to 
reach statistical significance when comparing with the controls because of the variability 
in the control group. But when considering the pooled group, again all the measures of 
GFR were able to demonstrate the difference to the controls at both 3 and 12 months as 
highly significant with all the P values less than 0.001 except for GFR/ECV at 1 year 
where P=0.0013.
From a clinical point of view, it is important to be able to demonstrate the benefits of 
switching to sirolimus for the renal and liver transplant patients considered separately. 
Clearly there are important differences between these groups of patients. In the liver 
transplant patients, the function of the patient’s native kidneys is monitored, whereas in 
the renal transplant patients it is the function of the transplanted organ. The function of 
the transplanted organ may well be deteriorating more rapidly than native kidneys 
independent of any drug effects but also may respond differently to the drugs. It is more 
challenging to show statistical significance when considering the renal and liver 
transplant groups separately because of the smaller numbers. It is here that there are 
differences in how well the different measures of GFR have been able to demonstrate 
statistical significances. In several of the comparisons this is a matter of some of the 
measures of GFR showing a difference as highly significant whereas others have only 
reached significant. But the most important differences are for the liver transplant 
patients at 12 months. Here GFR/ECV failed to demonstrate the rise in GFR in the 
switching patients as significant and GFR/ECV, GFR/ECVi and GFR/ECV2 all failed to 
show the difference between the switching and non-switching patients as significant. It
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is likely that if a greater number of patients had been studied then these differences 
would have reached significance. However this would appear to be a limitation with 
using measures of GFR/ECV for this particular study.
The order of the magnitude of the P values in the comparisons is essentially always the 
same. GFRbm gives the lowest followed by GFR (except in one out of 14 comparisons 
when these are the other way round). All the measures of GFR/ECV always had higher 
P values than the measures of GFR. Of the measures of GFR/ECV, GFR/ECV2 always 
had the lowest P value and in all but one comparison GFR/ECV had the highest.
It might have been expected that the measures of GFR and GFR/ECV based on the full 
plasma clearance curve would be subject to less experimental error than the measures 
based only on the late samples and therefore be superior for looking for changes in renal 
function. However there is no evidence of this and using measures based on the full 
plasma clearance curve had no obvious benefit. It could be concluded that in the case of 
performing serial GFR measurements on individual patients looking for changes in renal 
function that taking early blood samples as well as late blood samples is not indicated. 
Measurements based on the full plasma clearance curve might still be expected to give 
the most accurate assessment of absolute renal function.
Of the measures o f GFR/ECV based on the terminal rate constant it could be concluded 
that there is slightly less experimental error with GFR/ECV2 where the form of the 
correction for the one pool assumption includes the intercept B’ and the surface area.
There could be two contributing factors as to why the measures of GFR/ECV have been 
less good at demonstrating the significance of the changes in renal function. The first is 
that with the drug switch that as well as an increase in GFR there could also be a real 
increase in ECV. This would reduce the magnitude of the change in GFR/ECV which 
does fit with the results and would therefore with the same amount of variability make 
demonstrating the significance of the change in renal function more difficult. The second 
could be that there is increased experimental error when measuring GFR/ECV and that 
this makes the results more variable hence greater difficulty demonstrating statistical 
significance. This is one of the criticisms of using GFR/ECV derived from the rate 
constant of the terminal exponential compared with using a slope and intercept 
technique as in GFRbm (De Sadeleer et al 2 0 0 0 b). The argument is that with the single 
exponential fit to the late samples experimental error that leads to an error in fitting the 
slope with the slope intercept technique could be at least partially compensated for by 
the resulting error in the intercept. This was investigated in chapter 3 where it was 
argued that there is a balance between this compensating effect and the fact that the 
‘slope only’ approach avoids some of the sources of error that feed in to the slope- 
intercept approach. If there is greater experimental error with measures GFR/ECV 
compared with GFR it might be expected that there would be greater standard deviation 
especially in the control groups where there is little change in renal function. However in 
all cases in the control groups there was standard deviation was less with the measures 
of GFR/ECV than with GFR. In the control group if there is really little change in GFR 
and ECV between baseline and a subsequent measurement, then differences between the 
slopes fitted on the two occasions would be expected to be correlated with differences in 
the intercept. Fig 7.4 shows a plot of changes in slope against changes in intercept for 
the control group of all patients between baseline and 3 months. This does show a
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significant correlation at least when one outlier is removed. This implies, as expected, 
that some of the variation in the measures derived from the slope only are due to errors 
in fitting, which might be partially compensated for in the slope-intercept measures. 
However as observed, the standard deviation in the controls is smaller with slope only. 
However, the standard deviation in the switching patients is greater with the slope only 
than the slope intercept.
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Fig 7.4: Plot of the change in slope of the terminal exponential a2’ against change in intercept B’ 
at 3 months for all the non-switching patients. Also shown is the linear fit to the points with 
correlation coefficient and P value (n=30). Note one outlier shown in pink was omitted from the 
linear fit.
One explanation for these findings could be that in the switching patients the increase in 
extracellular fluid volume is variable and may not be seen in all cases. Hence, the 
average increase in GFR/ECV is slightly less than that in GFR and the variability is 
greater.
In summary, results show that in this study GFR/ECV does not appear to be the 
optimum measure for detecting changes in renal function. However, this finding may be 
particular to this study because the change in drug regime may be producing a change in 
ECV.
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Chapter 8: Radionuclide Evaluation of the Performance of Haemodialysis in vivo
8.1 INTRODUCTION
If a suitable gamma emitting radiopharmaceutical for measuring GFR is used it is 
possible to place an external gamma detecting probe somewhere on the patient’s body 
and to monitor the disappearance of the tracer from the body without taking any blood 
samples. It has been shown that this is possible using Tc-99m DTPA (Fleming et al 
1987, Rabito et al 1993, Juett et al 1995) (Cr-51 EDTA is not suitable because it is an 
inefficient gamma emitter, the abundance of the 320 keV gamma is about 10 % and the 
activities required to give a reasonable signal with an external probe would be 
prohibitive). If the probe is placed away from the kidneys and the bladder the signal 
picked up should reflect tracer in one or more compartments of the extracellular fluid 
volume. Although modelling, for example as in chapter 2, shows that the concentration 
of tracer in the 2 or 3 functional compartments will be different, by 2 hours after 
injection the concentrations are starting to track each other with constant ratios of 
concentrations between them and so the ‘terminal’ rate constant of clearance measured 
with an external probe should be reasonably independent of which compartments are 
contributing to the gamma signal. If it is accepted that the rate constant of the terminal 
exponential, after some correction for the one compartment assumption, is a good 
measure o f renal function, reflecting GFR normalised to the extracellular fluid volume, 
then from probe data it is possible to establish this measure of GFR without taking a 
blood sample. As a probe can give a near ‘real time’ estimate of renal function, one 
possibility is to investigate the effect on GFR of interventions. Rabito et al (1993) 
showed it was possible to use the technique in patients at risk of acute renal failure 
during the administration of potentially nephrotoxic contrast agents during angiography. 
Bauman et al 1998 showed the technique could be used immediate responses of GFR to 
adenosine infusion.
In this chapter an extension of the probe technique is presented, using a probe to monitor 
the disappearance of Tc-99m DTPA from the body during haemodialysis. This was used 
to measure the clearance of DTPA by dialysis in vivo as a measure of dialysis 
effectiveness. One of the specific questions to be answered was -  does the performance 
of the dialyser deteriorate during as session of dialysis due to plasma proteins clogging 
the semipermeable membrane (Hoenich 1995). The probe method was also used to 
measure the effect on DTPA clearance of changing some of the dialysis parameters, 
namely blood flow and dialysate flow, during a session of dialysis.
The conventional benchmark by which to assess the effectiveness of a single session of 
haemodialysis is urea removal (Sargeant 1983). This is calculated from the urea 
concentration in blood samples taken just prior to and just after dialysis and is 
conventionally expressed as the quotient, Kt/V, where K is blood urea clearance, t is 
time o f dialysis and V urea distribution volume. Dialysis removes many other soluble 
substances with a range of molecular sizes, and the permeability of the dialyser 
membrane will vary with molecular size. Urea is a relatively small and therefore 
relatively highly diffusible molecule. Because of this, its clearance by the dialyser is 
likely to be blood flow-dependent. This is when the concentrations in the blood and
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dialysate fluid reach complete equilibrium in a pass and therefore a change in blood 
flow, within a certain range, will have a big effect on the clearance. With larger 
molecules that equilibrate more slowly across the membrane, the clearance is more 
likely to be diffusion dependent, where full equilibrium is not reached and a change in 
blood flow has less of an effect on the clearance. Because of this, only assessing the 
performance of dialysis in vivo with urea may not give a very representative assessment 
of the dialysis efficiency for larger molecules. Therefore, there may be an important 
place for assessing the dialyser handling of different size molecules, for example Tc- 
99m DTPA which has a molecular weight of 492 Da.
8.2 METHODS
8.2.1 Com partm ent modeling
The two compartment model established in Chapter 2 was used to model the Tc-99m 
DTPA concentrations expected in the compartments with the modification that the 
clearance of the tracer can be turned on and off at different time points. In the model it is 
assumed that the patients have no residual renal function, so that before and after 
dialysis the tracer is just equilibrating between the two compartments. The mean 
normalised values from Chapter 2 were used for the compartment volumes and the 
intercompartmental diffusion constant. The volume of compartment 1 which includes 
plasma was 9.54 L, the volume of compartment 2 was 4.14 L and the 
intercompartmental diffusion constant was 0.0999 L/min.
The compartmental modeling was also used to calculate the expected magnitude of 
DTPA rebound, that is the percentage increase in DTPA concentration after finishing 
dialysis due to re-equilibration between the compartments. During dialysis ‘equilibrium’ 
is reached once the ratio of concentrations between the compartments has become 
constant, call this ratio X. Below is a mathematical solution for X starting with the 
equations that define the two compartment model (GFR here represents the dialyser 
clearance).
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X is therefore dependent on clearance and the intercompartmental diffusion constant k. 
In chapter 2 it was concluded that k scales with bodysize in the same manner as the 
distribution volumes.
Replace k with kmean.SA/1.73 and GFR with (K/V)DTpA.Vmean-SA/1.73 where k mean is 
the mean normalised k, SA is surface area and Vmean is mean normalised distribution 
volume of DTPA. Then X becomes:
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\ v Jf
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Which suggests that the magnitude o f X is independent of body size and only depends 
on the normalised clearance from the slope (KTV)dtpa- If at the end of dialysis the 
concentration in compartment 1 including plasma is Ci then the concentration in 
compartment 2 is X.Ci. The total amount of tracer remaining is X.C1.V2+C1.V1 which 
then with no further removal equilibrates between the two compartments giving a final 
concentration o f (X.Ci.V2+Ci.Vi)/(Vi+V2). Rebound defined as the fractional increase 
in concentration in plasma after dialysis is then:
JSTC^+C jKj
rebound = ■7,+V,
- c , W , + v s J f ( x - 1)
c, y, +/v, 1+/
Which predicts that the magnitude of the rebound is only dependent on the normalised 
clearance from the slope (K /V )dtpa
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8.2.2 Patients
Fifteen patients on long-term haemodialysis were recruited. Eleven were males and the 
age range was 45-80. They were all essentially anephric with glomerular filtration rates 
less than 5 ml/min/1.73 m2.
8.2.3 Procedures
Ninety minutes prior to the commencement of a session of dialysis, patients were 
injected intravenously with 150-200 MBq of Tc-99m-DTPA (Amersham Healthcare, 
Bucks) in 2 ml. Immediately prior to starting dialysis, a blood sample was taken to 
estimate the pre-dialysis distribution volume of Tc-99m DTPA. Dialysis was then 
started and continued for the patient’s usual session which was between 3 and 5 hours. 
Another blood sample was taken immediately after the termination of dialysis. In 6  of 
the patients an injection of 2 MBq of Cr-51 EDTA (Amersham Healthcare, Bucks) in 2 
ml was also given immediately after the termination of dialysis, and, after a further 
period of 90 min, a final blood sample was taken to estimate the post-dialysis 
distribution volume of Cr-51 EDTA. In some patients additional blood samples were 
obtained at points during dialysis. At each of these points a pair of samples were taken 
essentially simultaneously, one from the line going to the dialyser and one from the line 
taking blood from the dialyser back to the patient. These pairs of samples were used to 
estimate the dialyser Tc-99m-DTPA extraction fraction (see below). Patients were 
weighed immediately before and after dialysis, and a note made of the weight of any 
fluid intake during the dialysis session.
8.2.4 Probe system
A shielded housing was built through which the plastic line taking blood from the 
patient to the dialyser was fed and was attached to a heavily shielded 5 cm sodium 
iodide scintillation detector (see Fig 8.1). The housing was designed so that the line 
passed across the face o f the detector, which was connected to a PC based Multi 
Channel Analyser (MCA) system (Ortec Maestro, Oak Ridge, TN, USA) set to 
dynamically acquire counts in 1 -minute bins, thereby enabling the relative blood 
concentration of Tc-99m to be plotted continuously as a function of time throughout 
dialysis.
Fig 8.1: Photograph of the probe detector, with housing and tube. Housing contains lead 
shielding inside the wooden exterior.
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8.2.5 Sample Counting
Blood samples were centrifuged at 1000 G for 15 minutes and an accurate volume of 
between 1 and 3 ml plasma (depending on the volume available) was pipetted into 
counting tubes. The volume in the counting tubes was made up to 3 ml with deionised 
water. A standard was made for the Tc-99m DTPA by pipetting 0.1 ml of the 
administered solution into a 250 ml volumetric flask and making up the volume. A 
standard was made for the Cr-51 EDTA by pipetting 0.1 ml of the administered solution 
into a 100 ml volumetric flask and making up the volume. 3 ml of the standards was 
pipetted into counting tubes and counted along with the plasma samples, as was 3 ml 
deionised water as a background. The samples were counted on an automatic gamma 
counter (Wallac Wizard, Turku, Finland) for 1000 seconds with energy windows for Tc- 
99m and Cr-51. Counts were corrected for deadtime, then for background, then when 
appropriate for cross talk from Cr-51 into the Tc-99m window (crosstalk was 
consistently 15%) and finally for decay during the counting session. Concentrations of 
Tc-99m DTPA and Cr-51 EDTA in the samples were then expressed in percentage of 
the administered dose per litre from comparing with the standard counts.
8.2.6 Details of dialysis
The dialysis machine was a Fresenius 4008 and two different types of dialyser were used 
(Althin A-18 and Fresenius F-8). Dialysis session were 3 hours in 8 patients, 4 hours in 
6  patients and 5 hours in one patient. The initial blood flow rate (Qb) was 300 ml/min, 
except in three patients where it was 250, 270 and 350 ml/min respectively. The initial 
dialysate flow rate (Qd) was 500 ml/min in all patients. In 5 patients, these machine 
variables were left unaltered throughout dialysis. In 10 patients, Qb and Qd were changed 
in isolation for periods of 20 min starting 1 h after the onset of dialysis. The flow rates 
were returned to their respective baseline values for at least 15 min before making 
another change. The changes comprised a 33% reduction in Qb, a 60% increase in Qd 
(to 800 ml/min) and a 40% decrease in Qd (to 300 ml/min).
8.2.7 Data Analysis
Distribution volumes
The pre-dialysis distribution volume of Tc-99m DTPA(VDTPa) was calculated from the 
reciprocal of the plasma concentration of Tc-99m DTPA in the sample taken before 
commencing dialysis. Where relevant the post-dialysis distribution volume of Cr-51 
EDTA was calculated from the reciprocal of the plasma Cr-51 EDTA concentration in 
the sample taken 90 minutes after the administration of the Cr-51 EDTA
Tc-99m-DTPA clearance
From the probe data a single exponential was fitted to portions of the Tc-99m DTPA 
disappearance curve to give the rate constant, a. During periods where the clearance of 
Tc-99m DTPA is expected to be constant this rate constant is equivalent to the terminal 
rate constant in a normal GFR study, a  is therefore close to the quotient plasma DTPA 
clearance/volume of distribution [(K /V )dtpa] but would be expected to be an 
underestimate of this quotient by an amount that is dependent on a . Therefore to get a 
better estimate of (K /V ) dtpa the correction formula derived in chapter 2  to give 
GFR/ECV based solely on the terminal rate constant was used. Thus:
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(K /V )Dtpa = 0.9462 a + 23.11 a2
To get an estimate o f the absolute clearance of DTPA (K dtpa)  for the whole session of 
dialysis; (KTV)dtpa from a  from a fit to the whole disappearance curve excluding the 
first 60 minutes was multiplied by the pre-dialysis V dtpa- V dtpa would be expected to 
be changing slightly during dialysis due to ultrafiltration but the effect of this on 
clearance was assumed to be small. This estimate of overall K dtpa was made in all 
patients ignoring the periods during which changes in Qb and Qd were made.
The changes in Tc-99m DTPA clearance in response to changes in Qb and Qd were 
assessed by fitting a  to the portion of the curve during the change correcting this to get 
(KTV)dtpa and comparing this the average of the (K /V )dtpa derived from the average a 
from all the portions of the curve after 60 minutes where the machine parameters were at 
baseline.
Tc-99m DTPA extraction fraction
The Tc-99m DTPA extraction fraction was calculated from the pairs of samples taken 
from blood entering and leaving the dialyser being (concentration entering - 
concentration leaving)/concentration entering.
The plasma flow through the dialyser was calculated by multiplying the blood flow Qb 
by (1 -  haematocrit) and then an alternative estimate of extraction was made by dividing 
the DTPA clearance (K dpta)  by the plasma flow. The two estimates of extraction 
fraction were compared.
Urea clearance
The measure Kt/V for urea was calculated from the urea concentrations in a blood 
sample taken immediately prior to dialysis and a blood sample taken immediately after 
dialysis. Kt/V is calculated from the natural logarithm of the pre-to-post dialysis urea 
concentration ratio with small corrections for urea production during dialysis, 
ultrafiltration and rebound, nitrogen ratio (R). The equation used was from Daugirdas 
(1995).
R is the ratio of pre to post dialysis urea concentration in venous samples 
t is dialysis time in hours 
W is the pre-dialysis weight
UF is an estimate o f the total ultrafiltration from the weight change during dialysis 
Kt/V = [ln(R - 0.0081) + (4 -  3.5 R).(UF/W)].(l-0.46/t)+0.02
With a simple monoexponential clearance ln(R) is mathematically equivalent to a.t. To 
compare the performance of haemodialysis measured with urea to that measured with 
Tc-99m DTPA Kt/V is compared (K /V ) dtpa multiplied by time.
8.2.8 Computerized dialyser simulation
A computerised simulation was written to model the concentrations within a dialyser 
arranged such that dialysate and blood are flowing in opposite directions and that the 
dialysate entering the dialyser is across the membrane from blood just before it leaves 
the dialyser. The concentration of the solute to be modelled is assumed to be zero in the 
dialysate entering the dialyser. The dialyser is then considered to be divided into a finite 
number of cells ( 10 0 ) on each side of the dialysis membrane and the concentration 
within any one cell is assumed to be constant (Fig 8.2). The simulation models unit time
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intervals during which the solute flows between adjacent cells on the same side of the 
membrane whilst at the same time crossing the membrane as a result o f diffusion. The 
simulation is run until a steady state is reached, at which point there is a concentration 
gradient in blood and dialysate along the length of the membrane. The simulation was 
then used to find a mass transfer coefficient that gives a particular extraction fraction at 
the baseline blood and dialystate flow rates and then to model how changes in dialysate 
or blood flow rates would effect the extraction fraction. The effect of ultrafiltration was 
ignored. For Tc-99m-DTPA, the haematocrit was assumed to be 0.3 so that plasma flow 
rather than blood flow was used. It was assumed that urea moves freely between plasma 
and red cells within which concentrations would then be identical.
blood -
-  dialysate
97 98 99 100
Fig 8.2: Diagramatic representation of the computer simulated dialyser model.
8.2.9 Statistics
Results are expressed as the mean +/- SEM. Levels of association between variables was 
assessed by Pearson’s correlation coefficient. A P value o f less than 0.05 was 
considered to represent significance less than 0 .0 1  o be highly significant.
8.3 RESULTS
8.3.1 Com partm ent modeling
Results of the compartmental modelling are shown in Fig 8.3 for a Tc-99m DTPA 
clearance of 108 ml/min. The model predicts that during the period of dialysis the 
disappearance curve will be bi-exponential, the first exponential being due to the 
establishment of a concentration gradient between the compartments. The model 
predicts that after about 60 minutes of dialysis it is reasonable to assume that the 
disappearance curve is mono-exponential. The model also predicts that the 90 minutes 
after the first injection there is still a small difference between the concentrations in the 
two compartments. Ideally a longer period of equilibration would be left before taking 
the first blood sample and commencing dialysis, for example 150 minutes as shown 
modelled in Fig 8.4. However with a longer equilibration time, the total time for the 
patient study would be prohibitively long. With 90 minutes of equilibration the model 
predicts that the plasma DTPA concentration would be 1.3 % higher than it would be at 
complete equilibration, it was decided that this was acceptable error. The model also 
predicts a ‘rebound’ of the plasma Tc-99m-DTPA concentration when dialysis is
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terminated that is due to re-equilibration of concentrations between the two functional 
compartments.
Table 8.1 shows the expected concentration ratio X and expected rebound for the range 
of clearance values encountered.
(K/V)dtpa min 1 X rebound
0.004 1.24 7.4 %
0.005 1.32 9.6 %
0.006 1.39 11.9%
0.007 1.47 14.4 %
0.008 1.56 17.0%
Table 8.1: Mathematically expected values of X the ratio C2/C-i at equilibrium and rebound at 
different levels of clearance.
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Fig 8.3: Modelled concentrations in the functional compartment of the extracellular fluid volume. 
C1 and C2 are concentrations in compartment 1 and 2 respectively. Clearance from dialysis was 
108 ml/min. Yellow line is fit to C1 from 60 minutes after the start of dialysis to the end of 
dialysis.
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Fig 8.4: Modelled concentrations in the functional compartment of the extracellular fluid volume 
with a longer initial equilibration time of 150 minutes. C1 and C2 are concentrations in 
compartment 1 and 2 respectively. Clearance from dialysis was 108 ml/min.. Yellow line is fit to 
C1 from 60 minutes after the start of dialysis to the end of dialysis.
8.3.2 Rebound
In all the 6  patients where a blood sample was taken 90 minutes after the end o f dialysis 
this showed an increase in Tc-99m DTPA concentration compared to the sample taken 
immediately after dialysis. This demonstrates the predicted rebound. The average 
magnitude of the rebound was 12.7 % (2.9 %). The average ( K / V ) Dt pa  in these patients 
was 0.0059 min" 1 for which the prediction is a rebound of 11.7 %. Also the magnitude o f 
the rebound did appear to correlate with ( K / V ) DTPa  R=0.79 see Fig 8.5 although because 
o f the small numbers this was not significant 0.1>P>0.05.
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Fig 8 .5 : Points are the measured Tc-99m DTPA rebound plotted against (K /V )DTpa shown with 
the linear fit to these points with equation and correlation coefficient. Pink line is the predicted 
rebound.
8.3.3 Volumes of distribution of radiotracers and ultrafiltration rate
The average volume of distribution of Tc-99m-DTPA ( V d t p a )  prior to dialysis was 18.9 
(0.9) L or 17.1 (0.6) L/1.73m2. Post-dialysis volume of distribution of Cr-51-EDTA 
( V e d t a )  was measured in six patients. In these 6 , V e d t a  was less than V d t p a  by an 
average of 1.73 (0.74) L but they showed a good correlation with each other Fig 8 .6 . If it 
is assumed that the distribution volumes of Cr-51 EDTA and Tc-99m DTPA are 
equivalent and both represent extracellular fluid (ECF) volume, then the difference can 
be interpreted as change in ECF volume during dialysis. The reduction in body weight in 
these 6  patients was 1.48 (0.57) kg which corresponds reasonably with the reduction of 
1.73 L in ECF volume, implying that short term weight reduction is almost exclusively 
the result o f loss of fluid from the ECF compartment. Taking 1.5 L as representative of 
the average fluid loss and the time of dialysis as 240 minutes then the ultrafiltration rate 
Qf, is about 6  ml/min and was considered negligible compared with Qb.
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Fig 8.6: Correlation between post dialysis distribution volume of Cr-51 EDTA and pre-dialysis 
distribution volume of Tc-99m DTPAVedta, solid pink line is line of identity.
8.3.4 Tc-99m-DTPA clearance with unaltered parameters
In the 4 out o f 5 patients in whom the machine parameters (i.e Qb and Qd) were left 
unaltered over the entire period of dialysis, the Tc-99m-DTPA disappearance curve 
measured with the probe followed the pattern predicted by the modelling. After about 
60 min, it appeared mono-exponential and remained as such for as long as dialysis 
continued, examples are shown for the two dialysers in Fig 8.7 and 8 .8 . Two of these 
patients were dialysed with the A -18 dialyser and two with the F- 8  dialyser. In these 
four patients there was no significant difference between a  fitted between 90 and 120 
minutes and a  fitted to the last half hour of dialysis (P>0.05). In the one remaining 
patient there was a significant difference a  for 90 to 120 minutes was 0.00668 min ' 1 
(standard error 0.00015) and a for the last half hour o f dialysis 0.00591 (standard error 
0.00019) (P<0.01). This plot from this patient is shown in Fig 8.9. Therefore in 4 out of 
the 5 patients there was no evidence of the dialyser performance deteriorating during a 3 
or 4 hour dialysis session, however in one patient there was some evidence that the 
DTPA clearance may have decreased during a 3 hour dialysis session.
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Fig 8.7: Example of probe counts from patient on A18 where parameters were kept constant 
throughout. Pink line is fit to counts from 60 minutes onwards.
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Fig 8.8: Example of probe counts from patient on F-8 where parameters were kept constant 
throughout. Pink line is fit to counts from 60 minutes onwards.
183
100000  -
10000 I  1----------------------------------
0 50 100 150 200
m inutes
Fig 8.9: Example of probe counts from patient on F-8 where parameters were kept constant 
throughout which shows some evidence of the curve flattening during dialysis. Pink line is fit to 
counts from 60 minutes onwards.
8.3.5 Comparison between dialysers
Plasma clearance of DTPA ( K DTp a )  based on probe data from 1 hr after the onset of 
dialysis for the patients in whom Qb and Qd were left unaltered were similar between the 
2 dialysers: 103 and 104 ml/min for the A -18 and 107, 117 and 118 ml/min for the F-8 . 
Ignoring the influence of changes in Qb and Qd, the mean K DTp a  for all 7 patients 
dialysed with A-18 was 103 (2.7) ml/min and for the 8  patients dialysed with the F-8 ,
111 (5.3) ml/min (P > 0.05). Hence there was no significant difference between the 
dialysers and all further analysis considers patients from both dialysers together. The 
overall mean K d t p a  for all 15 patients was 108 (3.2) ml/min. The above comparison 
ignores the fact that in 3 patients the baseline Qb was not 300 ml/min however if  these 
patients are excluded there is even less difference between the two dialysers.
8.3.6 Effects of flow changes on Tc-99m-DTPA clearance from probe data
O f the 10 patients where there were changes made in the blood flow (Qb) and dialysate 
flow (Qd) two had baseline blood flows different to 300 ml/min being 270 and 350 
ml/min. However data from these two patients is pooled with the other patients. From 
the probe data a 33% reduction in blood flow led to on average a 7.2% (5.4%) reduction 
in DTPA clearance (Note the percentage change in ( K / V ) d t p a  will be the same as the 
percentage change in K d t p a ) -  There was a high degree of variability in the changes 
measured and this mean reduction was not significant (n=10, P>0.05). A 40% decrease 
in Qd (from 500 to 300 ml/min) led to significant decrease in DTPA clearance that was 
on average 15.6% (4.4) (n=10, P=0.01). A 60% increase in Qd (from 500 to 800 ml/min) 
led to an average increase in DTPA clearance of 4.2% (3.3) (n=8 , P>0.05) which was
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not significant. Fig 8.10 shows an example of the probe counts in a patient where flow 
changes were made.
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Fig 8.10: Example of probe counts with periods of changes in blood flow (Qb) and dialysate flow 
(Qd) shown. Yellow lines show the fit to the periods of change ad pink lines show the fit to 
periods of baseline flows.
8.3.7 Extraction fraction sample data
Only three patients had paired samples taken for measuring extraction fraction at 
baseline machine parameters and after the changes in Qb and Qd. Three further patients 
in whom no changes in flow were made had one set of paired samples taken and due to a 
protocol error four patients had paired samples taken after the flow changes but not at 
baseline. As a result of this, the data were considered statistically in two ways; one 
where all the measurements at a particular set o f machine parameters was averaged and 
compared in a non-paired manner and the other considering only the patients who had 
measurements before and after changes. The average Tc-99m DTPA extraction fraction 
measured from samples at Qb = 300 ml/min and Qd = 500 ml/min was 50.4 % (1.8 %) 
n=4. This compared very well with the average extraction fraction calculated from 
K d t p a  from the probe data and the plasma flow rate which was 51.0 % ( 1 .6 %) for the 1 2  
patients with the same parameters. The results for the mean extraction fractions are 
shown in Table 8.2. It can be seen that although the extraction fraction was higher when 
the blood flow was reduced to 200 ml/min the difference was not significant. The 
extraction fractions are converted in to clearance values by multiplying by the plasma 
flow calculated from Qb multiplied by (1 -  Haematocrit) and the results are then as 
shown in table 8.3. With Qd^OO ml/min the DTPA clearance was significantly lower 
with a Qb of 200 ml/min compared with a Qb of 300 ml/min. With Qb=300 ml/min the 
DTPA clearance was significantly lower with a Qd o f 300 ml/min compared with a Qd o f 
500 ml/min. With Qb=300 ml/min the DTPA clearance was not significantly higher with
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a Qd of 800 ml/min compared with a Qd of 500 ml/min in fact the average clearance was
slightly lower but not significantly.
Qb Qd n Extraction faction 
Mean (SEM)
300 500 4 50.4 % (1.8 %)
2 0 0 500 5 56.8 % (2.4 %)
300 300 5 39.3 % (2.0 %)**
300 800 5 45.3 % (2.1 %)
Table 8.2: Tc-99m DTPA extraction fractions at diFferent blood (Qb) and dialys
calculated from sample concentrations.
Qb Qd n K dtpa 
Mean (SEM)
3 0 0 5 0 0 4 1 0 6 ( 1 .9 )
2 0 0 5 0 0 5 7 8  (3 .2 )* *
3 0 0 3 0 0 5 8 0  (2 .7 )* *
3 0 0 8 0 0 5 9 3  (5 .8 )
Table 8.3: Tc-99m DTPA clearance at different blood (Qb) and dialysate (Qd) flow rates 
calculated from sample concentrations.
In the three patients where extraction fractions were measured at baseline and after a 
33% reduction in Qb (one of these patients had a baseline Qb of 350 ml/min) these 
showed a rise in extraction fraction of 9.6 % (1.6 %) which was significant (P<0.05). 
This reduction in Qb led to on average a fall in DTPA clearance of 21% (1.4%) which 
was significant (P<0.01). In the same patients a decrease in Qd from 500 to 300 ml/min 
led to on average a fall in DTPA clearance of 26 % (5.9%) which was significant 
(P<0.05). In the same patients an increase in Qd from 500 to 800 ml/min led to on 
average a very small rise in DTPA clearance of 0.9 % (1.2%) which was not significant 
(P>0.05).
The estimated clearance calculated from the extraction fractions is shown graphically in 
Fig 8.11 and 8.12.
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Fig 8.11: Plot of Tc-99m DTPA clearance calculated from sample concentrations against blood 
flow, dialysate flow was always 500 ml/min. Solid lines join points from the same patient.
Patients dialysed with the F-8 are shown in blue and patients dialysed with the A18 are shown in 
pink.
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Fig 8.12: Plot of Tc-99m DTPA clearance calculated from sample concentrations against 
dialysate flow. Solid lines join points from the same patient. Patients dialysed with the F-8 are 
shown in blue and patients dialysed with the A18 are shown in pink. Patient shown in pale blue 
had a blood flow of 350 ml/min all others were 300 ml/min.
A comparison of the absolute values of Tc-99m clearance derived from the probe 
technique and the paired sampling technique. For each set of paired samples the K d t p a  
derived from them was compared with the K d t p a  derived from the slope o f the probe
X
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curve at the appropriate point multiplied by the distribution volume o f DTPA derived 
from the pre-dialysis blood sample. The results are shown in Fig 8.13 which shows that 
there is quite a bit o f variability in the agreement between these to techniques and also 
that the probe technique tended to produce higher values. The mean difference between 
the techniques was 19 % and the difference was highly significant (p<0.001)
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Fig 8.13: Comparison of the absolute values of plasma clearance of Tc-99m DTPA derived from 
(1) (K/V)dtpa from corrected slope from the probe data multiplied by VDTPA from the pre-dialysis 
samples against (2) the extraction fraction measured from the paired samples multiplied by Qb 
multiplied by (1-Haematocrit).
8.3.8 Urea clearance
Kt/V was measured for the session of dialysis in 13 of the 15 patients. Mean Kt/V was 
1.035 (0.051). The volume of distribution of urea (Vurea) is close to total body water 
which was estimated as 40 L/1.73m2. The Urea clearance (K urea) was then estimated by 
multiplying Kt/V by V urea and dividing by the dialysis time in minutes. Mean urea 
clearance was 210 (7.8) ml/min. Urea extraction fraction was then calculated by dividing 
Kurea by the baseline blood flow (Qb). Mean urea extraction fraction was 71 % (2.9 %). 
Correlation between removal of urea and DTPA by the dialyser was investigated by 
plotting (K /V )d tp a  from the probe data multiplied by time against the urea Kt/V (Fig 
8.14) the correlation coefficient R was 0.8012 and this was a highly significant P<0.001. 
It is interesting to note that the magnitude of these two quantities is very similar, this 
means that the dialysis session removes a similar proportion of the total urea and Tc- 
99m DTPA. Note a value in either parameter of 1.2 means about 70 % is removed. The 
greater diffiisibility of urea means its extraction fraction is higher and its clearance is
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higher but as it has a greater volume of distribution the proportion removed from the 
body is similar.
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Fig 8.14: ( K /V ) Dtp a  multiplied by time plotted against the urea Kt/V with solid line showing the 
linear fit with equation and correlation coefficient
The fact that ( K / V ) Dt p a  is correlated with Kt/V will be partly due to the fact that in this 
group o f patients there was a variety o f dialysis times and patient sizes. For the patient 
dialysed for longer periods of time more urea and more DTPA will be removed and this 
will be reflected in Kt/V and obviously in ( K / V ) Dt p a  multiplied by the dialysis time . 
Similarly larger patients would have greater volumes o f distribution o f both urea and 
DTPA and for the same length o f dialysis would tend to have a lesser proportion of their 
total urea and DTPA removed than smaller patients and this would be reflected in a 
lower Kt/V and a lower ( K / V ) d t p a -  S o  to investigate if there was any correlation in the 
underlying clearance provided by the dialysers for the two solutes, plasma K Dt p a  
calculated by multiplying ( K / V ) Dt p a  by V d t p a  was plotted against Kurea as calculated 
above (Fig 8.15) showing no significant correlation (R=0.19, n=13, P>0.05). One of the 
reasons for this poor correlation could be the dependency of DTPA clearance on 
haematocrit. Therefore plasma K d t p a  as converted into a pseudo blood clearance by 
dividing by (1-haematocrit) and this was blood K d t p a  was plotted against Kurea (Fig 
8.16) giving a significant correlation (R=0.67, n=13, P<0.05).
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Fig 8.15: Plasma KDTPAfrom probe data plotted against Kurea with solid line showing the linear fit 
with equation and correlation coefficient.
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Fig 8.16: KDTPA from probe data divided by (1-haematocrit) to give a blood KDTPA plotted against 
KUrea with solid line showing the linear fit with equation and correlation coefficient.
8.3.9 Computerized dialyser simulation
To achieve an extraction fraction of 52% for Tc-99m DTPA and 74 % for urea the 
computerised dialyser model predicts that the diffusibility o f urea is 3.3 times higher 
than that of DTPA. This is consistent with the difference in diffusibility observed across 
the continuous vascular endothelium in vivo between urea and solutes of a similar size
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to Tc-99m DTPA (Levick 2000). The model then predicts that for DTPA the 33% 
reduction in Qb would give a 14 % decrease in clearance, the 40% reduction in Qd would 
give a smaller 6  % decrease in clearance and the 60% increase in Qd would give a small 
3 % increase in clearance. The model predicts that these changes in flow would have a 
greater effect on urea clearance. The results from the model for both Tc-99m DTPA and 
urea are shown in Table 8.4 along with a summary of the experimental results for DTPA 
for comparison.
Mean changes in Tc-99m DTPA
From probe 
data
From sample 
data
Predicted
DTPA
Predicted urea
33% reduction 
in Q b
-7%  (5.4%) -21% (1.5 %)* -14% -21  %
Qd reduction 
from 500 to 300 
ml/min
-16 % (4.4 %)* -26% (5.9 %)* -6 % -1 2 %
Qd increase 
from 500 to 800 
ml/min
+4 % (3.3 %) +0.9% (1.2 %) +3% +6 %
Table 8.4: Summary of experimental results for changes in Tc-99m DTPA clearance in response 
to changes in Qb and Qd from the sample data and the probe data along with the predicted 
changes from the computerised dialyser model for both Tc-99m DTPA and urea. * indicates 
significant differences from baseline (P<0.05).
8.4 DISCUSSION
The Tc-99m DTPA disappearance curve observed with the probe was o f a similar shape 
to that predicted by the modelling, being bi-exponential with the contribution of the 
relatively small magnitude faster exponential being minimal after about 1 hour. Also, the 
observed rebound in the concentration of Tc-99m DTPA after dialysis was essentially 
identical in magnitude to that predicted by the modelling and had the predicted 
dependence on normalised clearance. The fact that the model holds up well in the 
dialysis situation would appear to be extra support for the functional compartmental 
model being representative of the body’s handling of solutes like DTPA. In particular, it 
would be unlikely that the magnitude of the rebound would be as predicted if the ratio of 
the volumes of the two functional compartments and the rate at which DTPA mixes 
between them were not close to those in the model.
The estimate of extracellular fluid (ECF) volume prior to dialysis from the volume of 
distribution of Tc-99m-DTPA and the similar estimate after dialysis from the volume of 
distribution of Cr-51 EDTA enables an estimate of the change in ECF volume resulting 
from dialysis. Whether this is a reasonable estimate will depend on the distribution 
volumes of Tc-99m DTPA and Cr-51 EDTA being equivalent, there is some evidence to 
support this (Rehling et al 1984, Fleming et al 1991). If it is assumed that the mean 
change in distribution volume is representative of the change in ECV then the fact that 
the mean recorded patient weight change was very similar to the change in ECF volume
191
would suggest that weight lost over dialysis is almost exclusively accounted for by loss 
of ECF fluid, with no apparent change in intracellular fluid volume.
Four out the five patients where the flow rates on the dialysis machine were left 
unaltered throughout dialysis showed no sign of the clearance of DTPA reducing during 
dialysis. Although in the remaining patient there was some evidence of the rate constant 
changing over time, on balance it would seem unlikely that there is significant clogging 
of the dialyser membrane with plasma proteins over the course of a session of dialysis.
Kt/V is the variable conventionally used to quantify the effectiveness of dialysis 
(Sargent 1983). This is calculated from urea concentrations in blood samples taken 
before and after dialysis. Urea is a small highly diffusible molecule with a large volume 
of distribution but Kt/V for urea is assumed to be representative of the handling by the 
dialyser of a range of molecules of varying size. Johnsson et al (1999) neatly 
demonstrated an example of how there are differences between the dialysis of different 
size molecules. They showed that two different dialyser regimes, one with lower blood 
flow for longer, that gave the same clearance of urea measured with Kt/V gave 
significantly different clearance for the larger iohexol. When comparing urea and Tc- 
99m DTPA it is reassuring that urea Kt/V is correlated with the equivalent measure of 
DTPA removal, ( K /V ) d t p a  multiplied by time, showing that there is a clear relationship 
between the amount of urea and DTPA removed by the session of dialysis. However this 
correlation is at least partly due to the fact that there was a mixture of dialysis times and 
patient sizes in the group studied. When comparing the actual clearance of DTPA and 
urea provided by the dialyser it might not be expected that there would be any 
correlation because the clearance provided by the dialysers could be more or less 
constant and any variation in K d t p a  and Kurea could be largely due to experimental errors 
which in the study here should be independent of each other. Indeed when K d t p a  is 
compared with Kurea there is little correlation (R=0.19). However there is a fundamental 
difference between urea and DTPA. DTPA is excluded from red cells and therefore the 
amount of DTPA delivered to the dialyser is not only dependent on the blood flow rate 
but also on the haematocrit. Urea however freely enters red cells and the concentration 
in red cells is essentially the same as that in plasma, assuming that there is rapid 
equilibration of urea between red cells and plasma then the urea clearance would not be 
dependent on haematocrit. In the patients in the study haematocrit varied from 0.21 to 
0.40 and the higher the haematcrit the lower the clearance of DTPA. If the plasma 
clearance of DTPA is expressed as a blood clearance by dividing by (1-haematocrit) and 
this is compared with Kurea then there is a significant correlation (R=0.67, P<0.05). This 
indicates two things: firstly that there must be factors in an individual patient’s session 
of dialysis that affect both the urea clearance and the DTPA clearance. These factors 
could include the degree of access recirculation or variability in the manufacture of the 
dialysers. This is why there is a need to assess the effectiveness of dialysis in an 
individual rather than relying entirely on a prescription. Secondly this highlights that 
assessing dialyser effectiveness with urea will not give the best representation of the 
effectiveness for solutes that are excluded from red cells for which the patient’s 
haematocrit is a factor.
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There were differences in the assessment of the effect of changes in dialyser blood and 
dialysate flow rates between the two techniques: the probe technique and the sampling 
blood either side of the dialyser technique. These differences can probably be explained 
by experimental error. One thing that was clear was that a large increase in dialysate 
flow from the normal rate of 500 ml/min to 800 ml/min had very little benefit in terms of 
Tc-99m DTPA clearance and this was consistent with the prediction of the dialyser 
modelling. A big decrease in dialysate flow from 500 ml/min to 300 ml/min did lead to a 
significant reduction in Tc-99m DTPA clearance with both techniques. This reduction 
appeared greater than that predicted by the dialyser model. This could well be due to 
limitations in how well the model represents the real patterns of diffusion within the 
dialyser. The reduction in Tc-99m DTPA clearance observed due to a 33 % decrease in 
blood flow was reasonably consistent with the model with one technique giving less 
change than predicted and the other technique more change than predicted. The extent to 
which changes in blood and dialyser flow rates effect clearance o f a solute depend on the 
degree to which the exchange in the dialyser is flow limited or diffusion limited which 
varies with the diffusibility of the solute. Although there are limitations in the model an 
important point highlighted by it is that in general changes in flow rates would be 
expected to have a greater effect on urea clearance than DTPA clearance. Therefore, for 
example, an increase in urea clearance demonstrated by a change in dialysis prescription 
may well overestimate any increase in clearance of larger molecules. Or indeed as 
Johnson et al (1999) demonstrated, two prescriptions that give the same urea clearance 
can give different values of clearance for larger molecules.
To detect changes in Tc-99m DTPA clearance with changes in the flow parameters 
periods of change of only 2 0  minutes with 15 to 2 0  minutes between each changes is 
probably at the limit of the technique. For a change in slope that may only be about 10 % 
longer periods of change would be likely to give more reliable results. One reason is that 
after each change in clearance there will be a period when a re-equilibration of tracer 
between the two functional compartments and it would be preferable to leave a gap for 
this before starting to fit to the curve again.
There was clearly a significant bias between the absolute DTPA clearance estimated 
from the probe data technique and the sampling blood either side of the dialyser 
technique. This could be due to the fact that factors that affect one technique do not 
necessarily affect the other, one possibility being access recirculation. When dialysing a 
patient the two needles taking the blood from and returning it to the patient are usually 
inserted into the same arterio-venous fistula. This means that there is a chance that there 
is some mixing of the blood returning to the patient that has greatly reduced 
concentration o f solutes for example DTPA with the blood going to the dialyser. This is 
concept known as access recirculation -  this would be expected to reduce the overall 
clearance. But while the clearance measured with the probe would reflect this real 
reduction, the clearance calculated from the concentrations in the blood either side of the 
dialyser would not be affected by this and if access recirculation were a significant 
problem would therefore be an overestimate and would be expected to be greater than 
the clearance measured with the probe. However,it was observed that the clearance 
estimated from the probe was greater than that estimated from the sampling which
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cannot be explained by access recirculation. A more likely cause of the bias is the 
patients having some native clearance of Tc-99m DTPA this could result from residual 
renal function or extra-renal clearance. Native clearance will have a two fold effect on 
the clearance estimated from the probe data but no effect on the clearance estimated 
from the sample data. Firstly the ( K / V ) Dt p a  will reflect the true total clearance from the 
body i.e. the dialyser clearance plus any native clearance. Secondly any clearance of Tc- 
99m DTPA from the body during the 90 minutes that the DTPA is allowed to equilibrate 
will cause the estimate o f the volume of distribution ( V d t p a )  to be an overestimate. 
Using the compartmental model it was found the native Tc-99m DTPA clearance of 5 
ml/min would be expected to give a 9% difference between the techniques and a native 
clearance of 10  ml/min a 19% difference.
This study has demonstrated the usefulness of using radiotracers for investigating the 
efficacy of dialysis in vivo at least in the research setting. An interesting extension 
would be to simultaneously use two or more solutes o f different sizes labelled with 
different gamma emitting isotopes. The slope of the disappearance curve of the 
radiotracer measured with the probe provides a good measure of clearance normalised to 
the distribution volume of the tracer (K/V). This is equivalent to using the rate constant 
of the terminal exponential in the measurement of GFR as a normalised measure of 
GFR. The measure (K/V) is an appropriate measure of the effectiveness of dialysis for a 
particular individual and can be used to compare different parameters of dialysis either 
in different sessions or within one session. The only need to convert (K/V) into an 
absolute clearance is for making comparisons like between the two different dialysers in 
different groups of patients. Then removing the variation in (K/V) with the size of the 
patient is necessary to detect small differences. The extraction of paired blood samples 
from either side of the dialyser is a useful additional tool for directly measuring the 
extraction fraction of the radiotracer and comparing this under different conditions.
Using an external probe to measure the disappearance o f Tc-99m DTPA as means of 
measuring GFR is still an interesting avenue to pursue. With the miniaturisation of 
electronics it is possible to build an ambulatory monitoring system (Juett et al 1995) 
which could be a benefit to the patient. The real challenge is in the design o f a probe 
mounting system that is not affected by movement and reasonably shields the detector 
from the patients bladder and kidneys and perhaps other patients.
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Chapter 9: Conclusion
9.1 INTRODUCTION
The main theme of this work is the use of the rate constant o f the terminal exponential of 
the clearance of an injected tracer as a measure of glomerular filtration rate (GFR). This 
rate constant is an estimate of GFR divided by the distribution volume of the tracer. For 
tracers like Cr-51 EDTA their distribution volume is assumed to be close to extracellular 
fluid volume (ECV) therefore the rate constant provides a measure of GFR normalised 
to ECV. GFR normalised to ECV may be an ideal measure of renal function because it 
indicates what proportion of the ECV is filtered by the kidneys every minute and how 
quickly the kidneys can remove substances that are distributed in the ECV. There may 
also be an advantage in deriving GFR principally from the rate constant because its 
precision is not reliant on an accurate knowledge of the quantity of tracer injected or the 
accuracy of making up standards from the injected tracer solution.
9.2 CORRECTIONS FOR THE ONE POOL ASSUMPTION 
9.2.1: Magnitude of the correction for the rate constant
The rate constant derived from a single exponential fit when blood samples are taken at
2 .3  and 4 hours needs to be corrected for the one pool assumption to give GFR/ECV. 
The modelling predicts and the experimental data confirms that the magnitude o f this 
correction is only about half the magnitude of the correction required for the slope 
intercept GFR.
9.2.2: Fit of the corrections to the experimental data
Two forms of the correction for the rate constant were derived from experimental data. 
One is based entirely on the slope and is of the form GFR/ECV = a.a25 + b.c^ ’2 (where 
012’ is the terminal rate constant). The other is a significantly closer fit to the data but 
does require an estimate of the intercept and of surface area in the calculation being of 
the form GFR/ECV = a.o^’ + b.(1 .7 3 /SA).a2,2/B’ (where B’ is the intercept and SA is 
the body surface area). Both forms will be useful in different situations. These 
corrections give significantly closer fits to the experimental data than corrections for 
slope intercept GFR.
9.2.3: Effect of the third compartment
The bi-exponential nature of the clearance curve of for example Cr-51 EDTA, observed 
when sampling from 2 0  minutes onwards is due to the distribution volume behaving as 
two compartments. However the first compartment does not correspond to plasma 
having a volume more than 3 times that of plasma. The mixing between plasma and the 
extravascular portion of this first compartment occurs very rapidly with equilibrium 
more or less obtained by 5 minutes after injection with arterial sampling (Cousins et al 
1997). This mixing gives a ‘third’ exponential to the clearance curve that is only evident 
if samples are taken in the first 5 minutes. Corrections for the one pool assumption 
should correct for the effect of this ‘third’ exponential and a limitation of the corrections 
derived here from the experimental data is that because sampling started at 2 0  minutes
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the effect of any ‘third’ exponential is not included. The 3 compartment modelling 
predicts that failing to include this ‘third’ exponential when deriving corrections for the 
one pool assumption can leave up to a 5% error, both when correcting the rate constant 
to get GFR/ECV and when correcting the slope intercept GFR. Of the previously 
published corrections for the slope intercept GFR, Fleming et al (1991) is the most likely 
to correctly represent the ‘third’ exponential and was found to be the closest fit when a 
modelled third exponential was added to the experimental data. Coincidentally the 
correction suggested by the British Nuclear Medicine Society guidelines (Fleming et al 
2004) gives very similar results to Fleming et al (1991) and either could be justifiably 
used. Alternative corrections to the rate constant to give GFR/ECV were derived from 
the experimental data with the modelled ‘third’ exponential.
9.2.4 Corrections to give ECV
It is possible to estimate the distribution volume of the tracer and hence ECV from 1/B’ 
but a correction for the one pool assumption needs to be applied. The modelling and the 
experimental data show that the magnitude of this correction is much greater than that 
for slope intercept GFR. Therefore it is important to apply this correction before 
comparing 1/B’ with an expected ECV as a quality assurance check when performing a 
GFR with sampling from 2 hours onwards. Corrections for 1/B’ were derived from the 
experimental data with and without the modelled ‘third’ compartment.
9.2.5 Effect of true terminal rate constant not being reached by 2 hours.
In Bird et al (2004) included as appendix B, a large number of clinical routine GFR 
studies where samples were taken at around 2, 3 and 4 hours were studied. The mean 
ratio between the slope from the samples at 2 and 3 hours and the slope from the sample 
at 3 and 4 hours was significantly greater than unity (P<0.001) being 1.101 (Standard 
error of the mean 0.011). This implies that the terminal exponential has not been reached 
by 2 hours. From the two compartment model it is clear that there will be a contribution 
of the first exponential to the concentration of the sample at 2 hours. But this 
contribution would only account for a ratio of around 1.045. In the paper it was 
demonstrated that the fact that a terminal rate constant is not reached by 2  hours was 
more likely to be due to delayed mixing than protein binding of the tracer. In reality the 
interstitial space is probably behaving as more than two compartments and so the 
clearance curve has further exponentials terms; some of which have long half lives due 
to functional compartments that the tracer is slow to penetrate. Moore et al (2003) 
compared plasma clearance of Cr-51 EDTA up to 4 hours with renal clearance from 
urinary collections and found that the plasma clearance overestimated renal clearance by 
10%. They conclude that this is due to the plasma clearance curve not having reached a 
terminal exponential by 2 or even 4 hours. The fact that a true terminal exponential may 
not be reached by 2  hours does not necessarily mean that it is essential to take plasma 
samples at later times. An ideal correction for the one pool assumption would include 
this effect as well as the effect of missing the earlier exponential(s) and to achieve this 
should be derived from a complete plasma clearance curve including samples taken 
beyond 4 hours. Fleming et al (1991) did include samples up to 5 hours with the 
correction derived to correct the slope intercept GFR obtained when samples are taken 
between 2 and 4 hours as required.
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9.3 UNCERTAINTIES DUE TO EXPERIMENTAL ERRORS
9.3.1: Effect of experimental errors on GFR/ECV derived from the rate constant
Montecarlo techniques were used to look at all the experimental sources of uncertainty 
that lead to uncertainty in the measurement of GFR from samples taken at 2, 3 and 4 
hours. It was demonstrated that the measures of GFR/ECV derived from the rate 
constant are significantly more affected by the uncertainties in sample volumes and 
sample times and the uncertainty due to counting statistics than GFR derived from the 
slope and intercept. The overall uncertainties in these measures o f GFR/ECV are in fact 
dominated by the uncertainty due to counting statistics. Therefore any changes that 
improve the counting statistics would improve the precision of the measures of 
GFR/ECV derived from the rate constant. It was also demonstrated that there was 
significantly less uncertainty when using the correction of the form GFR/ECV = a. 012’ + 
b.(1 .7 3 /SA).a2,2/B’ compared to the correction of the form GFR/ECV = a.c^’ + b.c^’2.
9.3.2 Comparison of uncertainties in GFR/ECV and GFR
Overall there was no significant difference in the uncertainty in the measures of 
GFR/ECV (derived from the rate constant) and GFR (derived from the rate constant and 
the intercept and normalised to body surface area). However this was when quite a large 
uncertainty was included for the injection volume to represent the local clinical routine 
studies where the volume injected is only assessed by the volume drawn up in a 2  ml 
syringe. If however the volume injected is assessed by weighing then this source of 
uncertainty is much reduced. Therefore, when weighing of injection syringes is 
employed the uncertainty in GFR was significantly less than the uncertainty in the 
measures of GFR/ECV. It should be noted that in all the research studies reported in this 
work careful weighing of the injected volume of tracer was performed. Therefore it 
would be expected for these studies that the uncertainties in the measures of GFR/ECV 
derived from the rate constant would be greater than uncertainty in GFR derived from 
the rate constant and intercept.
9.4 NORMALISATION OF GFR
9.4.1 Alternative whole body parameters for normalising GFR
The assumption was made that it may be possible to determine which is the most 
appropriate measure of body size to use for normalising GFR, by comparing tightness of 
normal ranges. Although the number of subjects studied was small it was concluded that 
none of the other whole body parameters, as measured in the study, was likely to be to 
prove more appropriate than body surface area or ECV estimated from the distribution 
volume of the GFR tracer. The parameters studied included total body water, 
exchangeable potassium, which should reflect intracellular fluid volume and lean body 
mass. One implication being that of the divisions o f body fluid, extracellular fluid 
volume is more appropriate for normalising GFR than total body water or intracellular 
fluid volume.
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9.4.2 Comparison of body surface area and ECV for normalising GFR
In the larger group of 20 normal volunteers there was no significant difference in the 
tightness of the normal range of GFR normalised to body surface area and GFR 
normalised to ECV although the latter was slightly tighter.
9.4.3 Normalisation of GFR for children
In Bird et al (2003), included as Appendix A, a large number of routine GFRs on 
children and adults were studied comparing normalising GFR to body surface area and 
GFR normalised to ECV derived from the rate constant. In children GFR normalised to 
body surface area tends to give an underestimation of renal function compared to GFR 
normalised to ECV. GFR normalised to body surface area may give the impression that 
normal children’s renal function, corrected for size, is less than that of adults. In contrast, 
GFR normalised to ECV may be maximal at least by the age of one and decrease 
throughout life. Therefore the choice of normalisation parameter will significantly affect 
the assessment o f renal function in children. Also in the paper a formula was derived to 
estimate ECV from height and weight which can be used in place of estimated surface 
area to normalise slope intercept derived GFR.
9.5 REPRODUCIBILITY AND THE EFFECT OF FOOD INTAKE
9.5.1 Reproducibility
There was no significant difference in the reproducibility of GFR derived from the rate 
constant and the intercept between Cr-51 EDTA and iohexol measured with x-ray 
fluorescence (XRF). For both tracers, GFR derived from the rate constant and the 
intercept gave the best reproducibility. For Cr-51 EDTA the difference between the 
reproducibility of GFR derived from the rate constant and the intercept and GFR/ECV 
derived from the rate constant alone was fairly small and not significant. However for 
iohexol measured with XRF the difference was much larger and significant (P<0.05). 
This is consistent with GFR/ECV derived from the rate constant being particularly 
sensitive to experimental errors as there was significantly greater variability found in 
measuring plasma concentration of iohexol with XRF than in the measurement of Cr-51 
EDTA concentration. Using the two independent tracers for measuring GFR 
simultaneously it was possible to demonstrate that a significant portion of the variability 
between two repeat fasting measures of GFR was due to a real change in GFR.
9.5.2 Effect of food intake
GFR following normal breakfast was significantly greater than fasting GFR, the 
difference being around 5 ml/min. Measures of GFR derived from the rate constant and 
the intercept were better at demonstrating the significance of this effect than the 
measures derived from the rate constant alone. The effect of food intake shows that in 
order to maximise the precision of measurement of GFR it is worth standardising the 
food intake prior to the test. The effect of food intake was not observable with GFR 
estimated from plasma creatinine concentration, demonstrating that this method of 
estimating GFR is less sensitive for detecting small changes renal function.
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9.5.3 HPLC
When using high performance liquid chromatography (HPLC) for measuring plasma 
iohexol concentration in a small number of subjects, the reproducibility was 
significantly better when compared with all the subjects using XRF. The reproducibility 
was also significantly better when compared with all the subjects using Cr-51 EDTA. 
This importantly opens the possibility that using iohexol and measuring the 
concentrations with HPLC may be an improvement over using Cr-51 EDTA. Greater 
precision would improve the ability to determine changes in GFR and could 
significantly improve the clinical and research usefulness of the GFR test.
9.6 COMPARISON OF Cr-51 EDTA AND IOHEXOL AND PLASMA 
CREATININE
9.6.1 Distribution Volumes
The mean distribution volume of iohexol was significantly less than that of Cr-51 EDTA. 
This is in keeping with the observation that smaller molecules that distribute in the ECV 
have larger distribution volumes. The division of the distribution volume into two 
functional compartments was also different for the two tracers, with the volume of 
compartment 1 being significantly smaller for iohexol but the volume of compartment 2  
being slightly larger. The mean normalised distribution volume of Cr-51 EDTA was 
significantly greater in diabetics than normal volunteers.
9.6.2 Corrections for the one pool assumption
The differences in the distribution volumes between the two tracers mean that ideally 
different corrections for the one pool assumption would be needed. However it was 
demonstrated by use of modelling that the systematic error that would be introduced by 
using corrections derived for Cr-51 EDTA on iohexol clearances would be small.
9.6.3 Agreement between the tracers
The best agreement between measures of GFR measured with iohexol and Cr-51 EDTA 
was for GFR from the rate constant and intercept from the samples taken from 2 hours 
onwards after injection. This agreement was significantly better than for GFR derived 
from all the blood samples. The agreement for GFR derived from the rate constant and 
intercept was also significantly better than that for measures of GFR derived from the 
rate constant alone.
9.6.4 HPLC
For the studies where iohexol concentration was assayed with HPLC as well as XRF 
there was significantly better agreement with HPLC than XRF for both GFR derived 
from the rate constant and intercept and GFR derived from the rate constant alone. For 
the GFR derived from the rate constant and intercept with HPLC the limits of agreement 
were -8  % to + 2 % compared with -20 % to + 18 % with XRF.
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9.6.5 Estimated GFR from plasma creatinine
Taking GFR derived from the rate constant and intercept with Cr-51 EDTA as the gold 
standard, GFR similarly derived for iohexol measured with XRF was significantly more 
accurate than a GFR estimated from the plasma creatinine. The limits of agreement with 
GFR from plasma creatinine were roughly twice as wide as with the iohexol technique.
9.7 CHANGES IN RENAL FUNCTION IN A RANDOMISED CONTROLLED 
TRIAL
9.7.1 Results of the trial
The randomised control trial was able to clearly demonstrate the benefit in terms of renal 
function of switching from calcineurin inhibitors to sirolimus, for both renal and liver 
transplant patients.
9.7.2 Comparison of GFR and GFR/ECV
The measures of GFR derived from the rate constant and the intercept were shown to be 
slightly better at demonstrating the significance o f the changes in renal function than the 
measures of GFR/ECV derived from the rate constant alone.
9.7.3 Comparison of number of blood samples
In this study there was no obvious benefit of having early blood samples in addition to 
samples taken from 2 hours post injection onwards. This is consistent with the 
reproducibility data showing that GFR derived from all the blood samples was less 
reproducible than GFR derived from the rate constant and intercept of the late blood 
samples. It is also consistent with there being significantly better agreement between 
GFR for two tracers for GFR derived from the rate constant and intercept o f the late 
blood samples than from all the samples. Therefore for research studies looking for 
changes in renal function only late samples need to be taken.
9.8 PERFORMANCE OF HAEMODIALYSIS IN VIVO
9.8.1 Rebound
When looking at Tc-99m DTPA clearance in patients on haemodialysis the rise in 
plasma DTPA concentration after the termination of dialysis, known a rebound, was of 
the same magnitude as that predicted by the two compartment modelling.
9.8.2 Fluid removal
Fluid removed during dialysis appeared to be principally from the ECV.
9.8.3 Dialyser function over length of session
Using the rate constant of the disappearance of Tc-99m DTPA from the plasma during 
dialysis using a probe system it was demonstrated for the first time that there was no 
deterioration in dialyser function over a 4 hour session of dialysis.
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9.8.4 Changes in clearance detected with a probe system
Using the rate constant of the disappearance of Tc-99m DTP A from the plasma using a 
probe system during a single session of dialysis it was possible to demonstrate for the 
first time changes in clearance in response to changes in blood or dialysate flow.
9.9 POTENTIAL FUTURE WORK
9.9.1 Normalisation
An important question still to be answered is whether it is more appropriate, in terms of 
assessing an individual’s absolute renal function, to normalise GFR to ECV or body 
surface area. In particular it is important to include children in any assessment because 
with children the two approaches may give clinically significantly different results. 
However, even with adults it is a challenge to obtain approval and recruit normal 
volunteers, particularly for studies involving radioactivity and for children it is even 
more difficult. Therefore the proposal is to carefully examine clinically referred GFR 
studies and to pick studies that can be justifiably included as normal studies. Of 
approximately 1000 clinical GFRs performed in the local department per year, a 
considerable proportion are oncology patients having their GFR measured for the 
purpose of calculating chemotherapy doses and this includes children. It would be 
important to take into account the presence of fluid collections but otherwise many of 
these patients would be expected to have normal renal function. The plasma creatinine 
could be used as one independent assessment of whether renal function was normal. 
After identifying a sufficient number of studies that can be included as normal, a 
comparison would be made of GFR normalised to ECV and body surface area between 
adults and children and to determine which normalisation gives the tightest normal range 
for adults, children and both combined.
9.9.2 Iohexol reproducibility
The reproducibility of GFR measured with iohexol measured with HPLC was found to 
be significantly better than the reproducibility of GFR measured with Cr-51 EDTA. 
However this was with only 3 subjects for the HPLC comparing with 10 subjects for the 
Cr-51 EDTA. Improved reproducibility could significantly improve the clinical utility of 
the GFR test and therefore it is important to be sure that iohexol and HPLC are offering 
an advantage over Cr-51 EDTA. Therefore the proposal would be to do a further 
comparison of simultaneous Cr-51 EDTA and iohexol clearances in maybe 20 normal 
volunteers. Performing the study on two repeat occasions either both fasted or both after 
some standardised food intake to minimise variation due to food intake. Also in the light 
o f the findings here, the preparation protocol should ensure that subjects are hydrated as 
far as possible to a repeatable level. Only late samples would be taken but because the 
Montecarlo analysis has demonstrated the dominance of the uncertainty caused by 
counting statistics, the samples should be counted for Cr-51 for an extended period of 
time. This long counting could be in addition to a more standard counting time to check 
whether extended counting would improve reproducibility. This proposed study would 
also enable further investigation of the slight bias between GFR measured with iohexol 
and GFR measured with Cr-51 EDTA. Careful attention should be made to the absolute
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calibration of the HPLC system on each occasion that it used, to ensure that calibration 
problems can be eliminated as the cause of the bias.
9.9.3 Probe systems
One application for the use of the rate constant as a measure of GFR is using a probe 
system for measuring GFR after the administration of a radiotracer, without the need for 
taking blood samples. Although the concept of using a probe system is not new it would 
be interesting to revisit whether with new technology it would be possible to build a 
miniature ambulatory probe system that would be suitable for routine measurement of 
GFR. Although there is much new technology that would be useful in building such a 
system there still remains the challenge of designing the shielding and mounting system 
for the probe. It is essential that the distance between the detector and the area of body 
being monitored remains fixed while the subject moves. The detector must also be 
adequately shielded from the kidneys and bladder and other parts of the body which may 
move in and out o f the field of view of the detector. Miniature probes have been made 
that can be inserted into blood vessels (Pain et al 2004), but this is probably too invasive 
for routine use.
Another possible application of a probe system, that would not have to be ambulatory, 
would be to research the effect of exercise on GFR. In a similar manner to the dialysis 
study, the baseline rate constant would be established during a period of rest before a 
period of controlled exercise, ideally then returning to a baseline resting condition. This 
in fact would be equivalent to the study of Gleadhill et al (2000) performed on horses 
who found a very large decrease in GFR in response to exercise but discuss whether 
GFR would be more protected in humans. It would also be possible to use a probe 
system to look at the effect on GFR of a high protein meal. It would also be possible to 
investigate the immediate effects of significantly nephrotoxic drugs. There may also be 
other clinical roles for monitoring renal function in real time. One possibility being 
during particular major operations where there is a significant risk o f renal function 
being damaged by, for example, the clamping of major blood vessels. I
9.10 FINAL WORDS
The overall conclusion of this work is that although it may yet prove more appropriate to 
normalise GFR to ECV than to body surface area, because GFR/ECV derived from the 
rate constant alone was consistently found to be more susceptible to experimental errors, 
the use of the slope intercept GFR should not be abandoned. In particular, in pursuing 
the possibility of setting up a postal service using iohexol it would be sensible to ensure 
that the quantity of injected iohexol is accurately known so that an intercept can be 
calculated. However there will be particular applications or situations where a measure 
of GFR derived entirely from the rate constant will be useful.
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Glossary of Terms
ARSAC Administration o f Radioactive Substances Advisory Committee
AUC Area Under the Curve
BNMS British Nuclear Medicine Society
Bq Becquerel: SI unit o f activity equal to 1 disintegration per second
BSA Body Surface Area
Calcineurin inhibitors A class o f immunosuppressive drug 
CPM Counts per minute
Creatinine a breakdown product o f creatine phosphate
CRF Chronic Renal Failure
CV Coefficient of Variation (standard deviation / mean)
Cyclosporine An immunosuppressive drug that is a calcineurin inhibitor
Da Dalton: Unit of molecular mass approximately equal to the mass
of 1 proton or neutron
Dialysate Fluid that is used to remove waste products
Dialyser the ‘artificial kidney’ used in haemodialysis
Dialysis abbreviation of haemodialysis
DPM Disintegrations per minute
DTPA diethylenetriaminepentaacetic acid
DV Distribution Volume
DXA Dual energy x-ray absorptiometry
ECF Extracellular fluid
ECV Extracellular fluid volume
EDTA Etheylenediamine tetraaccetic acid
eGFR GFR estimated from the plasma creatinine concentration using the
formula o f Levey et al (2000)
Extrarenal As in extrarenal clearance meaning removed from the body by a
route other than through the kidneys
g Unit of acceleration
GFR Glomerular Filtration Rate
GFRbm GFR corrected with the Brochner Mortensen (1972) correction
GFRsi Slope intercept GFR
GFRss Single sample based GFR
H-3 tritium, radioactive isotope o f hydrogen
H aem atocrit the proportion o f blood by volume occupied by red blood cells
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Haemodialysis removal o f waste products from the blood with equipment
external to the body
HPLC High Performance Liquid Chromatography
Iohexol A non-ionic iodine containing radiographic contrast agent
Kt/V measure of the proportion of urea removed from the blood during
a haemodialysis session
Kurea urea clearance
MCA Multichannel analyser
Monte Carlo As in Monte Carlo analysis meaning to simulate the behaviour of
physical system using repeated random numbers
Nephrotoxic harmful to the kidneys
nGFR GFR normalised to body surface area
PC Personal Computer
Qb blood flow
Qd dialysate flow
Quench Absorption of scintillation light within the sample in liquid
scintillation counting
rms root mean square
SA Surface Area
SD Standard Deviation
SDD Standard Deviation of Differences
SEM Standard Error o f the Mean
Sirolimus An immunosuppressive drug
SQPE External standard quench index
Sv Sievert: SI unit o f absorbed radiation dose equivalent
Tacrolimus An immunosuppressive drug that is a calcineurin inhibitor
TCA Tri-chloro acetic acid
Tritium H-3, radioactive isotope o f hydrogen
UV Ultraviolet light
XRF X-ray fluorescence
p' beta particle
p+ positron
